U.S. patent application number 16/048191 was filed with the patent office on 2018-12-06 for compounds and methods for the targeted degradation of androgen receptor.
The applicant listed for this patent is Arvinas, Inc.. Invention is credited to Michael Berlin, Xin Chen, Andrew P. Crew, Craig M. Crews, Hanqing Dong, Yimin Qian, Lawrence Snyder, Jing Wang, Kurt Zimmermann.
Application Number | 20180346461 16/048191 |
Document ID | / |
Family ID | 56417710 |
Filed Date | 2018-12-06 |
United States Patent
Application |
20180346461 |
Kind Code |
A1 |
Crew; Andrew P. ; et
al. |
December 6, 2018 |
COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN
RECEPTOR
Abstract
The present invention relates to bifunctional compounds, which
find utility to degrade and (inhibit) Androgen Receptor. In
particular, the present invention is directed to compounds, which
contain on one end a VHL ligand which binds to the ubiquitin ligase
and on the other end a moiety which binds Androgen Receptor such
that Androgen Receptor is placed in proximity to the ubiquitin
ligase to effect degradation (and inhibition) of Androgen Receptor.
The present invention exhibits a broad range of pharmacological
activities associated with compounds according to the present
invention, consistent with the degradation/inhibition of Androgen
Receptor.
Inventors: |
Crew; Andrew P.; (Guilford,
CT) ; Dong; Hanqing; (Madison, CT) ; Wang;
Jing; (Milford, CT) ; Chen; Xin; (Trumbull,
CT) ; Qian; Yimin; (Plainsboro, NJ) ;
Zimmermann; Kurt; (Durham, CT) ; Crews; Craig M.;
(New Haven, CT) ; Berlin; Michael; (Flemington,
NJ) ; Snyder; Lawrence; (Killingworth, CT) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Arvinas, Inc. |
New Haven |
CT |
US |
|
|
Family ID: |
56417710 |
Appl. No.: |
16/048191 |
Filed: |
July 27, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15002303 |
Jan 20, 2016 |
|
|
|
16048191 |
|
|
|
|
62105210 |
Jan 20, 2015 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 25/28 20180101;
C07D 417/12 20130101; C07K 5/06165 20130101; C07D 413/14 20130101;
A61P 35/00 20180101; C07D 491/107 20130101; C07D 233/86 20130101;
C07D 417/14 20130101; A61K 45/06 20130101; C07D 401/04 20130101;
C07D 471/10 20130101; C07D 413/12 20130101 |
International
Class: |
C07D 417/14 20060101
C07D417/14; A61P 25/28 20060101 A61P025/28; A61P 35/00 20060101
A61P035/00; C07K 5/078 20060101 C07K005/078; C07D 413/14 20060101
C07D413/14; C07D 417/12 20060101 C07D417/12; C07D 471/10 20060101
C07D471/10; C07D 491/107 20060101 C07D491/107; C07D 401/04 20060101
C07D401/04; C07D 233/86 20060101 C07D233/86; C07D 413/12 20060101
C07D413/12; A61K 45/06 20060101 A61K045/06 |
Claims
1. A bifunctional compound that is represented by the chemical
structure: ABM-L-ULM, wherein: ULM is an E3 ubiquitin ligase
binding moiety, L is a bond or a chemical linker, and ABM is an
androgen receptor (AR) binding moiety that is represented by the
chemical structure: ##STR00838## wherein: W.sup.1 is aryl or
heteroaryl, independently substituted by 1 or more halo, hydroxyl,
nitro, CN, C.ident.CH, linear or branched C.sub.1-6 alkyl
optionally substituted by 1 or more halo or C.sub.1-6 alkoxyl,
linear or branched C.sub.1-6 alkoxyl optionally substituted by 1 or
more halo, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl; Y.sup.1, Y.sup.2
are each independently NR.sup.Y1, O, S; R.sup.1, R.sup.2, R.sup.Y1,
R.sup.Y2 are each independently H, linear or branched C.sub.1-6
alkyl optionally substituted by 1 or more halo or C.sub.1-6
alkoxyl, or R.sup.1, R.sup.2 together with the atom they are
attached to, form a 3-8 membered ring system containing 0-2
heteroatoms; W.sup.2 is a bond, C.sub.1-6 alkyl, C.sub.1-6
alicyclic, heterocyclic, aryl, or heteroaryl, each optionally
substituted by 1, 2 or 3 R.sup.W2; and each R.sup.W2 is
independently H, halo, C.sub.1-6 alkyl optionally substituted by 1
or more F, OC.sub.1-3alkyl optionally substituted by 1 or more --F,
OH, NH.sub.2, NR.sup.Y1R.sup.Y2, CN.
2. The bifunctional compound of claim 2, wherein ULM is a hydroxyl
prolyl moiety that binds Von Hippel-Lindau (VHL) E3 ubiquitin
ligase (VLM).
3. The bifunctional compound of claim 2, wherein the VLM is
represented by the structure: ##STR00839## wherein: W.sup.3 is
optionally substituted aryl, optionally substituted heteroaryl, or
##STR00840## each R.sub.9 and R.sub.10 is independently hydrogen,
optionally substituted alkyl, optionally substituted cycloalkyl,
optionally substituted hydroxyalkyl, optionally substituted
heteroaryl, or haloalkyl; or R.sub.9, R.sub.10, and the carbon atom
to which they are attached form an optionally substituted
cycloalkyl; R.sub.11 is optionally substituted heterocyclic,
optionally substituted alkoxy, optionally substituted heteroaryl,
optionally substituted aryl, ##STR00841## R.sub.12 is H or
optionally substituted alkyl; R.sub.13 is H, optionally substituted
alkyl, optionally substituted alkylcarbonyl, optionally substituted
(cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl,
optionally substituted arylcarbonyl, optionally substituted
(heterocyclyl)carbonyl, or optionally substituted aralkyl;
R.sub.14a, R.sub.14b, is each independently H, haloalkyl, or
optionally substituted alkyl; W.sup.5 is a phenyl or a 5-10
membered heteroaryl, R.sub.15 is H, halogen, CN, OH, NO.sub.2,
NR.sub.14aR.sub.14b, OR.sub.14a, CONR.sub.14aR.sub.14b, NR.sub.14a
COR.sub.14b, SO.sub.2NR.sub.14aR.sub.14b,
NR.sub.14aSO.sub.2R.sub.14b, optionally substituted alkyl,
optionally substituted haloalkyl, optionally substituted
haloalkoxy; aryl, heteroaryl, cycloalkyl, cycloheteroalkyl each
R.sub.16 is independently halo, optionally substituted alkyl,
optionally substituted haloalkyl, hydroxy, or optionally
substituted haloalkoxy; or ##STR00842## wherein R.sub.17 is H,
halo, optionally substituted C.sub.3-6cycloalkyl, optionally
substituted C.sub.1-6alkyl, optionally substituted
C.sub.1-6alkenyl, and C.sub.1-6haloalkyl, and Xa is S or O; o is 0,
1, 2, 3, or 4; each R.sub.18 is independently halo, optionally
substituted alkoxy, cyano, optionally substituted alkyl, haloalkyl,
haloalkoxy or a linker; and p is 0, 1, 2, 3, or 4.
4. The bifunctional compound of claim 3, wherein the VLM is
represented by the structure: ##STR00843## wherein: R.sub.9 is H;
R.sub.10 is isopropyl, tert-butyl, sec-butyl, cyclopentyl, or
cyclohexyl; R.sub.11 is ##STR00844## R.sub.12 is H; R.sub.13 is H,
optionally substituted alkyl, optionally substituted alkylcarbonyl,
optionally substituted (cycloalkyl)alkylcarbonyl, optionally
substituted aralkylcarbonyl, optionally substituted arylcarbonyl,
optionally substituted (heterocyclyl)carbonyl, or optionally
substituted aralkyl; R.sub.14a is H, haloalkyl, or optionally
substituted methyl, ethyl, isopropyl, cyclopropyl, or other alkyl;
and R.sub.15 is ##STR00845## wherein R.sub.17 is H, halo,
optionally substituted C.sub.3-6cycloalkyl, optionally substituted
C.sub.1-6alkyl, optionally substituted C.sub.1-6alkenyl, and
C.sub.1-6haloalkyl; and Xa is S or O.
5. The bifunctional compound of claim 3, wherein VLM is selected
from the group consisting of:
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthia-
zol-5-yl)benzyl)pyrrolidine-2-carboxamide;
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(thiazol-5-yl-
)benzyl)pyrrolidine-2-carboxamide;
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N--((S)-1-(4-(4-me-
thylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide;
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(oxazol-5-yl)-
benzyl)pyrrolidine-2-carboxamide hydrochloride;
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methyloxaz-
ol-5-yl)benzyl)pyrrolidine-2-carboxamide;
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-N-(4-chlorobenzyl)-4-hydroxy-
pyrrolidine-2-carboxamide hydrochloride;
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-N-(4-cyanobenzyl)-4-hydroxyp-
yrrolidine-2-carboxamide hydrochloride;
(2S,4R)-1-((S)-2-amino-3-methylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol--
5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride;
(2S,4R)-1-((S)-2-amino-3-methylbutanoyl)-4-hydroxy-N-(4-(thiazol-5-yl)ben-
zyl)pyrrolidine-2-carboxamide hydrochloride;
(2S,4R)-1-((S)-2-amino-3-methylbutanoyl)-4-hydroxy-N-(4-(4-methyloxazol-5-
-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride;
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(1-methyl-H-p-
yrazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride;
(2S,4R)-4-tert-butoxy-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-
-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide;
(2S,4R)-4-tert-butoxy-1-((S)-2-(6-fluoro-1-oxoisoindolin-2-yl)-3-methylbu-
tanoyl)-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxam-
ide; and
(2S,4R)-4-tert-butoxy-1-((S)-2-(7-cyano-1-oxoisoindolin-2-yl)-3-m-
ethylbutanoyl)-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-c-
arboxamide.
6. The bifunctional compound of claim 1, wherein the linker group
(L) comprises a chemical structural unit represented by the
formula: -(A).sub.q-, wherein: q is an integer greater than 1; and
each A is independently selected from the group consisting of a
bond, CR.sup.L1R.sup.L2, O, S, SO, SO.sub.2, NR.sup.L3,
SO.sub.2NR.sup.L3, SONR.sup.L3, CONR.sup.L3, NR.sup.L3 CONR.sup.L4,
NR.sup.L3SO.sub.2NR.sup.L4, CO, CR.sup.L1.dbd.CR.sup.L2, C.ident.C,
SiR.sup.L1R.sup.L2, P(O)R.sup.L1, P(O)OR.sup.L1,
NR.sup.L3C(.dbd.NCN)NR.sup.L4, NR.sup.L3C(.dbd.NCN),
NR.sup.L3C(.dbd.CNO.sub.2)NR.sup.4, C.sub.3-11cycloalkyl optionally
substituted with 0-6 R.sup.L1 and/or R.sup.L2 groups, C.sub.3-11
heterocyclyl optionally substituted with 0-6 R.sup.L1 and/or
R.sup.L2 groups, aryl optionally substituted with 0-6 R.sup.L1
and/or R.sup.L2 groups, heteroaryl optionally substituted with 0-6
R.sup.L1 and/or R.sup.L2 groups; wherein R.sup.L1, R.sup.L2,
R.sup.L3, R.sup.L4 and R.sup.L5 are each, independently, selected
from the group consisting of H, halo, C.sub.1-8alkyl,
OC.sub.1-8alkyl, SC.sub.1-8alkyl, NHC.sub.1-8alkyl,
N(C.sub.1-8alkyl).sub.2, C.sub.3-11cycloalkyl, aryl, heteroaryl,
C.sub.3-11 heterocyclyl, OC.sub.1-8cycloalkyl,
SC.sub.1-8cycloalkyl, NHC.sub.1-8cycloalkyl,
N(C.sub.1-8cycloalkyl).sub.2,
N(C.sub.1-8cycloalkyl)(C.sub.1-8alkyl), OH, NH.sub.2, SH,
SO.sub.2C.sub.1-8alkyl, P(O)(OC.sub.1-8alkyl)(C.sub.1-8alkyl),
P(O)(OC.sub.1-8alkyl).sub.2, CC--C.sub.1-8alkyl, CCH,
CH.dbd.CH(C.sub.1-8alkyl),
C(C.sub.1-8alkyl).dbd.CH(C.sub.1-8alkyl),
C(C.sub.1-8alkyl).dbd.C(C.sub.1-8alkyl).sub.2, Si(OH).sub.3,
Si(C.sub.1-8alkyl).sub.3, Si(OH)(C.sub.1-8alkyl).sub.2,
COC.sub.1-8alkyl, CO.sub.2H, halogen, CN, CF.sub.3, CHF.sub.2,
CH.sub.2F, NO.sub.2, SF.sub.5, SO.sub.2NHC.sub.1-8alkyl,
SO2N(C.sub.1-8alkyl).sub.2, SONHC.sub.1-8alkyl,
SON(C.sub.1-8alkyl).sub.2, CONHC.sub.1-8alkyl,
CON(C.sub.1-8alkyl).sub.2, N(C.sub.1-8alkyl)CONH(C.sub.1-8alkyl),
N(C.sub.1-8alkyl)CON(C.sub.1-8alkyl).sub.2, NHCONH(C.sub.1-8alkyl),
NHCON(C.sub.1-8alkyl).sub.2, NHCONH.sub.2,
N(C.sub.1-8alkyl)SO.sub.2NH(C.sub.1-8alkyl), N(C.sub.1-8alkyl)
SO.sub.2N(C.sub.1-8alkyl).sub.2, NH SO.sub.2NH(C.sub.1-8alkyl), NH
SO.sub.2N(C.sub.1-8alkyl).sub.2, and NH SO.sub.2NH.sub.2; and
wherein when q is greater than 1, R.sup.L1 or R.sup.L2 each,
independently, can be linked to another A group to form cycloalkyl
and/or heterocyclyl moeity that can be further substituted with 0-4
R.sup.L5 groups.
7. The bifunctional compound of claim 5, wherein the compound is a
member selected from the group consisting of Examples 1-149,
190-203, 205-338, 340-346, 348-386, 389-391, 394-397, 399-403, 408,
413, 414, 418-421, 423, 424, 426-431, 434, 435, 439, 440, 443,
451-453, 477-479, 545, 546, 554, 559, 565-567, 571, and 574-576, a
salt, a polymorph, isotopic derivative, and a prodrug thereof.
8. The bifunctional compound of claim 12, wherein the compound is
selected from the group consisting of: ##STR00846## ##STR00847##
##STR00848## ##STR00849##
9. A composition comprising an effective amount of the bifunctional
compound of claim 5, and a pharmaceutically acceptable carrier.
10. The composition of claim 9, wherein the composition further
comprises at least one additional bioactive agent.
11. The composition of claim 10, wherein the bioactive agent is an
anti-cancer agent.
12. A therapeutic composition comprising an effective amount of at
least two different bifunctional compounds of claim 1.
13. A method of treating a disease or disorder in a subject
comprising administering a composition comprising a
pharmaceutically acceptable carrier and an effective amount of the
bifunctional compound of claim 1 to a subject in need thereof,
wherein the compound is effective in treating or ameliorating at
least one symptom of the disease or disorder.
14. The method of claim 13, wherein the disease or disorder is
cancer or Kennedy's Disease or both.
15. The method of claim 14, wherein the cancer is prostate
cancer.
16. The method of claim 13, wherein the composition further
comprises an effective amount of at least one additional
anti-cancer agent.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional application of U.S.
Non-provisional patent application Ser. No. 15/002,303, filed 20
Jan. 2016, which claims the benefit of U.S. Provisional Patent
Application Ser. No. 62/105,210, filed 20 Jan. 2015, both of which
are entitled Compounds and Methods for the Targeted Degradation of
the Androgen Receptor, and incorporated herein by reference in
their entirety.
BACKGROUND
[0002] 1. Field of the Discovery
[0003] The present description relates to bifunctional compounds,
which are useful for the modifying the ubiquitination and
subsequent degradation of target polypeptides and proteins, in
particular, androgen receptor. In certain aspects, the compounds
comprise a Von Hippel-Lindau (VHL) binding moiety, which binds to
the VHL E3 ubiquitin ligase, a target protein binding moiety, which
binds to the target protein (e.g., androgen receptor), and
optionally a linker moiety which links the VHL binding moiety and
target protein binding moiety. These compounds work in such way
that the target protein/polypeptide is placed in proximity to the
ubiquitin ligase to effect degradation (and inhibition) of that
protein (e.g., androgen receptor).
[0004] 2. Background Information
[0005] Androgen Receptor (AR) belongs to a nuclear hormone receptor
family that is activated by androgens, such as testosterone and
dihydrotestosterone (Pharmacol. Rev. 2006, 58(4), 782-97; Vitam.
Horm. 1999, 55:309-52.). In the absence of androgens, AR is bound
by Heat Shock Protein 90 (Hsp90) in the cytosol. When an androgen
binds AR, its conformation changes to release AR from Hsp90 and to
expose the Nuclear Localization Signal (NLS). The latter enables AR
to translocate into the nucleus where AR acts as a transcription
factor to promote gene expression responsible for male sexual
characteristics (Endocr. Rev. 1987, 8(1):1-28; Mol. Endocrinol.
2002, 16(10), 2181-7). AR deficiency leads to Androgen
Insensitivity Syndrome, formerly termed testicular
feminization.
[0006] While AR is responsible for development of male sexual
characteristics, it is also a well-documented oncogene in certain
forms cancers including prostate cancers (Endocr. Rev. 2004, 25(2),
276-308). A commonly measured target gene of AR activity is the
secreted Prostate Specific Antigen (PSA) protein. The current
treatment regimen for prostate cancer involves inhibiting the
androgen-AR axis by two methods. The first approach relies on
reduction of androgens, while the second strategy aims to inhibit
AR function (Nat. Rev. Drug Discovery, 2013, 12,823-824). Despite
the development of effective targeted therapies, most patients
develop resistance and the disease progresses. An alternative
approach for the treatment of prostate cancer involves eliminating
the AR protein. Because AR is a critical driver of tumorigenesis in
many forms of prostate cancers, its elimination should lead to
therapeutically beneficial response.
[0007] There exists an ongoing need in the art for effective
treatments for diseases and conditions that are related to aberrant
AR regulation or activity, such as, for example, cancer, prostate
cancer, and Kennedy's Disease.
SUMMARY
[0008] The present disclosure describes compounds, including
compositions comprising the same, which function to recruit
endogenous proteins to an E3 ubiquitin ligase, e.g., Von
Hippel-Lindau (VHL) E3 ubiquitin ligase, for ubiquitination and
subsequent degradation, and methods of using the same. In
particular, the present disclosure provides bifunctional or
proteolysis targeting chimeric (PROTAC) compounds, which find
utility as modulators of targeted ubiquitination and degradation of
androgen receptor (AR). In addition, the description provides
methods of using an effective amount of the compounds as described
herein for the treatment or amelioration of a disease condition
including cancer, e.g., prostate cancer, and Kennedy's Disease.
[0009] Thus, in one aspect, the disclosure provides compounds which
function to recruit endogenous proteins, e.g., AR proteins, to E3
Ubiquitin Ligase for ubiquitination and degradation. In certain
embodiments, the compounds have the following general
structure:
ABM-L-ULM (I),
[0010] wherein ABM is an AR binding moiety, ULM is an E3 ligase
binding moiety, e.g., a VHL E3 ligase binding moiety (VLM), and L
is a bond or a linker moiety which links the ABM and ULM. As such,
in certain embodiments, the description provides compounds having
the following general structure:
ABM-L-VLM (II),
[0011] wherein ABM is an AR binding moiety, VLM is a VHL E3 ligase
binding moiety and L is a bond or a linker moiety which links the
ABM and VLM. In certain embodiments, the VLM comprises a hydroxyl
prolyl moiety.
[0012] In certain embodiments, the ULM is a moiety specific for an
E3 ubiquitin ligase such as, e.g., cereblon, mouse double minute 2
homolog (Mdm2), or inhibitor of apoptosis (IAP), wherein the ULM
moiety is coupled to an ABM as described herein.
[0013] It will be understood that the general structures are
exemplary and the respective moieties can be arranged spatially in
any desired order or configuration, e.g., ULM-L-ABM, and VLM-L-ABM
respectively.
[0014] In another aspect, the description provides AR binding
moieties (ABM). In an additional embodiment, the description
provides compounds having the following general structure: ABM-L,
wherein ABM is an AR binding moiety as described herein, and L is a
chemical linker moiety, or optionally a bond. In certain
embodiments, the ABM and/or L are coupled to a ULM as described
herein.
[0015] In any of the aspects or embodiments described herein, the
ABM is selected from following structures:
##STR00001##
[0016] wherein W.sup.1 is aryl or heteroaryl, independently
substituted by 1 or more halo, hydroxyl, nitro, CN, C.ident.CH,
C.sub.1-6 alkyl (linear, branched, optionally substituted by 1 or
more halo, C.sub.1-6alkoxyl), C.sub.1-6 alkoxyl (linear, branched,
optionally substituted by 1 or more halo), C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl; [0017] Y.sup.1, Y.sup.2 are each independently
NR.sup.Y1, O, S; [0018] Y.sup.3, Y.sup.4, Y.sup.5 are each
independently a bond, O, NR.sup.Y2, CR.sup.Y1R.sup.Y2, C.dbd.O,
C.dbd.S, SO, SO.sub.2; [0019] Q is a 3-6 membered alicyclic or
aromatic ring with 0-4 heteroatoms, optionally substituted with 0-6
R.sup.Q, each R.sup.Q, is independently H, C.sub.1-6 alkyl (linear,
branched, optionally substituted by 1 or more halo, C.sub.1-6
alkoxyl), or 2 R.sup.Q groups taken together with the atom they are
attached to, form a 3-8 membered ring system containing 0-2
heteroatoms); [0020] R.sup.1, R.sup.2, R.sup.a, R.sup.b, R.sup.Y1,
R.sup.Y2 are each independently H, C.sub.1-6 alkyl (linear,
branched, optionally substituted by 1 or more halo, C.sub.1-6
alkoxyl), or R.sup.1, R.sup.2 together with the atom they are
attached to, form a 3-8 membered ring system containing 0-2
heteroatoms); [0021] W.sup.2 is a bond, C.sub.1-6 alkyl, C.sub.1-6
alicyclic, heterocyclic, aryl, or heteroaryl, each optionally
substituted by 1, 2 or 3 R.sup.W2; and [0022] each R.sup.W2 is
independently H, halo, C.sub.1-6 alkyl (optionally substituted by 1
or more F), OC.sub.1-3alkyl (optionally substituted by 1 or more
--F), OH, NH.sub.2, NR.sup.Y1R.sup.Y2, CN.
[0023] In any of the aspects or embodiments described herein, the
ABM can comprise or consist of a structure as set forth herein, in
particular in any of the ABMs as provided in Examples 1-593.
[0024] In certain embodiments, the ULM (derivatized or configured
to be linked or coupled to an ABM via a linker (as indicated by the
dashed line)) has the structure,
##STR00002## [0025] wherein, W.sup.3 is optionally substituted
aryl, optionally substituted heteroaryl, or
[0025] ##STR00003## [0026] each R.sub.9 and R.sub.10 is
independently hydrogen, optionally substituted alkyl, optionally
substituted cycloalkyl, optionally substituted hydroxyalkyl,
optionally substituted heteroaryl, or haloalkyl; or R.sub.9,
R.sub.10, and the carbon atom to which they are attached form an
optionally substituted cycloalkyl; [0027] R.sub.11 is optionally
substituted heterocyclic, optionally substituted alkoxy, optionally
substituted heteroaryl, optionally substituted aryl,
[0027] ##STR00004## [0028] R.sub.12 is H or optionally substituted
alkyl; [0029] R.sub.13 is H, optionally substituted alkyl,
optionally substituted alkylcarbonyl, optionally substituted
(cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl,
optionally substituted arylcarbonyl, optionally substituted
(heterocyclyl)carbonyl, or optionally substituted aralkyl; [0030]
R.sub.14a, R.sub.14b, is each independently H, haloalkyl, or
optionally substituted alkyl; [0031] W.sup.5 is a phenyl or a 5-10
membered heteroaryl, [0032] R.sub.15 is H, halogen, CN, OH,
NO.sub.2, NR.sub.14aR.sub.14b, OR.sub.14a, CONR.sub.14aR.sub.14b,
NR.sub.14a COR.sub.14b, SO.sub.2NR.sub.14aR.sub.14b,
NR.sub.14aSO.sub.2R.sub.14b, optionally substituted alkyl,
optionally substituted haloalkyl, optionally substituted
haloalkoxy; aryl, heteroaryl, cycloalkyl, cycloheteroalkyl each
R.sub.16 is independently halo, optionally substituted alkyl,
optionally substituted haloalkyl, hydroxy, or optionally
substituted haloalkoxy; or
[0032] ##STR00005## wherein R.sub.17 is H, halo, optionally
substituted C.sub.3-6cycloalkyl, optionally substituted
C.sub.1-6alkyl, optionally substituted C.sub.1-6alkenyl, and
C.sub.1-6haloalkyl, and Xa is S or O; [0033] o is 0, 1, 2, 3, or 4;
[0034] each R.sub.18 is independently halo, optionally substituted
alkoxy, cyano, optionally substituted alkyl, haloalkyl, haloalkoxy
or a linker; and [0035] p is 0, 1, 2, 3, or 4.
[0036] In another embodiments, the ULM has the structure
##STR00006##
[0037] wherein [0038] R.sub.9 is H; [0039] R.sub.10 is isopropyl,
tert-butyl, sec-butyl, cyclopentyl, or cyclohexyl; [0040] R.sub.11
is
[0040] ##STR00007## [0041] R.sub.12 is H; [0042] R.sub.13 is H,
optionally substituted alkyl, optionally substituted alkylcarbonyl,
optionally substituted (cycloalkyl)alkylcarbonyl, optionally
substituted aralkylcarbonyl, optionally substituted arylcarbonyl,
optionally substituted (heterocyclyl)carbonyl, or optionally
substituted aralkyl; [0043] R.sub.14a is H, haloalkyl, or
optionally substituted methyl, ethyl, isopropyl, cyclopropyl, or
other alkyl; and [0044] R.sub.15 is
[0044] ##STR00008## wherein R.sub.17 is H, halo, optionally
substituted C.sub.3-6cycloalkyl, optionally substituted
C.sub.1-6alkyl, optionally substituted C.sub.1-6alkenyl, and
C.sub.1-6haloalkyl; and Xa is S or O.
[0045] In certain embodiments, an androgen receptor binding moiety
has a structure of
##STR00009## [0046] wherein W.sup.1 is aryl or heteroaryl,
independently substituted by 1 or more halo, hydroxyl, nitro, CN,
C.ident.CH, C.sub.1-6 alkyl (linear, branched, optionally
substituted by 1 or more halo, C.sub.1-6 alkoxyl), C.sub.1-6
alkoxyl (linear, branched, optionally substituted by 1 or more
halo), C.sub.2-6 alkenyl, C.sub.2-6 alkynyl; [0047] Y.sup.1,
Y.sup.2 are each independently NR.sup.Y1, O, S; [0048] Y.sup.3,
Y.sup.4, Y.sup.5 are each independently a bond, O, NR.sup.Y2,
CR.sup.Y1R.sup.Y2, C.dbd.O, C.dbd.S, SO, SO.sub.2; [0049] Q is a
3-6 membered alicyclic or aromatic ring with 0-4 heteroatoms,
optionally substituted with 0-6 R.sup.Q, each R.sup.Q, is
independently H, C.sub.1-6 alkyl (linear, branched, optionally
substituted by 1 or more halo, C.sub.1-6 alkoxyl), or 2 R.sup.Q
groups taken together with the atom they are attached to, form a
3-8 membered ring system containing 0-2 heteroatoms); [0050]
R.sup.1, R.sup.2, R.sup.a, R.sup.b, R.sup.Y1, R.sup.Y2 are each
independently H, C.sub.1-6 alkyl (linear, branched, optionally
substituted by 1 or more halo, C.sub.1-6 alkoxyl), or R.sup.1,
R.sup.2 together with the atom they are attached to, form a 3-8
membered ring system containing 0-2 heteroatoms); [0051] W.sup.2 is
a bond, C.sub.1-6 alkyl, C.sub.1-6 alicyclic, heterocyclic, aryl,
or heteroaryl, each optionally substituted by 1, 2 or 3 R.sup.W2;
and [0052] each R.sup.W2 is independently H, halo, C.sub.1-6 alkyl
(optionally substituted by 1 or more F), OC.sub.1-3alkyl
(optionally substituted by 1 or more --F), OH, NH.sub.2,
NR.sup.Y1R.sup.Y2, CN.
[0053] In certain additional embodiments, the compounds comprise a
plurality of E3 ligase binding moieties and/or a plurality of
ABMs.
[0054] In certain embodiments, the linker group (L) comprises a
chemical structural unit represented by the formula:
-A.sub.q- [0055] wherein [0056] q is an integer greater than 1; and
[0057] A is independently selected from the group consisting of a
bond, CR.sup.L1R.sup.L2, O, S, SO, SO.sub.2, NR.sup.L3,
SO.sub.2NR.sup.L3, SONR.sup.L3, CONR.sup.L3, NR.sup.L3 CONR.sup.L4,
NR.sup.L3SO.sub.2NR.sup.L4, CO, CR.sup.L1.dbd.CR.sup.L2, C.ident.C,
SiR.sup.L1R.sup.L2, P(O)R.sup.L1, P(O)OR.sup.L1,
NR.sup.L3C(.dbd.NCN)NR.sup.L4, NR.sup.L3C(.dbd.NCN),
NR.sup.L3C(.dbd.CNO.sub.2)NR.sup.L4, C.sub.3-11cycloalkyl
optionally substituted with 0-6 R.sup.L1 and/or R.sup.L2 groups,
C.sub.3-11 heterocyclyl optionally substituted with 0-6 R.sup.L1
and/or R.sup.L2 groups, aryl optionally substituted with 0-6
R.sup.L1 and/or R.sup.L2 groups, heteroaryl optionally substituted
with 0-6 R.sup.L1 and/or R.sup.L2 groups; [0058] wherein R.sup.L1,
R.sup.L2, R.sup.L3, R.sup.L4 and R.sup.L5 are each, independently,
selected from the group consisting of H, halo, C.sub.1-8alkyl,
OC.sub.1-8alkyl, SC.sub.1-8alkyl, NHC.sub.1-8alkyl,
N(C.sub.1-8alkyl).sub.2, C.sub.3-11cycloalkyl, aryl, heteroaryl,
C.sub.3-11 heterocyclyl, OC.sub.1-8cycloalkyl,
SC.sub.1-8cycloalkyl, NHC.sub.1-8cycloalkyl,
N(C.sub.1-8cycloalkyl).sub.2,
N(C.sub.1-8cycloalkyl)(C.sub.1-8alkyl), OH, NH.sub.2, SH,
SO.sub.2C.sub.1-8alkyl, P(O)(OC.sub.1-8alkyl)(C.sub.1-8alkyl),
P(O)(OC.sub.1-8alkyl).sub.2, CC--C.sub.1-8alkyl, CCH,
CH.dbd.CH(C.sub.1-8alkyl),
C(C.sub.1-8alkyl).dbd.CH(C.sub.1-8alkyl),
C(C.sub.1-8alkyl).dbd.C(C.sub.1-8alkyl).sub.2, Si(OH).sub.3,
Si(C.sub.1-8alkyl).sub.3, Si(OH)(C.sub.1-8alkyl).sub.2,
COC.sub.1-8alkyl, CO.sub.2H, halogen, CN, CF.sub.3, CHF.sub.2,
CH.sub.2F, NO.sub.2, SF.sub.5, SO.sub.2NHC.sub.1-8alkyl,
SO.sub.2N(C.sub.1-8alkyl).sub.2, SONHC.sub.1-8alkyl,
SON(C.sub.1-8alkyl).sub.2, CONHC.sub.1-8alkyl,
CON(C.sub.1-8alkyl).sub.2, N(C.sub.1-8alkyl)CONH(C.sub.1-8alkyl),
N(C.sub.1-8alkyl)CON(C.sub.1-8alkyl).sub.2, NHCONH(C.sub.1-8alkyl),
NHCON(C.sub.1-8alkyl).sub.2, NHCONH.sub.2,
N(C.sub.1-8alkyl)SO.sub.2NH(C.sub.1-8alkyl), N(C.sub.1-8alkyl)
SO.sub.2N(C.sub.1-8alkyl).sub.2, NH SO.sub.2NH(C.sub.1-8alkyl),
NHSO.sub.2N(C.sub.1-8alkyl).sub.2, and NHSO.sub.2NH.sub.2; and
[0059] wherein when q is greater than 1, R.sup.L1 or R.sup.L2 each,
independently, can be linked to another A group to form cycloalkyl
and/or heterocyclyl moeity that can be further substituted with 0-4
R.sup.L5 groups.
[0060] In certain embodiments, the description provides a
bifunctional compound having a structure selected from the group
consisting of Examples 1-593, a salt, a polymorph, and a prodrug
thereof.
[0061] In another aspect, the description provides compositions
comprising compounds as described herein, and a pharmaceutically
acceptable carrier. In certain embodiments, the compositions are
therapeutic or pharmaceutical compositions comprising an effective
amount of a compound as described herein and a pharmaceutically
acceptable carrier. In certain embodiments, the therapeutic or
pharmaceutical compositions comprise an additional biologically
active agent, e.g., an agent effective for the treatment of
cancer.
[0062] In any of the aspects or embodiments described herein, the
therapeutic compositions comprising compounds described herein can
be in any suitable dosage form, e.g., solid, or liquid, and
configured to be delivered by any suitable route, e.g., oral,
parenteral, intravenous, intraperitoneal, subcutaneous,
intramuscular, etc., and in any desired unit dosage form. For
example, in certain embodiments, the therapeutic composition as
described herein is configured to be administered or consumed by a
subject one or more times over a described time period, e.g., day,
week, month, etc.
[0063] In another aspect, the disclosure provides methods of
modulating protein ubiquitination and degradation in a subject,
e.g., a cell, a tissue, mammal, or human patient, the method
comprising administering an effective amount of a compound as
described herein or a composition comprising an effective amount of
the same to a subject, wherein the compound or composition
comprising the same is effective in modulating protein
ubiquitination and degradation of the protein in the subject. In
certain embodiments, the protein is androgen receptor (AR).
[0064] In another aspect, the disclosure provides methods of
modulating AR protein ubiquitination and degradation in a subject,
e.g., a cell, a tissue, mammal, or human patient, the method
comprising administering an effective amount of a compound as
described herein or a composition comprising an effective amount of
the same to a subject, wherein the compound or composition
comprising the same is effective in modulating AR protein
ubiquitination and degradation of the protein in the subject.
[0065] In another aspect, the disclosure provides methods of
treating or ameliorating a symptom of a disease related to AR
activity in a subject, e.g., a cell, a tissue, mammal, or human
patient, the method comprising administering an effective amount of
a compound as described herein or a composition comprising an
effective amount of the same to a subject in need thereof, wherein
the compound or composition comprising the same is effective in
treating or ameliorating a symptom of a disease related to AR
activity in the subject. In certain embodiments, the disease to be
treated is cancer, e.g., prostate cancer, or Kennedy's Disease. In
a preferred embodiment, the subject is a human.
[0066] In another aspect, the disclosure provides methods for
identifying the effects of the degradation of proteins of interest
in a biological system using compounds according to the present
invention.
[0067] In another aspect, the description provides kits comprising
compounds or compositions as described herein. The kit may be
promoted, distributed, or sold as a unit for performing the methods
of the present invention. In addition, the kits of the present
invention may preferably contain instructions which describe a
suitable use. Such kits can be conveniently used, e.g., in clinical
settings, to treat patients exhibiting symptoms of, e.g., cancer or
Kennedy's Disease.
[0068] Where applicable or not specifically disclaimed, any one of
the embodiments described herein are contemplated to be able to
combine with any other one or more embodiments, even though the
embodiments are described under different aspects of the invention.
As such, the preceding general areas of utility are given by way of
example only and are not intended to be limiting on the scope of
the present disclosure and appended claims. Additional objects and
advantages associated with the compositions, methods, and processes
of the present invention will be appreciated by one of ordinary
skill in the art in light of the instant claims, description, and
examples. For example, the various aspects and embodiments of the
invention may be utilized in numerous combinations, all of which
are expressly contemplated by the present description. These
additional advantages objects and embodiments are expressly
included within the scope of the present invention. The
publications and other materials used herein to illuminate the
background of the invention, and in particular cases, to provide
additional details respecting the practice, are incorporated by
reference.
BRIEF DESCRIPTION OF THE DRAWINGS
[0069] The accompanying drawings, which are incorporated into and
form a part of the specification, illustrate several embodiments of
the present invention and, together with the description, serve to
explain the principles of the invention. The drawings are only for
the purpose of illustrating an embodiment of the invention and are
not to be construed as limiting the invention. Further objects,
features and advantages of the invention will become apparent from
the following detailed description taken in conjunction with the
accompanying figures showing illustrative embodiments of the
invention, in which:
[0070] FIG. 1A and FIG. 1B. Illustration of general principle for
PROTAC function. FIG. 1A: Exemplary PROTACs comprise an androgen
receptor targeting moiety (ABM; darkly shaded rectangle), a Von
Hippel-Lindau (VHL) E3 ubiquitin ligase binding moiety (VLM;
lightly shaded triangle), and a linker moiety (L; black line)
coupling or tethering the ABM to the VLM (as described herein, L
can be absent or a bond or a chemical linker moiety). FIG. 1B
Illustrates the functional use of the PROTACs as described herein.
Briefly, the VLM recognizes and binds to Von Hippel-Lindau (VHL) E3
ubiquitin ligase, and the ABM binds and recruits androgen receptor
and brings it into close proximity to the Von Hippel-Lindau (VHL)
E3 ubiquitin ligase. Typically, the E3 ubiquitin ligase is
complexed with an E2 ubiquitin-conjugating protein, and either
alone or via the E2 protein catalyzes attachment of ubiquitin (dark
circles) to a lysine on the target protein via an isopeptide bond.
The poly-ubiquitinated protein (far right) is then targeted for
degradation by the proteosomal machinery of the cell.
[0071] FIG. 2. Apoptosis in VCaP cells. VCaP cells were cultured in
Charcoal Stripped Serum containing media supplemented with 0.1 nM
R1881 for 48 hrs. The degree of apoptosis was ascertained with
CaspaseGlo assay (Promega). These results demonstrated that PROTACs
are much more potent in inducing apoptosis than an AR antagonist
enzalutamide. Further, the degree of AR degradation correlates with
their ability to induce apoptosis in VCaP cells.
[0072] FIG. 3. Anti-proliferation in LNCaP F876L.
Anti-proliferation in LNCaP F876L cells observed with treatment
with Example 1 as compared to enzalutamide. LNCaP cells transduced
with AR F876L construct were cultured in Charcoal Stripped Serum
containing media.
[0073] FIG. 4. PSA suppression in LNCaP F876L. LNCaP cells
transduced with AR F876L construct were cultured in Charcoal
Stripped Serum containing media supplemented with 0.1 nM R1881 for
7 days. The results demonstrated that AR PROTAC is able to suppress
the transcriptional activity of AR in F876L containing cells.
[0074] FIG. 5. Prostate involution in C57B6 mouse model. 12-week
old male C57BL/6 mice were treated with AR PROTAC Example 163 and
its inactive epimer analog Compound A which is unable to bind to
VHL E3 ligase. Enzalutamide (PO, QD, 30 mpk), Example 163 (IP, QD,
1 and 3 mpk) and Compound A (IP, QD, 1 and 3 mpk) were administered
for 10 days, upon which the prostates were isolated and weighed.
These results demonstrated that the ability of PROTAC Example 163
to degrade AR leads to significant prostate involution in mice at
very low doses.
[0075] FIG. 6. Tumor growth inhibition in VCaP xenograft model.
VCaP cells were implanted into CB 17 scid mice subcutaneously. Once
the tumors were palpable, the mice were castrated, leading to
temporary tumor stasis. Upon regrowth of tumors, the mice were
dosed with enzalutamide (PO, QD, 30 mpk) or AR PROTAC Example 163
(IP, QD, at 30, 10 and 3 mpk) as indicated. Tumor growth inhibition
was observed in all treatment arms.
[0076] FIG. 7A and FIG. 7B. AR degradation of PROTAC is E3 ligase
dependent. FIG. 7A: AR PROTAC Example 1 was added to LNCaP cells at
indicated concentrations for 24 hours in the presence or absence of
10 uM VHL E3 ligase ligand compound B. FIG. 7B: LNCaP cells were
treated with AR PROTAC Example 1 and its inactive epimer analog
compound C which is unable to bind to VHL E3 ligase."
DETAILED DESCRIPTION
[0077] The following is a detailed description provided to aid
those skilled in the art in practicing the present invention. Those
of ordinary skill in the art may make modifications and variations
in the embodiments described herein without departing from the
spirit or scope of the present disclosure. All publications, patent
applications, patents, figures and other references mentioned
herein are expressly incorporated by reference in their
entirety.
[0078] The present description relates to the surprising and
unexpected discovery that an E3 ubiquitin ligase protein can
ubiquitinate a target protein, in particular androgen receptor,
once the E3 ubiquitin ligase protein and the target protein are
brought into proximity by a chimeric construct (e.g., PROTAC) as
described herein, in which a moiety that binds the E3 ubiquitin
ligase protein is coupled, e.g., covalently, to a moiety that bind
the androgen receptor target protein. Accordingly, the present
description provides compounds, compositions comprising the same,
and associated methods of use for ubiquitination and degradation of
a chosen target protein, e.g., androgen receptor (See FIG. 1A and
FIG. 1B).
[0079] The present description is related in certain aspects to
U.S. Patent Publication 2014/0356322A1, which is incorporated
herein by reference in its entirety for all purposes.
[0080] Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention belongs. The
terminology used in the description is for describing particular
embodiments only and is not intended to be limiting of the
invention.
[0081] Where a range of values is provided, it is understood that
each intervening value, to the tenth of the unit of the lower limit
unless the context clearly dictates otherwise (such as in the case
of a group containing a number of carbon atoms in which case each
carbon atom number falling within the range is provided), between
the upper and lower limit of that range and any other stated or
intervening value in that stated range is encompassed within the
invention. The upper and lower limits of these smaller ranges may
independently be included in the smaller ranges is also encompassed
within the invention, subject to any specifically excluded limit in
the stated range. Where the stated range includes one or both of
the limits, ranges excluding either both of those included limits
are also included in the invention.
[0082] The following terms are used to describe the present
invention. In instances where a term is not specifically defined
herein, that term is given an art-recognized meaning by those of
ordinary skill applying that term in context to its use in
describing the present invention.
[0083] The articles "a" and "an" as used herein and in the appended
claims are used herein to refer to one or to more than one (i.e.,
to at least one) of the grammatical object of the article unless
the context clearly indicates otherwise. By way of example, "an
element" means one element or more than one element.
[0084] The phrase "and/or," as used herein in the specification and
in the claims, should be understood to mean "either or both" of the
elements so conjoined, i.e., elements that are conjunctively
present in some cases and disjunctively present in other cases.
Multiple elements listed with "and/or" should be construed in the
same fashion, i.e., "one or more" of the elements so conjoined.
Other elements may optionally be present other than the elements
specifically identified by the "and/or" clause, whether related or
unrelated to those elements specifically identified. Thus, as a
non-limiting example, a reference to "A and/or B", when used in
conjunction with open-ended language such as "comprising" can
refer, in one embodiment, to A only (optionally including elements
other than B); in another embodiment, to B only (optionally
including elements other than A); in yet another embodiment, to
both A and B (optionally including other elements); etc.
[0085] As used herein in the specification and in the claims, "or"
should be understood to have the same meaning as "and/or" as
defined above. For example, when separating items in a list, "or"
or "and/or" shall be interpreted as being inclusive, i.e., the
inclusion of at least one, but also including more than one, of a
number or list of elements, and, optionally, additional unlisted
items. Only terms clearly indicated to the contrary, such as "only
one of" or "exactly one of," or, when used in the claims,
"consisting of," will refer to the inclusion of exactly one element
of a number or list of elements. In general, the term "or" as used
herein shall only be interpreted as indicating exclusive
alternatives (i.e., "one or the other but not both") when preceded
by terms of exclusivity, such as "either," "one of," "only one of,"
or "exactly one of."
[0086] The term "about" and the like, as used herein, in
association with numeric values or ranges, reflects the fact that
there is a certain level of variation that is recognized and
tolerated in the art due to practical and/or theoretical
limitations. For example, minor variation is tolerated due to
inherent variances in the manner in which certain devices operate
and/or measurements are taken. In accordance with the above, the
phrase "about" is normally used to encompass values within the
standard deviation or standard error.
[0087] In the claims, as well as in the specification above, all
transitional phrases such as "comprising," "including," "carrying,"
"having," "containing," "involving," "holding," "composed of," and
the like are to be understood to be open-ended, i.e., to mean
including but not limited to. Only the transitional phrases
"consisting of" and "consisting essentially of" shall be closed or
semi-closed transitional phrases, respectively, as set forth in the
United States Patent Office Manual of Patent Examining Procedures,
Section 2111.03.
[0088] As used herein in the specification and in the claims, the
phrase "at least one," in reference to a list of one or more
elements, should be understood to mean at least one element
selected from anyone or more of the elements in the list of
elements, but not necessarily including at least one of each and
every element specifically listed within the list of elements and
not excluding any combinations of elements in the list of elements.
This definition also allows that elements may optionally be present
other than the elements specifically identified within the list of
elements to which the phrase "at least one" refers, whether related
or unrelated to those elements specifically identified. Thus, as a
nonlimiting example, "at least one of A and B" (or, equivalently,
"at least one of A or B," or, equivalently "at least one of A
and/or B") can refer, in one embodiment, to at least one,
optionally including more than one, A, with no B present (and
optionally including elements other than B); in another embodiment,
to at least one, optionally including more than one, B, with no A
present (and optionally including elements other than A); in yet
another embodiment, to at least one, optionally including more than
one, A, and at least one, optionally including more than one, B
(and optionally including other elements); etc.
[0089] It should also be understood that, in certain methods
described herein that include more than one step or act, the order
of the steps or acts of the method is not necessarily limited to
the order in which the steps or acts of the method are recited
unless the context indicates otherwise.
[0090] The terms "co-administration" and "co-administering" or
"combination therapy" can refer to both concurrent administration
(administration of two or more therapeutic agents at the same time)
and time varied administration (administration of one or more
therapeutic agents at a time different from that of the
administration of an additional therapeutic agent or agents), as
long as the therapeutic agents are present in the patient to some
extent, preferably at effective amounts, at the same time. In
certain preferred aspects, one or more of the present compounds
described herein, are coadministered in combination with at least
one additional bioactive agent, especially including an anticancer
agent. In particularly preferred aspects, the co-administration of
compounds results in synergistic activity and/or therapy, including
anticancer activity.
[0091] The term "effective" can mean, but is in no way limited to,
that amount/dose of the active pharmaceutical ingredient, which,
when used in the context of its intended use, effectuates or is
sufficient to prevent, inhibit the occurrence, ameliorate, delay or
treat (alleviate a symptom to some extent, preferably all) the
symptoms of a condition, disorder or disease state in a subject in
need of such treatment or receiving such treatment. The term
effective subsumes all other effective amount or effective
concentration terms, e.g., "effective amount/dose,"
"pharmaceutically effective amount/dose" or "therapeutically
effective amount/dose," which are otherwise described or used in
the present application.
[0092] The effective amount depends on the type and severity of
disease, the composition used, the route of administration, the
type of mammal being treated, the physical characteristics of the
specific mammal under consideration, concurrent medication, and
other factors which those skilled in the medical arts will
recognize. The exact amount can be ascertainable by one skilled in
the art using known techniques (see, e.g., Lieberman,
Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art,
Science and Technology of Pharmaceutical Compounding (1999);
Pickar, Dosage Calculations (1999); and Remington: The Science and
Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott,
Williams & Wilkins).
[0093] The term "pharmacological composition," "therapeutic
composition," "therapeutic formulation" or "pharmaceutically
acceptable formulation" can mean, but is in no way limited to, a
composition or formulation that allows for the effective
distribution of an agent provided by the invention, which is in a
form suitable for administration to the physical location most
suitable for their desired activity, e.g., systemic
administration.
[0094] The term "pharmaceutically acceptable" or "pharmacologically
acceptable" can mean, but is in no way limited to, entities and
compositions that do not produce an adverse, allergic or other
untoward reaction when administered to an animal, or a human, as
appropriate.
[0095] The term "pharmaceutically acceptable carrier" or
"pharmacologically acceptable carrier" can mean, but is in no way
limited to, any and all solvents, dispersion media, coatings,
antibacterial and antifungal agents, isotonic and absorption
delaying agents, and the like, compatible with pharmaceutical
administration. Suitable carriers are described in the most recent
edition of Remington's Pharmaceutical Sciences, a standard
reference text in the field, which is incorporated herein by
reference. Preferred examples of such carriers or diluents include,
but are not limited to, water, saline, finger's solutions, dextrose
solution, and 5% human serum albumin. Liposomes and non-aqueous
vehicles such as fixed oils may also be used. The use of such media
and agents for pharmaceutically active substances is well known in
the art. Except insofar as any conventional media or agent is
incompatible with the active compound, use thereof in the
compositions is contemplated. Supplementary active compounds can
also be incorporated into the compositions.
[0096] The term "systemic administration" refers to a route of
administration that is, e.g., enteral or parenteral, and results in
the systemic distribution of an agent leading to systemic
absorption or accumulation of drugs in the blood stream followed by
distribution throughout the entire body. Suitable forms, in part,
depend upon the use or the route of entry, for example oral,
transdermal, or by injection. Such forms should not prevent the
composition or formulation from reaching a target cell (i.e., a
cell to which the negatively charged polymer is desired to be
delivered to). For example, pharmacological compositions injected
into the blood stream should be soluble. Other factors are known in
the art, and include considerations such as toxicity and forms
which prevent the composition or formulation from exerting its
effect. Administration routes which lead to systemic absorption
include, without limitations: intravenous, subcutaneous,
intraperitoneal, inhalation, oral, intrapulmonary and
intramuscular. The rate of entry of a drug into the circulation has
been shown to be a function of molecular weight or size. The use of
a liposome or other drug carrier comprising the compounds of the
instant invention can potentially localize the drug, for example,
in certain tissue types, such as the tissues of the reticular
endothelial system (RES). A liposome formulation which can
facilitate the association of drug with the surface of cells, such
as, lymphocytes and macrophages is also useful.
[0097] The term "local administration" refers to a route of
administration in which the agent is delivered to a site that is
apposite or proximal, e.g., within about 10 cm, to the site of the
lesion or disease.
[0098] The term "compound", as used herein, unless otherwise
indicated, refers to any specific chemical compound disclosed
herein and includes tautomers, regioisomers, geometric isomers, and
where applicable, stereoisomers, including optical isomers
(enantiomers) and other stereoisomers (diastereomers) thereof, as
well as pharmaceutically acceptable salts and derivatives
(including prodrug forms) thereof where applicable, in context.
Within its use in context, the term compound generally refers to a
single compound, but also may include other compounds such as
stereoisomers, regioisomers and/or optical isomers (including
racemic mixtures) as well as specific enantiomers or
enantiomerically enriched mixtures of disclosed compounds. The term
also refers, in context to prodrug forms of compounds which have
been modified to facilitate the administration and delivery of
compounds to a site of activity. It is noted that in describing the
present compounds, numerous substituents and variables associated
with same, among others, are described.
[0099] It is understood by those of ordinary skill that molecules
which are described herein are stable compounds as generally
described hereunder. When the bond is shown, both a double bond and
single bond are represented within the context of the compound
shown.
[0100] As used herein, "derivatives" can mean compositions formed
from the native compounds either directly, by modification, or by
partial substitution. As used herein, "analogs" can mean
compositions that have a structure similar to, but not identical
to, the native compound.
[0101] The term "Ubiquitin Ligase" refers to a family of proteins
that facilitate the transfer of ubiquitin to a specific substrate
protein, targeting the substrate protein for degradation. By way of
example, Von Hippel-Lindau E3 Ubiquitin Ligase or VCB E3 Ubiquitin
Ligase is protein that alone or in combination with an E2
ubiquitin-conjugating enzyme causes the attachment of ubiquitin to
a lysine on a target protein, and subsequently targets the specific
protein substrates for degradation by the proteasome. Thus, E3
ubiquitin ligase alone or in complex with an E2 ubiquitin
conjugating enzyme is responsible for the transfer of ubiquitin to
targeted proteins. In general, the ubiquitin ligase is involved in
polyubiquitination such that a second ubiquitin is attached to the
first; a third is attached to the second, and so forth.
Polyubiquitination marks proteins for degradation by the
proteasome. However, there are some ubiquitination events that are
limited to mono-ubiquitination, in which only a single ubiquitin is
added by the ubiquitin ligase to a substrate molecule.
Mono-ubiquitinated proteins are not targeted to the proteasome for
degradation, but may instead be altered in their cellular location
or function, for example, via binding other proteins that have
domains capable of binding ubiquitin. Further complicating matters,
different lysines on ubiquitin can be targeted by an E3 to make
chains. The most common lysine is Lys48 on the ubiquitin chain.
This is the lysine used to make polyubiquitin, which is recognized
by the proteasome.
[0102] The term "subject" is used throughout the specification to
describe a cell, tissue, or animal, preferably a mammal, e.g., a
human or a domesticated animal, to whom treatment, including
prophylactic treatment, with the compositions according to the
present invention is provided. For treatment of those infections,
conditions or disease states which are specific for a specific
animal such as a human patient, the term patient refers to that
specific animal, including a domesticated animal such as a dog or
cat or a farm animal such as a horse, cow, sheep, etc. In general,
in the present invention, the term patient refers to a human
patient unless otherwise stated or implied from the context of the
use of the term.
[0103] Compounds
[0104] In one aspect, the present invention provides compounds
useful for regulating protein activity. The composition comprises a
ubiquitin pathway protein binding moiety (preferably for an E3
ubiquitin ligase, alone or in complex with an E2 ubiquitin
conjugating enzyme which is responsible for the transfer of
ubiquitin to targeted proteins) according to a defined chemical
structure and a protein targeting moiety which are linked or
coupled together, preferably through a linker, wherein the
ubiquitin pathway protein binding moiety recognizes an ubiquitin
pathway protein and the targeting moiety recognizes a target
protein (e.g., androgen receptor). Such compounds may be referred
to herein as PROTAC compounds or PROTACs.
[0105] In one aspect, the description provides AR binding moieties
(ABM). In certain embodiments, the compounds having the following
general structure: ABM-L, wherein ABM is an AR binding moiety as
described herein, and L is a chemical linker moiety, e.g., a linker
as described herein, or optionally a bond. In certain embodiments,
the ABM and/or L are coupled to a ULM as described herein
below.
[0106] In another aspect, the disclosure provides compounds which
function to recruit androgen receptor (AR) proteins to E3 Ubiquitin
Ligase for ubiquitination and degradation. In certain embodiments,
the compounds have the following general structure:
ABM-L-ULM (I),
[0107] wherein ULM is an E3 ligase binding moiety, ABM is an AR
binding moiety, which binds to an AR protein and L is a bond or a
chemical linker moiety which links the ABM and ULM.
[0108] In certain embodiments, the ULM is a moiety specific for an
E3 ubiquitin ligase such as, e.g., Von Hippel-Lindau E3 ubiquitin
ligase (VHL), cereblon, mouse double minute 2 homolog (Mdm2), or
inhibitor of apoptosis (IAP), wherein the ULM moiety is coupled to
an ABM as described herein.
[0109] Without being bound by any particular theory, it is
hypothesized that due at least in part to the proximity of AR and
the E3 ubiquitin ligase, the AR is ubiquitinated by the ubiquitin
ligase and degraded. In certain embodiments, the ABM is chemically
linked or coupled directly to the ULM group. In certain additional
embodiments, the ABM is chemically linked or coupled to the ULM via
a chemical linker moiety. In additional embodiments, the
description provides compounds having the following general
structure:
ABM-L-VLM (II),
[0110] wherein ABM is an AR binding moiety and VLM is a Von
Hippel-Lindau E3 Ubiquitin Ligase (VHL) binding moiety, and L is a
bond or a chemical linker moiety which links the ABM and VLM. The
ULM or VLM group and ABM group may be covalently linked to the
linker group through any covalent bond which is appropriate and
stable to the chemistry of the linker.
[0111] In certain embodiments, the ULM or VLM comprises a
hydroxyprolyl moiety. The hydroxyl prolyl moiety has been shown to
be important for binding and recruiting of the VHL protein.
[0112] It will be understood that the general structures are
exemplary and the respective moieties can be arranged in any
desired order or configuration, e.g., ULM-L-ABM, and VLM-L-ABM
respectively. In certain additional embodiments, the compounds
comprise a plurality of E3 ligase binding moieties and/or a
plurality of ABMs.
[0113] In certain embodiments, ABM alone, without forming
ABM-L-ULM, provides desired properties in regulating protein
activity.
[0114] In any of the aspects or embodiments of compounds described
herein, unless indicated otherwise, the compounds are intended to
encompass pharmaceutically acceptable salts, enantiomers,
stereoisomers, solvates or polymorphs thereof.
[0115] Exemplary ULMs
[0116] In certain embodiments of the compounds as described herein,
the ULM comprises a chemical structure selected from the group
ULM-a:
##STR00010##
[0117] where a dashed line indicates the attachment of at least one
ABM, another ULM or VLM (i.e., ULM' or VLM'), or a chemical linker
moiety coupling at least one ABM, a ULM' or VLM' to the other end
of the linker;
[0118] X.sup.1, X.sup.2 are each independently a bond, O,
NR.sup.Y3, CR.sup.Y3R.sup.Y4, C.dbd.O, C.dbd.S, SO, SO.sub.2;
[0119] R.sup.Y3, R.sup.Y4 are each independently H, C.sub.1-6 alkyl
(linear, branched, optionally substituted by 1 or more halo,
C.sub.1-6 alkoxyl);
[0120] optionally substituted by 1-3 R.sup.P groups in the
pyrrolidine moiety, wherein each R.sup.P is independently H, halo,
--OH, C.sub.1-3alkyl;
[0121] W.sup.3 is an optionally substituted -T-N(R.sup.1aR.sup.1b),
-T-Aryl, an optionally substituted -T-Heteroaryl, an optionally
substituted -T-Heterocycle, an optionally substituted
--NR.sup.1-T-Aryl, an optionally substituted
--NR.sup.1-T-Heteroaryl or an optionally substituted
--NR.sup.1-T-Heterocycle, where T is covalently bonded to
X.sup.1;
[0122] each R.sup.1, R.sup.1a, R.sup.1b is independently H, a
C.sub.1-C.sub.6 alkyl group (linear, branched, optionally
substituted by 1 or more halo, --OH), R.sup.Y3C.dbd.O,
R.sup.Y3C.dbd.S, R.sup.Y3SO, R.sup.Y3SO.sub.2,
N(R.sup.Y3R.sup.Y4)C.dbd.O, N(R.sup.Y3R.sup.Y4)C.dbd.S,
N(R.sup.Y3R.sup.Y4)SO, N(R.sup.Y3R.sup.Y4)SO.sub.2;
[0123] T is an optionally substituted --(CH.sub.2).sub.n-- group,
wherein each one of the methylene groups may be optionally
substituted with one or two substituents, preferably selected from
halogen, a C.sub.1-C.sub.6 alkyl group (linear, branched,
optionally substituted by 1 or more halogen, --OH) or the sidechain
of an amino acid as otherwise described herein, preferably methyl,
which may be optionally substituted; and n is 0 to 6, often 0, 1,
2, or 3, preferably 0.
[0124] Alternatively, T may also be a --(CH.sub.2O).sub.n-- group,
a --(OCH.sub.2).sub.n-- group, a --(CH.sub.2CH.sub.2O).sub.n--
group, a --(OCH.sub.2CH.sub.2).sub.n-- group, each of which groups
is optionally substituted; and
[0125] W.sup.4 is an optionally substituted --NR.sup.1-T-Aryl, an
optionally substituted --NR.sup.1-T-Heteroaryl group or an
optionally substituted --NR.sup.1-T-Heterocycle, where --NR.sup.1
is covalently bonded to X.sup.2; R.sup.1 is H or CH.sub.3,
preferably H, and T is an optionally substituted
--(CH.sub.2).sub.n-- group, wherein each one of the methylene
groups may be optionally substituted with one or two substituents,
preferably selected from halogen, an amino acid sidechain as
otherwise described herein or a C.sub.1-C.sub.6 alkyl group
(linear, branched, optionally substituted by 1 or more halo, --OH),
preferably one or two methyl groups, which may be optionally
substituted; and n is 0 to 6, often 0, 1, 2 or 3, preferably 0 or
1.
[0126] Alternatively, T may also be a --(CH.sub.2O).sub.n-- group,
a --(OCH.sub.2).sub.n-- group, a --(CH.sub.2CH.sub.2O).sub.n--
group, a --(OCH.sub.2CH.sub.2).sub.n-- group, all of which groups
are optionally substituted.
[0127] In any of the embodiments described herein, W.sup.3 and/or
W.sup.4 can be attached to a linker moiety as described herein.
[0128] In certain embodiments, aryl groups for W.sup.3 include
optionally substituted phenyl or naphthyl groups, preferably phenyl
groups, wherein the phenyl or naphthyl group is optionally
substituted with a linker group to which is attached a ABM group
(including a ULM' group) and/or a halogen (preferably F or Cl), an
amine, monoalkyl- or dialkyl amine (preferably, dimethylamine), an
amido group (preferably a --(CH.sub.2).sub.m--NR.sub.1C(O)R.sub.2
group where m, R.sub.1 and R.sub.2 are the same as for R.sup.1), a
halogen (often F or Cl), OH, CH.sub.3, CF.sub.3, OMe, OCF.sub.3,
NO.sub.2, CN or a S(O).sub.2R.sub.S group (R.sub.S is a
C.sub.1-C.sub.6 alkyl group, an optionally substituted aryl,
heteroaryl or heterocycle group or a
--(CH.sub.2).sub.mNR.sub.1R.sub.2 group), each of which may be
substituted in ortho-, meta- and/or para-positions of the phenyl
ring, preferably para-), or an Aryl (preferably phenyl), heteroaryl
or heterocycle. Preferably said substituent phenyl group is an
optionally substituted phenyl group (i.e., the substituent phenyl
group itself is preferably substituted with at least one of F, Cl,
OH, SH, COOH, CH.sub.3, CF.sub.3, OMe, OCF.sub.3, NO.sub.2, CN or a
linker group to which is attached a ABM group (including a ULM'
group), wherein the substitution occurs in ortho-, meta- and/or
para-positions of the phenyl ring, preferably para-), a naphthyl
group, which may be optionally substituted including as described
above, an optionally substituted heteroaryl (preferably an
optionally substituted isoxazole including a methylsubstituted
isoxazole, an optionally substituted oxazole including a
methylsubstituted oxazole, an optionally substituted thiazole
including a methyl substituted thiazole, an optionally substituted
pyrrole including a methylsubstituted pyrrole, an optionally
substituted imidazole including a methylimidazole, a
benzylimidazole or methoxybenzylimidazole, an oximidazole or
methyloximidazole, an optionally substituted diazole group,
including a methyldiazole group, an optionally substituted triazole
group, including a methylsubstituted triazole group, a pyridine
group, including a halo-(preferably, F) or methylsubstituted
pyridine group or an oxapyridine group (where the pyridine group is
linked to the phenyl group by an oxygen) or an optionally
substituted heterocycle (tetrahydrofuran, tetrahydrothiophene,
pyrrolidine, piperidine, morpholine, piperazine,
tetrahydroquinoline, oxane or thiane. Each of the aryl, heteroaryl
or heterocyclic groups may be optionally substituted with a linker
group to which is attached a ABM group (including a ULM'
group).
[0129] In certain embodiments, heteroaryl groups for W.sup.3
include an optionally substituted quinoline (which may be attached
to the pharmacophore or substituted on any carbon atom within the
quinoline ring), an optionally substituted indole (including
dihydroindole), an optionally substituted indolizine, an optionally
substituted azaindolizine (2, 3 or 4-azaindolizine) an optionally
substituted benzimidazole, benzodiazole, benzoxofuran, an
optionally substituted imidazole, an optionally substituted
isoxazole, an optionally substituted oxazole (preferably methyl
substituted), an optionally substituted diazole, an optionally
substituted triazole, a tetrazole, an optionally substituted
benzofuran, an optionally substituted thiophene, an optionally
substituted thiazole (preferably methyl and/or thiol substituted),
an optionally substituted isothiazole, an optionally substituted
triazole (preferably a 1,2,3-triazole substituted with a methyl
group, a triisopropylsilyl group, an optionally substituted
--(CH.sub.2).sub.m--O--C.sub.1-C.sub.6 alkyl group or an optionally
substituted --(CH.sub.2).sub.m--C(O)--O--C.sub.1-C.sub.6 alkyl
group), an optionally substituted pyridine (2-, 3, or 4-pyridine)
or a group according to the chemical structure:
##STR00011##
[0130] where S.sup.c is CHR.sup.SS, NR.sup.URE, or O;
[0131] R.sup.HET is H, CN, NO.sub.2, halo (preferably Cl or F),
optionally substituted C.sub.1-C.sub.6 alkyl (preferably
substituted with one or two hydroxyl groups or up to three halo
groups (e.g. CF.sub.3), optionally substituted O(C.sub.1-C.sub.6
alkyl) (preferably substituted with one or two hydroxyl groups or
up to three halo groups) or an optionally substituted acetylenic
group --C.ident.C--R.sub.a where R.sub.a is H or a C.sub.1-C.sub.6
alkyl group (preferably C.sub.1-C.sub.3 alkyl);
[0132] R.sup.SS is H, CN, NO.sub.2, halo (preferably F or Cl),
optionally substituted C.sub.1-C.sub.6 alkyl (preferably
substituted with one or two hydroxyl groups or up to three halo
groups), optionally substituted O--(C.sub.1-C.sub.6 alkyl)
(preferably substituted with one or two hydroxyl groups or up to
three halo groups) or an optionally substituted
--C(O)(C.sub.1-C.sub.6 alkyl) (preferably substituted with one or
two hydroxyl groups or up to three halo groups);
[0133] R.sup.URE is H, a C.sub.1-C.sub.6 alkyl (preferably H or
C.sub.1-C.sub.3 alkyl) or a --C(O)(C.sub.1-C.sub.6 alkyl), each of
which groups is optionally substituted with one or two hydroxyl
groups or up to three halogen, preferably fluorine groups, or an
optionally substituted heterocycle, for example piperidine,
morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene,
piperidine, piperazine, each of which is optionally substituted;
and
[0134] Y.sup.C is N or C--R.sup.Yc, where R.sup.YC is H, OH, CN,
NO.sub.2, halo (preferably Cl or F), optionally substituted
C.sub.1-C.sub.6 alkyl (preferably substituted with one or two
hydroxyl groups or up to three halo groups (e.g. CF.sub.3),
optionally substituted O(C.sub.1-C.sub.6 alkyl) (preferably
substituted with one or two hydroxyl groups or up to three halo
groups) or an optionally substituted acetylenic group
--C.ident.C--R.sub.a where R.sub.a is H or a C.sub.1-C.sub.6 alkyl
group (preferably C.sub.1-C.sub.3 alkyl). Each of said heteroaryl
groups may be optionally substituted with a linker group to which
is attached a ABM group (including a ULM' group).
[0135] In additional embodiments, heterocycle groups for W.sup.3
include tetrahydroquinoline, piperidine, piperazine, pyrrolidine,
morpholine, tetrahydrofuran, tetrahydrothiophene, oxane and thiane,
each of which groups may be optionally substituted or a group
according to the chemical structure:
##STR00012##
[0136] where R.sup.PRO is H, optionally substituted C.sub.1-C.sub.6
alkyl or an optionally substituted aryl (phenyl or napthyl),
heteroaryl or heterocyclic group selected from the group consisting
of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole,
oximidazole, pyrrole, pyrolidine, furan, dihydrofuran,
tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine,
piperidine, piperazine, morpholine, quinoline, (each preferably
substituted with a C.sub.1-C.sub.3 alkyl group, preferably methyl
or a halo group, preferably F or Cl), benzofuran, indole,
indolizine, azaindolizine;
[0137] R.sup.PRO1 and R.sup.PRO2 are each independently H, an
optionally substituted C.sub.1-C.sub.3 alkyl group or together form
a keto group, and
[0138] each n is 0, 1, 2, 3, 4, 5, or 6 (preferably 0 or 1),
wherein each of said Heterocycle groups may be optionally
substituted with a linker group to which is attached a ABM group
(including a ULM' group) or a pharmaceutically acceptable salt,
stereoisomer, solvate or polymorph thereof.
[0139] In certain embodiments, W.sup.3 substituents for use in the
present invention also include specifically (and without limitation
to the specific compound disclosed) the W.sup.3 substituents which
are found in the identified compounds disclosed herein (which
includes the specific compounds which are disclosed in the present
specification, and the figures which are attached hereto). Each of
these W.sup.3 substituents may be used in conjunction with any
number of W.sup.4 substituents, which are also disclosed
herein.
[0140] In certain embodiments, Aryl groups for W.sup.4 include
optionally substituted phenyl or naphthyl groups, preferably phenyl
groups, wherein the phenyl group is optionally substituted with a
linker group to which is attached an ABMABM group (including a ULM'
group), a halogen (preferably F or Cl), an amine, monoalkyl- or
dialkyl amine (preferably, dimethylamine), F, Cl, OH, COOH,
C.sub.1-C.sub.6 alkyl, preferably CH.sub.3, CF.sub.3, OMe,
OCF.sub.3, NO.sub.2, or CN group (each of which may be substituted
in ortho-, meta- and/or para-positions of the phenyl ring,
preferably para-), an optionally substituted phenyl group (the
phenyl group itself is preferably substituted with a linker group
attached to a ABM group, including a ULM' group), and/or at least
one of F, Cl, OH, COOH, CH.sub.3, CF.sub.3, OMe, OCF.sub.3,
NO.sub.2, or CN group (in ortho-, meta- and/or para-positions of
the phenyl ring, preferably para-), a naphthyl group, which may be
optionally substituted, an optionally substituted heteroaryl,
preferably an optionally substituted isoxazole including a
methylsubstituted isoxazole, an optionally substituted oxazole
including a methylsubstituted oxazole, an optionally substituted
thiazole including a methyl substituted thiazole, an optionally
substituted isothiazole including a methyl substituted isothiazole,
an optionally substituted pyrrole including a methylsubstituted
pyrrole, an optionally substituted imidazole including a
methylimidazole, an optionally substituted benzimidazole or
methoxybenzylimidazole, an optionally substituted oximidazole or
methyloximidazole, an optionally substituted diazole group,
including a methyldiazole group, an optionally substituted triazole
group, including a methylsubstituted triazole group, an optionally
substituted pyridine group, including a halo- (preferably, F) or
methylsubstituted pyridine group or an oxapyridine group (where the
pyridine group is linked to the phenyl group by an oxygen), an
optionally substituted furan, an optionally substituted benzofuran,
an optionally substituted dihydrobenzofuran, an optionally
substituted indole, indolizine or azaindolizine (2, 3, or
4-azaindolizine), an optionally substituted quinoline, an
optionally substituted group according to the chemical
structure:
##STR00013##
[0141] where S.sup.C is CHR.sup.SS, NR.sup.URE, or O;
[0142] R.sup.HET is H, CN, NO.sub.2, halo (preferably Cl or F),
optionally substituted C.sub.1-C.sub.6 alkyl (preferably
substituted with one or two hydroxyl groups or up to three halo
groups (e.g. CF.sub.3), optionally substituted O(C.sub.1-C.sub.6
alkyl) (preferably substituted with one or two hydroxyl groups or
up to three halo groups) or an optionally substituted acetylenic
group --C.ident.C--R.sub.a where R.sub.a is H or a C.sub.1-C.sub.6
alkyl group (preferably C.sub.1-C.sub.3 alkyl);
[0143] R.sup.SS is H, CN, NO.sub.2, halo (preferably F or Cl),
optionally substituted C.sub.1-C.sub.6 alkyl (preferably
substituted with one or two hydroxyl groups or up to three halo
groups), optionally substituted O--(C.sub.1-C.sub.6 alkyl)
(preferably substituted with one or two hydroxyl groups or up to
three halo groups) or an optionally substituted
--C(O)(C.sub.1-C.sub.6 alkyl) (preferably substituted with one or
two hydroxyl groups or up to three halo groups);
[0144] R.sup.URE is H, a C.sub.1-C.sub.6 alkyl (preferably H or
C.sub.1-C.sub.3 alkyl) or a --C(O)(C.sub.1-C.sub.6 alkyl) each of
which groups is optionally substituted with one or two hydroxyl
groups or up to three halogen, preferably fluorine groups, or an
optionally substituted phenyl group, an optionally substituted
heteroaryl, or an optionally substituted heterocycle, preferably
for example piperidine, morpholine, pyrrolidine,
tetrahydrofuran);
[0145] R.sup.PRO is H, optionally substituted C.sub.1-C.sub.6 alkyl
or an optionally substituted aryl (phenyl or napthyl), heteroaryl
or heterocyclic group selected from the group consisting of
oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole,
oximidazole, pyrrole, pyrolidine, furan, dihydrofuran,
tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine,
piperidine, piperazine, morpholine, quinoline, (each preferably
substituted with a C.sub.1-C.sub.3 alkyl group, preferably methyl
or a halo group, preferably F or Cl), benzofuran, indole,
indolizine, azaindolizine;
[0146] R.sup.PRO1 and R.sup.PRO2 are each independently H, an
optionally substituted C.sub.1-C.sub.3 alkyl group or together form
a keto group; and
[0147] each n is independently 0, 1, 2, 3, 4, 5, or 6 (preferably 0
or 1), or an optionally substituted heterocycle, preferably
tetrahydrofuran, tetrahydrothiene, piperidine, piperazine or
morpholine (each of which groups when substituted, are preferably
substituted with a methyl or halo (F, Br, Cl), each of which groups
may be optionally substituted with a linker group to which is
attached a ABM group (including a ULM' group).
[0148] In certain preferred aspects,
##STR00014##
is a
##STR00015##
[0149] where R.sup.PRO and n are the same as above.
[0150] In certain embodiments, heteroaryl groups for W.sup.4
include an optionally substituted quinoline (which may be attached
to the pharmacophore or substituted on any carbon atom within the
quinoline ring), an optionally substituted indole, an optionally
substituted indolizine, an optionally substituted azaindolizine, an
optionally substituted benzofuran, including an optionally
substituted benzofuran, an optionally substituted isoxazole, an
optionally substituted thiazole, an optionally substituted
isothiazole, an optionally substituted thiophene, an optionally
substituted pyridine (2-, 3, or 4-pyridine), an optionally
substituted imidazole, an optionally substituted pyrrole, an
optionally substituted diazole, an optionally substituted triazole,
a tetrazole, an optionally substituted oximidazole, or a group
according to the chemical structure:
##STR00016##
[0151] where S.sup.c is CHR.sup.SS, NR.sup.URE, or O;
[0152] R.sup.HET is H, CN, NO.sub.2, halo (preferably Cl or F),
optionally substituted C.sub.1-C.sub.6 alkyl (preferably
substituted with one or two hydroxyl groups or up to three halo
groups (e.g. CF.sub.3), optionally substituted O(C.sub.1-C.sub.6
alkyl) (preferably substituted with one or two hydroxyl groups or
up to three halo groups) or an optionally substituted acetylenic
group --C.ident.C--R.sub.a where R.sub.a is H or a C.sub.1-C.sub.6
alkyl group (preferably C.sub.1-C.sub.3 alkyl);
[0153] R.sup.SS is H, CN, NO.sub.2, halo (preferably F or Cl),
optionally substituted C.sub.1-C.sub.6 alkyl (preferably
substituted with one or two hydroxyl groups or up to three halo
groups), optionally substituted O--(C.sub.1-C.sub.6 alkyl)
(preferably substituted with one or two hydroxyl groups or up to
three halo groups) or an optionally substituted
--C(O)(C.sub.1-C.sub.6 alkyl) (preferably substituted with one or
two hydroxyl groups or up to three halo groups);
[0154] R.sup.URE is H, a C.sub.1-C.sub.6 alkyl (preferably H or
C.sub.1-C.sub.3 alkyl) or a --C(O)(C.sub.1-C.sub.6 alkyl), each of
which groups is optionally substituted with one or two hydroxyl
groups or up to three halogen, preferably fluorine groups, or an
optionally substituted heterocycle, for example piperidine,
morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene,
piperidine, piperazine, each of which is optionally substituted,
and
[0155] Y.sup.C is N or C--R.sup.YC, where R.sup.YC is H, OH, CN,
NO.sub.2, halo (preferably Cl or F), optionally substituted
C.sub.1-C.sub.6 alkyl (preferably substituted with one or two
hydroxyl groups or up to three halo groups (e.g. CF.sub.3),
optionally substituted O(C.sub.1-C.sub.6 alkyl) (preferably
substituted with one or two hydroxyl groups or up to three halo
groups) or an optionally substituted acetylenic group
--C.ident.C--R.sub.a where R.sub.a is H or a C.sub.1-C.sub.6 alkyl
group (preferably C.sub.1-C.sub.3 alkyl), each of which groups may
be optionally substituted with a linker group to which is attached
a ABM group (including a ULM' group).
[0156] In certain embodiments, heterocycle groups for W.sup.4
include tetrahydrofuran, tetrahydrothiene, tetrahydroquinoline,
piperidine, piperazine, pyrrolidine, morpholine, oxane or thiane,
each of which groups may be optionally substituted, or a group
according to the chemical structure:
##STR00017##
preferably, a
##STR00018##
[0157] where R.sup.PRO is H, optionally substituted C.sub.1-C.sub.6
alkyl or an optionally substituted aryl, heteroaryl or heterocyclic
group;
[0158] R.sup.PRO1 and R.sup.PRO2 are each independently H, an
optionally substituted C.sub.1-C.sub.3 alkyl group or together form
a keto group and
[0159] each n is independently 0, 1, 2, 3, 4, 5, or 6 (often 0 or
1), each of which groups may be optionally substituted with a
linker group to which is attached a ABM group (including a ULM'
group) In additional embodiments, W.sup.4 substituents for use in
the present invention also include specifically (and without
limitation to the specific compound disclosed) the W.sup.4
substituents which are found in the identified compounds disclosed
herein (which includes the specific compounds which are disclosed
in the present specification, and the figures which are attached
hereto). Each of these W.sup.4 substituents may be used in
conjunction with any number of W.sup.3 substituents which are also
disclosed herein.
[0160] In certain additional embodiments, ULM-a, is optionally
substituted by 1-3 R.sup.P groups in the pyrrolidine moiety. Each
R.sup.P is independently H, halo, --OH, C.sub.1-3alkyl.
[0161] In any of the embodiments described herein, the W.sup.3,
W.sup.4 can independently be covalently coupled to a linker which
is attached one or more ABM groups.
[0162] In certain embodiments, ULM is a group (derivatized or
configured to be linked or coupled to an ABM via a linker (as
indicated by the dashed line) according to the chemical
structure:
##STR00019##
[0163] wherein, W.sup.3 is optionally substituted aryl, optionally
substituted heteroaryl, or
##STR00020##
[0164] each R.sub.9 and R.sub.10 is independently hydrogen,
optionally substituted alkyl, optionally substituted cycloalkyl,
optionally substituted hydroxyalkyl, optionally substituted
heteroaryl, or haloalkyl; or R.sub.9, R.sub.10, and the carbon atom
to which they are attached form an optionally substituted
cycloalkyl;
[0165] R.sub.11 is optionally substituted heterocyclic, optionally
substituted alkoxy, optionally substituted heteroaryl, optionally
substituted aryl,
##STR00021##
[0166] R.sub.12 is H or optionally substituted alkyl;
[0167] R.sub.13 is H, optionally substituted alkyl, optionally
substituted alkylcarbonyl, optionally substituted
(cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl,
optionally substituted arylcarbonyl, optionally substituted
(heterocyclyl)carbonyl, or optionally substituted aralkyl;
[0168] R.sub.14a, R.sub.14b, is each independently H, haloalkyl, or
optionally substituted alkyl;
[0169] W.sup.5 is a phenyl or a 5-10 membered heteroaryl,
[0170] R.sub.15 is H, halogen, CN, OH, NO.sub.2,
NR.sub.14aR.sub.14b, OR.sub.14a, CONR.sub.14aR.sub.14b, NR.sub.14a
COR.sub.14b, SO.sub.2NR.sub.14aR.sub.14b,
NR.sub.14aSO.sub.2R.sub.14b, optionally substituted alkyl,
optionally substituted haloalkyl, optionally substituted
haloalkoxy; aryl, heteroaryl, cycloalkyl, cycloheteroalkyl each
R.sub.16 is independently halo, optionally substituted alkyl,
optionally substituted haloalkyl, hydroxy, or optionally
substituted haloalkoxy;
[0171] o is 0, 1, 2, 3, or 4;
[0172] each R.sub.18 is independently halo, optionally substituted
alkoxy, cyano, optionally substituted alkyl, haloalkyl, haloalkoxy
or a linker; and
[0173] p is 0, 1, 2, 3, or 4.
[0174] In certain embodiments, R.sub.15 is
##STR00022##
wherein R.sub.17 is H, halo, optionally substituted
C.sub.3-6cycloalkyl, optionally substituted C.sub.1-6alkyl,
optionally substituted C.sub.1-6alkenyl, and C.sub.1-6haloalkyl;
and
[0175] Xa is S or O.
[0176] In certain embodiments, R.sub.17 is selected from the group
methyl, ethyl, isopropyl, and cyclopropyl.
[0177] In certain additional embodiments, R.sub.15 is selected from
the group consisting of:
##STR00023##
[0178] In certain embodiments, R.sub.11 is selected from the group
consisting of:
##STR00024## ##STR00025##
[0179] In certain embodiments, the ULM (derivatized or configured
to be linked or coupled to an ABM via a linker (as indicated by the
dashed line)) has the structure:
##STR00026##
[0180] wherein
[0181] R.sub.9 is H;
[0182] R.sub.10 is isopropyl, tert-butyl, sec-butyl, cyclopentyl,
or cyclohexyl;
[0183] R.sub.11 is
##STR00027##
[0184] R.sub.12 is H;
[0185] R.sub.13 is H, optionally substituted alkyl, optionally
substituted alkylcarbonyl, optionally substituted
(cycloalkyl)alkylcarbonyl, optionally substituted aralkylcarbonyl,
optionally substituted arylcarbonyl, optionally substituted
(heterocyclyl)carbonyl, or optionally substituted aralkyl;
[0186] R14a is H, haloalkyl, or optionally substituted methyl,
ethyl, isopropyl, cyclopropyl, or other alkyl; and
[0187] R15 is
##STR00028##
wherein R17 is H, halo, optionally substituted C3-6 cycloalkyl,
optionally substituted C1-6 alkyl, optionally substituted
C1-6alkenyl, and C1-6haloalkyl; and Xa is S or O.
[0188] In certain embodiments, the ULM or VLM is selected from the
group consisting of:
##STR00029## ##STR00030## ##STR00031##
attached to the linker moiety at the position indicated.
[0189] Exemplary Linkers
[0190] In certain embodiments, the compounds as described herein
include one or more ABM chemically linked or coupled to one or more
ULMs or VLMs via a chemical linker (L). In certain embodiments, the
linker group L is a group comprises one or more covalently
connected structural units of A (e.g. -A.sub.1 . . . A.sub.q-),
wherein A.sub.1 is coupled to an ABM moiety, and q is an integer
greater than or equal to 0. In certain embodiments, q is an integer
greater than or equal to 1.
[0191] In certain embodiments, e. g., where q is greater than 2,
A.sub.q is a group which is connected to a ULM or VLM moiety, and
A.sub.1 and A.sub.q are connected via structural units of A (number
of such structural units of A: q-2).
[0192] In certain embodiments, e. g., where q is 2, A.sub.q is a
group which is connected to A.sub.1 and to a ULM or VLM moiety.
[0193] In certain embodiments, e. g., where q is 1, the structure
of the linker group L is -A.sub.1-, and A.sub.1 is a group which is
connected to a ULM or VLM moiety and an ABM moiety.
[0194] In additional embodiments, q is an integer from 1 to 100, 1
to 90, 1 to 80, 1 to 70, 1 to 60, 1 to 50, 1 to 40, 1 to 30, 1 to
20, or 1 to 10.
[0195] In certain embodiments, A.sub.1 to A.sub.q are, each
independently, a bond, CR.sup.L1R.sup.L2, O, S, SO, SO.sub.2,
NR.sup.L3, SO.sub.2NR.sup.L3, SONR.sup.L3, CONR.sup.L3, NR.sup.L3
CONR.sup.L4, NR.sup.L3SO.sub.2NR.sup.L4, CO,
CR.sup.L1.dbd.CR.sup.L2, C.ident.C, SiR.sup.L1R.sup.L2,
P(O)R.sup.L1, P(O)OR.sup.L1, NR.sup.L3C(.dbd.NCN)NR.sup.L4,
NR.sup.L3C(.dbd.NCN), NR.sup.L3C(.dbd.CNO.sub.2)NR.sup.4,
C.sub.3-11cycloalkyl optionally substituted with 0-6 R.sup.L1
and/or R.sup.L2 groups, C.sub.3-11 heterocyclyl optionally
substituted with 0-6 R.sup.L1 and/or R.sup.L2 groups, aryl
optionally substituted with 0-6 R.sup.L1 and/or R.sup.L2 groups,
heteroaryl optionally substituted with 0-6 R.sup.L1 and/or R.sup.L2
groups, wherein R.sup.L1 or R.sup.L2, each independently, can be
linked to other A groups to form cycloalkyl and/or heterocyclyl
moeity which can be further substituted with 0-4 R.sup.L5
groups;
[0196] wherein R.sup.L1, R.sup.L2, R.sup.L3, R.sup.L4 and R.sup.L5
are, each independently, H, halo, C.sub.1-8alkyl, OC.sub.1-8alkyl,
SC.sub.1-8alkyl, NHC.sub.1-8alkyl, N(C.sub.1-8alkyl).sub.2, C3-11
cycloalkyl, aryl, heteroaryl, C.sub.3-11 heterocyclyl,
OC.sub.1-8cycloalkyl, SC.sub.1-8cycloalkyl, NHC.sub.1-8cycloalkyl,
N(C.sub.1-8cycloalkyl).sub.2,
N(C.sub.1-8cycloalkyl)(C.sub.1-8alkyl), OH, NH.sub.2, SH,
SO.sub.2C.sub.1-8alkyl, P(O)(OC.sub.1-8alkyl)(C.sub.1-8alkyl),
P(O)(OC.sub.1-8alkyl).sub.2, CC--C.sub.1-8alkyl, CCH,
CH.dbd.CH(C.sub.1-8alkyl),
C(C.sub.1-8alkyl).dbd.CH(C.sub.1-8alkyl),
C(C.sub.1-8alkyl).dbd.C(C.sub.1-8alkyl).sub.2, Si(OH).sub.3,
Si(C.sub.1-8alkyl).sub.3, Si(OH)(C.sub.1-8alkyl).sub.2,
COC.sub.1-8alkyl, CO.sub.2H, halogen, CN, CF.sub.3, CHF.sub.2,
CH.sub.2F, NO.sub.2, SF.sub.5, SO.sub.2NHC.sub.1-8alkyl,
SO.sub.2N(C.sub.1-8alkyl).sub.2, SONHC.sub.1-8alkyl,
SON(C.sub.1-8alkyl).sub.2, CONHC.sub.1-8alkyl,
CON(C.sub.1-8alkyl).sub.2, N(C.sub.1-8alkyl)CONH(C.sub.1-8alkyl),
N(C.sub.1-8alkyl)CON(C.sub.1-8alkyl).sub.2, NHCONH(C.sub.1-8alkyl),
NHCON(C.sub.1-8alkyl).sub.2, NHCONH.sub.2,
N(C.sub.1-8alkyl)SO.sub.2NH(C.sub.1-8alkyl), N(C.sub.1-8alkyl)
SO.sub.2N(C.sub.1-8alkyl).sub.2, NH SO.sub.2NH(C.sub.1-8alkyl), NH
SO.sub.2N(C.sub.1-8alkyl).sub.2, NH SO.sub.2NH.sub.2.
[0197] In certain embodiments, the linker (L) is selected from the
group consisting of):
##STR00032## ##STR00033## ##STR00034## ##STR00035##
[0198] In additional embodiments, the linker group is optionally
substituted (poly)ethyleneglycol having between 1 and about 100
ethylene glycol units, between about 1 and about 50 ethylene glycol
units, between 1 and about 25 ethylene glycol units, between about
1 and 10 ethylene glycol units, between 1 and about 8 ethylene
glycol units and 1 and 6 ethylene glycol units, between 2 and 4
ethylene glycol units, or optionally substituted alkyl groups
interdispersed with optionally substituted, O, N, S, P or Si atoms.
In certain embodiments, the linker is substituted with an aryl,
phenyl, benzyl, alkyl, alkylene, or heterocycle group. In certain
embodiments, the linker may be asymmetric or symmetrical.
[0199] In certain aspects the description provides a PROTAC
compound in which the linker is cleavable in vivo into a functional
E3 ligase binding moiety, and target protein binding moiety. In
this regard, and without being bound by any particular theory, it
is hypothesized that such a configuration can potentiate the
beneficial effects of the degradation activity of the intact PROTAC
molecule. Thus, in certain embodiments, the linker is configured or
"tuned" to have the desired kinetics of cleavage into functional
component molecules or active metabolites. In certain embodiments,
the enzyme responsible for cleavage of the linker is a liver
enzyme, such as, e.g., oxidases, peroxidase, reductases,
transferases, dehydrogenases, peroxidases. In certain embodiments,
the enzyme is at least one of cytochrome P450 oxidase, e.g.,
CYP3A4, Flavin-containing monooxygenase, alcohol dehydrogenase,
aldehyde dehydrogenase, monoamine oxidase, peroxidase, glutathione
S-transferase, cytochrome P450 reductase, sulfotransferase,
methyltransferase, N-acetyltransferase, glucuronosyltransferase,
transpeptidase, or combination thereof.
[0200] Exemplary Androgen Binding Moieties (ABMs)
[0201] In another aspect, the description provides AR binding
moieties (ABM), which in certain aspects and embodiments are
coupled to a linker and/or a ULM as described herein.
[0202] In any of the compounds described herein, the ABM comprises
a chemical moiety that binds to the androgen receptor (AR). Various
androgen receptor binding compounds have been described in
literature, including various androgen derivatives such as
testosterone, dihydrotestosterone, and metribolone (also known as
methyltrienolone or R1881), and non-steroidal compounds such as
bicalutamide, enzalutamide. Those of ordinary skill in the art
would appreciate that these androgen receptor binding compounds
could be potentially used as an ABM moiety in a PROTAC compound.
Such literature includes, but not limited to, G. F. Allan et. al,
Nuclear Receptor Signaling, 2003, 1, e009; R. H. Bradbury et. al,
Bioorganic & Medicinal Chemistry Letters, 2011 5442-5445; C.
Guo et. al, Bioorganic & Medicinal Chemistry Letters, 2012
2572-2578; P. K. Poutiainen et. al, J. Med. Chem. 2012, 55,
6316-6327 A. Pepe et. al, J. Med. Chem. 2013, 56, 8280-8297; M. E.
Jung et al, J. Med. Chem. 2010, 53, 2779-2796, which are
incorporated by reference herein.
[0203] In certain embodiments, the ABM comprises a structure
selected from, but not limited to the structures shown below, where
a dashed line indicates the attachment point of linker moiety:
##STR00036##
[0204] wherein W.sup.1 is aryl or heteroaryl, independently
substituted by 1 or more halo, hydroxyl, nitro, CN, C.ident.CH,
C.sub.1-6 alkyl (linear, branched, optionally substituted by 1 or
more halo, C.sub.1-6 alkoxyl), C.sub.1-6 alkoxyl (linear, branched,
optionally substituted by 1 or more halo), C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl;
[0205] Y.sup.1, Y.sup.2 are each independently NR.sup.Y1, O, S;
[0206] Y.sup.3, Y.sup.4, Y.sup.5 are each independently a bond, O,
NR.sup.Y2, CR.sup.Y1R.sup.Y2, C.dbd.O, C.dbd.S, SO, SO.sub.2;
[0207] Q is a 3-6 membered ring with 0-4 heteroatoms, optionally
substituted with 0-6 R.sup.Q, each R.sup.Q, is independently H,
C.sub.1-6 alkyl (linear, branched, optionally substituted by 1 or
more halo, C.sub.1-6 alkoxyl), or 2 R.sup.Q groups taken together
with the atom they are attached to, form a 3-8 membered ring system
containing 0-2 heteroatoms);
[0208] R.sup.1, R.sup.2, R.sup.a, R.sup.b, R.sup.Y1, R.sup.Y2 are
each independently H, C.sub.1-6 alkyl (linear, branched, optionally
substituted by 1 or more halo, C.sub.1-6 alkoxyl), or R.sup.1,
R.sup.2 together with the atom they are attached to, form a 3-8
membered ring system containing 0-2 heteroatoms);
[0209] W.sup.2 is a bond, C.sub.1-6 alkyl, or aryl, or heteroaryl,
each optionally substituted by 1, 2 or 3 R.sup.W2; and
[0210] each R.sup.W2 is independently H, halo, C.sub.1-6 alkyl
(optionally substituted by 1 or more F), OC.sub.1-3alkyl
(optionally substituted by 1 or more --F).
[0211] In any of the embodiments described herein, the W.sup.2 is
covalently coupled to one or more ULM or VLM groups, or a linker to
which is attached one or more ULM or VLM groups as described
herein.
[0212] In certain embodiments, W.sup.1 is
##STR00037##
[0213] wherein each R.sub.22 is independently halo, optionally
substituted alkyl, haloalkyl, cyano, or nitro; and
[0214] each R.sub.23 is independently H, halo, optionally
substituted alkyl, haloalkyl, cyano, or nitro.
[0215] In certain additional embodiments, W.sup.1 is selected from
the group consisting of:
##STR00038##
[0216] In certain embodiments, ABM is selected from the group
consisting of:
##STR00039## ##STR00040## ##STR00041## ##STR00042##
##STR00043##
[0217] In certain embodiments, the ABM comprises the structure:
##STR00044##
[0218] wherein W.sup.1 is aryl or heteroaryl, independently
substituted by 1 or more halo, hydroxyl, nitro, CN, C.ident.CH,
C.sub.1-6 alkyl (linear, branched, optionally substituted by 1 or
more halo, C.sub.1-6 alkoxyl), C.sub.1-6 alkoxyl (linear, branched,
optionally substituted by 1 or more halo), C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl;
[0219] Y.sup.3, Y.sup.4, Y.sup.5 are each independently a bond, O,
NR.sup.Y2, CR.sup.Y1R.sup.Y2, C.dbd.O, C.dbd.S, SO, SO.sub.2;
[0220] Q is a 4 membered alicyclic ring with 0-2 heteroatoms,
optionally substituted with 0-6 RV, each R.sup.Q, is independently
H, C.sub.1-6 alkyl (linear, branched, optionally substituted by 1
or more halo, C.sub.1-6 alkoxyl), or 2 R.sup.Q groups taken
together with the atom they are attached to, form a 3-8 membered
ring system containing 0-2 heteroatoms);
[0221] R.sup.Y1, R.sup.Y2 are each independently H, C.sub.1-6 alkyl
(linear, branched, optionally substituted by 1 or more halo,
C.sub.1-6 alkoxyl);
[0222] W.sup.2 is a bond, C.sub.1-6 alkyl, C.sub.1-6 alicyclic,
heterocyclic, aryl, or heteroaryl, each optionally substituted by
1, 2 or 3 R.sup.W2; and
[0223] each R.sup.2 is independently H, halo, C.sub.1-6 alkyl
(optionally substituted by 1 or more F), OC.sub.1-3alkyl
(optionally substituted by 1 or more --F), OH, NH.sub.2,
NR.sup.Y1R.sup.Y2, CN.
[0224] In an additional aspect, the description provides an
androgen receptor binding compound comprising a structure of:
##STR00045## [0225] wherein W.sup.1 is aryl or heteroaryl,
independently substituted by 1 or more halo, hydroxyl, nitro, CN,
C.ident.CH, C.sub.1-6 alkyl (linear, branched, optionally
substituted by 1 or more halo, C.sub.1-6 alkoxyl), C.sub.1-6
alkoxyl (linear, branched, optionally substituted by 1 or more
halo), C.sub.2-6 alkenyl, C.sub.2-6 alkynyl; [0226] Y.sup.1,
Y.sup.2 are each independently NR.sup.Y1, O, S; [0227] Y.sup.3,
Y.sup.4, Y.sup.5 are each independently a bond, O, NR.sup.Y2,
CR.sup.Y1R.sup.Y2, C.dbd.O, C.dbd.S, SO, SO.sub.2; [0228] Q is a
3-6 membered alicyclic or aromatic ring with 0-4 heteroatoms,
optionally substituted with 0-6 R.sup.Q, each R.sup.Q, is
independently H, C.sub.1-6 alkyl (linear, branched, optionally
substituted by 1 or more halo, C.sub.1-6 alkoxyl), or 2 R.sup.Q
groups taken together with the atom they are attached to, form a
3-8 membered ring system containing 0-2 heteroatoms); [0229]
R.sup.1, R.sup.2, R.sup.a, R.sup.b, R.sup.Y1, R.sup.Y2 are each
independently H, C.sub.1-6 alkyl (linear, branched, optionally
substituted by 1 or more halo, C.sub.1-6 alkoxyl), or R.sup.1,
R.sup.2 together with the atom they are attached to, form a 3-8
membered ring system containing 0-2 heteroatoms); [0230] W.sup.2 is
a bond, C.sub.1-6 alkyl, C.sub.1-6 alicyclic, heterocyclic, aryl,
or heteroaryl, each optionally substituted by 1, 2 or 3 R.sup.W2;
and [0231] each R.sup.W2 is independently H, halo, C.sub.1-6 alkyl
(optionally substituted by 1 or more F), OC.sub.1-3alkyl
(optionally substituted by 1 or more --F), OH, NH.sub.2,
NR.sup.Y1R.sup.Y2, CN.
[0232] In certain embodiments, the androgen receptor binding
compound of ABM-e is selected from the group consisting of: [0233]
trans-2-Chloro-4-[3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrile;
[0234]
cis-2-Chloro-4-[3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitril-
e; [0235] trans
6-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyri-
dazine-3-carboxamide; [0236] trans tert-Butyl
N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]carbamate;
[0237] trans
4-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benz-
amide; [0238] trans
5-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyra-
zine-2-carboxamide; [0239] trans
2-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyri-
midine-5-carboxamide; [0240]
4-Methoxy-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclo-
butyl]benzamide; [0241] trans
1-(2-Hydroxyethyl)-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcycl-
obutyl]-1H-pyrazole-4-carboxamide; [0242] trans
6-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyri-
dine-3-carboxamide; [0243] trans
4-[(5-Hydroxypentyl)amino]-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrame-
thylcyclobutyl]benzamide; and [0244] trans tert-Butyl
2-({5-[(4-{[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]car-
bamoyl}phenyl)aminopentyl}oxy)acetate.
[0245] The term "hydrocarbyl" shall mean a compound which contains
carbon and hydrogen and which may be fully saturated, partially
unsaturated or aromatic and includes aryl groups, alkyl groups,
alkenyl groups and alkynyl groups.
[0246] The term "alkyl" shall mean within its context a linear,
branch-chained or cyclic fully saturated hydrocarbon radical or
alkyl group, preferably a C.sub.1-C.sub.10, more preferably a
C.sub.1-C.sub.6, alternatively a C.sub.1-C.sub.3 alkyl group, which
may be optionally substituted. Examples of alkyl groups are methyl,
ethyl, n-butyl, sec-butyl, n-hexyl, n-heptyl, n-octyl, n-nonyl,
n-decyl, isopropyl, 2-methylpropyl, cyclopropyl, cyclopropylmethyl,
cyclobutyl, cyclopentyl, cyclopentylethyl, cyclohexylethyl and
cyclohexyl, among others. In certain preferred embodiments,
compounds according to the present invention which may be used to
covalently bind to dehalogenase enzymes. These compounds generally
contain a side chain (often linked through a polyethylene glycol
group) which terminates in an alkyl group which has a halogen
substituent (often chlorine or bromine) on its distil end which
results in covalent binding of the compound containing such a
moiety to the protein.
[0247] The term "Alkenyl" refers to linear, branch-chained or
cyclic C.sub.2-C.sub.10 (preferably C.sub.2-C.sub.6) hydrocarbon
radicals containing at least one C.dbd.C bond.
[0248] The term "Alkynyl" refers to linear, branch-chained or
cyclic C.sub.2-C.sub.10 (preferably C.sub.2-C.sub.6) hydrocarbon
radicals containing at least one C.ident.C bond.
[0249] The term "alkylene" when used, refers to a
--(CH.sub.2).sub.n-- group (n is an integer generally from 0-6),
which may be optionally substituted. When substituted, the alkylene
group preferably is substituted on one or more of the methylene
groups with a C.sub.1-C.sub.6 alkyl group (including a cyclopropyl
group or a t-butyl group), more preferably a methyl group, but may
also be substituted with one or more halo groups, preferably from 1
to 3 halo groups or one or two hydroxyl groups, O--(C.sub.1-C.sub.6
alkyl) groups or amino acid sidechains as otherwise disclosed
herein. In certain embodiments, an alkylene group may be
substituted with a urethane or alkoxy group (or other group) which
is further substituted with a polyethylene glycol chain (of from 1
to 10, preferably 1 to 6, often 1 to 4 ethylene glycol units) to
which is substituted (preferably, but not exclusively on the distal
end of the polyethylene glycol chain) an alkyl chain substituted
with a single halogen group, preferably a chlorine group. In still
other embodiments, the alkylene (often, a methylene) group, may be
substituted with an amino acid sidechain group such as a sidechain
group of a natural or unnatural amino acid, for example, alanine,
(3-alanine, arginine, asparagine, aspartic acid, cysteine, cystine,
glutamic acid, glutamine, glycine, phenylalanine, histidine,
isoleucine, lysine, leucine, methionine, proline, serine,
threonine, valine, tryptophan or tyrosine.
[0250] The term "unsubstituted" shall mean substituted only with
hydrogen atoms. A range of carbon atoms which includes C.sub.0
means that carbon is absent and is replaced with H. Thus, a range
of carbon atoms which is C.sub.0-C.sub.6 includes carbons atoms of
1, 2, 3, 4, 5 and 6 and for C.sub.0, H stands in place of carbon.
The term "substituted" or "optionally substituted" shall mean
independently (i.e., where more than substituent occurs, each
substituent is independent of another substituent) one or more
substituents (independently up to five substitutents, preferably up
to three substituents, often 1 or 2 substituents on a moiety in a
compound according to the present invention and may include
substituents which themselves may be further substituted) at a
carbon (or nitrogen) position anywhere on a molecule within
context, and includes as substituents hydroxyl, thiol, carboxyl,
cyano (C.ident.N), nitro (NO.sub.2), halogen (preferably, 1, 2 or 3
halogens, especially on an alkyl, especially a methyl group such as
a trifluoromethyl), an alkyl group (preferably, C.sub.1-C.sub.10,
more preferably, C.sub.1-C.sub.6), aryl (especially phenyl and
substituted phenyl for example benzyl or benzoyl), alkoxy group
(preferably, C.sub.1-C.sub.6 alkyl or aryl, including phenyl and
substituted phenyl), thioether (C.sub.1-C.sub.6 alkyl or aryl),
acyl (preferably, C.sub.1-C.sub.6 acyl), ester or thioester
(preferably, C.sub.1-C.sub.6 alkyl or aryl) including alkylene
ester (such that attachment is on the alkylene group, rather than
at the ester function which is preferably substituted with a
C.sub.1-C.sub.6 alkyl or aryl group), preferably, C.sub.1-C.sub.6
alkyl or aryl, halogen (preferably, F or Cl), amine (including a
five- or six-membered cyclic alkylene amine, further including a
C.sub.1-C.sub.6 alkyl amine or a C.sub.1-C.sub.6 dialkyl amine
which alkyl groups may be substituted with one or two hydroxyl
groups) or an optionally substituted --N(C.sub.0-C.sub.6
alkyl)C(O)(O--C.sub.1-C.sub.6 alkyl) group (which may be optionally
substituted with a polyethylene glycol chain to which is further
bound an alkyl group containing a single halogen, preferably
chlorine substituent), hydrazine, amido, which is preferably
substituted with one or two C.sub.1-C.sub.6 alkyl groups (including
a carboxamide which is optionally substituted with one or two
C.sub.1-C.sub.6 alkyl groups), alkanol (preferably, C.sub.1-C.sub.6
alkyl or aryl), or alkanoic acid (preferably, C.sub.1-C.sub.6 alkyl
or aryl). Substituents according to the present invention may
include, for example --SiR.sub.1R.sub.2R.sub.3 groups where each of
R.sub.1 and R.sub.2 is as otherwise described herein and R.sub.3 is
H or a C.sub.1-C.sub.6 alkyl group, preferably R.sub.1, R.sub.2,
R.sub.3 in this context is a C.sub.1-C.sub.3 alkyl group (including
an isopropyl or t-butyl group). Each of the above-described groups
may be linked directly to the substituted moiety or alternatively,
the substituent may be linked to the substituted moiety (preferably
in the case of an aryl or heteroaryl moiety) through an optionally
substituted --(CH.sub.2).sub.m-- or alternatively an optionally
substituted --(OCH.sub.2).sub.m, --(OCH.sub.2CH.sub.2).sub.m-- or
--(CH.sub.2CH.sub.2O).sub.m-- group, which may be substituted with
any one or more of the above-described substituents. Alkylene
groups --(CH.sub.2).sub.m-- or --(CH.sub.2).sub.n-- groups or other
chains such as ethylene glycol chains, as identified above, may be
substituted anywhere on the chain. Preferred substitutents on
alkylene groups include halogen or C.sub.1-C.sub.6 (preferably
C.sub.1-C.sub.3) alkyl groups, which may be optionally substituted
with one or two hydroxyl groups, one or two ether groups
(O--C.sub.1-C.sub.6 groups), up to three halo groups (preferably
F), or a sidechain of an amino acid as otherwise described herein
and optionally substituted amide (preferably carboxamide
substituted as described above) or urethane groups (often with one
or two C.sub.0-C6 alkyl substitutents, which group(s) may be
further substituted). In certain embodiments, the alkylene group
(often a single methylene group) is substituted with one or two
optionally substituted C.sub.1-C.sub.6 alkyl groups, preferably
C.sub.1-C.sub.4 alkyl group, most often methyl or O-methyl groups
or a sidechain of an amino acid as otherwise described herein. In
the present invention, a moiety in a molecule may be optionally
substituted with up to five substituents, preferably up to three
substituents. Most often, in the present invention moieties which
are substituted are substituted with one or two substituents.
[0251] The term "substituted" (each substituent being independent
of any other substituent) shall also mean within its context of use
C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, halogen, amido,
carboxamido, sulfone, including sulfonamide, keto, carboxy,
C.sub.1-C.sub.6 ester (oxyester or carbonylester), C.sub.1-C.sub.6
keto, urethane --O--C(O)--NR.sub.1R.sub.2 or
--N(R.sub.1)--C(O)--O--R.sub.1, nitro, cyano and amine (especially
including a C.sub.1-C.sub.6 alkylene-NR.sub.1R.sub.2, a mono- or
di-C.sub.1-C.sub.6 alkyl substituted amines which may be optionally
substituted with one or two hydroxyl groups). Each of these groups
contain unless otherwise indicated, within context, between 1 and 6
carbon atoms. In certain embodiments, preferred substituents will
include for example, --NH--, --NHC(O)--, --O--, .dbd.O,
--(CH.sub.2).sub.m-- (here, m and n are in context, 1, 2, 3, 4, 5
or 6), --S--, --S(O)--, SO.sub.2-- or --NH--C(O)--NH--,
--(CH.sub.2).sub.nOH, --(CH.sub.2).sub.nSH, --(CH.sub.2).sub.nCOOH,
C.sub.1-C.sub.6 alkyl, --(CH.sub.2).sub.nO--(C.sub.1-C.sub.6
alkyl), --(CH.sub.2).sub.nC(O)--(C.sub.1-C.sub.6 alkyl),
--(CH.sub.2).sub.nOC(O)--(C.sub.1-C.sub.6 alkyl),
--(CH.sub.2).sub.nC(O)O--(C.sub.1-C.sub.6 alkyl),
--(CH.sub.2).sub.nNHC(O)--R.sub.1,
--(CH.sub.2).sub.nC(O)--NR.sub.1R.sub.2, --(OCH.sub.2).sub.nOH,
--(CH.sub.2O).sub.nCOOH, C.sub.1-C.sub.6 alkyl,
--(OCH.sub.2).sub.nO--(C.sub.1-C.sub.6 alkyl),
--(CH.sub.2O).sub.nC(O)--(C.sub.1-C.sub.6 alkyl),
--(OCH.sub.2).sub.nNHC(O)--R.sub.1,
--(CH.sub.2O).sub.nC(O)--NR.sub.1R.sub.2, --S(O).sub.2--R.sub.S,
--S(O)--R.sub.S (R.sub.S is C.sub.1-C.sub.6 alkyl or a
--(CH.sub.2).sub.m--NR.sub.1R.sub.2 group), NO.sub.2, CN or halogen
(F, Cl, Br, I, preferably F or Cl), depending on the context of the
use of the substituent. R.sub.1 and R.sub.2 are each, within
context, H or a C.sub.1-C.sub.6 alkyl group (which may be
optionally substituted with one or two hydroxyl groups or up to
three halogen groups, preferably fluorine). The term "substituted"
shall also mean, within the chemical context of the compound
defined and substituent used, an optionally substituted aryl or
heteroaryl group or an optionally substituted heterocyclic group as
otherwise described herein. Alkylene groups may also be substituted
as otherwise disclosed herein, preferably with optionally
substituted C.sub.1-C.sub.6 alkyl groups (methyl, ethyl or
hydroxymethyl or hydroxyethyl is preferred, thus providing a chiral
center), a sidechain of an amino acid group as otherwise described
herein, an amido group as described hereinabove, or a urethane
group O--C(O)--NR.sub.1R.sub.2 group where R.sub.1 and R.sub.2 are
as otherwise described herein, although numerous other groups may
also be used as substituents. Various optionally substituted
moieties may be substituted with 3 or more substituents, preferably
no more than 3 substituents and preferably with 1 or 2
substituents. It is noted that in instances where, in a compound at
a particular position of the molecule substitution is required
(principally, because of valency), but no substitution is
indicated, then that substituent is construed or understood to be
H, unless the context of the substitution suggests otherwise.
[0252] The term "aryl" or "aromatic", in context, refers to a
substituted (as otherwise described herein) or unsubstituted
monovalent aromatic radical having a single ring (e.g., benzene,
phenyl, benzyl) or condensed rings (e.g., naphthyl, anthracenyl,
phenanthrenyl, etc.) and can be bound to the compound according to
the present invention at any available stable position on the
ring(s) or as otherwise indicated in the chemical structure
presented. Other examples of aryl groups, in context, may include
heterocyclic aromatic ring systems "heteroaryl" groups having one
or more nitrogen, oxygen, or sulfur atoms in the ring (monocyclic)
such as imidazole, furyl, pyrrole, furanyl, thiene, thiazole,
pyridine, pyrimidine, pyrazine, triazole, oxazole or fused ring
systems such as indole, quinoline, indolizine, azaindolizine,
benzofurazan, etc., among others, which may be optionally
substituted as described above. Among the heteroaryl groups which
may be mentioned include nitrogen-containing heteroaryl groups such
as pyrrole, pyridine, pyridone, pyridazine, pyrimidine, pyrazine,
pyrazole, imidazole, triazole, triazine, tetrazole, indole,
isoindole, indolizine, azaindolizine, purine, indazole, quinoline,
dihydroquinoline, tetrahydroquinoline, isoquinoline,
dihydroisoquinoline, tetrahydroisoquinoline, quinolizine,
phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline,
pteridine, imidazopyridine, imidazotriazine, pyrazinopyridazine,
acridine, phenanthridine, carbazole, carbazoline, perimidine,
phenanthroline, phenacene, oxadiazole, benzimidazole,
pyrrolopyridine, pyrrolopyrimidine and pyridopyrimidine;
sulfur-containing aromatic heterocycles such as thiophene and
benzothiophene; oxygen-containing aromatic heterocycles such as
furan, pyran, cyclopentapyran, benzofuran and isobenzofuran; and
aromatic heterocycles comprising 2 or more hetero atoms selected
from among nitrogen, sulfur and oxygen, such as thiazole,
thiadizole, isothiazole, benzoxazole, benzothiazole,
benzothiadiazole, phenothiazine, isoxazole, furazan, phenoxazine,
pyrazoloxazole, imidazothiazole, thienofuran, furopyrrole,
pyridoxazine, furopyridine, furopyrimidine, thienopyrimidine and
oxazole, among others, all of which may be optionally
substituted.
[0253] The term "substituted aryl" refers to an aromatic
carbocyclic group comprised of at least one aromatic ring or of
multiple condensed rings at least one of which being aromatic,
wherein the ring(s) are substituted with one or more substituents.
For example, an aryl group can comprise a substituent(s) selected
from: --(CH.sub.2).sub.nOH,
--(CH.sub.2).sub.n--O--(C.sub.1-C.sub.6)alkyl,
--(CH.sub.2).sub.n--O--(CH.sub.2).sub.n--(C.sub.1-C.sub.6)alkyl,
--(CH.sub.2).sub.n--C(O)(C.sub.0-C.sub.6) alkyl,
--(CH.sub.2).sub.n--C(O)O(C.sub.0-C.sub.6)alkyl,
--(CH.sub.2).sub.n--OC(O)(C.sub.0-C.sub.6)alkyl, amine, mono- or
di-(C.sub.1-C.sub.6 alkyl) amine wherein the alkyl group on the
amine is optionally substituted with 1 or 2 hydroxyl groups or up
to three halo (preferably F, Cl) groups, OH, COOH, C.sub.1-C.sub.6
alkyl, preferably CH.sub.3, CF.sub.3, OMe, OCF.sub.3, NO.sub.2, or
CN group (each of which may be substituted in ortho-, meta- and/or
para-positions of the phenyl ring, preferably para-), an optionally
substituted phenyl group (the phenyl group itself is preferably
substituted with a linker group attached to a ABM group, including
a ULM group), and/or at least one of F, Cl, OH, COOH, CH.sub.3,
CF.sub.3, OMe, OCF.sub.3, NO.sub.2, or CN group (in ortho-, meta-
and/or para-positions of the phenyl ring, preferably para-), a
naphthyl group, which may be optionally substituted, an optionally
substituted heteroaryl, preferably an optionally substituted
isoxazole including a methylsubstituted isoxazole, an optionally
substituted oxazole including a methylsubstituted oxazole, an
optionally substituted thiazole including a methyl substituted
thiazole, an optionally substituted isothiazole including a methyl
substituted isothiazole, an optionally substituted pyrrole
including a methylsubstituted pyrrole, an optionally substituted
imidazole including a methylimidazole, an optionally substituted
benzimidazole or methoxybenzylimidazole, an optionally substituted
oximidazole or methyloximidazole, an optionally substituted diazole
group, including a methyldiazole group, an optionally substituted
triazole group, including a methylsubstituted triazole group, an
optionally substituted pyridine group, including a
halo-(preferably, F) or methylsubstituted pyridine group or an
oxapyridine group (where the pyridine group is linked to the phenyl
group by an oxygen), an optionally substituted furan, an optionally
substituted benzofuran, an optionally substituted
dihydrobenzofuran, an optionally substituted indole, indolizine or
azaindolizine (2, 3, or 4-azaindolizine), an optionally substituted
quinoline, and combinations thereof.
[0254] "Carboxyl" denotes the group --C(O)OR, where R is hydrogen,
alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl or
substituted heteroaryl, whereas these generic substituents have
meanings which are identical with definitions of the corresponding
groups defined herein.
[0255] The term "heteroaryl" or "hetaryl" can mean but is in no way
limited to an optionally substituted quinoline (which may be
attached to the pharmacophore or substituted on any carbon atom
within the quinoline ring), an optionally substituted indole
(including dihydroindole), an optionally substituted indolizine, an
optionally substituted azaindolizine (2, 3 or 4-azaindolizine) an
optionally substituted benzimidazole, benzodiazole, benzoxofuran,
an optionally substituted imidazole, an optionally substituted
isoxazole, an optionally substituted oxazole (preferably methyl
substituted), an optionally substituted diazole, an optionally
substituted triazole, a tetrazole, an optionally substituted
benzofuran, an optionally substituted thiophene, an optionally
substituted thiazole (preferably methyl and/or thiol substituted),
an optionally substituted isothiazole, an optionally substituted
triazole (preferably a 1,2,3-triazole substituted with a methyl
group, a triisopropylsilyl group, an optionally substituted
--(CH.sub.2).sub.m--O--C.sub.1-C.sub.6 alkyl group or an optionally
substituted --(CH.sub.2).sub.m--C(O)--O--C.sub.1-C.sub.6 alkyl
group), an optionally substituted pyridine (2-, 3, or 4-pyridine)
or a group according to the chemical structure:
##STR00046##
[0256] where S.sup.c is CHR.sup.SS, NR.sup.URE, or O;
[0257] R.sup.HET is H, CN, NO.sub.2, halo (preferably Cl or F),
optionally substituted C.sub.1-C.sub.6 alkyl (preferably
substituted with one or two hydroxyl groups or up to three halo
groups (e.g. CF.sub.3), optionally substituted O(C.sub.1-C.sub.6
alkyl) (preferably substituted with one or two hydroxyl groups or
up to three halo groups) or an optionally substituted acetylenic
group --C.ident.C--R.sub.a where R.sub.a is H or a C.sub.1-C.sub.6
alkyl group (preferably C.sub.1-C.sub.3 alkyl);
[0258] R.sup.SS is H, CN, NO.sub.2, halo (preferably F or Cl),
optionally substituted C.sub.1-C.sub.6 alkyl (preferably
substituted with one or two hydroxyl groups or up to three halo
groups), optionally substituted O--(C.sub.1-C.sub.6 alkyl)
(preferably substituted with one or two hydroxyl groups or up to
three halo groups) or an optionally substituted
--C(O)(C.sub.1-C.sub.6 alkyl) (preferably substituted with one or
two hydroxyl groups or up to three halo groups);
[0259] R.sup.URE is H, a C.sub.1-C.sub.6 alkyl (preferably H or
C.sub.1-C.sub.3 alkyl) or a --C(O)(C.sub.1-C.sub.6 alkyl), each of
which groups is optionally substituted with one or two hydroxyl
groups or up to three halogen, preferably fluorine groups, or an
optionally substituted heterocycle, for example piperidine,
morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene,
piperidine, piperazine, each of which is optionally substituted,
and
[0260] Y.sup.C is N or C--R.sup.Yc, where R.sup.YC is H, OH, CN,
NO.sub.2, halo (preferably Cl or F), optionally substituted
C.sub.1-C.sub.6 alkyl (preferably substituted with one or two
hydroxyl groups or up to three halo groups (e.g. CF.sub.3),
optionally substituted O(C.sub.1-C.sub.6 alkyl) (preferably
substituted with one or two hydroxyl groups or up to three halo
groups) or an optionally substituted acetylenic group
--C.ident.C--R.sub.a where R.sub.a is H or a C.sub.1-C.sub.6 alkyl
group (preferably C.sub.1-C.sub.3 alkyl).
[0261] The terms "arylkyl" and "heteroarylalkyl" refer to groups
that comprise both aryl or, respectively, heteroaryl as well as
alkyl and/or heteroalkyl and/or carbocyclic and/or heterocycloalkyl
ring systems according to the above definitions.
[0262] The term "arylalkyl" as used herein refers to an aryl group
as defined above appended to an alkyl group defined above. The
arylalkyl group is attached to the parent moiety through an alkyl
group wherein the alkyl group is one to six carbon atoms. The aryl
group in the arylalkyl group may be substituted as defined
above.
[0263] The term "heterocycle" refers to a cyclic group which
contains at least one heteroatom, i.e., O, N or S, and may be
aromatic (heteroaryl) or non-aromatic. Thus, the heteroaryl
moieties are subsumed under the definition of heterocycle,
depending on the context of its use. Exemplary heterocyclics
include: azetidinyl, benzimidazolyl, 1,4-benzodioxanyl,
1,3-benzodioxolyl, benzoxazolyl, benzothiazolyl, benzothienyl,
dihydroimidazolyl, dihydropyranyl, dihydrofuranyl, dioxanyl,
dioxolanyl, ethyleneurea, 1,3-dioxolane, 1,3-dioxane, 1,4-dioxane,
furyl, homopiperidinyl, imidazolyl, imidazolinyl, imidazolidinyl,
indolinyl, indolyl, isoquinolinyl, isothiazolidinyl, isothiazolyl,
isoxazolidinyl, isoxazolyl, morpholinyl, naphthyridinyl,
oxazolidinyl, oxazolyl, pyridone, 2-pyrrolidone, pyridine,
piperazinyl, N-methylpiperazinyl, piperidinyl, phthalimide,
succinimide, pyrazinyl, pyrazolinyl, pyridyl, pyrimidinyl,
pyrrolidinyl, pyrrolinyl, pyrrolyl, quinolinyl, tetrahydrofuranyl,
tetrahydropyranyl, tetrahydroquinoline, thiazolidinyl, thiazolyl,
thienyl, tetrahydrothiophene, oxane, oxetanyl, oxathiolanyl, thiane
among others.
[0264] Heterocyclic groups can be optionally substituted with a
member selected from the group consisting of alkoxy, substituted
alkoxy, cycloalkyl, substituted cycloalkyl, cycloalkenyl,
substituted cycloalkenyl, acyl, acylamino, acyloxy, amino,
substituted amino, aminoacyl, aminoacyloxy, oxyaminoacyl, azido,
cyano, halogen, hydroxyl, keto, thioketo, carboxy, carboxyalkyl,
thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol,
thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl,
heteroaryloxy, heterocyclic, heterocyclooxy, hydroxyamino,
alkoxyamino, nitro, --SO-alkyl, --SO-substituted alkyl, --SOaryl,
--SO-heteroaryl, --SO2-alkyl, --SO2-substituted alkyl, --SO2-aryl,
oxo (.dbd.O), and --SO2-heteroaryl. Such heterocyclic groups can
have a single ring or multiple condensed rings. Examples of
nitrogen heterocycles and heteroaryls include, but are not limited
to, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine,
pyridazine, indolizine, isoindole, indole, indazole, purine,
quinolizine, isoquinoline, quinoline, phthalazine,
naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine,
carbazole, carboline, phenanthridine, acridine, phenanthroline,
isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine,
imidazolidine, imidazoline, piperidine, piperazine, indoline,
morpholino, piperidinyl, tetrahydrofuranyl, and the like as well as
N-alkoxy-nitrogen containing heterocycles. The term "heterocyclic"
also includes bicyclic groups in which any of the heterocyclic
rings is fused to a benzene ring or a cyclohexane ring or another
heterocyclic ring (for example, indolyl, quinolyl, isoquinolyl,
tetrahydroquinolyl, and the like).
[0265] The term "cycloalkyl" can mean but is in no way limited to
univalent groups derived from monocyclic or polycyclic alkyl groups
or cycloalkanes, as defined herein, e.g., saturated monocyclic
hydrocarbon groups having from three to twenty carbon atoms in the
ring, including, but not limited to, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl and the like. The term
"substituted cycloalkyl" can mean but is in no way limited to a
monocyclic or polycyclic alkyl group and being substituted by one
or more substituents, for example, amino, halogen, alkyl,
substituted alkyl, carbyloxy, carbylmercapto, aryl, nitro, mercapto
or sulfo, whereas these generic substituent groups have meanings
which are identical with definitions of the corresponding groups as
defined in this legend.
[0266] "Heterocycloalkyl" refers to a monocyclic or polycyclic
alkyl group in which at least one ring carbon atom of its cyclic
structure being replaced with a heteroatom selected from the group
consisting of N, O, S or P. "Substituted heterocycloalkyl" refers
to a monocyclic or polycyclic alkyl group in which at least one
ring carbon atom of its cyclic structure being replaced with a
heteroatom selected from the group consisting of N, O, S or P and
the group is containing one or more substituents selected from the
group consisting of halogen, alkyl, substituted alkyl, carbyloxy,
carbylmercapto, aryl, nitro, mercapto or sulfo, whereas these
generic substituent group have meanings which are identical with
definitions of the corresponding groups as defined in this
legend.
[0267] Exemplary AR-PROTAC Compounds
[0268] As described above, in certain aspects, the description
provides bifunctional PROTAC compounds comprising at least one ABM
group, a linker, and at least one ULM (or VLM) group as described
herein.
[0269] In certain embodiments, the compound is selected from the
group consisting of compounds 1-593 (as described in Tables 2-17),
and salts and polymorphs thereof.
[0270] In certain embodiments, the compound is selected from the
group consisting of:
##STR00047## ##STR00048## ##STR00049## ##STR00050## ##STR00051##
##STR00052## ##STR00053## ##STR00054## ##STR00055## ##STR00056##
##STR00057## ##STR00058## ##STR00059## ##STR00060## ##STR00061##
##STR00062## ##STR00063## ##STR00064## ##STR00065## ##STR00066##
##STR00067## ##STR00068## ##STR00069## ##STR00070## ##STR00071##
##STR00072## ##STR00073## ##STR00074## ##STR00075## ##STR00076##
##STR00077## ##STR00078## ##STR00079## ##STR00080##
##STR00081##
[0271] In another embodiment, the present invention provides a
library of compounds. The library comprises more than one compound
wherein each compound has a formula of ABM-L-ULM, wherein ULM is a
ubiquitin pathway protein binding moiety (preferably, an E3
ubiquitin ligase moiety as otherwise disclosed herein), e.g., a
VLM, and ABM is an AR protein binding moiety, wherein ABM is
coupled (preferably, through a linker moiety) to ULM, and wherein
the ubiquitin pathway protein binding moiety recognizes an
ubiquitin pathway protein, in particular, an E3 ubiquitin
ligase.
[0272] The present description includes, where applicable, the
compositions comprising the pharmaceutically acceptable salts, in
particular, acid or base addition salts of compounds of the present
invention.
[0273] The term "pharmaceutically acceptable salt" is used
throughout the specification to describe, where applicable, a salt
form of one or more of the compounds described herein which are
presented to increase the solubility of the compound in the gastic
juices of the patient's gastrointestinal tract in order to promote
dissolution and the bioavailability of the compounds.
Pharmaceutically acceptable salts include those derived from
pharmaceutically acceptable inorganic or organic bases and acids,
where applicable. Suitable salts include those derived from alkali
metals such as potassium and sodium, alkaline earth metals such as
calcium, magnesium and ammonium salts, among numerous other acids
and bases well known in the pharmaceutical art. Sodium and
potassium salts are particularly preferred as neutralization salts
of the phosphates according to the present invention.
[0274] The acids which are used to prepare the pharmaceutically
acceptable acid addition salts of the aforementioned base compounds
useful in this invention are those which form non-toxic acid
addition salts, i.e., salts containing pharmacologically acceptable
anions, such as the hydrochloride, hydrobromide, hydroiodide,
nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate,
lactate, citrate, acid citrate, tartrate, bitartrate, succinate,
maleate, fumarate, gluconate, saccharate, benzoate,
methanesulfonate, ethanesulfonate, benzenesulfonate,
p-toluenesulfonate and pamoate [i.e.,
1,1'-methylene-bis-(2-hydroxy-3 naphthoate)]salts, among numerous
others.
[0275] Pharmaceutically acceptable base addition salts may also be
used to produce pharmaceutically acceptable salt forms of the
compounds or derivatives according to the present invention. The
chemical bases that may be used as reagents to prepare
pharmaceutically acceptable base salts of the present compounds
that are acidic in nature are those that form non-toxic base salts
with such compounds. Such non-toxic base salts include, but are not
limited to those derived from such pharmacologically acceptable
cations such as alkali metal cations (eg., potassium and sodium)
and alkaline earth metal cations (eg, calcium, zinc and magnesium),
ammonium or water-soluble amine addition salts such as
N-methylglucamine-(meglumine), and the lower alkanolammonium and
other base salts of pharmaceutically acceptable organic amines,
among others.
[0276] Compositions
[0277] In another aspect, the description provides compositions
comprising compounds as described herein, including salts thereof,
and a pharmaceutically acceptable carrier. In certain embodiments,
the compositions are therapeutic or pharmaceutical compositions
comprising an effective amount of a compound as described herein
and a pharmaceutically acceptable carrier.
[0278] The amount of compound in a pharmaceutical composition of
the instant invention that may be combined with the carrier
materials to produce a single dosage form will vary depending upon
the host and disease treated, the particular mode of
administration. Generally, an amount between 0.1 mg/kg and 1000
mg/kg body weight/day of active ingredients is administered
dependent upon potency of the agent. Toxicity and therapeutic
efficacy of such compounds can be determined by standard
pharmaceutical procedures in cell cultures or experimental animals,
e.g., for determining the LD50 (the dose lethal to 50% of the
population) and the ED50 (the dose therapeutically effective in 50%
of the population). The dose ratio between toxic and therapeutic
effects is the therapeutic index and it can be expressed as the
ratio LD50/ED50. Compounds that exhibit large therapeutic indices
are preferred. While compounds that exhibit toxic side effects may
be used, care should be taken to design a delivery system that
targets such compounds to the site of affected tissue in order to
minimize potential damage to uninfected cells and, thereby, reduce
side effects. The data obtained from the cell culture assays and
animal studies can be used in formulating a range of dosage for use
in humans. The dosage of such compounds lies preferably within a
range of circulating concentrations that include the ED50 with
little or no toxicity. The dosage may vary within this range
depending upon the dosage form employed and the route of
administration utilized. For any compound used in the method of the
invention, the therapeutically effective dose can be estimated
initially from cell culture assays. A dose may be formulated in
animal models to achieve a circulating plasma concentration range
that includes the IC50 (i.e., the concentration of the test
compound which achieves a half-maximal inhibition of symptoms) as
determined in cell culture. Such information can be used to more
accurately determine useful doses in humans. Levels in plasma may
be measured, for example, by high performance liquid
chromatography.
[0279] The compositions of the present invention may be formulated
in a conventional manner using one or more pharmaceutically
acceptable carriers and may also be administered in
controlled-release formulations. Pharmaceutically acceptable
carriers that may be used in these pharmaceutical compositions
include, but are not limited to, ion exchangers, alumina, aluminum
stearate, lecithin, serum proteins, such as human serum albumin,
buffer substances such as phosphates, glycine, sorbic acid,
potassium sorbate, partial glyceride mixtures of saturated
vegetable fatty acids, water, salts or electrolytes, such as
prolamine sulfate, disodium hydrogen phosphate, potassium hydrogen
phosphate, sodium chloride, zinc salts, colloidal silica, magnesium
trisilicate, polyvinyl pyrrolidone, cellulose-based substances,
polyethylene glycol, sodium carboxymethylcellulose, polyacrylates,
waxes, polyethylene-polyoxypropylene-block polymers, polyethylene
glycol and wool fat.
[0280] The active compound is included in the pharmaceutically
acceptable carrier or diluent in an amount sufficient to deliver to
a patient a therapeutically effective amount for the desired
indication, without causing serious toxic effects in the patient
treated. A preferred dose of the active compound for all of the
herein-mentioned conditions is in the range from about 10 ng/kg to
300 mg/kg, preferably 0.1 to 100 mg/kg per day, more generally 0.5
to about 25 mg per kilogram body weight of the recipient/patient
per day. A typical topical dosage will range from 0.01-5% wt/wt in
a suitable carrier.
[0281] The compound is conveniently administered in any suitable
unit dosage form, including but not limited to one containing less
than 1 mg, 1 mg to 3000 mg, preferably 5 to 500 mg of active
ingredient per unit dosage form. An oral dosage of about 25-250 mg
is often convenient.
[0282] The active ingredient is preferably administered to achieve
peak plasma concentrations of the active compound of about
0.00001-30 mM, preferably about 0.1-30 .mu.M. This may be achieved,
for example, by the intravenous injection of a solution or
formulation of the active ingredient, optionally in saline, or an
aqueous medium or administered as a bolus of the active ingredient.
Oral administration is also appropriate to generate effective
plasma concentrations of active agent.
[0283] The concentration of active compound in the drug composition
will depend on absorption, distribution, inactivation, and
excretion rates of the drug as well as other factors known to those
of skill in the art. It is to be noted that dosage values will also
vary with the severity of the condition to be alleviated. It is to
be further understood that for any particular subject, specific
dosage regimens should be adjusted over time according to the
individual need and the professional judgment of the person
administering or supervising the administration of the
compositions, and that the concentration ranges set forth herein
are exemplary only and are not intended to limit the scope or
practice of the claimed composition. The active ingredient may be
administered at once, or may be divided into a number of smaller
doses to be administered at varying intervals of time.
[0284] If administered intravenously, preferred carriers are
physiological saline or phosphate buffered saline (PBS).
[0285] In one embodiment, the active compounds are prepared with
carriers that will protect the compound against rapid elimination
from the body, such as a controlled release formulation, including
implants and microencapsulated delivery systems. Biodegradable,
biocompatible polymers can be used, such as ethylene vinyl acetate,
polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and
polylactic acid. Methods for preparation of such formulations will
be apparent to those skilled in the art.
[0286] Liposomal suspensions may also be pharmaceutically
acceptable carriers. These may be prepared according to methods
known to those skilled in the art, for example, as described in
U.S. Pat. No. 4,522,811 (which is incorporated herein by reference
in its entirety). For example, liposome formulations may be
prepared by dissolving appropriate lipid(s) (such as stearoyl
phosphatidyl ethanolamine, stearoyl phosphatidyl choline,
arachadoyl phosphatidyl choline, and cholesterol) in an inorganic
solvent that is then evaporated, leaving behind a thin film of
dried lipid on the surface of the container. An aqueous solution of
the active compound are then introduced into the container. The
container is then swirled by hand to free lipid material from the
sides of the container and to disperse lipid aggregates, thereby
forming the liposomal suspension.
[0287] Modes of Administration
[0288] In any of the aspects or embodiments described herein, the
therapeutic compositions comprising compounds described herein can
be in any suitable dosage form configured to be delivered by any
suitable route. For example, the compounds can be administered by
any appropriate route, for example, orally, parenterally,
intravenously, intradermally, subcutaneously, or topically,
including transdermally, in liquid, cream, gel, or solid form,
rectally, nasally, buccally, vaginally or via an implanted
reservoir or by aerosol form.
[0289] The term "parenteral" as used herein includes subcutaneous,
intravenous, intramuscular, intra-articular, intra-synovial,
intrasternal, intrathecal, intrahepatic, intralesional and
intracranial injection or infusion techniques. Preferably, the
compositions are administered orally, intraperitoneally or
intravenously.
[0290] The compounds as described herein may be administered in
single or divided doses by the oral, parenteral or topical routes.
Administration of the active compound may range from continuous
(intravenous drip) to several oral administrations per day (for
example, Q.I.D.) and may include oral, topical, parenteral,
intramuscular, intravenous, sub-cutaneous, transdermal (which may
include a penetration enhancement agent), buccal, sublingual and
suppository administration, among other routes of administration.
Enteric coated oral tablets may also be used to enhance
bioavailability of the compounds from an oral route of
administration. The most effective dosage form will depend upon the
pharmacokinetics of the particular agent chosen as well as the
severity of disease in the patient.
[0291] Administration of compounds as sprays, mists, or aerosols
for intra-nasal, intra-tracheal or pulmonary administration may
also be used. Compounds as described herein may be administered in
immediate release, intermediate release or sustained or controlled
release forms. Sustained or controlled release forms are preferably
administered orally, but also in suppository and transdermal or
other topical forms. Intramuscular injections in liposomal form may
also be used to control or sustain the release of compound at an
injection site.
[0292] Sterile injectable forms of the compositions as described
herein may be aqueous or oleaginous suspension. These suspensions
may be formulated according to techniques known in the art using
suitable dispersing or wetting agents and suspending agents. The
sterile injectable preparation may also be a sterile injectable
solution or suspension in a non-toxic parenterally-acceptable
diluent or solvent, for example as a solution in 1,3-butanediol.
Among the acceptable vehicles and solvents that may be employed are
water, Ringer's solution and isotonic sodium chloride solution. In
addition, sterile, fixed oils are conventionally employed as a
solvent or suspending medium. For this purpose, any bland fixed oil
may be employed including synthetic mono- or di-glycerides. Fatty
acids, such as oleic acid and its glyceride derivatives are useful
in the preparation of injectables, as are natural
pharmaceutically-acceptable oils, such as olive oil or castor oil,
especially in their polyoxyethylated versions. These oil solutions
or suspensions may also contain a long-chain alcohol diluent or
dispersant, such as Ph. Helv or similar alcohol.
[0293] The pharmaceutical compositions as described herein may be
orally administered in any orally acceptable dosage form including,
but not limited to, capsules, tablets, aqueous suspensions or
solutions. In the case of tablets for oral use, carriers which are
commonly used include lactose and corn starch. Lubricating agents,
such as magnesium stearate, are also typically added. For oral
administration in a capsule form, useful diluents include lactose
and dried corn starch. When aqueous suspensions are required for
oral use, the active ingredient is combined with emulsifying and
suspending agents. If desired, certain sweetening, flavoring or
coloring agents may also be added. Oral compositions will generally
include an inert diluent or an edible carrier. They may be enclosed
in gelatin capsules or compressed into tablets. For the purpose of
oral therapeutic administration, the active compound or its prodrug
derivative can be incorporated with excipients and used in the form
of tablets, troches, or capsules. Pharmaceutically compatible
binding agents, and/or adjuvant materials are included as part of
the composition.
[0294] The tablets, pills, capsules, troches and the like can
contain any of the following ingredients, or compounds of a similar
nature: a binder such as microcrystalline cellulose, gum tragacanth
or gelatin; an excipient such as starch or lactose, a dispersing
agent such as alginic acid, Primogel, or corn starch; a lubricant
such as magnesium stearate or Sterotes; a glidant such as colloidal
silicon dioxide; a sweetening agent such as sucrose or saccharin;
or a flavoring agent such as peppermint, methyl salicylate, or
orange flavoring. When the dosage unit form is a capsule, it can
contain, in addition to material of the above type, a liquid
carrier such as a fatty oil. In addition, dosage unit forms can
contain various other materials which modify the physical form of
the dosage unit, for example, coatings of sugar, shellac, or
enteric agents.
[0295] The active compound or pharmaceutically acceptable salt
thereof can be administered as a component of an elixir,
suspension, syrup, wafer, chewing gum or the like. A syrup may
contain, in addition to the active compounds, sucrose as a
sweetening agent and certain preservatives, dyes and colorings and
flavors.
[0296] Alternatively, the pharmaceutical compositions as described
herein may be administered in the form of suppositories for rectal
administration. These can be prepared by mixing the agent with a
suitable non-irritating excipient, which is solid at room
temperature but liquid at rectal temperature and therefore will
melt in the rectum to release the drug. Such materials include
cocoa butter, beeswax and polyethylene glycols.
[0297] The pharmaceutical compositions of this invention may also
be administered topically. Suitable topical formulations are
readily prepared for each of these areas or organs. Topical
application for the lower intestinal tract can be effected in a
rectal suppository formulation (see above) or in a suitable enema
formulation. Topically-acceptable transdermal patches may also be
used. For topical applications, the pharmaceutical compositions may
be formulated in a suitable ointment containing the active
component suspended or dissolved in one or more carriers. Carriers
for topical administration of the compounds of this invention
include, but are not limited to, mineral oil, liquid petrolatum,
white petrolatum, propylene glycol, polyoxyethylene,
polyoxypropylene compound, emulsifying wax and water. In certain
preferred aspects of the invention, the compounds may be coated
onto a stent which is to be surgically implanted into a patient in
order to inhibit or reduce the likelihood of occlusion occurring in
the stent in the patient.
[0298] Alternatively, the pharmaceutical compositions can be
formulated in a suitable lotion or cream containing the active
components suspended or dissolved in one or more pharmaceutically
acceptable carriers. Suitable carriers include, but are not limited
to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl
esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and
water.
[0299] For ophthalmic use, the pharmaceutical compositions may be
formulated as micronized suspensions in isotonic, pH adjusted
sterile saline, or, preferably, as solutions in isotonic, pH
adjusted sterile saline, either with our without a preservative
such as benzylalkonium chloride. Alternatively, for ophthalmic
uses, the pharmaceutical compositions may be formulated in an
ointment such as petrolatum.
[0300] The pharmaceutical compositions of this invention may also
be administered by nasal aerosol or inhalation. Such compositions
are prepared according to techniques well-known in the art of
pharmaceutical formulation and may be prepared as solutions in
saline, employing benzyl alcohol or other suitable preservatives,
absorption promoters to enhance bioavailability, fluorocarbons,
and/or other conventional solubilizing or dispersing agents.
[0301] Solutions or suspensions used for parenteral, intradermal,
subcutaneous, or topical application can include the following
components: a sterile diluent such as water for injection, saline
solution, fixed oils, polyethylene glycols, glycerine, propylene
glycol or other synthetic solvents; antibacterial agents such as
benzyl alcohol or methyl parabens; antioxidants such as ascorbic
acid or sodium bisulfite; chelating agents such as
ethylenediaminetetraacetic acid; buffers such as acetates, citrates
or phosphates and agents for the adjustment of tonicity such as
sodium chloride or dextrose. The parental preparation can be
enclosed in ampoules, disposable syringes or multiple dose vials
made of glass or plastic.
[0302] It should also be understood that a specific dosage and
treatment regimen for any particular patient will depend upon a
variety of factors, including the activity of the specific compound
employed, the age, body weight, general health, sex, diet, time of
administration, rate of excretion, drug combination, and the
judgment of the treating physician and the severity of the
particular disease or condition being treated.
[0303] A patient or subject in need of therapy using compounds as
described herein can be treated by administering to the patient
(subject) an effective amount of the compound including
pharmaceutically acceptable salts, solvates or polymorphs, thereof
optionally in a pharmaceutically acceptable carrier or diluent,
either alone, or in combination with other known agents.
[0304] Co-Administration
[0305] Disease states of conditions which may be treated using
compounds or compositions according to the present description
include, but not limited to, for example, cancer (e.g., prostate
cancer), and Kennedy's disease. In certain embodiments, the
therapeutic or pharmaceutical compositions comprise an effective
amount of an additional biologically or bioactive active agent,
e.g., an agent effective for the treatment of cancer, that is
co-administered.
[0306] The term "coadministration" or "combination therapy" shall
mean that at least two compounds or compositions are administered
to the patient at the same time, such that effective amounts or
concentrations of each of the two or more compounds may be found in
the patient at a given point in time. Although compounds according
to the present invention may be co-administered to a patient at the
same time, the term embraces both administration of two or more
agents at the same time or at different times, provided that
effective concentrations of all coadministered compounds or
compositions are found in the subject at a given time. In certain
preferred aspects of the present invention, one or more of the
present compounds described above, are coadministered in
combination with at least one additional bioactive agent,
especially including an anticancer agent. In particularly preferred
aspects of the invention, the co-administration of compounds
results in synergistic therapeutic, including anticancer
therapy.
[0307] In another aspect, the description provides a composition
comprising an effective amount of two or more of the PROTAC
compounds as described herein, and a pharmaceutically acceptable
carrier. In certain embodiments, the composition further comprises
an effective or synergistic amount of another bioactive agent that
is not a PROTAC compound.
[0308] Pharmaceutical compositions comprising combinations of an
effective amount of at least one bifunctional compound according to
the present invention, and one or more of the compounds otherwise
described herein, all in effective amounts, in combination with a
pharmaceutically effective amount of a carrier, additive or
excipient, represents a further aspect of the present
invention.
[0309] The term "bioactive agent" is used to describe an agent,
other than the PROTAC compounds described herein, which is used in
combination with the present compounds as an agent with biological
activity to assist in effecting an intended therapy, inhibition
and/or prevention/prophylaxis for which the present compounds are
used. Preferred bioactive agents for use herein include those
agents which have pharmacological activity similar to that for
which the present compounds are used or administered and include
for example, anti-cancer agents.
[0310] The term "additional anti-cancer agent" is used to describe
an anti-cancer agent, which may be combined with PROTAC compounds
according to the present description to treat cancer. These agents
include, for example, everolimus, trabectedin, abraxane, TLK 286,
AV-299, DN-101, pazopanib, GSK690693, RTA 744, ON 0910.Na, AZD 6244
(ARRY-142886), AMN-107, TKI-258, GSK461364, AZD 1152, enzastaurin,
vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263,
a FLT-3 inhibitor, an androgen receptor inhibitor, a VEGFR
inhibitor, an EGFR TK inhibitor, an aurora kinase inhibitor, a
PIK-1 modulator, a Bcl-2 inhibitor, an HDAC inhbitor, a c-MET
inhibitor, a PARP inhibitor, a Cdk inhibitor, an EGFR TK inhibitor,
an IGFR-TK inhibitor, an anti-HGF antibody, a PI3 kinase
inhibitors, an AKT inhibitor, a JAK/STAT inhibitor, a checkpoint-1
or 2 inhibitor, a focal adhesion kinase inhibitor, a Map kinase
kinase (mek) inhibitor, a VEGF trap antibody, pemetrexed,
erlotinib, dasatanib, nilotinib, decatanib, panitumumab, amrubicin,
oregovomab, Lep-etu, nolatrexed, azd2171, batabulin, ofatumumab,
zanolimumab, edotecarin, tetrandrine, rubitecan, tesmilifene,
oblimersen, ticilimumab, ipilimumab, gossypol, Bio 111,
131-I-TM-601, ALT-110, BIO 140, CC 8490, cilengitide, gimatecan,
IL13-PE38QQR, INO 1001, IPdR.sub.1 KRX-0402, lucanthone, LY317615,
neuradiab, vitespan, Rta 744, Sdx 102, talampanel, atrasentan, Xr
311, romidepsin, ADS-100380, sunitinib, 5-fluorouracil, vorinostat,
etoposide, gemcitabine, doxorubicin, liposomal doxorubicin,
5'-deoxy-5-fluorouridine, vincristine, temozolomide, ZK-304709,
seliciclib; PD0325901, AZD-6244, capecitabine, L-Glutamic acid,
N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]-
benzoyl]-, disodium salt, heptahydrate, camptothecin, PEG-labeled
irinotecan, tamoxifen, toremifene citrate, anastrazole, exemestane,
letrozole, DES (diethylstilbestrol), estradiol, estrogen,
conjugated estrogen, bevacizumab, IMC-IC11, CHIR-258);
3-[5-(methylsulfonylpiperadinemethyl)-indolylj-quinolone,
vatalanib, AG-013736, AVE-0005, the acetate salt of [D-Ser(Bu t)
6,Azgly 10] (pyro-Glu-His-Trp-Ser-Tyr-D-Ser(Bu
t)-Leu-Arg-Pro-Azgly-NH 2 acetate
[C.sub.59H.sub.84N.sub.18Oi.sub.4-(C.sub.2H.sub.4O.sub.2).sub.x
where x=1 to 2.4], goserelin acetate, leuprolide acetate,
triptorelin pamoate, medroxyprogesterone acetate,
hydroxyprogesterone caproate, megestrol acetate, raloxifene,
bicalutamide, flutamide, nilutamide, megestrol acetate, CP-724714;
TAK-165, HKI-272, erlotinib, lapatanib, canertinib, ABX-EGF
antibody, erbitux, EKB-569, PKI-166, GW-572016, lonafarnib,
BMS-214662, tipifarnib; amifostine, NVP-LAQ824, suberoyl analide
hydroxamic acid, valproic acid, trichostatin A, FK-228, SU11248,
sorafenib, KRN951, aminoglutethimide, arnsacrine, anagrelide,
L-asparaginase, Bacillus Calmette-Guerin (BCG) vaccine, adriamycin,
bleomycin, buserelin, busulfan, carboplatin, carmustine,
chlorambucil, cisplatin, cladribine, clodronate, cyproterone,
cytarabine, dacarbazine, dactinomycin, daunorubicin,
diethylstilbestrol, epirubicin, fludarabine, fludrocortisone,
fluoxymesterone, flutamide, gleevec, gemcitabine, hydroxyurea,
idarubicin, ifosfamide, imatinib, leuprolide, levamisole,
lomustine, mechlorethamine, melphalan, 6-mercaptopurine, mesna,
methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide,
octreotide, oxaliplatin, pamidronate, pentostatin, plicamycin,
porfimer, procarbazine, raltitrexed, rituximab, streptozocin,
teniposide, testosterone, thalidomide, thioguanine, thiotepa,
tretinoin, vindesine, 13-cis-retinoic acid, phenylalanine mustard,
uracil mustard, estramustine, altretamine, floxuridine,
5-deooxyuridine, cytosine arabinoside, 6-mecaptopurine,
deoxycoformycin, calcitriol, valrubicin, mithramycin, vinblastine,
vinorelbine, topotecan, razoxin, marimastat, COL-3, neovastat,
BMS-275291, squalamine, endostatin, SU5416, SU6668, EMD121974,
interleukin-12, IM862, angiostatin, vitaxin, droloxifene,
idoxyfene, spironolactone, finasteride, cimitidine, trastuzumab,
denileukin diftitox, gefitinib, bortezimib, paclitaxel,
cremophor-free paclitaxel, docetaxel, epithilone B, BMS-247550,
BMS-310705, droloxifene, 4-hydroxytamoxifen, pipendoxifene,
ERA-923, arzoxifene, fulvestrant, acolbifene, lasofoxifene,
idoxifene, TSE-424, HMR-3339, ZK186619, topotecan, PTK787/ZK
222584, VX-745, PD 184352, rapamycin,
40-O-(2-hydroxyethyl)-rapamycin, temsirolimus, AP-23573, RAD001,
ABT-578, BC-210, LY294002, LY292223, LY292696, LY293684, LY293646,
wortmannin, ZM336372, L-779,450, PEG-filgrastim, darbepoetin,
erythropoietin, granulocyte colony-stimulating factor,
zolendronate, prednisone, cetuximab, granulocyte macrophage
colony-stimulating factor, histrelin, pegylated interferon alfa-2a,
interferon alfa-2a, pegylated interferon alfa-2b, interferon
alfa-2b, azacitidine, PEG-L-asparaginase, lenalidomide, gemtuzumab,
hydrocortisone, interleukin-11, dexrazoxane, alemtuzumab,
all-transretinoic acid, ketoconazole, interleukin-2, megestrol,
immune globulin, nitrogen mustard, methylprednisolone, ibritgumomab
tiuxetan, androgens, decitabine, hexamethylmelamine, bexarotene,
tositumomab, arsenic trioxide, cortisone, editronate, mitotane,
cyclosporine, liposomal daunorubicin, Edwina-asparaginase,
strontium 89, casopitant, netupitant, an NK-1 receptor antagonist,
palonosetron, aprepitant, diphenhydramine, hydroxyzine,
metoclopramide, lorazepam, alprazolam, haloperidol, droperidol,
dronabinol, dexamethasone, methylprednisolone, prochlorperazine,
granisetron, ondansetron, dolasetron, tropisetron, pegfilgrastim,
erythropoietin, epoetin alfa, darbepoetin alfa and mixtures
thereof.
[0311] Methods of Treatment
[0312] In another aspect, the disclosure provides methods of
modulating protein ubiquitination and degradation in a subject,
e.g., a cell, a tissue, mammal, or human patient, the method
comprising administering an effective amount of a PROTAC compound
as described herein or a composition comprising an effective amount
of the same to a subject, wherein the compound or composition
comprising the same is effective in modulating protein
ubiquitination and degradation of the protein in the subject. In
certain embodiments, the protein is androgen receptor (AR).
[0313] In certain embodiments, the description provides a method
for regulating protein activity of the androgen receptor in a
patient in need comprising administering to said patient an amount
of a compound as described herein to a patient.
[0314] In still additional embodiments, the description provides a
method of treating a disease state or condition in a patient
wherein dysregulated protein activity is responsible for said
disease state or condition, said method comprising administering to
said patient an effective amount of a compound as described herein
to said patient in order to regulate said protein activity in said
patient. In certain embodiments, the protein is AR.
[0315] The terms "treat", "treating", and "treatment", etc., as
used herein, refer to any action providing a benefit to a patient
for which the present compounds may be administered, including the
treatment of any disease state or condition which is modulated
through the protein to which the present compounds bind. Disease
states or conditions, including cancer, which may be treated using
compounds according to the present invention are set forth
hereinabove.
[0316] In another aspect, the disclosure provides methods of
modulating AR protein ubiquitination and degradation in a subject,
e.g., a cell, a tissue, mammal, or human patient, the method
comprising administering an effective amount of a compound as
described herein or a composition comprising an effective amount of
the same to a subject, wherein the compound or composition
comprising the same is effective in modulating AR protein
ubiquitination and degradation of the protein in the subject.
[0317] In another aspect, the disclosure provides methods of
treating or ameliorating a symptom of a disease related to AR
activity in a subject, e.g., a cell, a tissue, mammal, or human
patient, the method comprising administering an effective amount of
a compound as described herein or a composition comprising an
effective amount of the same to a subject in need thereof, wherein
the compound or composition comprising the same is effective in
treating or ameliorating a symptom of a disease related to AR
activity in the subject.
[0318] In certain embodiments, the disease or disorder is asthma,
multiple sclerosis, cancer, prostate cancer, Kenney's disease,
ciliopathies, cleft palate, diabetes, heart disease, hypertension,
inflammatory bowel disease, mental retardation, mood disorder,
obesity, refractive error, infertility, Angelman syndrome, Canavan
disease, Coeliac disease, Charcot-Marie-Tooth disease, Cystic
fibrosis, Duchenne muscular dystrophy, Haemochromatosis,
Haemophilia, Klinefelter's syndrome, Neurofibromatosis,
Phenylketonuria, Polycystic kidney disease, (PKD1) or 4 (PKD2)
Prader-Willi syndrome, Sickle-cell disease, Tay-Sachs disease,
Turner syndrome. The method according to claim 48 wherein said
cancer is squamous-cell carcinoma, basal cell carcinoma,
adenocarcinoma, hepatocellular carcinomas, and renal cell
carcinomas, cancer of the bladder, bowel, breast, cervix, colon,
esophagus, head, kidney, liver, lung, neck, ovary, pancreas,
prostate, and stomach; leukemias; benign and malignant lymphomas,
particularly Burkitt's lymphoma and Non-Hodgkin's lymphoma; benign
and malignant melanomas; myeloproliferative diseases; sarcomas,
including Ewing's sarcoma, hemangiosarcoma, Kaposi's sarcoma,
liposarcoma, myosarcomas, peripheral neuroepithelioma, synovial
sarcoma, gliomas, astrocytomas, oligodendrogliomas, ependymomas,
gliobastomas, neuroblastomas, ganglioneuromas, gangliogliomas,
medulloblastomas, pineal cell tumors, meningiomas, meningeal
sarcomas, neurofibromas, and Schwannomas; bowel cancer, breast
cancer, prostate cancer, cervical cancer, uterine cancer, lung
cancer, ovarian cancer, testicular cancer, thyroid cancer,
astrocytoma, esophageal cancer, pancreatic cancer, stomach cancer,
liver cancer, colon cancer, melanoma; carcinosarcoma, Hodgkin's
disease, Wilms' tumor or teratocarcinomas. In certain embodiments,
the disease to be treated is cancer, e.g., prostate cancer, or
Kennedy's Disease. In a preferred embodiment, the subject is a
human.
[0319] In another aspect, the disclosure provides methods of
treating or ameliorating a symptom of a disease related to AR
activity in a subject, e.g., a cell, a tissue, mammal, or human
patient, the method comprising administering an effective amount of
a compound as described herein or a composition comprising an
effective amount of the same and an effective or synergistic amount
of another bioactive agent to a subject in need thereof, wherein
the composition comprising the same is effective in treating or
ameliorating a symptom of a disease related to AR activity in the
subject. In certain embodiments, the disease to be treated is
cancer, e.g., prostate cancer, or Kennedy's Disease. In a preferred
embodiment, the subject is a human. In certain additional
embodiments, the additional bioactive agent is an anti-cancer
agent.
[0320] In alternative aspects, the present invention relates to a
method for treating a disease state by degrading a protein or
polypeptide through which a disease state or condition is modulated
comprising administering to said patient or subject an effective
amount of at least one compound as described hereinabove,
optionally in combination with an additional bioactive agent. The
method according to the present invention may be used to treat a
large number of disease states or conditions including cancer, by
virtue of the administration of effective amounts of at least one
compound described herein.
[0321] In another aspect, the disclosure provides methods for
identifying the effects of the degradation of proteins of interest
in a biological system using compounds according to the present
invention.
[0322] Kits
[0323] In another aspect, the description provides kits comprising
compounds or compositions as described herein. The kit may be
promoted, distributed, or sold as a unit for performing the methods
of the present invention. In addition, the kits of the present
invention may preferably contain instructions which describe a
suitable use. Such kits can be conveniently used, e.g., in clinical
settings, to treat patients exhibiting symptoms of, e.g., cancer or
Kennedy's Disease.
EXAMPLES
[0324] General Chemistry--Analysis and Synthesis
[0325] Unless otherwise noted, all materials/reagents were obtained
from commercial suppliers and used without further purification.
Reactions were monitored by LC-MS and/or thin layer chromatography
(TLC) on silica gel 60 F254 (0.2 mm) pre-coated aluminum foil or
glass-backed and visualized using UV light. Flash chromatography
(alternatively called "ISCO chromatography") was performed using an
ISCO CombiFiash RF 75 PSI or equivalent with RediSep normal-phase
silica gel cartridges. Preparative TLC was performed on Whatman
LK6F Silica Gel 60A size 20.times.20 cm plates with a thickness of
1000 m or equivalent.
[0326] .sup.1HNMR (300 or 400 MHz) and .sup.13CNMR (100.6 MHz)
spectra were recorded on Bruker spectrometers at rt with TMS or the
residual solvent peak as the internal standard. The line positions
or multiples are given in (.delta.) and the coupling constants (J)
are given as absolute values in Hertz (Hz). The multiplicities in
.sup.1HNMR spectra are abbreviated as follows: s (singlet), d
(doublet), t (triplet), q (quartet), m (multiplet), br or broad
(broadened).
[0327] Preparative HPLC purifications were performed on a
Waters.RTM. UV-Directed Purification System equipped with 2545
Binary Gradient Module, 2767 Sample Manager and 2489 UV/Visible
Detector, controlled by MassLynx V4.1 software. All purification
work was completed using the following columns: Atlantis Prep T3
OBD Column, SunFire Prep C18 OBD Column and XBridge Prep Phenyl OBD
Column. The mobile phases were water (with 0.1% TFA or 0.01%
NH.sub.4HCO.sub.3) and acetonitrile; all reagents used were of HPLC
grade. The flow rate was 30 ml/min. After the columns, a 1:1000 LC
packings flow splitter allowed transfer of a small portion of the
eluent into the UV detector. The electrospray source was set at 3.0
kV capillary voltage, 30 V conevoltage, 110.degree. C. source
temperature, 350.degree. C. desolvation temperature, 600 L/h
desolvation gas flow, and 60 L/h cone gas flow. For the analyzer,
the multiplier was set at 550 for preparative tune method.
[0328] Analytical LC-MS data was collected on a Shimadzu LCMS-2020
with a mobile phase of 0.05% TFA in Acetonitrile (A) and 0.05% TFA
in HPLC grade water (B); 0.1% FA in Acetonitrile (A) and 0.1% FA in
HPLC grade water (B); Acetonitrile (A) and 5 mM ammonium
bicarbonate in HPLC grade water (B).
[0329] Shimadzu LCMS-2020 equipped with LC-20AD or 30AD pumps,
SPD-M20A PDA and Alltech 3300 ELSD. The system uses the following
conditions for 2.0 min, 2.6 min, 3 min, 3.6 min, 5 min or 5.6 min
run time.
[0330] 2.0 minute run: Kinetex XB-C 18 100A column, 2.6 rpm,
3.0.times.50 mm. The flow rate is 1.5 mL/min, the run time is 2.0
min, and the gradient profiles are 0.01 min 10% A, 1.10 min 100% A,
1.60 min 100% A, 1.70 min 10% A, 2.00 min 10% A.
[0331] 2.6 minute run: Shim-pack VP-ODS column, 2.2 m, 3.0.times.50
mm. The flow rate is 1.5 mL/min, the run time is 2.6 min, and the
gradient profiles are 0.01 min 5% A, 1.20 min 100% A, 2.20 min 100%
A, 2.30 min 5% A, 2.60 min 5% A.
[0332] 3.0 minute run: ACE UltraCore Super C18 column, 2.5 m,
3.0.times.50 mm. The flow rate is 1.5 mL/min, the run time is 3.0
min, and the gradient profiles are 0.01 min 10% A, 2.00 min 95% A,
2.60 min 95% A, 2.70 min 10% A, 3.00 min 10% A.
[0333] 3.6 minute run: Shim-pack VP-ODS column, 2.2 am,
3.0.times.50 mm. The flow rate is 1.5 mL/min, the run time is 3.6
min, and the gradient profiles are 0.01 min 5% A, 2.20 min 100% A,
3.20 min 100% A, 3.30 min 5% A, 3.60 min 5% A.
[0334] 5.0 minute run: ACE UltraCore Super C18 column, 2.5 am,
3.0.times.50 mm. The flow rate is 1.5 mL/min, the run time is 5.0
min, and the gradient profiles are 0.01 min 10% A, 4.00 min 60% A,
4.70 min 60% A, 4.80 min 10% A, 5.00 min 10% A.
[0335] 5.6 minute run: Shim-pack VP-ODS column, 2.2 jam,
3.0.times.50 mm. The flow rate is 1.5 mL/min, the run time is 5.6
min, and the gradient profiles are 0.01 min 5% A, 3.00 min 50% A,
5.00 min 50% A, 5.20 min 5% A, 5.60 min 5% A
[0336] Alternatively, analytical LC-MS data was collected on
Agilent infinity 1260 LC, Agilent 6230 TOF mass spectrometer. The
analysis is conducted on a Poroshell 120 EC C18 column (50
mm.times.3.0 mm internal diameter 2.7 .mu.m packing diameter) at
45.degree. C.
[0337] The solvents employed are:
[0338] A=0.1% v/v solution of formic acid in water.
[0339] B=0.1% v/v solution of formic acid in acetonitrile.
[0340] The gradient employed are as follows:
TABLE-US-00001 TABLE 1 Exemplary Column Gradients Time Flow Rate
(minutes) (mL/min) % A % B 0 1 95 5 0.5 1 95 5 3.0 1 1 99 4.0 1 1
99 4.1 1 95 5 4.5 1 95 5
[0341] The UV detection is an averaged signal from wavelength of
210 nm to 350 nm and mass spectra are recorded on a mass
spectrometer using positive mode electrospray ionization.
[0342] Unless otherwise noted, all compounds were prepared with
LC-MS purity >95%.
[0343] Chemical Synthesis
[0344] A PROTAC of ABM-L-ULM, or their pharmaceutically acceptable
salts, polymorphic forms, prodrugs, solvate forms and isotope
containing derivatives thereof, may be prepared by the general
approaches described below (scheme 3-4), together with synthetic
methods known in the art of organic chemistry, or modifications and
derivatizations that are familiar to those of ordinary skill in the
art.
[0345] Scheme 3:
##STR00082##
[0346] Scheme 4:
##STR00083##
[0347] More specifically, The compounds of the Formula I, or their
pharmaceutically acceptable salts, may be prepared by the general
approaches described below (scheme 5-6), together with synthetic
methods known in the art of organic chemistry, or modifications and
derivatizations that are familiar to those of ordinary skill in the
art.
[0348] Scheme 5:
##STR00084##
[0349] Scheme 6:
##STR00085##
[0350] In schemes 3-6, L, ABM, ULM groups, W.sup.1, W.sup.2,
W.sup.3, W.sup.4, X.sup.1, X.sup.2, Y.sup.1, Y.sup.2, R.sup.1,
R.sup.2, and R.sup.P are as define above. RG.sup.1, RG.sup.2,
RG.sup.3 and RG.sup.4 are moieties with suitable reacting groups
that would be necessary to enable the synthetic chemistry to
connect intermediate A, intermediate L and intermediate V together
into PROTAC compounds of Formula I via covalent bond formation
chemistries. These chemistries, depends on specific reacting
groups, include but not limited to, amide formation, ester
formation, carbamate formation, urea formation, ether formation,
amine formation and various C--C, C.dbd.C bond formation. The stage
1 and stage 2 transformations in scheme 5 and scheme 6 may involve
1 or multiple synthetic steps. These are routine methods known in
the art such as those methods disclosed in standard reference books
such as the Compendium of Organic Synthetic Methods, Vol. I-VI
(Wiley-Interscience); or the Comprehensive Organic Transformations,
by R. C. Larock (Wiley-Interscience). Unless otherwise indicated,
the substituents in the schemes are defined as above. Isolation and
purification of the products is accomplished by standard
procedures, which are known to a chemist of ordinary skill.
[0351] In certain examples, for the chemistry described in schemes
3-6, RG.sup.1 is a moiety with a suitable nucleophile such as --OH
and RG.sup.2 is a moiety with a suitable leaving group such as
halogen, -OMs, or -OTs. In a typical procedure, a RG.sup.1
containing intermediate is reacted with a RG.sup.2 containing
intermediate in a suitable solvent. Suitable solvents include, but
are not limited to, water, ethers such as THF, glyme, and the like;
chlorinated solvents such as DCM, 1,2-dichloroethane (DCE) or CHCI3
and the like, toluene, benzene and the like, DMF, DMSO, MeCN. If
desired, mixtures of these solvents are used. A base may be added
to the reaction to facilitate the reaction. Suitable bases include,
but are not limited to, Cs.sub.2CO.sub.3, K.sub.2CO.sub.3, and the
like. The above process may be carried out at temperatures between
about -78.degree. C. and about 150.degree. C. Preferably, the
reaction is carried out between about 20.degree. C. and about
120.degree. C.
[0352] In another example, chemistry described in schemes 3-6,
RG.sup.3 is a moiety contains a --COOH group and RG.sup.4 is a
moiety contains a suitable amine group. In a typical procedure, a
RG.sup.3 containing intermediate is reacted with a RG.sup.4
containing intermediate in a suitable solvent in the presence of a
suitable amide coupling reagent. Suitable solvents include, but are
not limited to, water, ethers such as THF, glyme, and the like;
chlorinated solvents such as DCM, 1,2-dichloroethane (DCE) or
CHCl.sub.3 and the like, toluene, benzene and the like, DMF, DMSO,
MeCN. If desired, mixtures of these solvents are used. In this
case, the preferred solvents are DMF or DCM. A suitable amide
coupling reagent include, but are not limited to, DCC, EDC, HATU,
HBTU, PyBOP and the like. A base is often added to the reaction.
Suitable bases include, but are not limited to, TEA, DIPEA, and the
like. The above process may be carried out at temperatures between
about -78.degree. C. and about 150.degree. C. Preferably, the
reaction is carried out between about 0.degree. C. and about
100.degree. C.
[0353] Although not explicitly shown in schemes 3-6, a chemist of
ordinary skill would realize that during any of the synthetic
sequences it may be necessary and/or desirable to protect sensitive
or reactive groups on any of the molecules concerned. This can be
achieved by means of conventional protecting groups, such as those
described in T. W. Greene, Protective Groups in Organic Chemistry,
John Wiley & Sons (1981); T. W. Greene and P. G. M. Wuts,
Protective Groups in Organic Chemistry, John Wiley & Sons
(1991), and T. W. Greene and P. G. M. Wuts, Protective Groups in
Organic Chemistry, John Wiley & Sons, 1999, which are hereby
incorporated by reference in their entireties.
[0354] When a general or exemplary synthetic procedure is referred
to, one skilled in the art can readily determine the appropriate
reagents, if not indicated, extrapolating from the general or
exemplary procedures. Some of the general procedures are given as
examples for preparing specific compounds. One skilled in the art
can readily adapt such procedures to the synthesis of other
compounds. Representation of an unsubstituted position in
structures shown or referred to in the general procedures is for
convenience and does not preclude substitution as described
elsewhere herein. For specific groups that can be present, either
as R groups in the general procedures or as optional substituents
not shown, refer to the descriptions in the remainder of this
document, including the claims, summary and detailed
description.
[0355] The process to produce compounds of the present invention is
preferably carried out at about atmospheric pressure although
higher or lower pressures can be used if desired. Substantially
equimolar amounts of reactants are preferably used although higher
or lower amounts can also be used.
[0356] The compounds of Formulae II-IV (below), or their
pharmaceutically acceptable salts, may be prepared by the methods
similar to chemistry illustrated above for synthesis of compounds
of Formula I (scheme 3-6), together with synthetic methods known in
the art of organic chemistry, or modifications and derivatizations
that are familiar to those of ordinary skill in the art:
##STR00086##
[0357] For compounds of Formulae II-IV, L, ABM, ULM groups,
W.sup.1, W.sup.2, W.sup.3, W.sup.4, X.sup.1, X.sup.2, Y.sup.1,
Y.sup.2, R.sup.1, R.sup.2, R.sup.P, R.sup.a, R.sup.b, R.sup.c and
R.sup.d are as define above.
[0358] In certain embodiments, ABM compounds are active without
forming bifunctional compounds of formula II-IV.
Synthesis of ABM Moieties
ABM-1:
2-chloro-4-(3-(4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazol-
idin-1-yl)benzonitrile
##STR00087##
[0359] Step 1: Synthesis of 2-chloro-4-isothiocyanatobenzonitrile
(B)
[0360] To a stirred solution of 4-amino-2-chlorobenzonitrile (A, 1
g, 6.55 mmol) in dichloromethane (9 mL) was added sodium
bicarbonate (2.21 g, 26.31 mmol) and water (9 mL). The resulting
mixture was cooled to 0.degree. C., to which thiophosgene (817 mg,
7.11 mmol) was added in drop wise in 30 min at 0.degree. C. The
resulting mixture was then warmed up to rt and stirred at rt for 1
h. The reaction mixture was diluted with dichloromethane (200 mL),
washed with brine (50 mL.times.2), dried over anhydrous sodium
sulfate and then concentrated under reduced pressure to give a
crude residue. The residue was purified by flash silica gel
chromatography (eluent: ethyl acetate/petroleum ether (v:v=1:30))
to give desired product (yield: 71%) .sup.1HNMR (400 MHz,
CDCl.sub.3): .delta. 7.69 (d, J=8.0 Hz, 1H), 7.38 (s, 1H), 7.28 (m,
1H);
Step 2: Synthesis of
2-chloro-4-[3-(4-hydroxyphenyl)-5-imino-4,4-dimethyl-2-sulfanylideneimida-
zolidin-1-yl]benzonitrile (D)
[0361] To a stirred solution of
2-chloro-4-isothiocyanatobenzonitrile (B, 399 mg, 2.05 mmol) in
toluene (5 mL) was added
2-[(4-hydroxyphenyl)amino]-2-methylpropanenitrile (C, 300 mg, 1.70
mmol) and 4-dimethylaminopyridine (312 mg, 2.55 mmol). The
resulting solution was then heated in an oil bath to 100.degree. C.
and stirred at the same temperature for 16 h. LC-MS indicated
formation of the desired product. The reaction mixture was
concentrated under vacuum to give a crude reside which was purified
by flash silica gel chromatography (eluent: ethyl acetate/petroleum
ether (v:v=1:1)) to give desired product (yield: 48%) as a brown
solid. LC-MS (ES.sup.+): m/z 370.95 [MH.sup.+], t.sub.R=0.74 min
(2.0 minute run);
Step 3: Synthesis of
2-chloro-4-[3-(4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-sulfanylideneimidazo-
lidin-1-yl]benzonitrile (ABM-1)
[0362] To a stirred solution of
2-chloro-4-[3-(4-hydroxyphenyl)-5-imino-4,4-dimethyl-2-sulfanylideneimida-
zolidin-1-yl]benzonitrile (D, 300 mg, 0.81 mmol) in methanol (6 mL)
was added aqueous hydrogen chloride (2N, 3.0 mL). The resulting
solution was then heated in an oil bath to 100.degree. C. and
stirred at the same temperature for 2 h. The reaction mixture was
diluted with water (30 mL), extracted with ethyl acetate (60
mL.times.3), washed with water (50 mL), dried over anhydrous sodium
sulfate and concentrated under vacuum to give titled product
(yield: 93%) as a yellow solid, which was used for the next step
without any further purifications. LC-MS (ES.sup.+): m/z 372.00
[MH.sup.+], t.sub.R=0.97 min (2.0 minute run).
[0363] Unless otherwise noted, the following intermediates and
their analogs (for examples, but not limited to, analogs with
substitutions such as halogens) were synthesized according to
similar procedures described above for the synthesis of ABM-1, by
utilizing corresponding starting materials and reagents.
ABM-2:
2-fluoro-4-(3-(4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazol-
idin-1-yl)benzonitrile
##STR00088##
[0364] ABM-3:
4-(3-(4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(t-
rifluoromethyl)benzonitrile
##STR00089##
[0365] ABM-4:
5-(3-(4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-3-(t-
rifluoromethyl)picolinonitrile
##STR00090##
[0366] ABM-5:
4-(3-(4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-me-
thoxybenzonitrile
##STR00091##
[0367] ABM-6:
4-(3-(4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-me-
thylbenzonitrile
##STR00092##
[0368] ABM-7:
3-chloro-5-(3-(4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-
-yl)picolinonitrile
##STR00093##
[0369] ABM-8:
4-(1-(4-hydroxyphenyl)-4-oxo-2-thioxo-8-oxa-1,3-diazaspiro[4.5]decan-3-yl-
)-2-(trifluoromethyl)benzonitrile
##STR00094##
[0370] ABM-9:
4-(1-(4-hydroxyphenyl)-8-methyl-4-oxo-2-thioxo-1,3,8-triazaspiro[4.5]deca-
n-3-yl)-2-(trifluoromethyl)benzonitrile
##STR00095##
[0371] ABM-10:
4-(5-(4-hydroxyphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl)-2-(t-
rifluoromethyl)benzonitrile
##STR00096##
[0372] ABM-11:
5-(5-(4-hydroxyphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl)-3-(t-
rifluoromethyl)picolinonitrile
##STR00097##
[0373] ABM-12:
4-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoim-
idazolidin-1-yl)phenyl)butanoic Acid
##STR00098##
[0374] ABM-13:
2-chloro-4-(3-(4'-hydroxybiphenyl-4-yl)-4,4-dimethyl-5-oxo-2-thioxoimidaz-
olidin-1-yl)benzonitrile
##STR00099##
[0375] ABM-14:
4-(3-(4'-hydroxybiphenyl-4-yl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1--
yl)-2-(trifluoromethyl)benzonitrile
##STR00100##
[0376] ABM-15:
5-(3-(4'-hydroxybiphenyl-4-yl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1--
yl)-3-(trifluoromethyl)picolinonitrile
##STR00101##
[0377] ABM-16:
4-(3-(3-fluoro-4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-
-yl)-2-(trifluoromethyl)benzonitrile
##STR00102##
[0378] ABM-17:
1-(4-hydroxyphenyl)-5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2--
thioxoimidazolidin-4-one
##STR00103##
[0379] ABM-18:
4-(3-(3,5-difluoro-4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolid-
in-1-yl)-2-(trifluoromethyl)benzonitrile
##STR00104##
[0380] ABM-19:
4-(3-(4-hydroxyphenyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-(triflu-
oromethyl)benzonitrile
##STR00105##
[0381] ABM-20:
4-(3-(6-hydroxypyridin-3-yl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl-
)-2-(trifluoromethyl)benzonitrile
##STR00106##
[0382] ABM-21:
2-chloro-4-(3-(3-fluoro-4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimida-
zolidin-1-yl)benzonitrile
##STR00107##
[0383] ABM-22:
4-(3-(3-fluoro-4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-
-yl)-2-methoxybenzonitrile
##STR00108##
[0384] ABM-23:
5-(3-(3-fluoro-4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-
-yl)-3-(trifluoromethyl)picolinonitrile
##STR00109##
[0385] ABM-24:
5-(3-(2-fluoro-4'-hydroxybiphenyl-4-yl)-4,4-dimethyl-5-oxo-2-thioxoimidaz-
olidin-1-yl)-3-(trifluoromethyl)picolinonitrile
##STR00110##
[0386] ABM-25:
4-(4,4-dimethyl-5-oxo-3-(4-(piperidin-4-yl)phenyl)-2-thioxoimidazolidin-1-
-yl)-2-(trifluoromethyl)benzonitrile
##STR00111##
[0387] ABM-26:
trans-2-Chloro-4-[3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrile
##STR00112##
[0388] ABM-27:
cis-2-Chloro-4-[3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrile
##STR00113##
[0389] ABM-28: trans
6-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyri-
dazine-3-carboxamide
##STR00114##
[0390] ABM-29: trans tert-Butyl
N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]carbamate
##STR00115##
[0391] ABM-30: trans
4-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benz-
amide
##STR00116##
[0392] Step 1: Synthesis of tert-butyl
(4-((trans-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carb-
amoyl)phenyl)carbamate
[0393] A suspension of 4-((tert-butoxycarbonyl)amino)benzoic acid
(1.50 g, 6.34 mmol) in methylene dichloride (40 mL) was charged
with N,N-diisopropylethylamine (3.30 mL, 19.0 mmol), followed by
4-(trans-3-amino-2,2,4,4-tetramethylcyclobutoxy)-2-chlorobenzonitrile
hydrochloride (2.0 g, 6.34 mmol). The mixture was stirred for
several minutes and then charged with HATU (2.41 g, 6.34 mmol). The
reaction mixture was allowed to stir at room temperature for 2 h.
The mixture was diluted with methylene dichloride (40 mL), washed
with aqueous 1N HCl (2.times.), saturated aqueous sodium
bicarbonate (2.times.), brine, and dried over anhydrous
Na.sub.2SO.sub.4. The crude product was used in next step;
Step 2: synthesis of trans
4-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]benz-
amide
[0394] 4M HCl in Dioxane (1.38 mL, 40.0 mmol) was added to a
pre-mixed solution of tert-butyl
(4-((trans-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl)carb-
amoyl)phenyl)carbamate (2.00 g, 4.01 mmol) in MeOH (2 mL) and left
to stir at rt for 1 h till completion. The reaction mixture was
concentrated in vacuo to a solid, which was dissolved with 5% MeOH
in DCM. The organic layer was washed with sodium bicarbonate
(2.times.), filtered through a Biotage Universal Phase Separator
and then concentrated in vacuo to a solid. The crude product was
recrystallized from EtOH/Heptanes to afford the desired product as
a white solid, 1.2 g, 75% yield. .sup.1H NMR (400 MHz, METHANOL-d4)
.delta. 7.72 (d, J=8.80 Hz, 1H), 7.61 (d, J=8.61 Hz, 2H), 7.13 (d,
J=2.35 Hz, 1H), 6.98 (dd, J=2.45, 8.71 Hz, 1H), 6.69 (d, J=8.61 Hz,
2H), 4.28 (s, 1H), 4.12 (s, 1H), 1.27 (s, 6H), 1.22 (s, 6H). LC-MS
(ES+): m/z 398.16/400.15 [MH.sup.+].
ABM-31: trans
5-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyra-
zine-2-carboxamide
##STR00117##
[0395] ABM-32: trans
2-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyri-
midine-5-carboxamide
##STR00118##
[0396] ABM-33:
4-Methoxy-N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclo-
butyl]benzamide
##STR00119##
[0397] ABM-34: trans
1-(2-Hydroxyethyl)-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcycl-
obutyl]-1H-pyrazole-4-carboxamide
##STR00120##
[0398] ABM-35: trans
6-Amino-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]pyri-
dine-3-carboxamide
##STR00121##
[0399] ABM-36: trans
4-[(5-Hydroxypentyl)amino]-N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetrame-
thylcyclobutyl]benzamide
##STR00122##
[0400] ABM-37: trans tert-Butyl
2-({5-[(4-{[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]car-
bamoyl}phenyl)aminopentyl}oxy)acetate
##STR00123##
[0401] Synthesis of ULM Moieties
ULM-1:
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-meth-
ylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
##STR00124## ##STR00125##
[0402] Step 1: Synthesis of
4-(4-methyl-1,3-thiazol-5-yl)benzonitrile (G)
[0403] To a stirred solution of 4-bromobenzonitrile (E, 20 g,
109.88 mmol) in DMA (250 mL) under a nitrogen atmosphere was added
4-methyl-1,3-thiazole (F, 21.88 g, 220.67 mmol), palladium (II)
acetate (743 mg, 3.31 mmol) and potassium acetate (21.66 g, 220.71
mmol) at rt. The resulting solution was heated to 150.degree. C.
and stirred at this temperature for 5 h, LC-MS indicated formation
of the desired product. The reaction was cooled to rt, diluted with
1 L of water and extracted with ethyl acetate (300 mL.times.3). The
organic layers were combined, washed with saturated aqueous
solution of sodium chloride (200 mL), dried over anhydrous sodium
sulfate and then concentrated under reduced pressure to give a
crude residue, which was purified by flash silica gel
chromatography (eluent: ethyl acetate/petroleum ether, v:v=1:5) to
give the G (yield: 91%) as a white solid.
Step 2: Synthesis of
[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methanamine (H)
[0404] To a stirred solution of
4-(4-methyl-1,3-thiazol-5-yl)benzonitrile (G, 35.0 g, 174.8 mmol)
in tetrahydrofuran (1000 mL) was added LiAlH.sub.4 (20.0 g, 526.3
mmol) in portions at 0.degree. C. in 10 min under a nitrogen
atmosphere. The resulting solution was then stirred at 60.degree.
C. for 3 h. LC-MS indicated formation of the desired product. The
reaction was then cooled to 0.degree. C., quenched by the addition
water (20 mL, added slowly), aq. solution of NaOH (15%, 20 mL) and
water (60 mL). The resulting mixture was then extracted with ethyl
acetate (300 mL.times.2). The organic layers were combined, washed
with saturated aqueous solution of sodium chloride (100 mL), dried
over anhydrous sodium sulfate and then concentrated under reduced
pressure to give a crude residue, which was purified by flash
silica gel chromatography (eluent: dichloromethane/methanol
(v:v=10:1)) to give H (yield: 56%) as a yellow oil.
Step 1: synthesis of tert-butyl
(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}carbamo-
yl)pyrrolidine-1-carboxylate (J)
[0405] To a stirred solution of
(2S,4R)-1-[(tert-butoxy)carbonyl]-4-hydroxypyrrolidine-2-carboxylic
acid (I, 2.7 g, 11.7 mmol) in N,N-dimethylformamide (20 mL) was
added DIEA (2.52 g, 19.50 mmol), HATU (4.47 g, 11.76 mmol) and
[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methanamine (H, 2.0 g, 9.79
mmol) at rt. The resulting mixture was stirred at rt overnight,
LC-MS indicated formation of the desired product. The reaction
mixture was diluted with water (20 mL) and extracted with ethyl
acetate (50 mL.times.3). The organic layers were combined, washed
with saturated aqueous solution of sodium chloride (50 mL), dried
over anhydrous sodium sulfate and then concentrated under reduced
pressure to give a crude residue, which was purified by flash
silica gel chromatography (eluent: dichloromethane/methanol
(v:v=20:1)) to give J (yield: 56%) as a yellow solid.
Step 2: Synthesis of
(2S,4R)-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolid-
ine-2-carboxamide hydrochloride (K)
[0406] To a stirred solution of tert-butyl
(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}carbamo-
yl)pyrrolidine-1-carboxylate (J, 45 g, 107.78 mmol), was added a
solution of hydrogen chloride in dioxane (4N, 300 mL). The
resulting solution was stirred at 20.degree. C. for 2 h. The solids
were collected by filtration to give K (yield: 98%) as a yellow
solid, which was used for the next step without any further
purification.
Step 3: Synthesis of tert-butyl
N-[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phenyl]met-
hyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
(M)
[0407] To a stirred solution of
(2S)-2-{[(tert-butoxy)carbonyl]amino}-3,3-dimethylbutanoic acid (L,
15.7 g, 68.0 mmol) in N,N-dimethylformamide (500 mL) was added DIEA
(29.2 g, 225.9 mmol), HATU (25.9 g, 68.1 mmol) and
(2S,4R)-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolid-
ine-2-carboxamide hydrochloride (K, 20.0 g, 56.5 mmol) at rt.
[0408] The resulting solution was stirred at rt for 16 h, LC-MS
indicated formation of the desired product. The reaction mixture
was diluted by water (200 mL) and extracted with ethyl acetate (200
mL.times.3). The organic layers were combined, washed with
saturated aqueous solution of sodium chloride (50 mL.times.2),
dried over anhydrous sodium sulfate and then concentrated under
reduced pressure to give a crude residue, which was purified by
flash silica gel chromatography (eluent: ethyl acetate/petroleum
ether (v:v=2:1)) to give M (yield: 51%) as a yellow solid.
Step 4: Synthesis of
(2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1-
,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide
hydrochloride (ULM-1)
[0409] To a stirred solution of tert-butyl
N-[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phenyl]met-
hyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
(M, 12 g, 22.61 mmol) in dioxane (20 mL) was added a solution of
hydrogen chloride in dioxane (4N, 80 mL) at rt. The resulting
solution was stirred at rt for 2 h, LC-MS indicated formation of
the desired product. Precipitated solids were collected by
filtration to give ULM-1 (yield: 48%) as a yellow solid. .sup.1HNMR
(400 MHz, CD.sub.3OD): .delta. 9.84-9.82 (s, 1H), 7.58-7.54 (m,
4H), 4.71-4.41 (m, 4H), 4.13-4.08 (m, 1H), 3.86-3.71 (m, 2H), 3.36
(s, 1H), 2.60-2.58 (s, 3H), 2.35-2.07 (m, 2H), 1.19-1.12 (m, 9H).
LC-MS (ES.sup.+): m/z 431.11 [MH.sup.+], t.sub.R=0.73 min (2.0
minute run).
ULM-2:
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(thiazo-
l-5-yl)benzyl)pyrrolidine-2-carboxamide
##STR00126##
[0411] ULM-2 was synthesized according to similar procedure
described above for the synthesis of ULM-1, utilizing
4-bromobenzonitrile and 1,3-thiazole as starting materials. LC-MS
(ES.sup.+): m/z 417.10 [MH.sup.+], t.sub.R=0.51 min (2.0 minute
run).
ULM-3:
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N--((S)-1-(4-
-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide
##STR00127##
[0412] Step 1: Synthesis of tert-butyl
N-[(1S)-1-(4-bromophenyl)ethyl]carbamate (O)
[0413] To a stirred mixture of (1S)-1-(4-bromophenyl)ethan-1-amine
(N, 10.0 g, 49.98 mmol) in dichloromethane (100 mL) was added
Et.sub.3N (10.0 g, 99.01 mmol) and (Boc).sub.2O (13.0 g, 59.63
mmol). The resulting mixture was stirred at rt for 2 h. The bulk of
solvent was then removed under reduced pressure to give a crude
residue, which was purified by flash silica gel chromatography
(eluent: ethyl acetate/petroleum ether, v:v=1:10) to give O (yield:
99%) as a white solid.
Step 2: Synthesis of tert-butyl
N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamate
(P)
[0414] To a stirred solution of tert-butyl
N-[(1S)-1-(4-bromophenyl)ethyl]carbamate (0, 15.0 g, 49.97 mmol) in
DMA (100 mL), under an atmosphere of nitrogen, was added
4-methyl-1,3-thiazole (9.9 g, 99.84 mmol), potassium acetate (9.8
g, 99.86 mmol) and Pd(OAc).sub.2 (112.5 mg, 0.50 mmol) at rt. The
resulting mixture was then stirred at 120.degree. C. for 2 h. The
reaction mixture was then cooled to rt, diluted by water (120 mL),
and extracted with ethyl acetate (200 mL.times.3). The organic
layers were combined, dried over anhydrous sodium sulfate and then
concentrated under reduced pressure to give a crude residue, which
was purified by flash silica gel chromatography (eluent: ethyl
acetate/petroleum ether, v:v=1:5) to give P (yield: 47%) as a white
solid. LC-MS (ES.sup.+): m/z 319.13 [MH.sup.+], t.sub.R=0.97 min
(2.0 minute run).
Step 3. Synthesis of
(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethan-1-amine
hydrochloride (Q)
[0415] To a stirred solution of tert-butyl
N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]carbamate (P,
7.5 g, 23.55 mmol) in methanol (20 mL) was bubbled in hydrogen
chloride (gas) at rt for 2 h. Then the resulting mixture was
concentrated under vacuum to give Q (yield: 86%) as a white solid,
which was used in the next step without any further
purifications.
[0416] Intermediate Q was converted to ULM-3 in a similar manner as
described for the conversion of H to ULM-1. .sup.1H NMR (300 MHz,
DMSO): .delta. 8.99 (s, 1H), 8.57-8.55 (d, J=7.8 Hz, 1H), 8.01 (br.
s, 3H), 7.46-7.43 (d, J=8.4 Hz, 2H), 7.39-7.37 (d, J=8.4 Hz, 2H),
4.98-4.90 (m, 1H), 4.57-4.51 (m, 1H), 4.34 (br. s, 1H), 3.94-3.92
(m, 1H), 3.69-3.66 (m, 1H), 3.53-3.49 (m, 1H), 2.52 (s, 3H),
2.10-2.07 (m, 1H), 1.83-1.81 (m, 1H), 1.40-1.30 (m, 3H), 1.03 (s,
9H). LC-MS (ES.sup.+): m/z 445.05 [MH.sup.+], t.sub.R=0.53 min (2.0
minute run).
ULM-4:
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(oxazol-
-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride
##STR00128##
[0417] Step 1: 1. Synthesis of 4-(1,3-oxazol-5-yl)benzonitrile
(S)
[0418] To a stirred solution of 4-formylbenzonitrile (R, 1.0 g,
7.63 mmol) in methanol (40 mL) was added
[[(4-methylbenzene)sulfonyl]methyl](methyliumylidyne)azanuide (1.6
g, 8.40 mmol) and potassium carbonate (1.4 g, 9.91 mmol), the
resulting mixture was stirred at rt for 1.5 h. The bulk of solvent
was then removed under reduced pressure. The residue was diluted
with saturated aqueous sodium bicarbonate (20 mL) and was extracted
with dichloromethane (30 mL.times.3). The organic layers were
combined, washed with brine (30 mL), dried over anhydrous sodium
sulfate and concentrated under vacuum to give a crude product,
which was purified by re-crystallization using dichloromethane and
hexane to give S (1.0 g) as a white solid. .sup.1H NMR (400 MHz,
DMSO) .delta. 8.56 (s, 1H), 7.97-7.83 (m, 5H); LC-MS (ES.sup.+):
m/z 170.95 [MH.sup.+], t.sub.R=0.79 min (2.0 minute run).
Step 2. Synthesis of [4-(1,3-oxazol-5-yl)phenyl]methanamine (T)
[0419] To a stirred solution of 4-(1,3-oxazol-5-yl)benzonitrile (S,
900.0 mg, 5.29 mmol) in methanol (15 mL) was added Raney-Ni (900
mg) and aq. ammonium hydroxide (3.0 mL). Hydrogen gas was then
introduced into the reaction mixture via a balloon. The resulting
mixture was stirred at rt for 16 h. The solids were then removed by
filtration and the solution was concentrated under vacuum to give T
(yield: 81%) as brown oil, which was used in the next step without
any further purifications. LC-MS (ES.sup.+): m/z 175.90 [MH.sup.+],
t.sub.R=0.26 min (2.0 minute run).
[0420] Intermediate T was converted to ULM-4 in a similar manner as
described for the conversion of H to ULM-1. LC-MS (ES.sup.+): m/z
400.96 [MH.sup.+], t.sub.R=0.66 min (2.0 minute run).
ULM-5:
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-meth-
yloxazol-5-yl)benzyl)pyrrolidine-2-carboxamide
##STR00129##
[0422] [4-(4-methyl-1,3-oxazol-5-yl)phenyl]methanamine (V) was
synthesized according to similar procedure described above for the
synthesis of [4-(1,3-oxazol-5-yl)phenyl]methanamine (T).
[0423] Intermediate V was converted to ULM-5 in a similar manner as
described for the conversion of H to ULM-1. LC-MS (ES.sup.+): m/z
415.10 [MH.sup.+], t.sub.R=1.17 min (2.6 minute run).
ULM-6:
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-N-(4-chlorobenzyl)-4-h-
ydroxypyrrolidine-2-carboxamide hydrochloride
##STR00130##
[0425] ULM-6 was synthesized according to similar procedure
described above for the synthesis of ULM-1, utilizing
4-chlorobenzonitrile as the starting material.
ULM-7:
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-N-(4-cyanobenzyl)-4-hy-
droxypyrrolidine-2-carboxamide hydrochloride
##STR00131##
[0427] ULM-7 was synthesized according to similar procedure
described above for the synthesis of ULM-1, utilizing
4-cyanobenzonitrile as the starting material.
ULM-8:
(2S,4R)-1-((S)-2-amino-3-methylbutanoyl)-4-hydroxy-N-(4-(4-methylth-
iazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride
##STR00132##
[0429] ULM-8 was synthesized according to similar procedure
described above for the synthesis of ULM-1, utilizing
(S)-2-(tert-butoxycarbonylamino)-3-methylbutanoic acid and
4-methyl-1,3-thiazole (F) as starting materials.
ULM-9:
(2S,4R)-1-((S)-2-amino-3-methylbutanoyl)-4-hydroxy-N-(4-(thiazol-5--
yl)benzyl)pyrrolidine-2-carboxamide hydrochloride
##STR00133##
[0431] ULM-9 was synthesized according to similar procedure
described above for the synthesis of ULM-1, utilizing
(S)-2-(tert-butoxycarbonylamino)-3-methylbutanoic acid and
1,3-thiazole as starting materials.
ULM-10:
(2S,4R)-1-((S)-2-amino-3-methylbutanoyl)-4-hydroxy-N-(4-(4-methylo-
xazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride
##STR00134##
[0433] ULM-10 was synthesized according to similar procedure
described above for the synthesis of ULM-5, utilizing
(S)-2-(tert-butoxycarbonylamino)-3-methylbutanoic acid as starting
material.
ULM-11:
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(1-met-
hyl-1H-pyrazol-5-yl)benzyl)pyrrolidine-2-carboxamide
hydrochloride
##STR00135##
[0435] ULM-11 was synthesized according to similar procedure
described above for the synthesis of ULM-1, utilizing
1-methylpyrazole as the starting material.
ULM-12:
(2S,4R)-4-tert-butoxy-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)-
-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamid-
e
##STR00136## ##STR00137##
[0436] Step 1: Synthesis of
2-hydroxy-4-(4-methyl-1,3-thiazol-5-yl)benzonitrile (BH)
[0437] To a stirred solution of 4-bromo-2-hydroxybenzonitrile (BG,
28 g, 141.40 mmol) in DMA (300 mL) was added 4-methyl-1,3-thiazole
(28.1 g, 283.40 mmol), potassium acetate (28 g, 285.31 mmol) and
palladium (II) acetate (940 mg, 4.19 mol) at rt under an atmosphere
of nitrogen. The resulting mixture was then heated to 150.degree.
C. and stirred at this temperature for 2.5 h, LC-MS indicated
formation of the desired product. The reaction was then cooled to
rt, diluted by water (1000 mL) and then extracted with ethyl
acetate (500 mL.times.3). The organic layers were combined, dried
over anhydrous sodium sulfate and concentrated under reduced
pressure to give a crude residue, which was purified by a flash
silica gel chromatography (eluent: ethyl acetate/petroleum ether
(v:v=1:1) to give BH (yield: 78%) as a yellow solid. LC-MS
(ES.sup.+): m/z 216.95 [MH.sup.+], t.sub.R=1.25 min (2.6 minute
run).
Step 1: 2-(aminomethyl)-5-(4-methyl-1,3-thiazol-5-yl)phenol
(BI)
[0438] To a stirred solution of
2-hydroxy-4-(4-methyl-1,3-thiazol-5-yl)benzonitrile (BH, 15.6 g,
72.14 mmol) in tetrahydrofuran (400 mL) under an atmosphere of
nitrogen was added LiAlH.sub.4 (11 g, 289.86 mmol) in several
portions at 10.degree. C. The resulting mixture was then heated to
reflux for 3 h, LC-MS indicated formation of the desired product.
The reaction was then cooled to 0.degree. C., quenched by the water
(10 mL, added slowly and drop wise), 15% NaOH (aq.) (30 mL) and
water (10 mL). The solids precipitated were removed by filtration,
the solution phase was concentrated under reduced pressure followed
by high vacuum pump to give BI (yield: 65%). LC-MS (ES.sup.+): m/z
220.85 [MH.sup.+], t.sub.R=1.02 min (2.6 minute run).
Step 3. Synthesis of 9H-fluoren-9-ylmethyl
(2S,4R)-4-(tert-butoxy)-2-({[2-hydroxy-4-(4-methyl-1,3-thiazol-5-yl)pheny-
l]methyl}carbamoyl)pyrrolidine-1-carboxylate (BJ)
[0439] To a stirred solution of
(2S,4R)-4-(tert-butoxy)-1-[(9H-fluoren-9-ylmethoxy)carbonyl]pyrrolidine-2-
-carboxylic acid (BI, 18.6 g) in N,N-dimethylformamide (250 mL) was
added DIEA (7.9 g, 61.24 mmol), HATU (17.3 g, 45.53 mmol) and
2-(aminomethyl)-5-(4-methyl-1,3-thiazol-5-yl)phenol (20 g, 90.79
mmol) at rt. The resulting mixture was stirred overnight at rt, and
LC-MS indicated formation of the desired product. The reaction
mixture was diluted by water (200 mL) and then extracted with ethyl
acetate (300 mL.times.3). The organic layers were combined, dried
over anhydrous sodium sulfate and concentrated under reduced
pressure to give a crude residue, which was purified by flash
silica gel chromatography (eluent: dichloromethane/methanol
(v:v=25:1)) to give BJ (yield: 31%) as a yellow oil. LC-MS
(ES.sup.+): m/z 611.20 [MH.sup.+], t.sub.R=1.12 min (2.0 minute
run).
Step 4: Synthesis of
(2S,4R)-4-(tert-butoxy)-N-{[2-hydroxy-4-(4-methyl-1,3-thiazol-5-yl)phenyl-
]methyl}pyrrolidine-2-carboxamide (BK)
[0440] To a stirred solution of 9H-fluoren-9-ylmethyl
(2S,4R)-4-(tert-butoxy)-2-({[2-hydroxy-4-(4-methyl-1,3-thiazol-5-yl)pheny-
l]methyl}carbamoyl)pyrrolidine-1-carboxylate (BJ, 17.2 g, 28.12
mmol) in dichloromethane (270 mL) was added piperidine (30 mL,
280.00 mmol) at rt. The resulting solution was stirred at rt for 3
h, and LC-MS indicated formation of the desired product. The
reaction mixture was concentrated under vacuum to give a crude
residue, which was then diluted by dichloromethane (300 mL), washed
with water (300 mL.times.2), dried over anhydrous sodium sulfate
and concentrated under reduced pressure to give a crude residue,
which was purified by flash silica gel chromatography (eluent:
dichloromethane/methanol (v:v=20:1)) to give BK (yield: 71%) as a
yellow oil. LC-MS (ES.sup.+): m/z 389.95 [MH.sup.+], t.sub.R=0.88
min (2.0 minute run).
Step 5: Synthesis of
(2S,4R)-4-(tert-butoxy)-N-{[2-hydroxy-4-(4-methyl-1,3-thiazol-5-yl)phenyl-
]methyl}-1-[(2S)-3-methyl-2-(1-oxo-2,3-dihydro-1H-isoindol-2-yl)butanoyl]p-
yrrolidine-2-carboxamide ULM-12)
[0441] To a stirred solution of
(2S)-3-methyl-2-(1-oxo-2,3-dihydro-1H-isoindol-2-yl)butanoic acid
(3.6 g, 15.43 mmol) in N,N-dimethylformamide (50 mL) was added DIEA
(2.7 g, 20.93 mmol), HATU (5.89 g, 15.49 mmol) and
(2S,4R)-4-(tert-butoxy)-N-{[2-hydroxy-4-(4-methyl-1,3-thiazol-5-yl)phenyl-
]methyl}pyrrolidine-2-carboxamide (BK, 4.0 g, 10.27 mmol) at rt.
The resulting solution was stirred overnight at rt, and LC-MS
indicated formation of the desired product. The reaction was
diluted by the water (100 mL) and extracted with dichloromethane
(100 mL.times.3). The organic layers were combined, dried over
anhydrous sodium sulfate and concentrated under reduced pressure to
give a crude residue, which was purified by a flash silica gel
chromatography (eluent: ethyl acetate/petroleum ether (v:v=2:1)) to
give ULM-12 (yield: 43%) as a yellow solid. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.88 (s, 1H), 7.83-7.81 (d, J=7.6 Hz, 1H),
7.66-7.63 (m, 2H), 7.61-7.59 (m, 1H), 7.36-7.34 (d, J=8.0 Hz, 1H),
6.94-6.87 (d, J=6.4 Hz, 1H), 4.88 (s, 1H), 4.56-4.39 (m, 6H),
3.88-3.81 (m, 2H), 2.51 (s, 3H), 2.47-2.45 (m, 1H), 2.15-2.13 (m,
2H), 1.16-1.14 (d, J=6.4 Hz, 3H) 1.02 (s, 9H), 0.89-0.86 (d, J=6.4
Hz, 3H); LC-MS (ES.sup.+): m/z 605.40 [MH.sup.+], t.sub.R=1.91 min
(3.6 minute run).
[0442] Unless otherwise noted, the following intermediates and
their analogs (for examples, but not limited to, analogs with
substitutions such as halogens) were synthesized according to
similar procedures described above for the synthesis of ULM-12, by
utilizing corresponding starting materials and reagents.
ULM-13:
(2S,4R)-4-tert-butoxy-1-((S)-2-(6-fluoro-1-oxoisoindolin-2-yl)-3-m-
ethylbutanoyl)-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-c-
arboxamide
##STR00138##
[0443] ULM-14:
(2S,4R)-4-tert-butoxy-1-((S)-2-(7-cyano-1-oxoisoindolin-2-yl)-3-methylbut-
anoyl)-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxami-
de
##STR00139##
[0444] Synthesis of Linker Chemistry, L
L-1: 2-(3-(5-(tosyloxy)pentyloxy)propoxy)acetic Acid
##STR00140##
[0445] Step 1: Synthesis of
({[5-(prop-2-en-1-yloxy)pentyl]oxy}methyl)benzene
[0446] To a stirred solution of 5-(benzyloxy)pentan-1-ol (W, 4.0 g,
20.59 mmol) in N,N-dimethylformamide (50 mL) was added sodium
hydride (1.24 g, 51.67 mmol) in portions at 0.degree. C. under an
atmosphere of nitrogen. The resulting mixture was then stirred at
rt for 1 h. To this mixture was added 3-bromoprop-1-ene (3.71 g,
30.67 mmol), the reaction mixture was stirred overnight at
60.degree. C. in an oil bath. LC-MS indicated formation of the
desired product. The reaction mixture was cooled to 0.degree. C.
and then quenched by water (100 mL), the resulting mixture was
extracted with ethyl acetate (200 mL.times.2). The organic layers
were combined, washed with saturated aqueous solution of sodium
chloride (60 mL), dried over anhydrous sodium sulfate and then
concentrated under reduced pressure to give a crude residue. The
residue was purified by a flash silica gel chromatography (eluent:
ethyl acetate/petroleum ether (v:v=1:40)) to give 4.57 g of X.
.sup.1H NMR (300 MHz, CDCl.sub.3): .delta. 7.36 (s, 4H), 7.32 (m,
1H), 5.98 (m, 1H), 5.33 (m, 1H), 5.21 (m, 1H), 4.53 (s, 2H), 3.99
(m, 2H), 3.53 (m, 4H), 1.72 (m, 4H), 1.52 (m, 2H). LC-MS
(ES.sup.+): m/z 235.00 [MH.sup.+], t.sub.R=1.18 min (2.0 minute
run).
Step 2: Synthesis of 3-{[5-(benzyloxy)pentyl]oxy}propan-1-ol
(Y)
[0447] To a 250-mL round-bottom flask with 9-BBN (0.5 M in THF, 77
mL) was added a solution of
({[5-(prop-2-en-1-yloxy)pentyl]oxy}methyl)benzene (X, 3.0 g, 12.80
mmol) in anhydrous tetrahydrofuran (20 mL) with stirring at
0.degree. C. under an atmosphere of nitrogen. The resulting
solution was stirred overnight at rt. LC-MS indicated formation of
the desired product. Methanol (15 mL, with 30% sodium hydroxide and
30% H.sub.2O.sub.2) was added to the reaction and the resulting
mixture was stirred at rt for 2 h. This mixture was then extracted
with ethyl acetate (20 mL.times.3). The organic layers were
combined, washed with saturated aqueous solution of sodium chloride
(100 mL), dried over anhydrous sodium sulfate and then concentrated
under reduced pressure to give a crude residue. The residue was
purified by a flash silica gel chromatography (eluent: ethyl
acetate/petroleum ether (v:v=1:1)) to provide 1.96 g of Y as light
yellow oil. .sup.1H NMR (300 MHz, CDCl.sub.3): .delta.7.34 (m, 5H),
4.49 (s, 2H), 3.75 (m, 2H), 3.59 (m, 2H), 3.49 (m, 4H), 2.65 (bs,
1H), 1.84 (m, 2H), 1.68 (m, 4H), 1.50 (m, 2H). LC-MS (ES.sup.+):
m/z 253.17 [MH.sup.+], t.sub.R=1.44 min (2.6 minute run).
Step 3: Synthesis of tert-butyl
2-(3-{[5-(benzyloxy)pentyl]oxy}propoxy)acetate (Z)
[0448] To a stirred solution of
3-{[5-(benzyloxy)pentyl]oxy}propan-1-ol (Y, 3.7 g, 14.66 mmol) in
dichloromethane (30 mL) was added a solution of NaOH in water (37%,
30 mL) followed by tert-butyl 2-bromoacetate (11.39 g, 58.39 mmol)
and TBACl (4.17 g). The resulting mixture was stirred at rt
overnight. LC-MS indicated formation of the desired product. The
reaction mixture was then extracted with ethyl acetate (50
mL.times.3). The organic layers were combined, washed with
saturated aqueous solution of sodium chloride (60 mL), dried over
anhydrous sodium sulfate and then concentrated under reduced
pressure to give a crude residue. The residue was purified by a
flash silica gel chromatography (eluent: ethyl acetate/petroleum
ether (v:v=1:2) to give 3.2 g of Z as a yellow oil. .sup.1H NMR
(400 MHz, CDCl.sub.3): .delta.7.34 (s, 4H), 7.29 (m, 1H), 4.50 (s,
4H), 4.3 (m, 2H), 3.51 (m, 4H), 3.42 (m, 2H), 1.98 (m, 2H), 1.67
(m, 4H), 1.48 (s, 9H), 1.46 (m, 2H). LC-MS (ES.sup.+): m/z 367.25
[MH.sup.+], t.sub.R=1.28 min (2.0 minute run).
Step 4: Synthesis of tert-butyl
2-[3-[(5-hydroxypentyl)oxy]propoxy]acetate (AA)
[0449] To a stirred solution of tert-butyl
2-(3-{[5-(benzyloxy)pentyl]oxy}propoxy)acetate (Z, 3.2 g, 8.73
mmol) in methanol (30 mL) was added AcOH (1.5 mL), palladium on
carbon (1.5 g) under an atmosphere of nitrogen. Hydrogen was then
introduced to the reaction mixture via a hydrogen balloon, and the
reaction was stirred at rt for 3 h. The solid material was removed
by filtration, the solution was concentrated under vacuum to
provide 2.3 g of AA as light yellow oil, which was used for the
next step without any further purifications. LC-MS (ES.sup.+): m/z
277.10 [MH.sup.+], t.sub.R=0.86 min (2.0 minute run).
Step 5: Synthesis of tert-butyl
2-[3-({5-[(4-methylbenzenesulfonyl)oxy]pentyl}oxy)propoxy]acetate
(AB)
[0450] To a stirred solution of tert-butyl
2-[3-[(5-hydroxypentyl)oxy]propoxy]acetate (AA, 2.3 g, 8.32 mmol)
in dichloromethane (30 mL) was added 4-methylbenzene-1-sulfonyl
chloride (3.17 g, 16.63 mmol), triethylamine (2.52 g, 24.90 mmol)
and 4-dimethylaminopyridine (203 mg, 1.66 mmol) at rt. The
resulting mixture was stirred overnight at rt. The resulting
mixture was concentrated under reduced pressure to give a crude
residue, which was purified by a flash silica gel chromatography
(eluent: ethyl acetate/petroleum ether (v:v=1:2) to give 2.6 g of
AB as a yellow oil. .sup.1H NMR (300 MHz, CDCl.sub.3): .delta. 7.77
(d, J=8.1 Hz, 2H), 7.36 (d, J=8.1 Hz, 2H), 4.51 (s, 2H), 4.31 (m,
2H), 4.13 (m, 2H), 3.52 (m, 4H), 2.05 (s, 3H), 1.97 (m, 2H), 1.69
(m, 4H), 1.48 (s, 9H), 1.46 (m, 2H). LC-MS (ES.sup.+): m/z 431.20
[MH.sup.+], t.sub.R=1.21 min (2.0 minute run).
Step 1: Synthesis of
2-[3-({5-[(4-methylbenzenesulfonyl)oxy]pentyl}oxy)propoxy]acetic
Acid (L-1)
[0451] To a stirred solution of tert-butyl
2-[3-({5-[(4-methylbenzenesulfonyl)oxy]pentyl}oxy)propoxy]acetate
(AB, 1.3 g, 3.02 mmol) in dichloromethane (10 mL) was added
trifluoroacetic acid (10 mL) at rt. The resulting solution was
stirred at rt for 3 h. The reaction mixture was then concentrated
under vacuum to give 1.5 g (crude) of L-1, which was used for next
step without any further purification. LC-MS (ES.sup.+): m/z 375.34
[MH.sup.+], t.sub.R=1.39 min (2.6 minute run).
[0452] The following Linkers (L) were prepared in a similar manner
as for the preparation of L-1.
L-2: 2-(3-(3,3-dimethyl-5-(tosyloxy)pentyloxy)propoxy)acetic
Acid
##STR00141##
[0453] L-3: 2-(3-(3-hydroxy-5-(tosyloxy)pentyloxy)propoxy)acetic
Acid
##STR00142##
[0454] L-4: 2-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)acetic
Acid
##STR00143##
[0456] To a stirred solution of ethyl
2-[2-(2-{2-[(4-methylbenzenesulfonyl)oxy]ethoxy}ethoxy)ethoxy]acetate
(AC, 2 g, 5.12 mmol, 1.00 equiv) in methanol (20 mL) was added a
solution of NaOH (500 mg, 12.50 mmol) in water (4 mL), and the
resulting mixture was stirred at rt for 2 h. Aqueous hydrogen
chloride (1 M) was then added to the reaction mixture to adjust pH
to .about.5. Solids precipitated were collected by filtration to
give L-4 (yield: 98%). Mass (ES.sup.+): m/z 363, [MH.sup.+].
[0457] The following Linkers (L) were prepared in a similar manner
as for the preparation of L-4.
L-5:
2-(2-((2R,3R)-3-(2-(tosyloxy)ethoxy)butan-2-yloxy)ethoxy)acetic
Acid
##STR00144##
[0458] L-6:
2-(2-((2S,3S)-3-(2-(tosyloxy)ethoxy)butan-2-yloxy)ethoxy)acetic
Acid
##STR00145##
[0459] L-7: 2-(4-(4-(tosyloxy)butoxy)butoxy)acetic Acid
##STR00146##
[0460] Step 1: Synthesis of
4-{4-[(4-methylbenzenesulfonyl)oxy]butoxy}butan-1-ol (AE)
[0461] To a stirred solution of 4-(4-hydroxybutoxy)butan-1-ol (AD,
2 g, 12.33 mmol) in dichloromethane (20 mL) was added Ag.sub.2O
(4.25 g, 18.49 mmol), KI (409 mg, 2.46 mmol) and TsCl (2.345 g,
12.30 mmol). The resulting mixture was stirred at rt for 12 h. The
inorganic salt formed was removed by filtration and the organic
solution was concentrated under reduced pressure to give a crude
residue. The residue was purified by flash silica gel
chromatography (eluent: ethyl acetate/petroleum ether (v:v=1:1)) to
give AE (yield: 28%) as a colorless oil.
Step 2: Synthesis of ethyl
2-(4-{4-[(4-methylbenzenesulfonyl)oxy]butoxy}butoxy)acetate
(AF)
[0462] To a stirred solution of
4-{4-[(4-methylbenzenesulfonyl)oxy]butoxy}butan-1-ol (AE, 1.1 g,
3.48 mmol) in dichloromethane (10 mL) was slowly added
BF.sub.3.Et.sub.2O (49.4 mg, 0.35 mmol) followed by ethyl
2-diazoacetate (794 mg, 6.96 mmol) at 0.degree. C. The resulting
mixture was stirred overnight at rt. The reaction was then quenched
by water (2.0 mL). The resulting mixture was extracted with
dichloromethane (50 mL.times.3), the organic layers were combined,
dried over anhydrous sodium sulfate and then concentrated under
reduced pressure to give a crude residue. The residue was purified
by flash silica gel chromatography (eluent: ethyl acetate/petroleum
ether (v:v=1:4) to give AF (yield: 93 as light yellow oil. Mass
(ES.sup.+): m/z 403.10 [MH.sup.+].
Step 3: Synthesis of
2-(4-{4-[(4-methylbenzenesulfonyl)oxy]butoxy}butoxy)acetic Acid
(L-7)
[0463] To a stirred solution of ethyl
2-(4-{4-[(4-methylbenzenesulfonyl)oxy]butoxy}butoxy)acetate (AF,
1.3 g, 3.23 mmol) in methanol (25 mL) was added a solution of NaOH
(388 mg, 9.70 mmol) in water (6 mL) at rt. The resulting solution
was stirred at rt for 4 h. The bulk of organic solvent was removed
under reduced pressure, to the resulting mixture was added aqueous
hydrogen chloride (1.0 M) to adjust the pH=.about.5. The solution
was then extracted with ethyl acetate (250 mL.times.3), the organic
layers were combined and dried over anhydrous sodium sulfate,
concentrated under reduced pressure to give I-7 (yield: 93%) as
light yellow oil. Mass (ES.sup.+): m/z 375.05 [MH.sup.+].
L-8: tert-butyl 2-(3-(4-(tosyloxy)butoxy)propoxy)acetate
##STR00147##
[0464] Step 1. Synthesis of 3-[4-(benzyloxy)butoxy]propan-1-ol
(AH)
[0465] To a stirred solution of propane-1,3-diol (1.52 g, 19.98
mmol) in N,N-dimethylformamide (20 mL) was added sodium hydride
(840 mg, 35.00 mmol) at rt, the resulting mixture was stirred at rt
for 30 min. Then to the mixture was added 4-(benzyloxy) butyl
4-methylbenzene-1-sulfonate (AG, 6.68 g, 19.97 mmol) and the
reaction was stirred overnight at 50.degree. C. TLC indicated
formation of the desired product, at this time the reaction was
allowed to cool down to rt. Water (10 mL) was added slowly to
quench the reaction; the resulting mixture was then extracted with
ethyl acetate (80 mL.times.2). The organic layers were combined,
washed with saturated aqueous solution of sodium chloride (20 mL),
dried over anhydrous sodium sulfate and then concentrated under
reduced pressure to give a crude residue, which was purified by
flash silica gel chromatography (eluent: ethyl acetate/petroleum
ether (v:v=1:2)) to give AH (yield: 67%) as a light yellow oil.
.sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 7.38-7.29 (m, 5H), 4.52
(m, 2H), 3.80 (m, 2H), 3.61 (m, 2H), 3.49-3.46 (m, 4H), 2.04 (m,
2H), 1.82 (m, 2H), 1.68 (m, 2H); Mass (ES.sup.+): m/z 239.05
[MH.sup.+].
Step 2. Synthesis of tert-butyl
2-[3-[4-(benzyloxy)butoxy]propoxy]acetate (AI)
[0466] To a stirred solution of 3-[4-(benzyloxy)butoxy]propan-1-ol
(AH, 2.38 g, 9.99 mmol) in dichloromethane (15 mL) was added
tert-butyl 2-bromoacetate (7.76 g, 39.78 mmol), TBAC (2.78 g, 10.00
mmol) followed by aqueous sodium hydroxide (37%, 15 mL). The
resulting mixture was stirred overnight at rt. The reaction mixture
was then extracted with dichloromethane (100 mL.times.3), the
organic layers were combined, washed with saturated aqueous
solution of sodium chloride (20 mL), dried over anhydrous sodium
sulfate and then concentrated under reduced pressure to give a
crude residue. The residue was purified by flash silica gel
chromatography (eluent: ethyl acetate/petroleum ether (v:v=1:5)) to
give AI (yield 57%) as a yellow oil. Mass (ES.sup.+): m/z 353.10
[MH.sup.+].
Step 3. Synthesis of tert-butyl
2-[3-(4-hydroxybutoxy)propoxy]acetate (AJ)
[0467] To a stirred mixture of tert-butyl
2-[3-[4-(benzyloxy)butoxy]propoxy]acetate (AI, 1 g, 2.84 mmol),
palladium on carbon (10%, 200 mg) in methanol (20 mL) was added
acetic acid (0.05 mL) under a nitrogen atmosphere. Hydrogen was
then introduced to the reaction mixture via a balloon, the reaction
was then stirred overnight at rt. The insoluble solids were removed
by filtration and the solution phase was concentrated under reduced
pressure to give the desired product (yield: 94%) as a yellow oil.
Mass (ES.sup.+): m/z 263.05 [MH.sup.+].
Step 4. Synthesis of tert-butyl
2-(3-{4-[(4-methylbenzenesulfonyl)oxy]butoxy}propoxy)acetate
(L-8)
[0468] To a stirred solution of tert-butyl
2-[3-(4-hydroxybutoxy)propoxy]acetate (AJ, 700 mg, 2.67 mmol) in
dichloromethane (10 mL) was added 4-methylbenzene-1-sulfonyl
chloride (558.4 mg, 2.93 mmol), TEA (539.5 mg, 5.33 mmol) and
4-dimethylaminopyridine (32.6 mg, 0.27 mmol). The resulting mixture
was stirred overnight at rt. The bulk of solvent was removed under
reduced pressure to give a crude residue, which was purified by
flash silica gel chromatography (eluent: ethyl acetate/petroleum
ether (v:v=1:2)) to give titled product (yield: 52%) as a yellow
oil. .sup.1H NMR (300 MHz, CDCl.sub.3) .delta.7.79 (d, J=8.4 Hz,
2H), 7.35 (d, J=8.0 Hz, 2H), 4.05 (m, 2H), 3.95 (s, 2H), 3.59 (m,
2H), 3.48 (m, 2H), 3.38 (m, 2H), 2.46 (s, 3H), 1.82 (m, 2H), 1.70
(m, 2H), 1.57 (m, 2H), 1.50 (s, 9H); Mass (ES.sup.+): m/z 417.05
[MH.sup.+].
L-9: tert-butyl 2-(4-(3-(tosyloxy)propoxy)butoxy)acetate
##STR00148##
[0470] L-9 was prepared in a similar manner as that used to prepare
L-8, except that AK was used in place of AG. Mass (ES.sup.+): m/z
439.15 [MNa.sup.+].
[0471] L-10: tert-butyl
2-(6-(tosyloxy)hexa-2,4-diynyloxy)acetate
##STR00149##
Step 1: Synthesis of tert-butyl
2-[(6-hydroxyhexa-2,4-diyn-1-yl)oxy]acetate (AP)
[0472] To a stirred solution of hexa-2,4-diyne-1,6-diol (AO, 100
mg, 0.91 mmol) in N, N-dimethylformamide (5 mL) was added sodium
hydride (32 mg, 1.33 mmol) at 0.degree. C. The resulting mixture
was then warmed up to rt and stirred at rt for 30 min. The reaction
mixture was cooled to 0.degree. C. followed by addition of
tert-butyl 2-bromoacetate (176 mg, 0.90 mmol), and the resulting
mixture was stirred at 0.degree. C. for 2 h. LC-MS indicated
formation of the desired product. The reaction was then quenched by
water (10 mL, added slowly) at 0.degree. C., and was extracted with
ethyl acetate (20.times.2 mL). The organic layers were combined,
dried over anhydrous sodium sulfate and then concentrated under
reduced pressure to give a crude residue, which was purified by
flash silica gel chromatography (eluent: ethyl acetate/petroleum
ether (v:v=1:2)) to give AP (yield: 49%) as a yellow oil.
Step 2. Synthesis of tert-butyl
2-({6-[(4-methylbenzenesulfonyl)oxy]hexa-2,4-diyn-1-yl}oxy)acetate
(L-10)
[0473] To a stirred solution of tert-butyl
2-[(6-hydroxyhexa-2,4-diyn-1-yl) oxy]acetate (AP, 50 mg, 0.22 mmol)
in ether (2 mL) was added 4-toluenesulfonyl chloride (51 mg, 0.27
mmol) at 0.degree. C., followed by potassium hydroxide (125 mg,
2.23 mmol) in several batches at 0.degree. C. The resulting mixture
was stirred at 0.degree. C. for 4 h. LC-MS indicated formation of
the desired product. Water (10 mL) was added to the reaction, and
the resulting mixture was extracted with ethyl acetate (20
mL.times.2). The organic layers were combined, dried over anhydrous
sodium sulfate and then concentrated under reduced pressure to give
a crude residue, which was purified by flash silica gel
chromatography (eluent: ethyl acetate/petroleum ether (v:v=1:2)) to
give L-10 (yield: 71%) as a yellow oil. .sup.1H NMR (300 MHz,
CDCl.sub.3): .delta. 7.83 (d, J=6.0 Hz, 2H), 7.39 (d, J=6.0 Hz,
2H), 4.79 (s, 2H), 4.37 (s, 2H), 4.05 (s, 2H), 2.48 (s, 3H), 1.51
(s, 9H); LC-MS (ES.sup.+): m/z 401.05 [MNa.sup.+], t.sub.R=1.71 min
(2.6 minute run).
[0474] The following Linkers (L) were prepared in a similar manner
as for the preparation of L-10.
L-11: tert-butyl 3-(6-(tosyloxy)hexa-2,4-diynyloxy)propanoate
##STR00150##
[0475] L-12: tert-butyl
4-(6-(tosyloxy)hexa-2,4-diynyloxy)butanoate
##STR00151##
[0476] L-13: ethyl 2-(2-(2-aminoethoxy)ethoxy)acetate
hydrochloride
##STR00152##
[0477] Step 1: Synthesis of tert-butyl
N-[2-(2-hydroxyethoxy)ethyl]carbamate (AR)
[0478] To a stirred solution of 2-(2-aminoethoxy)ethan-1-ol (AQ,
5.25 g, 49.94 mmol) in tetrahydrofuran (100 mL) was added aqueous
solution of sodium bicarbonate (20% (w/w), 40 ml) and (Boc).sub.2O
(11.4 g, 52.23 mmol, added in several batches) at 0.degree. C. The
resulting mixture was then warmed up slowly to rt and stirred at rt
for 5 h. The bulk of organic solvent was removed under reduced
pressure and the resulting residue was diluted with water (300 mL),
extracted with of ethyl acetate (100 mL.times.3). The organic
layers were combined, washed with saturated aqueous solution of
sodium chloride (20 mL.times.2), dried over anhydrous sodium
sulfate and then concentrated under reduced pressure to give AR
(yield: 98%) as colorless oil.
Step 2: Synthesis of ethyl
2-[2-(2-{[(tert-butoxy)carbonyl]amino}ethoxy)ethoxy]acetate
(AS)
[0479] To a stirred solution of tert-butyl
N-[2-(2-hydroxyethoxy)ethyl]carbamate (AR, 4.0 g, 19.49 mmol) in
dichloromethane (30 mL) was added 1-diazo-3-methoxypropan-2-one
(3.34 g, 29.27 mmol) and BF.sub.3-Et.sub.2O (0.2 mL) at rt. The
resulting solution was stirred at rt for 2 h. Water (20 mL) was
added to the reaction mixture, organic layer was separated and
washed with brine (20 mL), dried over anhydrous sodium sulfate and
concentrated under reduced pressure to give a crude residue. The
residue was purified by flash silica gel chromatography (eluent:
ethyl acetate/petroleum ether (v:v=1:2)) to give AS (yield: 18%) as
yellow solid. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 4.25-4.22
(q, J=7.2 Hz, 2H), 4.14 (s, 2H), 3.74 (b, 2H), 3.72 (b, 1H),
3.67-3.32 (m, 4H), 1.414 (s, 9H), 1.31 (t, J=7.2 Hz, 3H).
Step 3: Synthesis of ethyl 2-[2-(2-aminoethoxy)ethoxy]acetate
hydrochloride (L-13)
[0480] To a stirred solution of ethyl
2-[2-(2-{[(tert-butoxy)carbonyl]amino}ethoxy)ethoxy]acetate (AS,
500 mg, 1.72 mmol) in 1,4-dioxane (10 mL) was introduced hydrogen
chloride (gas) via bubbling at rt for 2 h. The solvent was then
removed under vacuum to give L-13 (yield: 99%). LC-MS (ES.sup.+):
m/z 192.00 [MH.sup.+], t.sub.R=0.41 min (2.0 minute run).
L-14: ethyl 2-(5-aminopentyloxy)acetate
##STR00153##
[0481] Step 1: Synthesis of tert-butyl 5-hydroxypentylcarbamate
(AU)
[0482] To a stirred solution of 5-aminopentan-1-ol (AT, 3.1 g,
30.05 mmol) in dichloromethane (30 mL) was added di-tert-butyl
dicarbonate (6.56 g, 30.06 mmol) at 0.degree. C. The resulting
mixture was then stirred at rt for 4 h. The solvent was removed
under reduced pressure to give a crude residue which was purified
by flash silica gel chromatography (eluent: ethyl acetate/petroleum
ether (v:v=1:2)) to give AU (yield: 98%) as a colorless oil. LC-MS
(ES.sup.+): m/z 204.00 [MH.sup.+], t.sub.R=1.29 min (2.6 minute
run).
Step 2: Synthesis of ethyl
2-[(5-{[(tert-butoxy)carbonyl]amino}pentyl)oxy]acetate (AV)
[0483] To a stirred solution of tert-butyl
N-(5-hydroxypentyl)carbamate (AU, 1.5 g, 7.38 mmol) in
dichloromethane (10 mL) was added BF.sub.3-Et.sub.2O (0.1 mL) at
0.degree. C. To this mixture was then added a solution of ethyl
2-diazoacetate (850 mg, 7.45 mmol) in dichloromethane (2 mL) at
0.degree. C. The resulting mixture was allowed to warm up to rt and
stirred at rt for 2 h. Saturated aqueous sodium bicarbonate (30 mL)
was added to the reaction, the resulting mixture was extracted with
ethyl acetate (150 mL.times.3). The organic layers were combined,
dried over anhydrous sodium sulfate and then concentrated under
reduced pressure to give a crude residue, which was purified by
flash silica gel chromatography (eluent: ethyl acetate/petroleum
ether (v:v=1:7)) to give AV (yield: 15%) as a colorless oil. LC-MS
(ES.sup.+): m/z 290.05 [MH.sup.+], t.sub.R=1.55 min (2.6 minute
run).
Step 3: Synthesis of ethyl 2-(5-aminopentyloxy)acetate (L-14)
[0484] To a stirred solution of ethyl ethyl
2-[(5-{[(tert-butoxy)carbonyl]amino}pentyl)oxy]acetate (AV, 400 mg,
1.38 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid
(5 mL) at rt. The resulting solution was stirred at rt for 2 h. The
reaction mixture was then concentrated under vacuum to give L-14
(yield: 84%) as a yellow oil. LC-MS (ES.sup.+): m/z 190.00
[MH.sup.+], t.sub.R=1.01 min (2.6 minute run).
L-15: methyl 2-(2-(2-(methylamino)ethoxy)ethoxy)acetate
##STR00154##
[0485] Step 1: Synthesis of 2-[2-(benzylamino)ethoxy]ethan-1-ol
(AX)
[0486] To a stirred solution of 2-(2-aminoethoxy)ethan-1-ol (AW,
5.0 g) and benzaldehyde (5.0 g) in THF (50 mL) was added sodium
triacetoxyborohydride (15.8 g, 74.5 mmol) at 0.degree. C. The
resulting solution was then stirred at rt for 4 h. Water (50 mL)
was added to the reaction and the resulting mixture was extracted
with ethyl acetate (50 mL.times.2). The organic layers were
combined, dried over anhydrous sodium sulfate and then concentrated
under reduced pressure to give a crude residue, which was purified
by flash silica gel chromatography (eluent:
dichloromethane/methanol (v:v=3:1) to give AX (yield: 85%) as a
white solid. LC-MS (ES.sup.+): m/z 195.95[MH.sup.+], t.sub.R=0.22
min (2.0 minute run).
Step 2: Synthesis of 2-{2-[benzyl(methyl)amino]ethoxy}ethan-1-ol
(AY)
[0487] To a stirred solution of 2-[2-(benzylamino)ethoxy]ethan-1-ol
(AX, 10.0 g) in methanol (200 mL) was added formaldehyde (38% in
water) (4.9 mL) and triacetoxyborohydride (17.0 g) at rt. The
resulting solution was stirred at rt for 2 h. Saturated aq. sodium
bicarbonate (100 mL) was added to the reaction, and bulk of organic
solvent was then removed under reduced pressure. The resulting
mixture was extracted with ethyl acetate (200 mL.times.3). The
organic layers were combined, dried over anhydrous sodium sulfate
and then concentrated under reduced pressure followed by high
vacuum pump to give AY (yield: 33%) as a yellow oil. LC-MS
(ES.sup.+): m/z 210.00 [MH.sup.+], t.sub.R=0.43 min (2.0 minute
run).
Step 3: Synthesis of methyl
2-(2-{2-[benzyl(methyl)amino]ethoxy}ethoxy)acetate (AZ)
[0488] To a stirred solution of
2-{2-[benzyl(methyl)amino]ethoxy}ethan-1-ol (AY, 2 g) in
dichloromethane (20 mL) was added a solution of sodium hydroxide
(37%) in water (20 mL) followed by tert-butyl 2-bromoacetate (7.76
g) and TBAC (2.78 g) at rt. The resulting mixture was stirred at rt
for 15 h. The aqueous layer was separated, and to which aq.
hydrogen chloride (4N) was added to adjust the pH to .about.3
before it was concentrated under reduced pressure to give a crude
residue. Methanol (20 mL) was then added to this residue and
insoluble salts were filtered out. The solution was concentrated
under vacuum to give
2-(2-[2-[benzyl(methyl)amino]ethoxy]ethoxy)acetic acid (yield: 78%)
as a yellow oil. To a stirred solution of
2-(2-{2-[benzyl(methyl)amino]ethoxy}ethoxy)acetic acid (2 g, 7.48
mmol, 1.00 equiv) prepare above in methanol (50 mL) was slowly
added sulfuric acid (2 mL) at rt. The resulting solution was
stirred at 70.degree. C. in an oil bath for 3 h. The bulk of
solvent was removed under reduced pressure to give a residue, which
was diluted with H.sub.2O (30 mL). Sodium carbonate was then added
to the mixture to adjust the pH to .about.8. The mixture was then
extracted with ethyl acetate (50 mL.times.2), the organic layers
were combined, dried over anhydrous sodium sulfate and then
concentrated under reduced pressure followed by high vacuum pump to
give AZ (yield: 29%) as a yellow oil. LC-MS (ES.sup.+): m/z 281.95
[MH.sup.+], t.sub.R=0.30 min (2.0 minute run).
Step 4: Synthesis of methyl
2-{2-[2-(methylamino)ethoxy]ethoxy}acetate (L-15)
[0489] To a stirred mixture of methyl
2-(2-{2-[benzyl(methyl)amino]ethoxy}ethoxy)acetate (AZ, 600 mg,
2.13 mmol) and palladium on carbon (300 mg) in methanol (30 mL)
under a nitrogen atmosphere was charged with hydrogen gas via a
balloon. The resulting mixture was stirred at rt for 15 h. The
solid material was removed by filtration and the solution was
concentrated under vacuum to give L-15 (400 mg) as yellow oil,
which was used for next step without any further purifications.
LC-MS (ES.sup.+): m/z 191.95 [MH.sup.+], t.sub.R=0.31 min (2.0
minute run).
L-16: ethyl 2-(5-(methylamino)pentyloxy)acetate
##STR00155##
[0490] Step 1: Synthesis of ethyl
2-[(5-{[(tert-butoxy)carbonyl](methyl)amino}pentyl)oxy]acetate
(BB)
[0491] To a stirred solution of ethyl
2-[(5-{[(tert-butoxy)carbonyl]amino}pentyl)oxy]acetate (BA, 1.1 g,
3.8 mmol) in N,N-dimethylformamide (10 mL) was added CH.sub.3I
(0.71 mL, 11.4 mmol) at 0.degree. C., followed by sodium hydride
(304 mg, 7.60 mmol, 60% in mineral oil) in several portions at
0.degree. C. The resulting mixture was stirred at rt for 16 h.
Water (1.0 mL) was added and the resulting mixture was extracted
with ethyl acetate (50 mL.times.2). The organic layers were
combined, washed with saturated aqueous solution of sodium chloride
(100 mL), dried over anhydrous sodium sulfate and then concentrated
under reduced pressure to give a crude residue which was purified
by a flash silica gel chromatography (eluent: ethyl
acetate/petroleum ether (v:v=1:10)) to give BB (yield: 21%) as a
yellow oil. LC-MS (ES.sup.+): m/z 326.20 [MNa.sup.+], t.sub.R=1.55
min (2.6 minute run).
Step 2: Synthesis of ethyl 2-{[5-(methylamino)pentyl]oxy}acetate
(L-16)
[0492] To a stirred solution of ethyl
2-[(5-{[(tert-butoxy)carbonyl](methyl)amino}pentyl)oxy]acetate (BB,
240 mg, 0.79 mmol) in dichloromethane (5 mL) was added
trifluoroacetic acid (0.5 mL). The resulting solution was stirred
at rt for 16 h. The solvents were removed under reduced pressure
followed by high vacuum pump to give L-16 (yield: 99%) as a yellow
oil. LC-MS (ES.sup.+): m/z 204.20 [MH.sup.+], t.sub.R=0.56 min (2.0
minute run).
L-17: 2-(3-(2-(tosyloxy)ethoxy)propoxy)acetic Acid
##STR00156##
[0493] Step 1: Synthesis of tert-butyl
2-{3-[2-(benzyloxy)ethoxy]propoxy}acetate (BD)
[0494] To a stirred solution of 3-[2-(benzyloxy)ethoxy]propan-1-ol
(BC, 1.8 g, 8.56 mmol) and tert-butyl 2-bromoacetate (6.6 g, 33.84
mmol, 4.00 equiv) in dichloromethane (40 mL) was added TBAC (2.4 g)
and aq. Solution of sodium hydroxide (37%, 40 mL). The resulting
mixture was stirred at rt overnight. LC-MS indicated formation of
the desired product. The reaction mixture was then extracted with
ethyl acetate (150.times.3 mL), the organic layers combined, dried
over anhydrous sodium sulfate and concentrated under reduced
pressure to give a crude residue, which was purified by a flash
silica gel chromatography (eluent: ethyl acetate/petroleum ether
(v:v=1:2) to give BD (yield: 90%) as a colorless oil. .sup.1H NMR
(300 MHz, CDCl.sub.3): .delta. 7.35-7.27 (m, 5H), 4.57 (s, 2H),
3.94 (s, 2H), 3.63-3.57 (m, 8H), 1.96-1.87 (m, 2H), 1.47 (s, 9H);
LC-MS (ES.sup.+): m/z 347.10 [MNa.sup.+], t.sub.R=1.72 min (2.6
minute run).
Step 2: Synthesis of tert-butyl
2-[3-(2-hydroxyethoxy)propoxy]acetate (BE)
[0495] To a stirred mixture of tert-butyl
2-{3-[2-(benzyloxy)ethoxy]propoxy}acetate (BD, 2.5 g, 7.71 mmol)
and palladium on carbon (2.0 g) in methanol (20 mL) under a
nitrogen atmosphere was introduced hydrogen gas via a balloon. The
resulting mixture was stirred overnight at rt under hydrogen gas
atmosphere. LC-MS indicated completion of the reaction. The solids
were removed by filtration, the solution was concentrated under
vacuum to give BE (yield: 99%) as a colorless oil. LC-MS
(ES.sup.+): m/z 257.10 [MNa.sup.+], t.sub.R=1.21 min (2.6 minute
run).
Step 3: Synthesis of tert-butyl
2-(3-{2-[(4-methylbenzenesulfonyl)oxy]ethoxy}propoxy)acetate
(BF)
[0496] To a stirred solution of tert-butyl
2-[3-(2-hydroxyethoxy)propoxy]acetate (BE, 1.8 g, 7.68 mmol) in
dichloromethane (50 mL) was added 4-toluenesulfonyl chloride (2.2
g, 11.54 mmol), triethylamine (2.33 g, 23.03 mmol) and
4-dimethylaminopyridine (95 mg, 0.78 mmol). The resulting mixture
was stirred overnight at rt. LC-MS indicated formation of the
desired product. The reaction mixture was concentrated under
reduced pressure to give a crude residue, which was purified by a
flash silica gel chromatography (eluent: ethyl acetate/petroleum
ether (v:v=1:2) to give BF (yield: 80%) as a yellow oil. H NMR (400
MHz, CDCl.sub.3): .delta. 7.80 (d, J=8.0 Hz, 2H), 7.34 (d, J=8.4
Hz, 2H), 4.15 (t, J=3.6 Hz, 2H), 3.93 (s, 2H), 3.61 (t, J=3.6 Hz,
2H), 3.55-3.49 (m, 4H), 2.45 (s, 3H), 1.85-1.78 (m, 2H), 1.48 (s,
9H); LC-MS (ES.sup.+): m/z 411.00 [MNa.sup.+], t.sub.R=1.12 min
(2.0 minute run).
Step 4: Synthesis of
2-(3-{2-[(4-methylbenzenesulfonyl)oxy]ethoxy}propoxy)acetic Acid
(L-17)
[0497] To a stirred solution of tert-butyl
2-(3-{2-[(4-methylbenzenesulfonyl)oxy]ethoxy}propoxy)acetate (BF,
400 mg, 1.03 mmol) in dichloromethane (3 mL) was added
trifluoroacetic acid (1 mL) at rt. The resulting solution was
stirred at rt for 1 h. LC-MS indicated completion of the reaction.
The reaction mixture was concentrated under reduced pressure to
give L-17 (350 mg) as a yellow oil, which was used for next step
without further purifications. LC-MS (ES.sup.+): m/z 332.90
[MH.sup.+], t.sub.R=0.81 min (2.0 minute run).
[0498] Unless otherwise noted, the following intermediates and
their analogs (for examples, but not limited to, analogs with
substitutions such as halogens) were synthesized according to
similar procedures described above for the synthesis of L-17, by
utilizing corresponding starting materials and reagents.
L-18: 2-(2-hydroxyethoxy)ethyl 4-methylbenzenesulfonate
##STR00157##
[0499] L-19: ethyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate
##STR00158##
[0500] L-20: ethyl 3-(2-(2-(tosyloxy)ethoxy)ethoxy)propanoate
##STR00159##
[0501] L-21: ethyl 5-(tosyloxy)pentanoate
##STR00160##
[0502] L-22: ethyl 3-(2-(tosyloxy)ethoxy)propanoate
##STR00161##
[0503] L-23: ethyl 2-(5-(tosyloxy)pentyloxy)acetate
##STR00162##
[0504] L-24: ethyl 3-(5-(tosyloxy)pentyloxy)propanoate
##STR00163##
[0505] L-25: 5-hydroxypentyl 4-methylbenzenesulfonate
##STR00164##
[0506] L-26: ethyl 2-(5-(tosyloxy)pentyloxy)acetate
##STR00165##
[0507] L-27: ethyl 2-(3-(tosyloxy)propoxy)acetate
##STR00166##
[0508] L-28: ethyl 2-(2-(tosyloxy)ethoxy)acetate
##STR00167##
[0509] L-29: ethyl 2-(4-(2-(tosyloxy)ethoxy)butoxy)acetate
##STR00168##
[0510] L-30: 2-(2-(2-hydroxyethoxy)ethoxy)ethyl
4-methylbenzenesulfonate
##STR00169##
[0511] L-31: 2-((2R,3R)-3-(2-hydroxyethoxy)butan-2-yloxy)ethyl
4-methylbenzenesulfonate
##STR00170##
[0512] SYNTHESIS OF EXAMPLES
Example 1:
(2S,4R)-1-((S)-2-(2-(3-(5-(4-(3-(4-cyano-3-(trifluoromethyl)phe-
nyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)phenoxy)pentyloxy)propox-
y)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)be-
nzyl)pyrrolidine-2-carboxamide
##STR00171##
[0513] Step 1: Synthesis of tert-butyl
2-(3-{[5-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-s-
ulfanylideneimidazolidin-1-yl}phenoxy)pentyl]oxy}propoxy)acetate
(BG)
[0514] To a stirred solution of tert-butyl
2-[3-[(5-[[(4-methylbenzene)sulfonyl]oxy]pentyl)oxy]propoxy]acetate
(AB, 150 mg, 0.35 mmol) in acetonitrile (10 mL) was added
4-[3-(4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-y-
l]-2-(trifluoromethyl)benzonitrile (ABM-3, 141 mg, 0.35 mmol) and
potassium carbonate (144 mg, 1.04 mmol). The resulting mixture was
stirred overnight at 80.degree. C. in an oil bath. LC-MS indicated
formation of the desired product. The reaction mixture was then
extracted with ethyl acetate (20 mL.times.2). The organic layers
were combined, washed with saturated aqueous solution of sodium
chloride (20 mL), dried over anhydrous sodium sulfate and then
concentrated under reduced pressure to give a crude residue, which
was purified by flash silica gel chromatography (eluent: ethyl
acetate/petroleum ether, v:v=1:1) to give 0.22 g of BG as a yellow
oil. .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 7.96 (s, 2H), 7.86
(d, J=8.6 Hz, 1H), 7.19 (d, J=8.8 Hz, 2H), 7.02 (d, J=8.6 Hz, 2H),
4.50 (s, 2H), 4.30 (t, J=6.4 Hz, 2H), 4.02 (t, J=6.4 Hz, 2H), 3.53
(m, 2H), 3.44 (m, 2H), 1.96-1.80 (m, 4H), 1.69-1.53 (m, 2H), 1.49
(s, 6H), 1.48 (s, 9H), 1.44-1.22 (m, 2H); Mass (ES.sup.+): m/z
686.35 [MNa.sup.+].
Step 2: synthesis of
2-(3-[[5-(4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-s-
ulfanylideneimidazolidin-1-yl]phenoxy)pentyl]oxy]propoxy)acetic
Acid (BH)
[0515] To a stirred solution of tert-butyl
2-(3-{[5-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-s-
ulfanylideneimidazolidin-1-yl}phenoxy)pentyl]oxy}propoxy)acetate
(BG, 220 mg, 0.33 mmol) in dioxane (4.0 mL) was added hydrogen
chloride (2N in water, 1.0 mL). The resulting mixture was stirred
at 80.degree. C. for 2 h. LC-MS indicated formation of the desired
product. The resulting mixture was concentrated under reduced
pressure to provide 200 mg of BH as light yellow oil. Mass
(ES.sup.+): m/z 608.25 [MH.sup.+].
Step 3: Synthesis of Example 1
[0516] To a stirred solution of
2-(3-[[5-(4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-s-
ulfanylideneimidazolidin-1-yl]phenoxy)pentyl]oxy]propoxy)acetic
acid (BH, 160 mg, 0.26 mmol) in N,N-dimethylformamide (5 mL) was
added
(2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1-
,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide
hydrochloride (ULM-1, 182 mg, 0.39 mmol), DIPEA (151 mg, 1.17
mmol), EDCI (101 mg, 0.53 mmol) and HOBt (70 mg, 0.52 mmol). The
resulting mixture was stirred at rt for 5 h and LC-MS indicated
formation of the desired product. Water (20 mL) was added to the
reaction, the resulting mixture was extracted with ethyl acetate
(20 mL.times.2). The organic layers were combined, washed with
saturated aqueous solution of sodium chloride (20 mL), dried over
anhydrous sodium sulfate and then concentrated under reduced
pressure to give a crude residue. The residue was purified by
Prep-HPLC to give 60 mg of Example 1 as a white solid. .sup.1H NMR
(400 MHz, CD.sub.3OD): .delta. 8.88 (s, 1H), 8.16 (d, J=8.0 Hz,
2H), 8.00 (s, 1H), 7.49-7.42 (m, 4H), 7.28 (d, J=8.8 Hz, 2H), 7.06
(m, 2H), 4.87 (s, 1H), 4.59 (m, 3H), 4.37 (m, 1H), 4.05 (m, 4H),
3.88 (m, 2H), 3.65 (m, 2H), 3.58 (m, 2H), 3.50 (m, 2H), 2.48 (s,
3H), 2.25 (m, 1H), 2.10 (m, 1H), 1.90 (m, 2H), 1.80 (m, 2H), 1.66
(m, 2H), 1.56 (s, 8H), 1.04 (s, 9H); LC-MS (ES.sup.+): m/z 1020.20
[MH.sup.+], t.sub.R=2.28 min (3.6 minute run).
Example 2:
(2S,4R)-1-((S)-2-(2-(3-(5-(4-(3-(6-cyano-5-(trifluoromethyl)pyr-
idin-3-yl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)phenoxy)pentyloxy)-
propoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-
-yl)benzyl)pyrrolidine-2-carboxamide
##STR00172##
[0517] Step 1: Synthesis of
2-[3-({5-[(4-methylbenzenesulfonyl)oxy]pentyl}oxy)propoxy]acetic
Acid (L-1)
[0518] To a stirred solution of tert-butyl
2-[3-({5-[(4-methylbenzenesulfonyl)oxy]pentyl}oxy)propoxy]acetate
(AB, 1.3 g, 3.02 mmol) in dichloromethane (10 mL) was added
trifluoroacetic acid (10 mL) at rt. The resulting solution was
stirred at rt for 3 h. The reaction mixture was then concentrated
under vacuum to give 1.5 g (crude) of L-1, which was used for next
step without any further purification. LC-MS (ES.sup.+): m/z 375.34
[MH.sup.+], t.sub.R=1.39 min (2.6 minute run).
Step 2: Synthesis of
(2S,4R)-1-[(2S)-3,3-dimethyl-2-{2-[3-({5-[(4-methylbenzenesulfonyl)oxy]pe-
ntyl}oxy)propoxy]acetamido}butanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-
-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (BI)
[0519] To a stirred solution
2-[3-({5-[(4-methylbenzenesulfonyl)oxy]pentyl}oxy)propoxy]acetic
acid (L-1, 1.5 g, 4.01 mmol) in N,N-dimethylformamide (20 mL) was
added HATU (1.36 g, 3.58 mmol), DIEA (0.7 mL) and
(2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1-
,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (ULM-1, 1.3
g, 3.02 mmol) at rt. The resulting mixture was stirred for 2 h at
rt. It was then diluted with water (100 mL) and extracted with
ethyl acetate (100 mL.times.3). The organic layers were combined,
washed with saturated aqueous solution of sodium chloride (60 mL),
dried over anhydrous sodium sulfate and then concentrated under
reduced pressure to give a crude residue, which was purified by
flash silica gel chromatography (eluent: dichloromethane/methanol
(v:v=10:1)) to give 0.5 g of BI. LC-MS (ES.sup.+): m/z 787.34
[MH.sup.+], t.sub.R=1.87 min (3.0 minute run).
Step 3: Synthesis of
(2S,4R)-1-[(2S)-2-[2-(3-{[5-(4-{3-[6-cyano-5-(trifluoromethyl)pyridin-3-y-
l]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidiin-1-yl}phenoxy)pentyl]oxy-
}propoxy)acetamido]-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-th-
iazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (Example 2)
[0520] To a stirred solution of
5-[3-(4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-y-
l]-3-(trifluoromethyl)pyridine-2-carbonitrile (ABM-4, 52 mg, 0.13
mmol),
(2S,4R)-1-[(2S)-3,3-dimethyl-2-{2-[3-({5-[(4-methylbenzenesulfonyl)oxy]pe-
ntyl}oxy)propoxy]acetamido}butanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-
-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (BI, 100 mg, 0.13
mmol) in N,N-dimethylformamide (10 mL) was added potassium
carbonate (34 mg, 0.25 mmol) under an atmosphere of nitrogen. The
resulting solution was stirred for 2 h at 80.degree. C. The
resulting mixture was concentrated under vacuum to give a crude
residue, which was purified by Prep-HPLC to give 38.1 mg of Example
2 as a white solid. .sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 9.12
(s, 1H), 8.83 (s, 1H), 8.63 (s, 1H), 7.44-7.39 (m, 4H), 7.00 (d,
J=9.0 Hz, 2H), 7.20 (d, J=9.0 Hz, 2H), 4.80-4.26 (m, 5H), 4.06-3.65
(m, 6H), 3.62-3.35 (m, 6H), 2.43 (s, 3H), 2.21-2.01 (m, 2H),
1.85-1.65 (m, 4H), 1.60-1.42 (m, 10H), 1.00 (s, 9H): LC-MS
(ES.sup.+): m/z 1021.12 [MH.sup.+], t.sub.R=2.36 min (3.6 minute
run).
[0521] Unless otherwise noted, the following examples were
synthesized according to analogous procedures described above for
synthesis of examples 1 and 2, utilizing corresponding reagents,
intermediates, and starting materials.
[0522] When referring to the specific exemplary compounds presented
herein, the specification uses the terms "example #." For example,
compound 1 (Table 2) is also referred to as Example 1.
TABLE-US-00002 TABLE 2 Exemplary Compounds. Ex # Structure Compound
name and Analytical data 1 ##STR00173##
(2S,4R)-1-((S)-2-(2-(3-(5-(4-(3-(4-cyano-
3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-
oxo-2-thioxoimidazolidin-1-yl)phenoxy)
pentyloxy)propoxy)acetamido)-3,3-
dimethylbutanoyl)-4-hydroxy-N-(4-(4-
methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide 1H NMR (400
MHz, CDCl3): .delta. 7.96 (s, 2H), 7.86 (d, J = 8.6 Hz, 1H), 7.19
(d, J = 8.8 Hz, 2H), 7.02 (d, J = 8.6 Hz, 2H), 4.50 (s, 2H), 4.30
(t, J = 6.4 Hz, 2H), 4.02 (t, J = 6.4 Hz, 2H), 3.53 (m, 2H), 3.44
(m, 2H), 1.96-1.80 (m, 4H), 1.69-1.53 (m, 2H), 1.49 (s, 6H), 1.48
(s, 9H), 1.44-1.22 (m, 2H); Mass (ES+): m/z 686.35 [MNa+] 2
##STR00174## (2S,4R)-1-((S)-2-(2-(3-(5-(4-(3-(6-cyano-
5-(trifluoromethyl)pyridin-3-yl)-5,5-
dimethyl-4-oxo-2-thioxoimidazolidin-1-
yl)phenoxy)pentyloxy)propoxy)acetamido)-
3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-
methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide 1H NMR (300
MHz, CD3OD): .delta. 9.12 (s, 1H), 8.83 (s, 1H), 8.63 (s, 1H),
7.44-7.39 (m, 4H), 7.00 (d, J = 9.0 Hz, 2H), 7.20 (d, J = 9.0 Hz,
2H), 4.80-4.26 (m, 5H), 4.06- 3.65 (m, 6H), 3.62-3.35 (m, 6H), 2.43
(s, 3H), 2.21-2.01 (m, 2H), 1.85-1.65 (m, 4H), 1.60-1.42 (m, 10H),
1.00 (s, 9H): LC-MS (ES+): m/z 1021.12 [MH+], tR = 2.36 min (3.6
minute run). 3 ##STR00175## Prepared from ABM-16, L-1, and ULM-1
(2S,4R)-1-[(2S)-2-[2-(3-{[5-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}-2-
fluorophenoxy)pentyl]oxy}propoxy)
acetamido]-3,3-dimethylbutanoyl]-4-
hydroxy-N-{[4-(4-methyl-1,3-thiazol-
5-yl)phenyl]methyl}pyrrolidine-2- carboxamide .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.84 (s, 1H), 8.13-8.09 (m, 2H), 8.01-7.93 (m,
1H), 7.51- 7.31 (m, 4H), 7.21-7.01 (m, 3H), 4.70-4.41 (m, 4H),
4.35-4.22 (m, 1H), 4.15-4.03 (m, 2H), 3.95-3.90 (m, 2 H), 3.90-3.73
(m, 2H), 3.61- 3.56 (m, 2 H), 3.56-3.51 (m, 2 H), 3.50-3.42 (m, 2
H), 2.45 (s, 3H), 2.21-2.10 (m, 1 H), 2.10-2.12 (m, 1H), 1.92-1.70
(m, 4H), 1.63- 1.50 (m, 3 H), 3.50-1.45 (m, 7H), 1.04 (s, 9H);
LC-MS (ES.sup.+): m/z 1038.31 [MH.sup.+], t.sub.R = 2.35 min (3.6
minute run) 4 ##STR00176## Prepared from ABM-3, L-1, and ULM-3
(2S,4R)-1-[(2S)-2-[2-(3-{[5-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}
phenoxy)pentyl]oxy}propoxy)acetamido]-3,3-
dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-
(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl] pyrrolidine-2-carboxamide
.sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.88 (s, 1H), 8.58 (d, J
= 7.5 Hz, 1H), 8.16 (m, 2H), 8.00 (m, 1H), 7.53 (d, J = 9.3 Hz,
1H), 7.42 (m, 4H), 7.26 (m, 2H), 7.05 (m, 2H), 5.01 (m, 1H), 4.72
(d, J = 9.3 Hz, 1H), 4.58 (m, 1H), 4.44 (s, 1H), 4.04 (m, 4H),
3.83-3.49 (m, 8H), 2.48 (s, 3H), 2.20 (m, 1H), 1.83 (m, 5H), 1.50
(m, 13H), 1.03 (s, 9H); LC-MS (ES.sup.+): m/z 518.20 [M + 2]/2,
t.sub.R = 3.67 min, (5.6 minute run) 5 ##STR00177## Prepared from
ABM-17, L-1, and ULM-1
(2S,4R)-1-[(2S)-2-[2-(3-{[5-(4-{5,5-dimethyl-
3-[4-nitro-3-(trifluoromethyl)phenyl]-4-oxo-
2-sulfanylideneimidazolidin-1-yl}phenoxy)
pentyl]oxy}propoxy)acetamido]-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.82 (s, 1H), 8.15-8.13
(m, 2H), 8.01-7.93 (m, 1H), 7.51-7.31 (m, 4H), 7.22-7.22 (m, 2H),
7.22- 7.05 (m, 2H), 4.71 (s, 1 H), 4.60-4.35 (m, 3 H), 4.32-4.24
(m, 1H), 4.120-3.95 (m, 4H), 3.93-3.75 (m, 2H), 3.62-3.52 (m, 2 H),
3.51- 3.41 (m, 2 H), 3.40-3.35 (m, 2H), 2.45 (s, 3H), 2.24-2.10 (m,
1H), 2.09-2.01 (m, 1H), 1.90- 1.72 (m, 4H), 1.65-1.52 (m, 3 H),
1.51-1.34 (m, 7H), 1.00 (s, 9H); LC-MS (ES.sup.+): m/z 1040.32
[MH.sup.+], t.sub.R = 2.52 min (3.6 minute run) 6 ##STR00178##
Prepared from ABM-6, L-1, and ULM-1
(2S,4R)-1-[(2S)-2-(2-{3-[(5-{4-[3-(4-cyano-
3-methylphenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenoxy}
pentyl)oxy]propoxy(acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamid
.sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.88 (s, 1H), 7.83 (d, J
= 8.0 Hz, 1H), 7.53 (m, 6H), 7.28 (d, J = 9.2 Hz, 2H), 7.06 (d, J =
8.8 Hz, 2H), 4.71 (s, 1H), 4.59 (m, 3H), 4.39 (d, J = 15.6 Hz, 1H),
4.05 (m, 4H), 3.88 (m, 2H), 3.68 (m, 4H), 3.52 (m, 2H), 2.61 (s,
3H), 2.50 (s, 3H), 2.25 (m, 1H), 2.10 (m, 1H), 1.93 (m, 4H), 1.68
(m, 10H), 1.06 (s, 9H); LC-MS (ES.sup.+): m/z 483.95 [M + 2]/2,
t.sub.R = 2.28 min (3.60 minute run). 7 ##STR00179## Prepared from
ABM-2, L-1, and ULM-1 (2S,4R)-1-[(2S)-2-(2-{3-[(5-{4-[3-(4-cyano-
3-fluorophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenoxy}
pentyl)oxy]propoxy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (300 MHz, CD3OD): .delta. 8.87 (s, 1H), 7.91 (t, J =
7.8 Hz, 1H), 7.63 (d, J = 8.1 Hz, 1H), 7.54-7.41 (m, 5H), 7.26 (d,
J = 8.7, 2H), 7.03 (d, J = 9.0 Hz, 2H), 4.70 (s, 1H), 4.61- 4.4.51
(m, 3H), 4.37-4.32 (m, 1H), 4.04-3.98 (m, 4H), 3.98-3.81 (m, 2H),
3.67-3.63 (m, 2H), 3.57 (t, J = 6.6 Hz, 2H), 3.57 (t, J = 6.6 Hz,
1H), 2.48 (s, 3H), 2.23-2.09 (m, 2H), 1.92- 1.79 (m, 4H), 1.67-1.53
(m, 10H), 1.03 (s, 9H); LC-MS (ES.sup.+): m/z 970.55 [MH.sup.+],
t.sub.R = 1.55 min (3.6 minute run) 8 ##STR00180## Prepared from
ABM-1, L-1, and ULM-1 2S,4R)-1-[(2S)-2-(2-{3-[(5-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenoxy
(pentyl)oxy]propoxy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 9.00 (s, 1H), 7.98 (d, J
= 8.4 Hz, 1H), 7.87 (s, 1H), 7.66 (d, J = 10.4 Hz, 1H), 7.50 (m,
4H), 7.29 (d, J = 8.8 Hz, 2H), 7.06 (d, J = 8.8 Hz, 2H), 4.71 (s,
1H), 4.62 (m, 3H), 4.39 (d, J = 15.6 Hz, 1H), 4.05 (m, 4H), 3.89
(m, 2H), 3.68 (m, 4H), 3.52 (m, 2H), 2.50 (s, 3H), 2.25 (m, 1H),
2.10 (m, 1H), 1.93 (m, 4H), 1.68 (m, 2H), 1.59 (m, 8H), 1.05 (s,
9H); LC-MS (ES.sup.+): m/z 986.25 [MH.sup.+], t.sub.R = 3.44 min.
(5.00 minute run) 9 ##STR00181## Prepared from ABM-5, L-1, and
ULM-1 (2S,4R)-1-[(2S)-2-(2-{3-[(5-{4-[3-(4-
cyano-3-methoxyphenyl)-5,5-dimethyl-
4-oxo-2-sulfanylideneimidazolidin-1-yl]
phenoxy}pentyl)oxy]propoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-
(4-methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.88 (s, 1H), 7.77 (d, J
= 8.0 Hz, 1H), 7.49-7.42 (m, 4H), 7.37 (d, J = 1.6 Hz, 1H),
7.18-7.16 (m, 3H), 7.06-7.04 (m, 2H), 4.71 (s, 1H), 4.62-4.54 (m,
3H), 4.39 (d, J = 15.6 Hz, 1H), 4.05-4.00 (m, 7H), 3.91-3.80 (m,
2H), 3.72-3.49 (m, 6H), 2.50 (s, 3H), 2.27-2.07 (m, 2H), 1.93-1.81
(m, 4H), 1.66-1.56 (m, 10H), 1.06 (s, 9H); LC-MS (ES.sup.+): m/z
982.55 [MH.sup.+], t.sub.R = 2.67 min (5.0 minute run) 10
##STR00182## Prepared from ABM-16, L-1, and ULM-3
(2S,4R)-1-[(2S)-2-[2-(3-{[5-(4-{3-[4-
cyano-3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-
1-yl}-2-fluorophenoxy)pentyl]oxy}propoxy)
acetamido]-3,3-dimethylbutanoyl]-4-hydroxy-
N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-
yl)phenyl]ethyl]pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz,
DMSO) .delta. 8.98 (s, 1H), 8.44-8.40 (m, 2H), 8.27 (s, 1H), 8.08
(d, J = 8.4 Hz, 1H), 7.45-7.28 (m, 7H), 7.17 (d, J = 8.7 Hz, 1H),
5.12 (d, J = 3.3 Hz, 1H), 4.92- 4.88 (m, 1H), 4.52-4.45 (m, 2H),
4.28 (s, 1H), 4.12 (t, J = 6.6 Hz, 2H), 3.92 (s, 2H), 3.58- 3.38
(m, 8H), 2.45 (s, 3H), 2.08-2.02 (m, 1H), 1.83-1.74 (m, 5H),
1.61-1.46 (m, 11H), 1.38 (d, J = 6.9 Hz. 2H), 0.93 (s, 9H); LC-MS
(ES.sup.+): m/z 1052.40 [MH.sup.+], t.sub.R = 1.79 min 11
##STR00183## Prepared from ABM-18, L-1, and ULM-3
(2S,4R)-1-[(2S)-2-[2-(3-{[5-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}-2,6-
difluorophenoxy)pentyl]oxy}propoxy)
acetamido]-3,3-dimethylbutanoyl]-4-
hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-
5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
DMSO) .delta. 8.98 (s, 1H), 8.45-8.39 (m, 2H), 8.26 (s, 1H), 8.07
(d, J = 8.4 Hz, 1H), 7.44-7.28 (m, 7H), 5.12 (d, J = 3.6 Hz, 1H),
4.92-4.88 (m, 1H), 4.55 (d, J = 9.6 Hz, 1H), 4.44 (t, J = 8.0 Hz,
1H), 4.28 (s, 1H), 4.20 (t, J = 6.8 Hz, 2H), 3.91 (s, 2H),
3.57-3.37 (m, 8H), 2.45 (s, 3H), 2.08-2.02 (m, 1H), 1.80-1.71 (m,
5H), 1.61-1.46 (m, 10H), 1.38 (d, J = 6.8 Hz, 3H), 0.93 (s, 9H);
Mass (ES.sup.+): m/z 1070.50 [MH.sup.+] 12 ##STR00184## Prepared
from ABM-3, L-2, and ULM-1
(2S,4R)-1-[(2S)-2-[2-(3-{[5-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}
phenoxy)-3,3-dimethylpentyl]oxy}propoxy)
acetamido]-3,3-dimethylbutanoyl]-4-hydroxy-
N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]
methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz, CD.sub.3OD):
.delta. 8.88 (s, 1H), 8.15 (m, 2H), 8.01 (m, 1H), 7.49 (m, 4H),
7.30 (d, J = 9.2 Hz, 2H), 7.06 (d, J = 8.8 Hz, 2H), 4.71 (s, 1H),
4.61 (m, 3H), 4.39 (m, 1H), 4.13 (m, 2H), 3.98 (m, 2H), 3.88 (m,
1H), 3.84 (m, 1H), 3.66 (m, 2H), 3.59 (m, 4H), 2.49 (s, 3H), 2.28
(m, 1H), 2.14 (m, 1H), 1.91 (m, 2H), 1.81 (m, 2H), 1.64 (m, 2H),
1.56 (s, 6H), 1.05 (m, 15H); LC-MS (ES.sup.+): m/z 1048.55
[MH.sup.+], t.sub.R = 1.86 min (3.0 minute run). 13 ##STR00185##
Prepared from ABM-3, L-3, and ULM-1
(2S,4R)-1-[(2S)-2-[2-(3-{[5-(4-{3-[4-
cyano-3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-
1-yl}phenoxy)-3-hydroxypentyl]oxy}
propoxy)acetamido]-3,3-dimethylbutanoyl]-
4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)
phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.86 (s, 1H), 8.16-8.13 (d, J = 7.8 Hz, 2H),
8.00-7.96 (d, J = 9.9 Hz, 1H), 7.78-7.40 (m, 4H), 7.29-7.26 (d, J =
9.9 Hz, 2H), 7.07-7.04 (d, J = 8.7 Hz, 2H), 4.70-4.33 (m, 5H),
4.19-4.13 (m, 2H), 4.04-3.81 (m, 5H), 3.65-3.56 (m, 6H), 2.47 (s,
3H), 2.23-1.70 (m, 8H), 1.54 (s, 6H), 1.02 (d, J = 6.0 Hz, 9H).
LC-MS (ES.sup.+): m/z 1036.35 [MH.sup.+], t.sub.R = 1.51 min (3.0
minute run). 14 ##STR00186## Prepared from ABM-3, L-1, and ULM-6
(2S,4R)-N-[(4-chlorophenyl)methyl]-1-
[(2S)-2-[2-(3-{[5-(4-{3-[4-cyano-3-
(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-
yl}phenoxy)pentyl]oxy}propoxy)acetamido]-
3,3-dimethylbutanoyl]-4-hydroxypyrrolidine- 2-carboxamide NMR (400
MHz, CD.sub.3OD) .delta. 8.13-8.17 (m, 2H), 7.99 (d, J = 7.8 Hz,
1H), 7.32-7.36 (m, 2H), 7.25-7.31 (m, 4H), 7.05 (d, J = 9.0 Hz,
2H), 4.51-4.57 (m, 2H), 4.47 (d, J = 16.0 Hz, 2H), 4.27 (d, J =
14.9 Hz, 2H), 4.04 (t, J = 6.5 Hz, 1H), 3.99 (d, J= 3.5 Hz, 2H),
3.64-3.68 (m, 2H), 3.56-3.61 (m, 2H), 3.50 (t, J = 6.3 Hz, 2H),
2.17-2.24 (m, 1H), 2.07 (dd, J = 3.9, 13.3 Hz, 1H), 1.89-1.92 (m,
2H), 1.81-1.86 (m, 1H), 1.64-1.70 (m, 1H), 1.57-1.61 (m, 1H), 1.30
(br. s., 6H), 0.99-1.07 (m, 9H), 0.91 (t, J = 6.8 Hz, 4H). LC-MS
(ES.sup.+): m/z 957.35 [MH.sup.+] 15 ##STR00187## Prepared from
ABM-3, L-1, and ULM-7 (2S,4R)-1-[(2S)-2-[2-(3-{[5-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}
phenoxy)pentyl]oxy}propoxy)acetamido]-3,3-
dimethylbutanoyl]-N-[(4-cyanophenyl)
methyl]-4-hydroxypyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.11-8.17 (m, 2H), 7.98 (d, J = 8.6 Hz, 1H),
7.64 (d, J = 8.6 Hz, 2H), 7.53 (d, J = 8.2 Hz, 2H), 7.26 (d, J =
9.0 Hz, 2H), 7.03 (d, J = 9.0 Hz, 2H), 4.68 (s, 1H), 4.58 (d, J =
16.0 Hz, 2H), 4.54 (d, J = 9.4 Hz, 1H), 4.48 (br. s., 1H), 4.03 (t,
J = 6.3 Hz, 2H), 3.97 (d, J = 2.7 Hz, 1H), 3.84-3.88 (m, 1H), 3.78
(dd, J = 3.5, 11.0 Hz, 1H), 3.61-3.66 (m, 2H), 3.55-3.60 (m, 2H),
3.49 (t, J = 6.3 Hz, 2H), 1.88-1.92 (m, 1H), 1.80-1.85 (m, 2H),
1.63-1.68 (m, 2H), 1.55- 1.59 (m, 2H), 1.25-1.33 (m, 6H), 1.00 (br.
s., 9H), 0.89 (t, J = 6.8 Hz, 4H). LC-MS (ES.sup.+): m/z 949.38
[MH.sup.+]. 16 ##STR00188## Prepared from ABM-3, L-4, and ULM-1
(2S,4R)-1-[(2S)-2-[2-(2-{2-[2-(4-{3-[4-
cyano-3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-
1-yl}phenoxy)ethoxy]ethoxy}ethoxy)
acetamido]-3,3-dimethylbutanoyl]-4-hydroxy-
N-{[4-(4-methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.89 (s, 1 H), 8.18-8.15 (d, J = 8.4 Hz, 2 H),
8.01-7.99 (m, 1 H), 7.49-7.42 (m, 4 H), 7.31-7.28 (d, J = 10.0 Hz,
2 H), 7.10-7.07 (m, 2 H), 4.72 (s, 1 H), 4.61-4.52 (m, 3 H),
4.38-4.34 (m, 1 H), 4.19-4.17 (m, 2 H), 4.10-4.05 (m, 2 H), 3.91-
3.80 (m, 4 H), 3.77-3.72 (m, 8 H), 2.49 (s, 3 H), 2.24-2.05 (m, 2
H), 1.54 (s, 6 H), 1.06 (s, 9 H); LC-MS (ES.sup.+): m/z 1008.50
[MH.sup.+], t.sub.R = 1.49 min (3.0 minute run). 17 ##STR00189##
Prepared from ABM-19, L-4, and ULM-1
(2S,4R)-1-[(2S)-2-[2-(2-{2-[2-(4-{3-[4-
cyano-3-(trifluoromethyl)phenyl]-5,5-
dimethyl-2,4-dioxoimidazolidin-1-yl}
phenoxy)ethoxy]ethoxy}ethoxy)acetamido]-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4- (4-methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.84-8.89 (m, 1 H), 8.67 (t, J = 5.67 Hz, 1 H),
8.25 (s, 1 H), 8.08-8.15 (m, 2 H), 7.67 (d, J = 9.00 Hz, 1 H), 7.43
(q, J = 8.22 Hz, 4 H), 7.30 (d, J = 8.22 Hz, 2 H), 7.00-7.08 (m, 2
H), 4.70 (d, J = 9.78 Hz, 1 H), 4.45-4.61 (m, 3 H), 4.35 (dd, J =
15.85, 4.89 Hz, 1 H), 4.12-4.17 (m, 2 H), 4.04 (d, J = 3.91 Hz, 2
H), 3.77-3.90 (m, 4 H), 3.67-3.75 (m, 8 H), 2.47 (d, J = 0.78 Hz, 3
H), 2.22 (dd, J = 12.91,
8.61 Hz, 1 H), 2.03-2.12 (m, 1 H), 1.46-1.55 (m, 6 H), 0.98-1.10
(m, 9 H); Mass (ES.sup.+): m/z 992.38 [MH.sup.+] 18 ##STR00190##
Prepared from ABM-16, L-4, and ULM-1
(2S,4R)-1-[(2S)-2-[2-(2-{2-[2-(4-{3-[4-
cyano-3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-
1-yl}-2-fluorophenoxy)ethoxy]ethoxy}
ethoxy)acetamido]-3,3-dimethylbutanoyl]-
4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)
phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD): 8.89 (s, 1H), 8.18-8.16 (d, J = 7.2 Hz, 2H), 8.01-7.99
(d, J = 8.4 Hz, 1H), 7.49-744 (m, 4H), 7.28-7.21 (m, 2H), 7.16-7.14
(m, 1H), 4.71 (s, 1H), 4.61-4.53 (m, 3H), 4.35-4.31 (m, 1H), 4.28-
4.26 (m, 2H), 4.10-4.06 (m, 2H), 3.94-3.81 (m, 3H), 3.81-3.80 (m,
1H), 3.80-3.75 (m, 8H), 2.49 (s, 3H), 2.26-2.24 (m, 1H), 2.11- 2.09
(m, 1H), 1.57 (s, 6H), 1.03 (s, 9H); LC-MS (ES.sup.+): m/z 1026.34
[MH.sup.+], t.sub.R = 2.73 min (5.6 minute run). 19 ##STR00191##
Prepared from ABM-17, L-4, and ULM-1
(2S,4R)-1-[(2S)-2-[2-(2-{2-[2-(4-{5,5-
dimethyl-3-[4-nitro-3-(trifluoromethyl)
phenyl]-4-oxo-2-sulfanylideneimidazolidin-
1-yl}phenoxy)ethoxy]ethoxy}ethoxy)
acetamido]-3,3-dimethylbutanoyl]-4-
hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2- carboxamide (400 MHz, CD.sub.3OD):
.delta. 8.89 (s, 1H), 8.19-8.16 (m, 2H), 8.05-8.02 (m, 1H),
7.49-7.42 (m, 4H), 7.31-7.29 (d, J = 8.8 Hz, 2H), 7.09-7.07 (d, J =
8.8 Hz, 2H), 4.71 (s, 1H), 4.61-4.52 (m, 3H), 4.38- 4.34 (m, 1H),
4.23-4.17 (m, 2H), 4.06-4.01 (m, 2H), 3.91-3.80 (m, 4H), 3.78-3.68
(m, 8H), 2.49 (s, 3H), 2.27-2.22 (m, 1H), 2.13-2.07 (m, 1H), 1.56
(s, 6H), 1.06 (s, 9H); LC-MS (ES.sup.+): m/z 1028.50 [MH.sup.+],
t.sub.R = 2.62 min (5.0 minute run). 20 ##STR00192## Prepared from
ABM-3, L-4, and ULM-3 (2S,4R)-1-[(2S)-2-[2-(2-{2-[2-(4-{3-[4-
cyano-3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-
1-yl}phenoxy)ethoxy]ethoxy}ethoxy)
acetamido]-3,3-dimethylbutanoyl]-4
-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-
thiazol-5-yl)phenyl]ethyl]pyrrolidine- 2-carboxamide .sup.1H NMR
(300 MHz, CD.sub.3OD): .delta. 8.90 (s, 1H), 8.16-8.13 (d, J = 8.1
Hz, 2H), 8.00- 7.97 (d, J = 8.1 Hz, 1H), 7.45-7.35 (m, 4H),
7.30-7.27 (d, J = 9.0 Hz, 2H), 7.11- 7.08 (d, J = 9.0 Hz, 2H),
5.03-5.00 (m, 1H), 4.69 (s, 1H), 4.60-4.57 (m, 1H), 4.54-4.43 (m,
1H), 4.23-4.22 (m, 2H), 4.12-4.10 (m, 2H), 3.99-3.88 (m, 3H),
3.83-3.71 (m, 9H), 2.54 (s, 3H), 2.24-2.04 (m, 1H), 2.00-1.94 (m,
1H), 1.57 (s, 9H), 1.03 (s, 9H). LC-MS (ES.sup.+): m/z 1022.56
[MH.sup.+], t.sub.R = 2.07 min (3.6 minute run). 21 ##STR00193##
Prepared from ABM-4, L-4, and ULM-1
(2S,4R)-1-[(2S)-2-[2-(2-{2-[2-(4-{3-[6-
cyano-5-(trifluoromethyl)pyridin-3-yl]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-
1-yl}phenoxy)ethoxy]ethoxy}ethoxy)
acetamido]-3,3-dimethylbutanoyl]-4-
hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2- carboxamide .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 9.12 (s, 1H), 8.83 (s, 1H), 8.63 (s, 1H),
7.70-7.50 (m, 1 H), 7.47-7.30 (m, 4 H), 7.22 (d, J = 9 Hz, 2 H),
7.02 (d, J = 9 Hz, 2 H), 4.80- 4.26 (m, 5H), 4.25-4.06 (m, 4H),
3.92-3.78 (m, 3 H), 3.75-3.60 (m, 8H), 2.43 (s, 3H), 2.20-2.10 (m,
1 H), 2.10-2.01 (m, 1 H), 1.52 (s, 6H), 1.00 (s, 9H); LC-MS
(ES.sup.+): m/z 1009.12 [MH.sup.+], t.sub.R = 2.16 min (3.6 minute
run). 22 ##STR00194## Prepared from ABM-3, L-5, and ULM-1
(2S,4R)-1-[(2S)-2-(2-{[(2R,3R)-3-{2-[2-
(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]- 5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl}phenoxy)
ethoxy]ethoxy}butan-2-yl]oxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-
(4-methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.81-8.94 (m, 1 H), 8.17
(d, J = 7.43 Hz, 2 H), 8.01 (d, J = 8.61 Hz, 1 H), 7.73-7.89 (m, 1
H), 7.37- 7.57 (m, 3 H), 7.21-7.36 (m, 2 H), 7.01-7.17 (m, 2 H),
5.48-5.54 (m, 1 H), 3.36-4.88 (m, 20 H), 3.20-3.29 (m, 2 H),
2.43-2.52 (m, 2 H), 2.16-2.30 (m, 1 H), 2.03-2.16 (m, 1 H), 1.52-
1.59 (m, 3 H), 1.39 (d, J = 4.30 Hz, 9 H), 1.11- 1.21 (m, 3 H),
1.06 (s, 3 H); Mass (ES.sup.+): m/z 1036.47 [MH.sup.+] 23
##STR00195## Prepared from ABM-3, L-6, and ULM-1
(2S,4R)-1-[(2S)-2-[2-(2-{[(2R,3R)-3-[2-(4-
{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-
1-yl}phenoxy)ethoxy]butan-2-yl]oxy}
ethoxy)acetamido]-3,3-dimethylbutanoyl]-
4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-
5-yl)phenyl]methyl}pyrrolidine-2- carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.86 (s, 1 H), 8.12-8.17 (m, 2 H), 7.98 (dd, J
= 8.22, 1.96 Hz, 1 H), 7.39-7.48 (m, 4 H), 7.24- 7.30 (m, 2 H),
7.03-7.08 (m, 2 H), 4.70 (s, 1 H), 4.58-4.63 (m, 2 H), 4.55 (d, J =
15.65 Hz, 2 H), 4.50 (br. s., 1 H), 4.15 (d, J = 4.30 Hz, 2 H),
4.02 (d, J = 7.83 Hz, 1 H), 3.88- 3.94 (m, 2 H), 3.71-3.75 (m, 2
H), 3.63-3.68 (m, 2 H), 3.56-3.61 (m, 1 H), 3.47-3.52 (m, 1 H),
2.44-2.50 (m, 3 H), 2.19-2.25 (m, 1 H), 2.06-2.11 (m, 1 H), 1.53
(s, 6 H), 1.35 (d, J = 6.65 Hz, 3 H), 1.11 (d, J = 6.26 Hz, 6 H),
1.01-1.07 (m, 9 H); Mass (ES.sup.+): m/z 1036.47 24 ##STR00196##
Prepared from ABM-3, L-7, and ULM-1
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-
cyano-3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-
1-yl}phenoxy)butoxy]butoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-
(4-methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.90 (s, 1H), 8.17-8.15
(d, J = 8.4 Hz, 2H), 8.01- 8.01 (d, J = 1.6 Hz, 1H), 7.49-7.42 (m,
4H), 7.30-7.27 (d, J = 11.6 Hz, 2H), 7.06- 7.04 (d, J = 8.8 Hz,
2H), 4.71 (s, 1H), 4.61- 4.54 (m, 3H), 4.38-4.34 (m, 1H), 4.07-4.04
(m, 2H), 3.40-3.95 (m, 2H), 3.91-3.83 (m, 2H), 3.61-3.58 (m, 2H),
3.52-3.50 (m, 4H), 2.50 (s, 3H), 2.05-2.14 (m, 1H), 2.20-2.30 (m,
1H), 1.89-1.86 (m, 2H), 1.79-1.723 (m, 6H), 1.56 (s, 6H), 1.06 (s,
9H); LC-MS (ES.sup.+): m/z 1020.30 [MH.sup.+], t.sub.R = 4.06 min
(5.6 minute run). 25 ##STR00197## Prepared from ABM-16, L-7, and
ULM-3 (2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}-2-
fluorophenoxy)butoxy]butoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-
1-[4-(4-methyl-1,3-thiazol-5-
yl)phenyl]ethyl]pyrrolidine-2-carboxainide .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.88 (s, 1H), 8.17-8.14 (d, J = 7.5 Hz, 2H),
8.00-7.97 (d, J = 8.4 Hz, 1H), 7.46-7.39 (m, 4H), 7.27-7.12 (m,
3H), 5.01-4.86 (m, 1H), 4.69 (s, 1H), 4.60-4.55 (t, J = 7.5 Hz,
1H), 4.44 (m, 1H), 4.19-4.17 (t, J = 6.0 Hz, 2H), 3.98-3.97 (d, J =
2.7 Hz, 2H), 3.87-3.76 (m, 2H), 3.61-3.49 (m, 6H), 2.48 (s, 3H),
2.17 (m, 1H), 2.00- 1.89 (m, 3H), 1.84-1.75 (m, 2H), 1.74-1.71 (m,
4H), 1.58 (s, 6H), 1.52-1.49 (m, 3H), 1.04 (s, 9H); Mass
(ES.sup.+): m/z 1052.20 [MH.sup.+] 26 ##STR00198## Prepared from
ABM-16, L-7, and ULM-3 (2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}-2-
fluorophenoxy)butoxy]butoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4- methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 8.88 (s, 1 H), 8.17-8.15 (m, 2 H), 8.00-7.99
(d, J = 6.4 Hz, 1 H), 7.49-7.42 (m, 4 H), 7.23-7.13 (m, 3 H), 4.71
(s, 1 H), 4.61-4.52 (m, 3 H), 4.38- 4.34 (m, 1 H), 4.00-3.83 (m, 3
H), 3.61-3.49 (m, 6 H), 2.49 (s, 3 H), 2.30-2.10 (m, 2 H),
1.92-1.89 (m, 2 H), 1.79-1.73 (m, 6 H), 1.72 (s, 6 H), 1.05 (s, 9
H); LC-MS (ES.sup.+): m/z 1038.50 [MH.sup.+], t.sub.R = 3.05 min
(5.0 minute run). 27 ##STR00199## Prepared from ABM-16, L-8, and
ULM-1 (2S,4R)-1-[(2S)-2-(2-{3-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}-2-
fluorophenoxy)butoxy]propoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4- methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.87 (s, 1H), 8.10 (d, J = 8.6 Hz, 2H), 7.93
(m, 1H), 7.37 (m, 4H), 7.11 (m, 3H), 4.83-4.48 (m, 5H), 4.12 (m,
2H), 3.94 (m, 2H), 3.78 (m, 2H), 3.50 (m, 6H), 2.44 (s, 3H), 2.05
(m, 2H), 1.73 (m, 6H), 1.52 (s, 6H), 1.00 (s, 9H); LC-MS
(ES.sup.+): m/z 1024.10 [MH.sup.+], t.sub.R = 2.79 min (5.6 minute
run). 28 ##STR00200## Prepared from ABM-3, L-8, and ULM-1
(2S,4R)-1-[(2S)-2-(2-{3-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}
phenoxy)butoxy]propoxy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4- methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 8.88 (s, 1H), 8.14 (m, 2H), 7.97 (m, 1H),
7.49-7.41 (m, 4H), 7.26 (m, 2H), 7.02 (m, 2H), 4.70 (s, 1H),
4.61-4.52 (m, 3H), 4.38-4.33 (m, 1H), 4.03 (t, J = 6.3 Hz, 2H),
3.98 (s, 2H), 3.86-3.82 (m, 2H), 3.68-3.51 (m, 6H), 2.48 (s, 3H),
2.23- 2.09 (m, 2H), 1.93-1.73 (m, 6H), 1.55 (s, 6H), 1.02 (s, 9H);
LC-MS (ES.sup.+): m/z 1006.50 [MH.sup.+], t.sub.R = 2.81 min (5.6
minute run). 29 ##STR00201## Prepared from ABM-3, L-8, and ULM-8
(2S,4R)-1-[(2S)-2-(2-{3-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}
phenoxy)butoxy]propoxy}acetamido)-3-
methylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-
1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine- 2-carboxamide .sup.1H
NMR (400 MHz, CD.sub.3OD): .delta. 8.88 (s, 1H), 8.17 (d, J = 8.8
Hz, 2H), 8.01 (m, 1H), 7.47 (m, 4H), 7.30 (d, J = 8.8 Hz, 2H), 7.06
(d, J = 8.8 Hz, 2H), 4.66 (m, 1H), 4.61 (m, 1H), 4.54 (m, 2H), 4.42
(m, 1H), 4.08 (m, 2H), 4.01 (m, 2H), 3.85 (m, 2H), 3.67 (m, 2H),
3.61 (m, 2H), 3.56 (m, 2H), 2.50 (s, 3H), 2.25 (m, 1H), 2.16 (m,
2H), 1.93 (m, 4H), 1.78 (m, 2H), 1.56 (s, 6H), 1.03 (m, 3H), 0.96
(m, 3H); LC-MS (ES.sup.+): m/z 992.55 [MH.sup.+], t.sub.R = 3.39
min (5.6 minute run). 30 ##STR00202## Prepared from ABM-4, L-8, and
ULM-1 (2S,4R)-1-[(2S)-2-(2-{3-[4-(4-{3-[6-cyano-
5-(trifluoromethyl)pyridin-3-yl]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-
1-yl}phenoxy)butoxy]propoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4- methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 9.15-9.10 (m, 1H), 8.80 (s, 1H), 8.66-8.62 (m,
1H), 7.45- 7.36 (m, 4H), 7.25-7.18 (m, 2H), 7.02-6.92 (m, 2H),
4.70-4.62 (m, 1H), 4.60-4.44 (m, 3H), 4.35-4.26 (m, 1H), 4.10-3.90
(m, 4H), 3.89-3.69 (m, 2H), 3.65-3.40 (m, 6H), 2.44 (s, 4H),
2.20-2.01 (m, 2H), 1.88-1.60 (m, 6H), 1.52 (s, 6H), 1.00 (s, 9H);
LC-MS (ES.sup.+): m/z 1007.30 [MH.sup.+], t.sub.R = 1.71 min (3.0
minute run). 31 ##STR00203## Prepared from ABM-1, L-8, and ULM-1
(2S,4R)-1-[(2S)-2-{2-[3-(4-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenoxy}
butoxy)propoxy]acetamido}-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4- methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 8.87 (s, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.87
(s, 1H), 7.66 (m, 1H), 7.49 (m, 4H), 7.28 (m, 2H), 7.05 (m, 2H),
4.71 (s, 1H), 4.59 (m, 3H), 4.38 (m, 1H), 4.07 (m, 4H), 3.987 (m,
2H), 3.68 (m, 6H), 2.48 (s, 3H), 2.27 (m, 2H), 1.93 (m, 6H), 1.54
(s, 6H), 1.03 (s, 9H). LC-MS (ES.sup.+): m/z 486.40 [M/2H.sup.+],
t.sub.R = 2.21 min (3.6 minute run). 32 ##STR00204## Prepared from
ABM-5, L-8, and ULM-1 (2S,4R)-1-[(2S)-2-{2-[3-(4-{4-[3-(4-cyano-
3-methoxyphenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenoxy}
butoxy)propoxy]acetamido}-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.89 (s, 1H), 7.75 (d, J
= 8.4 Hz, 1H), 7.49-7.42 (m, 4H), 7.37 (s, 1H), 7.27 (d, J = 8.8
Hz, 2H), 7.18- 7.15 (m, 1H), 7.06-7.04 (m, 2H), 4.88 (s, 1H),
4.59-4.46 (m, 3H), 4.38-4.35 (m, 1H), 4.07- 4.00 (m, 2H), 3.99-3.87
(m, 5H), 3.88-3.76 (m, 2H), 3.68-3.60 (m, 2H), 3.59-3.55 (m, 2H),
3.54-3.53 (m, 2H), 2.49 (s, 3H), 2.28- 2.19 (m, 1H), 2.14-2.05 (m,
1H), 1.93-1.86 (m, 4H), 1.80-1.78 (m, 2H), 1.54 (s, 6H), 1.04 (s,
9H); LC-MS (ES.sup.+): m/z 968.35 [MH.sup.+], t.sub.R = 2.57 min
(5.6 minute run). 33 ##STR00205## Prepared from ABM-3, L-8, and
ULM-2 (2S,4R)-1-[(2S)-2-(2-{3-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}
phenoxy)butoxy]propoxy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(1,3-
thiazol-5-yl)phenyl]methyl}pyrrolidine-2- carboxamide .sup.1H NMR
(400 MHz, CD.sub.3OD): .delta. 8.94 (s, 1H), 8.16 (d, J = 8.8 Hz,
3H), 8.00 (d, J = 1.6 Hz, 1H), 7.61 (d, J = 8.0 Hz, 2H), 7.44 (d, J
= 8.0 Hz, 2H), 7.28 (d, J = 8.8 Hz, 2H), 7.04 (d, J = 8.8 Hz, 2H),
4.71 (s, 1H), 4.61-4.51 (m, 3H), 4.37-4.33 (m, 1H), 4.07-4.03 (m,
2H), 4.01-3.96 (m, 2H), 3.88- 3.82 (m, 1H), 3.81-3.77 (m, 1H),
3.69- 3.3.62 (m, 2H), 3.61-3.55 (m, 2H), 3.54- 3.53 (m, 2H),
2.28-2.19 (m, 1H), 2.14-2.05 (m, 1H), 1.96-1.84 (m, 4H), 1.80-1.74
(m, 2H), 1.56 (s, 6H), 1.06 (s, 9H); LC-MS (ES.sup.+): m/z 496.85
[MH/2.sup.+], t.sub.R = 1.60 min (3.0 minute run). 34 ##STR00206##
Prepared from ABM-3, L-8, and ULM-4
(2S,4R)-1-[(2S)-2-(2-{3-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}
phenoxy)butoxy]propoxy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(1,3-
oxazol-5-yl)phenyl]methyl}pyrrolidine-2- carboxamide .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.24 (s, 1H), 8.17 (d, J = 8.0 Hz,
2H), 8.01 (dd, J = 8.0, 1.6 Hz, 1H), 7.70 (d, J = 8.0 Hz, 2H),
7.49- 7.45 (m, 3H), 7.29 (d, J = 8.8 Hz, 2H), 7.06 (d, J = 8.8 Hz,
2H), 4.72 (s, 1H),
4.61-4.51 (m, 3H), 4.37 (m, 1H), 4.08-3.83 (m, 6H), 3.69-3.54 (m,
6H), 2.15-2.05 (m, 2H), 1.93- 1.76 (m, 6H), 1.56 (s, 6H), 1.03 (s,
9H); LC-MS (ES.sup.+): m/z 976.45 [MH.sup.+], t.sub.R = 1.69 min
(3.0 minute run). 35 ##STR00207## Prepared from ABM-3, L-8, and
ULM-5 (2S,4R)-1-[(2S)-2-(2-{3-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}
phenoxy)butoxy]propoxy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4- methyl-1,3-oxazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.16-8.14 (d, J = 8.8 Hz, 3 H), 7.98-7.98 (d, J
= 2.0 Hz, 1 H), 7.61-7.59 (d, J = 8.4 Hz, 2 H), 7.49-7.47 (d, J =
8.4 Hz, 2 H), 7.29-7.27 (d, J = 8.8 Hz, 2 H), 7.05-7.03 (d, J = 8.8
Hz, 2 H), 4.71- 4.52 (m, 4 H), 4.37-4.34 (m, 1 H), 4.07- 3.99 (m, 4
H), 3.87-3.82 (m, 2 H), 3.68-3.53 (m, 6 H), 2.41 (s, 3 H),
2.21-2.00 (m, 2 H), 1.93-1.76 (m, 6 H), 1.55 (s, 6 H), 1.05 (s, 9
H); LC-MS (ES.sup.+): m/z 990.60 [MH.sup.+], t.sub.R = 3.50 min
(5.6 minute run). 36 ##STR00208## Prepared from ABM-1, L-8, and
ULM-9 (2S,4R)-1-[(2S)-2-{2-[3-(4-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenoxy}
butoxy)propoxy]acetamido}-3- methylbutanoyl]-4-hydroxy-N-{[4-(1,3-
thiazol-5-yl)phenyl]methyl}pyrrolidine-2- carboxamide .sup.1H NMR
(400 MHz, CD.sub.3OD): .delta. 8.89 (s, 1H), 8.12 (s, 1H), 7.90 (d,
J = 8.4 Hz, 1H), 7.82 (s, 1H), 7.62-7.56 (m, 3H), 7.40 (d, J = 8.4
Hz, 2H), 7.23 (d, J = 8.4 Hz, 2H), 7.00 (s, 2H), 4.61-4.52 (m, 1H),
4.51-4.40 (m, 2H), 4.39-4.36 (m, 1H), 4.03-3.95 (m, 4H), 3.78-3.74
(m, 2H), 3.63-3.27 (m, 7H), 2.23-1.98 (m, 3H), 1.89-1.71 (m, 6H),
1.50 (s, 6H), 0.97 (d, J = 6.6 Hz, 3H), 0.89 (d, J = 6.6 Hz, 3H);
LC-MS (ES.sup.+): m/z 944.25 [MH.sup.+], t.sub.R = 1.51 min (3.0
minute run). 37 ##STR00209## Prepared from ABM-1, L-8, and ULM-1
(2S,4R)-1-[(2S)-2-{2-[3-(4-{4-[3-(5-chloro-
6-cyanopyridin-3-yl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenoxy}
butoxy)propoxy]acetamido}-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4- methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 8.87-8.86 (m, 2 H), 8.44 (s, 1 H), 7.49-7.42
(m, 4 H), 7.29-7.27 (d, J = 8.8 Hz, 2 H), 7.06-7.04 (d, J = 8.8 Hz,
2 H), 4.72 (s, 1 H), 4.59-4.52 (m, 3 H), 4.39-4.35 (m, 1 H),
4.08-3.99 (m, 4 H), 3.96-3.83 (m, 2 H), 3.68-3.59 (m, 6 H), 2.50
(s, 3 H), 2.15-2.05 (m, 2 H), 1.92-1.88 (m, 6 H), 1.56 (s, 6 H),
1.04 (s, 9 H); LC-MS (ES.sup.+): m/z 973.30 [MH.sup.+], t.sub.R =
1.58 min (3.0 minute run). 38 ##STR00210## Prepared from ABM-1,
L-8, and ULM-5 (2S,4R)-1-[(2S)-2-{2-[3-(4-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenoxy}
butoxy)propoxy]acetamido}-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4- methyl-1,3-oxazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.20 (s, 1 H), 7.97-7.95 (d, J = 8.4 Hz, 1 H),
7.87 (s, 1 H), 7.66-7.59 (m, 3 H), 7.49-7.47 (d, J = 8.4 Hz, 2 H),
7.28-7.26 (d, J = 9.2 Hz, 2 H), 7.05- 7.03 (d, J = 8.8 Hz, 2 H),
4.71 (s, 1 H), 4.57- 4.52 (m, 3 H), 4.38-4.34 (m, 1 H), 4.07-3.99
(m, 4 H), 3.87-3.80 (m, 2 H), 3.67-3.53 (m, 6 H), 2.42 (s, 1 H),
2.20-2.00 (m, 2 H), 1.93- 1.77 (m, 6 H), 1.54 (s, 6 H), 1.06 (s, 9
H); LC-MS (ES.sup.+): m/z 956.30 [MH.sup.+], t.sub.R = 1.56 min
(3.0 minute run). 39 ##STR00211## Prepared from ABM-1, L-8, and
ULM-10 (2S,4R)-1-[(2S)-2-{2-[3-(4-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenoxy}
butoxy)propoxy]acetamido}-3- methylbutanoyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-oxazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.15 (s, 1 H), 7.97-7.95
(d, J = 8.4 Hz, 1 H), 7.87 (s, 1 H), 7.66-7.60 (m, 3 H), 7.48-7.45
(d, J = 8.4 Hz, 2 H), 7.28-7.26 (d, J = 9.2 Hz, 2 H), 7.06- 7.03
(d, J = 9.2 Hz, 2 H), 4.66-4.41 (m, 5 H), 4.07-3.99 (m, 4 H),
3.85-3.83 (m, 2 H), 3.66-3.53 (m, 6 H), 2.41 (s, 3 H), 2.25-2.00
(m, 3 H), 1.93-1.77 (m, 6 H), 1.53 (s, 6 H), 1.03-1.02 (d, J = 6.8
Hz, 3 H), 0.95-0.93 (d, J = 6.8 Hz, 3 H); LC-MS (ES.sup.+): m/z
942.30 [MH.sup.+], t.sub.R = 1.50 min (3.0 minute run). 40
##STR00212## Prepared from ABM-20, L-8, and ULM-1
(2S,4R)-1-[(2S)-2-[2-(3-{4-[(5-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}pyridin-
2-yl)oxy]butoxy}propoxy)acetamido]-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.81 (s, 1 H), 8.16-8.03
(m, 3 H), 8.00-7.90 (m, 1 H), 7.70-7.60 (m, 1 H), 7.51-7.30 (m,
4H), 6.91- 6.80 (m, 1 H), 4.67 (s, 1 H), 4.60-4.40 (m, 4 H),
4.32-4.21 (m, 3 H), 3.89-3.70 (m, 4 H), 3.65-3.40 (m, 6 H), 2.41
(s, 3 H), 2.23- 2.01 (m, 2 H), 1.90-1.62 (m, 6 H), 1.55 (s, 6 H),
1.02 (s, 9 H); LC-MS (ES.sup.+): m/z, 1007.35 [MH.sup.+], t.sub.R =
1.58 min (3.0 minute run). 41 ##STR00213## Prepared from ABM-21,
L-8, and ULM-1 (2S,4R)-1-[(2S)-2-{2-[3-(4-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]-2-
fluorophenoxy}butoxy)propoxy]acetamido}-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4- (4-methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 8.88 (s, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.88
(s, 1H), 7.66- 7.64 (m, 1H), 7.48-7.39 (m, 4H), 7.22-7.19 (m, 2H),
7.14 (s, 1H), 4.71 (s, 1H), 4.59-4.47 (m, 3H), 4.36 (d, J = 15.6
Hz, 1H), 4.14 (t, J = 6.4 Hz, 2H), 4.00 (d, J = 3.6 Hz, 2H),
3.87-3.78 (m, 2H), 3.67-3.54 (m, 6H), 2.45 (s, 3H), 2.26-2.21 (m,
1H), 2.13-2.04 (m, 1H), 1.93-1.89 (m, 4H), 1.83-1.74 (m, 2H), 1.55
(s, 6H), 1.04 (s, 9H); LC-MS (ES.sup.+): m/z 990.35 [MH.sup.+],
t.sub.R = 1.59 min (3.0 minute run). 42 ##STR00214## Prepared from
ABM-22, L-8, and ULM-1 (2S,4R)-1-[(2S)-2-{2-[3-(4-{4-[3-(4-cyano-
3-methoxyphenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]-2-
fluorophenoxy}butoxy)propoxy]acetamido}-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.98 (s, 1 H), 7.77-7.75
(d, J = 8.4 Hz, 2 H), 7.49-7.42 (m, 4 H), 7.36-7 (s, 1 H),
7.21-7.14 (m, 4 H), 4.71 (s, 1 H), 4.59-4.52 (m, 3 H), 4.39-4.35
(m, 1 H), 4.16-4.13 (m, 2 H), 4.00-3.98 (m, 5 H), 3.99-3.83 (m, 2
H), 3.68-3.66 (m, 2 H), 2.50 (s, 3 H), 2.30-2.10 (m, 2 H),
1.93-1.89 (m, 4 H), 1.80-1.76 (m, 2 H), 1.55 (s, 6 H), 1.03 (s, 9
H); LC-MS (ES.sup.+): m/z 986.45 [MH.sup.+], t.sub.R = 1.65 min
(3.0 minute run). 43 ##STR00215## Prepared from ABM-8, L-8, and
ULM-1 (2S,4R)-1-[(2S)-2-(2-{3-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-4-oxo-2-
sulfanylidene-8-oxa-1,3-diazaspiro[4.5]
decan-1-yl}phenoxy)butoxy]propoxy}
acetamido)-3,3-dimethylbutanoyl]-4-
hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.98-8.83 (s, 1 H), 8.18-8.16 (d, J = 8.4 Hz, 2
H), 8.01- 7.99 (m, 1 H), 7.49-7.42 (m, 4 H), 7.42-7.24 (d, J = 8.4
Hz, 2 H), 7.08-7.06 (d, J = 8.4 Hz, 2 H), 4.80 (s, 1 H), 4.72 (s, 1
H), 4.59-4.34 (m, 3 H), 4.20-4.08 (m, 6 H), 3.99-3.87 (m, 4 H),
3.67-3.56 (m, 6 H), 2.49 (s, 3 H), 2.21- 1.87 (m, 12 H), 1.05 (s, 9
H); LC-MS (ES.sup.+): m/z 1048.45 [MH.sup.+], t.sub.R = 1.73 min
(3.0 minute run). 44 ##STR00216## Prepared from ABM-21, L-8, and
ULM-5 (2S,4R)-1-[(2S)-2-{2-[3-(4-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]-2-
fluorophenoxy}butoxy)propoxy]acetamido}-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4- (4-methyl-1,3-oxazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 8.15 (s, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.87
(s, 1H), 7.66- 7.60 (m, 3H), 7.48 (d, J = 8.4 Hz, 2H), 7.24- 7.14
(m, 3H), 4.71 (s, 1H), 4.61-4.52 (m, 3H), 4.38-4.33 (m, 1H), 4.14
(m, 2H), 4.00 (d, J = 4.0 Hz, 3H), 3.88-3.82 (m, 2H), 3.68-3.54 (m,
6H), 2.42 (s, 3H), 2.27-2.18 (m, 1H), 2.13- 2.04 (m, 1H), 1.93-1.89
(m, 4H), 1.88-1.80 (m, 2H), 1.55 (s, 6H), 1.06 (s, 9H); LC-MS
(ES.sup.+): m/z 974.25 [MH.sup.+], t.sub.R = 1.57 min (3.0 minute
run). 45 ##STR00217## Prepared from ABM-21, L-8, and ULM-4
(2S,4R)-1-[(2S)-2-{2-[3-(4-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]-2-
fluorophenoxy}butoxy)propoxy]acetamido}-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-
(1,3-oxazol-5-yl)phenyl]methyl}pyrrolidine- 2-carboxamide .sup.1H
NMR (400 MHz, CD.sub.3OD): .delta. 8.24 (s, 1H), 7.96 (d, J = 8.4
Hz, 1H), 7.87 (s, 1H), 7.70- 7.7.64 (m, 3H), 7.49-7.40 (m, 3H),
7.22 (d, J = 8.4 Hz, 2H), 7.14 (d, J = 8.0 Hz, 1H), 4.71 (s, 1H),
4.60-4.51 (m, 3H), 4.38-4.34 (m, 1H), 4.18-4.11 (m, 2H), 4.00-3.96
(m, 2H), 3.92-3.76 (m, 2H), 3.68-3.55 (m, 6H), 2.27- 2.21 (m, 1H),
2.18-2.06 (m, 1H), 1.95-1.86 (m, 4H), 1.83-1.72 (m, 2H), 1.55 (s,
6H), 1.06 (s, 9H); LC-MS (ES.sup.+): m/z 960.30 [MH.sup.+], t.sub.R
= 1.54 min (3.0 minute run). 46 ##STR00218## Prepared from ABM-21,
L-8, and ULM-2 (2S,4R)-1-[(2S)-2-{2-[3-(4-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]-2-
fluorophenoxy}butoxy)propoxy]acetamido}-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-
(1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine- 2-carboxamide .sup.1H
NMR (400 MHz, CD.sub.3OD): .delta. 8.94 (s, 1H), 8.15 (s, 1H), 7.96
(d, J = 8.4 Hz, 1H), 7.87 (s, 1H), 7.66-7.61 (m, 3H), 7.44 (d, J =
8.4 Hz, 2H), 7.19-7.12 (m, 3H), 4.71 (s, 1H), 4.60-4.51 (m, 3H),
4.38-4.34 (m, 1H), 4.17-4.11 (m, 2H), 3.99-3.94 (m, 2H), 3.88-3.75
(m, 2H), 3.71-3.55 (m, 6H), 2.37-2.20 (m, 1H), 2.13-2.06 (m, 1H),
1.94-1.89 (m, 4H), 1.80-1.77 (m, 2H), 1.55 (s, 6H), 1.03 (s, 9H);
LC-MS (ES.sup.+): m/z 976.25 [MH.sup.+], t.sub.R = 1.57 min (3.0
minute run). 47 ##STR00219## Prepared from ABM-23, L-8, and ULM-4
(2S,4R)-1-[(2S)-2-(2-{3-[4-(4-{3-[6-cyano-
5-(trifluoromethyl)pyridin-3-yl]-5,5-dimethyl-
4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-
fluorophenoxy)butoxy]propoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-
(1,3-oxazol-5-yl)phenyl]methyl}pyrrolidine- 2-carboxamide .sup.1H
NMR (300 MHz, CD.sub.3OD) .delta. 9.16 (s, 1 H), 8.67 (s, 1 H),
8.23 (s, 1 H), 7.69-7.66 (d, J = 8.1 Hz, 2 H), 7.48-7.43 (m, 3 H),
7.22-7.15 (m, 3 H), 4.70 (s, 1 H), 4.60-4.49 (m, 3 H), 4.36-4.31
(m, 1 H), 4.16-4.12 (m, 2 H), 3.99 (m, 2 H), 3.86-3.81 (m, 2 H),
3.67-3.53 (m, 6 H), 2.22-2.08 (m, 2 H), 1.95-1.75 (m, 6 H), 1.57
(s, 6 H), 1.04 (s, 9 H); LC-MS (ES.sup.+): m/z 995.10 [MH.sup.+],
t.sub.R = 2.26 min (3.6 minute run). 48 ##STR00220## Prepared from
ABM-23, L-8, and ULM-1 (2S,4R)-1-[(2S)-2-(2-{3-[4-(4-{3-[6-cyano-
5-(trifluoromethyl)pyridin-3-yl]-5,5-dimethyl-
4-oxo-2-sulfanylideneimidazolidin-1-yl}-
2-fluorophenoxy)butoxy]propoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4- methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 9.16 (s, 1 H), 8.87 (s, 1 H), 8.67 (s, 1 H),
7.48-7.40 (m, 4 H), 7.24-7.12 (m, 3 H), 4.70 (s, 1 H), 4.62- 4.46
(m, 3 H), 4.38-4.32 (m, 1 H), 4.15-4.09 (m, 2 H), 3.99 (s, 2 H),
3.90-3.78 (m, 2 H), 3.67-3.52 (m, 6 H), 2.47 (s, 3 H), 2.27-2.17
(m, 1 H), 2.16-2.06 (m, 1 H), 1.94-1.83 (m, 4 H), 1.82-1.71 (m, 2
H), 1.57 (s, 6 H), 1.04 (s, 9 H); LC-MS (ES.sup.+): m/z 1025.30
[MH.sup.+], t.sub.R = 2.27 min, (3.6 minute run) 49 ##STR00221##
Prepared from ABM-22, L-8, and ULM-4
(2S,4R)-1-[(2S)-2-{2-[3-(4-{4-[3-(4-cyano-
3-methoxyphenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]-2-
fluorophenoxy}butoxy)propoxy]acetamido}-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-
(1,3-oxazol-5-yl)phenyl]methyl}pyrrolidine- 2-carboxamide .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.25 (s, 1H), 7.77 (d, J = 8.0
Hz, 1H), 7.70 (d, J = 8.4 Hz, 2H), 7.50 (m, 3H), 7.36 (m, 1H), 7.24
(m, 4H), 4.71 (s, 1H), 4.60 (m, 3H), 4.37 (m, 1H), 4.16 (m, 2H),
4.01 (m, 5H), 3.88 (m, 1H), 3.83 (m, 1H), 3.69 (m, 6H), 2.28 (m,
1H), 2.14 (m, 1H), 1.94 (m, 4H), 1.81 (m, 2H), 1.56 (s, 6H), 1.06
(m, 9H); LC-MS (ES.sup.+): m/z 956.45 [MH.sup.+], t.sub.R = 2.17
min (3.6 minute run). 50 ##STR00222## Prepared from ABM-21, L-8,
and ULM-11 (2S,4R)-1-[(2S)-2-{2-[3-(4-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]-2-
fluorophenoxy}butoxy)propoxy]acetamido}-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4- (1-methyl-1H-pyrazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz,
CD.sub.3OD) .delta. 7.96-7.93 (d, J = 8.1 Hz, 1 H), 7.86 (s, 1 H),
7.65-7.61 (d, J = 9.6 Hz, 1 H), 7.50-7.41 (m, 5 H), 7.23- 7.10 (m,
3 H), 6.34 (s, 1 H), 4.71 (s, 1 H), 4.61-4.46 (m, 3 H), 4.41-4.34
(m, 1 H), 4.18- 4.09 (m, 2 H), 3.98 (s, 2 H), 3.90-3.79 (m, 5 H),
3.66-3.51 (m, 6 H), 2.28-2.16 (m, 1 H), 2.14-2.01 (m, 1 H),
1.93-1.83 (m, 4 H), 1.81- 1.72 (m, 2 H), 1.54 (s, 6 H), 1.04 (s, 9
H); LC-MS (ES.sup.+): m/z 973.35 [MH.sup.+], t.sub.R = 1.55 min, (3
minute run) 51 ##STR00223## Prepared from ABM-9, L-8, and ULM-1
(2S,4R)-1-[(2S)-2-(2-{3-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-8-methyl-4-oxo-
2-sulfanylidene-1,3,8-triazaspiro[4.5]decan-
1-yl}phenoxy)butoxy]propoxy(acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4
-methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.81 (s, 1 H), 8.16-8.03
(m, 2 H), 8.00-7.90 (m, 1 H), 7.50- 7.30 (m, 4 H), 7.23-7.15 (m,
2H), 7.05-6.90 (m, 2 H), 4.67 (s, 1 H), 4.60-4.30 (m, 4 H),
4.12-3.91 (m, 4 H), 3.80-3.70 (m, 2 H), 3.65- 3.40 (m, 6 H),
2.80-2.61 (m, 4 H), 2.41 (s, 3 H), 2.25-2.11 (m, 6 H), 2.10-1.60
(m, 9 H), 1.02 (s, 9 H); LC-MS (ES.sup.+): m/z, 531.35 [M/2 +
H].sup.+, t.sub.R = 1.86 min (3.6 minute run). 52 ##STR00224##
Prepared from ABM-3, L-9, and ULM-1
(2S,4R)-1-[(2S)-2-(2-{4-[3-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}
phenoxy)propoxy]butoxy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.83 (s, 1H), 8.12-8.10
(m, 2H), 7.96
(d, J = 8.1 Hz, 1H), 7.44-7.37 (m, 4H), 7.25 (d, J = 8.7 Hz, 2H),
7.02 (d, J = 8.7 Hz, 2H), 4.66-4.29 (m, 5H), 4.09-3.78 (m, 6H),
3.60-3.47 (m, 6H), 2.44 (s, 3H), 2.19-1.97 (m, 4H), 1.70-1.63 (m,
4H), 1.50 (s, 6H), 1.00 (s, 9H); LC-MS (ES.sup.+): m/z 1006.30 [M
H.sup.+], t.sub.R = 1.71 min (3.0 minute run). 53 ##STR00225##
Prepared from ABM-16, L-9, and ULM-1
(2S,4R)-1-[(2S)-2-(2-{4-[3-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}-2-
fluorophenoxy)propoxy]butoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-
(4-methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.98 (s, 1 H), 8.17-8.15
(d, J = 8.4 Hz, 2 H), 8.01- 7.99 (m, 1 H), 7.49-7.42 (m, 4 II),
7.42- 7.20 (m, 3 H), 4.80 (s, 1 H), 4.71-4.70 (d, J = 2.8 Hz, 1 H),
4.59-4.51 (m, 4 H), 4.38- 4.20 (m, 4 H), 3.99-3.87 (m, 2 H), 3.65-
3.52 (m, 6 H), 2.50 (s, 3 H), 2.10-2.05 (m, 4 H), 1.72 (m, 4 H),
1.56 (s, 6 H), 1.03 (s, 9 H); LC-MS (ES.sup.+): m/z 1025.50
[MH.sup.+], t.sub.R = 3.50 min (5.6 minute run).
Example 54:
(2S,4R)-1-((S)-2-(2-(6-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dime-
thyl-4-oxo-2-thioxoimidazolidin-1-yl)phenoxy)hexa-2,4-diynyloxy)acetamido)-
-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrroli-
dine-2-carboxamide
##STR00226##
[0523] Step 1: Synthesis of tert-butyl
2-{[6-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulf-
anylideneimidazolidin-1-yl}phenoxy)hexa-2,4-diyn-1-yl]oxy}acetate
(BJ)
[0524] This material was synthesized according to a similar
procedure described in reaction step 1 for the synthesis of Example
1. LC-MS (ES.sup.+): m/z 634.05 [MNa.sup.+], t.sub.R=1.26 min (2.0
minute run).
Step 2: Synthesis of
2-{[6-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulf-
anylideneimidazolidin-1-yl}phenoxy)hexa-2,4-diyn-1-yl]oxy}acetic
Acid (BK)
[0525] This material was synthesized according to a similar
procedure described in reaction step 2 for the synthesis of example
1. LC-MS (ES.sup.+): m/z 556.10 [MH.sup.+], t.sub.R=1.54 min (2.6
minute run).
Step 3: Synthesis of
(2S,4R)-1-[(2S)-2-(2-{[6-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-di-
methyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}phenoxy)hexa-2,4-diyn-1-yl]o-
xy}acetamido)-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol--
5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (Example 54)
[0526] This material was synthesized according to a similar
procedure described in reaction step 3 for the synthesis of Example
1. .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.88 (s, 1H), 8.15
(d, J=8.4 Hz, 2H), 8.00 (d, J=1.6 Hz, 1H), 7.49-7.43 (m, 4H), 7.34
(d, J=8.8 Hz, 2H), 7.14 (d, J=8.8 Hz, 2H), 4.93 (s, 2H), 4.71 (s,
1H), 4.60-4.34 (m, 6H), 4.08 (s, 2H), 3.90-3.80 (m, 2H), 2.49 (s,
3H), 2.25-2.22 (m, 1H), 2.13-2.05 (m, 1H), 1.56 (s, 6H), 1.03 (s,
9H); LC-MS (ES.sup.+): m/z 968.45 [MH.sup.+], t.sub.R=1.67 min (3.0
minute run).
TABLE-US-00003 TABLE 3 Exemplary Compounds. Ex # Structure Compound
name and Analytical data 55 ##STR00227## Prepared from ABM-3, L-11,
and ULM-1 (2S,4R)-1-[(2S)-2-(3-{[6-(4-{3-[4-cyano-3-
(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-
2-sulfanylideneimidazolidin-1-yl}phenoxy)hexa-
2,4-diyn-1-yl]oxy}propanamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-
thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR
(400 MHz, CD.sub.3OD): .delta. 8.88 (s, 1H), 8.16 (d, J = 8.8 Hz,
2H), 7.99 (d, J = 1.6 Hz, 1H), 7.49-7.42 (m, 4H), 7.33 (d, J = 8.8
Hz, 2H), 7.14 (d, J = 8.8 Hz, 2H), 4.93 (s, 2H), 4.66 (s, 1H),
4.60-4.38 (m, 3H), 4.38-4.27 (m, 3H), 3.92-3.80 (m, 4H), 2.63-2.59
(m, 1H), 2.58-2.49 (m, 4H), 2.26-2.18 (m, 1H), 2.13-2.05 (m, 1H),
1.56 (s, 6H), 1.03 (s, 9H); LC-MS (ES.sup.+): m/z 982.40
[MH.sup.+], t.sub.R = 3.35 min (5.6 minute run). 56 ##STR00228##
Prepared from ABM-3, L-12, and ULM-1
(2S,4R)-1-[(2S)-2-(4-{[6-(4-{3-[4-cyano-3-
(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-
2-sulfanylideneimidazolidin-1-yl}phenoxy)hexa-
2,4-diyn-1-yl]oxy}butanamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-
1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2- carboxamide .sup.1H
NMR (400 MHz, CD.sub.3OD): .delta. 8.88 (s, 1H), 8.16 (d, J = 8.8
Hz, 2H), 7.99 (d, J = 1.6 Hz, 1H), 7.49-7.42 (m, 4H), 7.35 (d, J =
8.8 Hz, 2H), 7.14 (d, J = 8.8 Hz, 2H), 4.93 (s, 2H), 4.63 (s, 1H),
4.59-4.51 (m, 3H), 4.38-4.27 (d, J = 12.4 Hz, 1H), 4.25 (s, 2H),
3.93-3.79 (m, 2H), 3.53 (t, J = 6.0 Hz, 2H), 2.50 (s, 3H),
2.49-2.33 (m, 2H), 2.26-2.18 (m, 1H), 2.13-2.05 (m, 1H), 1.90-1.86
(m, 2H), 1.57 (s, 6H), 1.02 (s, 9H); LC-MS (ES.sup.+): m/z 996.40
[MH.sup.+], t.sub.R = 3.41 min (5.6 minute run). 57 ##STR00229##
Prepared from ABM-16, L-10, and ULM-1
(2S,4R)-1-[(2S)-2-(2-{[6-(4-{3-[4-cyano-3-
(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-
2-sulfanylideneimidazolidin-1-yl}-2-fluorophenoxy)
hexa-2,4-diyn-1-yl]oxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-
1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2- carboxamide .sup.1H
NMR (400 MHz, CD.sub.3OD): .delta. 8.88 (s, 1H), 8.16 (d, J = 8.0
Hz, 2H), 8.00 (d, J = 1.2 Hz, 1H), 7.49-7.43 (m, 4H), 7.36-7.29 (m,
2H), 7.19 (d, J = 8.0 Hz, 1H), 5.03 (s, 2H), 4.71 (s, 1H),
4.61-4.42 (m, 3H), 4.41-4.33 (m, 3H), 4.09 (s, 2H), 3.90-3.80 (m,
2H), 2.49 (s, 3H), 2.27- 2.15 (m, 1H), 2.12-2.06 (m, 1H), 1.56 (s,
6H), 1.03 (s, 9H); LC-MS (ES.sup.+): m/z 986.30 [MH.sup.+], t.sub.R
= 1.58 min (3.0 minute run). 58 ##STR00230## Prepared from ABM-1,
L-10, and ULM-1 (2S,4R)-1-[(2S)-2-{2-[(6-{4-[3-(3-chloro-4-
cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenoxy}hexa-
2,4-diyn-1-yl)oxy]acetamido}-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl- 1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 8.88 (s, 1H), 7.96 (d, J = 8.4 Hz, 1H), 7.87
(s, 1H), 7.66-7.64 (m, 1H), 7.49-7.43 (m, 4H), 7.33 (d, J = 8.8 Hz,
1H), 7.14 (d, J = 9.2 Hz, 1H), 4.94 (s, 2H), 4.71 (s, 1H),
4.61-4.42 (m, 3H), 4.41-4.29 (m, 3H), 4.09 (s, 2H), 3.92-3.86 (m,
1H), 3.82-3.77 (m, 1H), 2.49 (s, 3H), 2.27-2.18 (m, 1H), 2.12-2.06
(m, 1H), 1.52 (s, 6H), 1.01 (s, 9H); LC-MS (ES.sup.+): m/z 934.20
[MH.sup.+], t.sub.R = 1.54 min (3.0 minute run). 59 ##STR00231##
Prepared from ABM-1, L-10, and ULM-5
(2S,4R)-1-[(2S)-2-{2-[(6-{4-[3-(3-chloro-4-
cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenoxy}hexa-
2,4-diyn-1-yl)oxy]acetamido}-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl- 1,3-oxazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 8.15 (s, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.87
(s, 1H), 7.66-7.58 (m, 3H), 7.49-7.47 (m, 2H), 7.35-7.31 (m, 2H),
7.14 (d, J = 8.8 Hz, 2H), 4.94 (s, 2H), 4.71 (s, 1H), 4.63-4.57 (m,
3H), 4.41-4.28 (m, 3H), 4.09 (s, 2H), 3.90-3.86 (m, 1H), 3.82-3.77
(m, 1H), 2.42 (s, 3H), 2.27-2.20 (m, 1H), 2.12-2.02 (m, 1H), 1.55
(s, 6H), 1.03 (s, 9H); LC-MS (ES.sup.+): m/z 918.25 [MH.sup.+],
t.sub.R = 1.51 min (3.0 minute run). 60 ##STR00232## Prepared from
ABM-21, L-10, and ULM-4 (2S,4R)-1-[(2S)-2-{2-[(6-{4-[3-(3-chloro-4-
cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]-2-
fluorophenoxy}hexa-2,4-diyn-1-yl)oxy]
acetamido}-3,3-dimethylbutanoyl]-4-hydroxy-
N-{[4-(1,3-oxazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.23 (s, 1H), 7.94 (d, J
= 8.1 Hz, 1H), 7.86 (s, 1H), 7.70-7.63 (m, 3H), 7.49-7.43 (m, 3H),
7.36-7.21 (m, 2H), 7.18-7.12 (m, 1H), 5.12 (s, 2H), 4.71 (s, 1H),
4.61-4.47 (m, 3H), 4.44-4.29 (m, 3H), 4.09 (s, 2H), 3.89-3.79 (m,
2H), 2.22-2.18 (m, 1H), 2.12- 2.06 (m, 1H), 1.55 (s, 6H), 1.02 (s,
9H); LC-MS (ES.sup.+): m/z 922.15 [MH.sup.+], t.sub.R = 2.53 min
(5.0 minute run). 61 ##STR00233## Prepared from ABM-16, L-10, and
ULM-4 (2S,4R)-1-[(2S)-2-(2-{[6-(4-{3-[4-cyano-3-
(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-
2-sulfanylideneimidazolidin-1-yl}-2-
fluorophenoxy)hexa-2,4-diyn-1-yl]oxy}
acetamido)-3,3-dimethylbutanoyl]-4-hydroxy-
N-{[4-(1,3-oxazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.23 (s, 1H), 8.15 (d, J
= 7.5 Hz, 2H), 7.98 (d, J = 9.0 Hz, 1H), 7.71 (d, J = 7.8 Hz, 2H),
7.49-7.40 (m, 3H), 7.36-7.21 (m, 2H), 7.18-7.12 (m, 1H), 5.02 (s,
2H), 4.71 (s, 1H), 4.59-4.47 (m, 3H), 4.44-4.29 (m, 3H), 4.09 (s,
2H), 3.89-3.74 (m, 2H), 2.22- 2.18 (m, 1H), 2.12-2.01 (m, 1H), 1.57
(s, 6H), 1.04 (s, 9H); LC-MS (ES.sup.+): m/z 956.20 [MH.sup.+],
t.sub.R = 2.60 min (5.0 minute run).
Example 62:
(2S,4R)-1-((S)-2-tert-butyl-16-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)--
5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)phenyl)-4,13-dioxo-6,9-dioxa--
3,12-diazahexadecane)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolid-
ine-2-carboxamide
##STR00234##
[0527] Step 1: Synthesis of ethyl
2-(2-{2-[4-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-
-sulfanylideneimidazolidin-1-yl}phenyl)butanamido]ethoxy}ethoxy)acetate
(BL)
[0528] To a stirred solution of
4-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanyl-
ideneimidazolidin-1-yl}phenyl)butanoic acid (ABM-12, 417 mg, 0.88
mmol) in N,N-dimethylformamide (10 mL) was added HATU (669 mg, 1.76
mmol), DIEA (454 mg, 3.51 mmol) and ethyl
2-[2-(2-aminoethoxy)ethoxy]acetate hydrochloride (L-13, 400 mg,
1.76 mmol) at 0.degree. C. The resulting solution was stirred at
0.degree. C. for 30 min, and then it was warmed up to rt and
stirred at rt for 15 h. A mixture of water/ice (1:1, 50 mL) was
added to the reaction, the resulting mixture was extracted with
ethyl acetate (100 mL.times.3). The organic layers were combined,
washed with saturated aqueous solution of sodium chloride (20
mL.times.2), dried over anhydrous sodium sulfate and then
concentrated under reduced pressure to give a crude residue, which
was purified by flash silica gel chromatography (eluent: ethyl
acetate/petroleum ether (v:v=1:1) to give BL (yield: 35%) as a
yellow solid. LC-MS (ES.sup.+): m/z 649.15[MH.sup.+], t.sub.R=1.05
min (2.0 minute run).
Step 2: Synthesis of
2-(2-{2-[4-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-
-sulfanylideneimidazolidin-1-yl}phenyl)butanamido]ethoxy}ethoxy)acetic
Acid (BM)
[0529] To a stirred solution of ethyl
2-(2-{2-[4-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-
-sulfanylideneimidazolidin-1-yl}phenyl)butanamido]ethoxy}ethoxy)acetate
(BL, 200 mg, 0.31 mmol) in methanol (10 mL) was added a solution of
NaOH (123 mg, 3.08 mmol) in water (10 mL) at rt. The resulting
solution was then heated to 50.degree. C. and stirred at this
temperature for 2 h. The bulk of organic solvent was removed under
reduced pressure. To the remaining residue was added aqueous
hydrogen chloride (1 M) to adjust the pH to .about.3. The resulting
mixture was extracted with ethyl acetate (50 mL.times.2), the
organic layers were combined, washed with saturated aqueous
solution of sodium chloride (20 mL.times.2), dried over anhydrous
sodium sulfate and then concentrated under reduced pressure
followed by high vacuum pump to give BM (yield: 78%) as a yellow
solid. LC-MS (ES.sup.+): m/z 621.20 [MH.sup.+], t.sub.R=0.96 min
(2.0 minute run).
Step 3: Synthesis of
(2S,4R)-1-[(2S)-2-[2-(2-{2-[4-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5-
,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}phenyl)butanamido]ethox-
y}ethoxy)acetamido]-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-th-
iazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (Example 62)
[0530] To a stirred solution of
2-(2-{2-[4-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-
-sulfanylideneimidazolidin-1-yl}phenyl)butanamido]ethoxy}ethoxy)acetic
acid (BM, 200 mg, 0.32 mmol) in N,N-dimethylformamide (20 mL) was
added HATU (245 mg, 0.64 mmol), DIEA (166 mg, 1.28 mmol) and
(2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1-
,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide
hydrochloride (ULM-1, 226 mg, 0.48 mmol) at 0.degree. C. The
resulting solution was stirred at 0.degree. C. for 30 min, and then
it was warmed up to rt and stirred at rt for 15 h. A mixture of
water/ice (1:1, 50 mL) was added to the reaction, the resulting
mixture was extracted with ethyl acetate (100 mL.times.3). The
organic layers were combined, washed with saturated aqueous
solution of sodium chloride (50 mL), dried over anhydrous sodium
sulfate and then concentrated under reduced pressure to give a
crude residue, which was purified by Prep-HPLC to give Example 62
(yield: 6%) as a yellow solid. .sup.1H NMR (400 MHz, CD.sub.3OD):
.delta. 8.89 (s, 1H), 8.18-8.16 (d, J=8.4 Hz, 2H), 8.01-7.99 (d,
J=8.0 Hz, 1H), 7.47-7.41 (m, 4H), 7.38-7.36 (d, J=8.4 Hz, 2H),
7.30-7.28 (d, J=8.4 Hz, 2H), 4.87 (s, 1H), 4.78-4.60 (m, 3H),
4.39-4.35 (d, J=15.2 Hz, 1H), 4.04-3.98 (m, 2H), 3.98-3.85 (m, 2H),
3.72-3.60 (m, 7H), 3.50-3.49 (m, 1H), 2.71-2.69 (m, 2H), 2.49 (s,
3H), 2.45-2.28 (m, 3H), 2.25-2.10 (m, 1H), 2.10-1.95 (m, 2H), 1.58
(s, 6H), 1.09 (s, 9H); LC-MS (ES.sup.+): m/z 1033.50 [MH.sup.+],
t.sub.R=3.06 min (5.6 minute run).
[0531] Examples 63-65 were synthesized according to similar
procedure described for synthesis of example 62, by using
corresponding starting materials and intermediates.
TABLE-US-00004 TABLE 4 Exemplary Compounds. Ex # Structure Compound
name and Analytical data 63 ##STR00235## Prepared from ABM-12,
L-14, and ULM-1 (2S,4R)-1-[(2S)-2-[2-({5-[4-(4-{3-[4-cyano-3-
(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}phenyl)
butanamido]pentyl}oxy)acetamido]-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl- 1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
DMSO): .delta. 8.98 (s, 1H), 8.60 (m, 1H), 8.40 (d, J = 8.0 Hz,
1H), 8.30 (s, 1H), 8.10 (d, J = 8.0 Hz, 1H), 7.79 (m, 1H), 7.40 (m,
4H), 7.36 (m, 3H), 7.29 (d, J = 8.0 Hz, 2H), 5.16 (m, 1H), 4.57 (d,
J = 9.2 Hz, 1H), 4.45 (m, 4H), 3.92 (m, 2H), 3.66 (m, 2H), 3.48 (m,
2H), 3.07 (m, 2H), 2.64 (m, 2H), 2.51 (m, 3H), 2.14 (m, 3H), 1.90
(m, 3H), 1.57 (m, 2H), 1.50 (s, 6H), 1.44 (m, 2H), 1.36 (m, 2H),
0.94 (s, 9H); LC-MS (ES.sup.+): m/z 516.65 [M + 2]/2, t.sub.R =
2.55 min. (5.0 minute run). 64 ##STR00236## Prepared from ABM-12,
L-15, and ULM-1 (2S,4R)-1-[(2S)-2-[2-(2-{2-[4-(4-{3-[4-cyano-3-
(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}phenyl)-N-
methylbutanamido]ethoxy}ethoxy)acetamido]-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-
(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine- 2-carboxamide
.sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.87 (s, 1H), 8.17- 8.14
(d, J = 8.4 Hz, 2H), 8.01-7.98 (d, J = 8.7 Hz, 1H), 7.47-7.31 (m,
6H), 7.28-7.13 (d, J = 8.1 Hz, 2H), 4.71 (s, 1H), 4.61-4.51 (m,
3H), 4.38-4.33 (d, J = 15.2 Hz, 1H), 4.04-4.02 (m, 2H), 3.86-3.81
(m, 2H), 3.69-3.60 (m, 7H), 3.59-3.52 (m, 1H), 3.10 (s, 2H), 2.97
(s, 1H), 2.75-2.73 (m, 2H), 2.46 (s, 3H), 2.46-2.41 (m, 2H),
2.38-2.23 (m, 1H), 2.21-2.09 (m, 1H), 1.99-1.91 (m, 2H), 1.55 (s,
6H), 1.02 (s, 9H); LC-MS (ES.sup.+): m/z 1047.80 [MH.sup.+],
t.sub.R = 2.09 min (3.6 minute run). 65 ##STR00237## Prepared from
ABM-12, L-16, and ULM-1
(2S,4R)-1-[(2S)-2-[2-({5-[4-(4-{3-[4-cyano-3-
(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}phenyl)-N-
methylbutanamido]pentyl}oxy)acetamido]-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine- 2-carboxamide
.sup.1H NMR (400 MHz, DMSO) .delta. 8.98 (s, 1H), 8.60 (s, 1H),
8.40 (d, J = 8.0 Hz, 1H), 8.30 (s, 1H), 8.10 (d, J = 8.0 Hz, 1H),
7.46-7.27 (m, 9H), 5.15 (s, 1H), 4.57-4.55 (m, 1H), 4.47-4.23 (m,
4H), 3.92-3.85 (m, 2H), 3.68-3.59 (m, 2H), 3.47 (s, 2H), 3.29-3.20
(m, 2H), 2.91-2.64 (m, 5H), 2.44 (s, 3H), 2.33-2.30 (m, 2H),
2.09-2.03 (m, 1H), 1.95-1.81 (m, 3H), 1.59- 1.46 (m, 10H),
1.30-1.24 (m, 2H), 0.94 (s, 9H); Mass (ES.sup.+): m/z 1045.40
[MH.sup.+]
Example 66:
2-(2-(4'-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thio-
xoimidazolidin-1-yl)biphenyl-4-yloxy)ethoxy)ethyl
(S)-1-((2S,4R)-4-hydroxy-2-(4-(4-methylthiazol-5-yl)benzylcarbamoyl)pyrro-
lidin-1-yl)-3,3-dimethyl-1-oxobutan-2-ylcarbamate
##STR00238##
[0532] Step 1: Synthesis of
4-[3-(4-{4-[2-(2-hydroxyethoxy)ethoxy]phenyl}phenyl)-4,4-dimethyl-5-oxo-2-
-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
(BN)
[0533] To a stirred solution of
4-{3-[4-(4-hydroxyphenyl)phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidaz-
olidin-1-yl}-2-(trifluoromethyl)benzonitrile (ABM-14, 610.5 mg,
1.27 mmol) in N,N-dimethylformamide (10 mL) was added
K.sub.2CO.sub.3 (318.46 mg, 2.29 mmol) and
2-{2-[(4-methylbenzenesulfonyl)oxy]ethoxy}ethan-1-ol (L-18, 300 mg,
1.15 mmol) at rt. The resulting mixture was then stirred at
80.degree. C. for 2 hours in an oil bath, LC-MS indicated formation
of the desired product. The reaction mixture was cooled down to rt,
water (20 mL) was added and the resulting mixture was extracted
with ethyl acetate (100 mL.times.2). The organic layers were
combined, washed with saturated aqueous solution of sodium chloride
(20 mL), dried over anhydrous sodium sulfate and then concentrated
under reduced pressure to give a crude residue which was purified
by a flash silica gel chromatography (eluent: ethyl
acetate/petroleum ether (v:v=7:3) to give BN (yield: 66%) as a
light yellow oil. LC-MS (ES.sup.+): m/z 570, [MH.sup.+],
t.sub.R=1.60 min (2.0 minute run).
Step 2: synthesis of
2-{2-[4-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-su-
lfanylideneimidazolidin-1-yl}phenyl)phenoxy]ethoxy}ethyl
N-[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phenyl]met-
hyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
(Example 66)
[0534] To a stirred solution of
4-[3-(4-{4-[2-(2-hydroxyethoxy)ethoxy]phenyl}phenyl)-4,4-dimethyl-5-oxo-2-
-sulfanylideneimidazolidin-2-(trifluoromethyl)benzonitrn-1-yl]-2-(trifluor-
omethyl)benzonitrile (200 mg, 0.35 mmol) in dichloromethane (10 mL)
was added triethylamine (106.5 mg, 1.05 mmol), followed by
triphosgene (36.5 mg, 0.12 mmol) which was added slowly in 30 min
at 0.degree. C. To this mixture was then added
(2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1-
,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide
hydrochloride (ULM-1, 196.9 mg, 0.42 mmol) at 0.degree. C. The
resulting mixture was then warmed up to rt and stirred at rt for 2
hours. Water (20 mL) was added to the reaction and the resulting
mixture was extracted with dichloromethane (50 mL.times.3). The
organic layers were combined, washed with saturated aqueous
solution of sodium chloride (20 mL), dried over anhydrous sodium
sulfate and then concentrated under reduced pressure to give a
crude residue, which was purified by Prep-HPLC to give Example 66
(yield: 6%) as a white solid. .sup.1H-NMR (400 MHz, CD.sub.3OD):
.delta. 8.88 (s, 1H), 8.20-8.17 (m, 2H), 8.04-8.02 (d, J=8.0 Hz,
1H), 7.77-7.72 (m, 2H), 7.65-7.59 (m, 2H), 7.48-7.42 (m, 6H),
7.08-7.06 (d, J=8.4 Hz, 2H), 4.61-4.53 (m, 1H), 4.47-4.44 (s, 1H),
4.38-4.34 (m, 2H), 4.25-4.20 (m, 4H), 3.92-3.90 (m, 3H), 3.82-3.79
(m, 3H), 2.48 (s, 3H), 2.26-2.21 (m, 1H), 2.13-1.09 (m, 1H), 1.61
(s, 6H), 1.30 (s, 1H), 1.04 (s, 9H); LC-MS (ES.sup.+): m/z 1026.40
[MH.sup.+], t.sub.R=2.23 min (3.0 minute run).
Example 67:
(2S,4R)-1-((S)-2-(2-(2-(2-(4'-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5--
dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)biphenyl-4-yloxy)ethoxy)ethoxy)ac-
etamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl-
)pyrrolidine-2-carboxamide
##STR00239##
[0535] Step 1: Synthesis of ethyl
2-(2-{2-[4-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-
-sulfanylideneimidazolidin-1-yl}phenyl)phenoxy]ethoxy}ethoxy)acetate
(BO)
[0536] To a stirred solution of
4-{3-[4-(4-hydroxyphenyl)phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidaz-
olidin-1-yl}-2-(trifluoromethyl)benzonitrile (ABM-14, 300 mg, 0.62
mmol) in N,N-dimethylformamide (10 mL) was added K.sub.2CO.sub.3
(172 mg, 1.24 mmol) and ethyl
2-(2-{2-[(4-methylbenzenesulfonyl)oxy]ethoxy}ethoxy)acetate (L-19,
237.4 mg, 0.69 mmol). The resulting mixture was stirred at
80.degree. C. in an oil bath for 2 hours. The reaction was cooled
down to rt, water (50 mL) was added and the resulting mixture was
extracted with ethyl acetate (100 mL.times.2). The organic layers
were combined, washed with saturated aqueous solution of sodium
chloride (30 mL.times.3), dried over anhydrous sodium sulfate and
then concentrated under reduced pressure to give a crude residue,
which was purified by a flash silica gel chromatography (eluent:
ethyl acetate/petroleum ether (v:v=3:7)) to give BO (yield: 48%) as
light yellow oil. LC-MS (ES.sup.+): m/z 656, [MH.sup.+],
t.sub.R=1.19 min (2.0 minute run).
Step 2: Synthesis of
2-(2-{2-[4-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-
-sulfanylideneimidazolidin-1-yl}phenyl)phenoxy]ethoxy}ethoxy)acetic
Acid (BP)
[0537] To a stirred solution of ethyl
2-(2-{2-[4-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-
-sulfanylideneimidazolidin-1-yl}phenyl)phenoxy]ethoxy}ethoxy)acetate
(BO, 198 mg, 0.30 mmol) in ethanol (5 mL) was added a solution of
sodium hydroxide (36.3 mg, 0.91 mmol) in water (2 mL) at rt. The
resulting solution was stirred overnight at rt, the bulk of organic
solvent was then removed under reduced pressure. To the remaining
aqueous residue was added hydrogen chloride in water (1N) to adjust
the pH to .about.5.0, and the resulting mixture was extracted with
ethyl acetate (250 mL.times.2). The organic layers were combined,
dried over anhydrous sodium sulfate and concentrated under reduced
pressure followed by high vacuum pump to give BP (yield: 99%) as a
light yellow oil. LC-MS (ES.sup.+): m/z 628, [MH.sup.+],
t.sub.R=1.08 min (2.0 minute run).
Step 3: Synthesis of
(2S,4R)-1-[(2S)-2-[2-(2-{2-[4-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5-
,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}phenyl)phenoxy]ethoxy}e-
thoxy)acetamido]-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiaz-
ol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (Example 67)
[0538] To a stirred solution of
2-(2-{2-[4-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-
-sulfanylideneimidazolidin-1-yl}phenyl)phenoxy]ethoxy}ethoxy)acetic
acid (BP, 190 mg, 0.30 mmol) in N,N-dimethylformamide (10 mL) was
added HATU (149.7 mg, 0.39 mmol), DIEA (156.4 mg, 1.21 mmol) and
(2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1-
,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide
hydrochloride (ULM-1, 183.9 mg, 0.39 mmol). The resulting solution
was stirred at rt for 2 hours. Water (50 mL) was added and the
resulting mixture was extracted with ethyl acetate (100
mL.times.2). The organic layers were combined, washed with
saturated aqueous solution of sodium chloride (25 mL.times.3),
dried over anhydrous sodium sulfate and then concentrated under
reduced pressure to give a crude residue, which was purified
Prep-HPLC to give Example 67 (yield: 17%) as a white solid.
.sup.1H-NMR (400 MHz, CD.sub.3OD): .delta. 8.82 (s, 1H), 8.19-8.16
(d, J=9.0 Hz, 2H), 8.02-8.00 (d, J=8.1 Hz, 1H), 7.72-7.69 (d, J=8.1
Hz, 2H), 7.61-7.55 (m, 2H), 7.46-7.37 (m, 6H), 7.08-7.01 (m, 2H),
4.71 (s, 1H), 4.61-4.51 (m, 1H), 4.47 (s, 2H), 4.38-4.31 (m, 1H),
4.23-4.20 (m, 2H), 4.01 (s, 2H), 3.96-3.78 (m, 4H), 3.63 (s, 4H),
2.43 (s, 3H), 2.27-2.20 (m, 1H), 2.13-2.04 (m, 1H), 1.61 (s, 6H),
1.04 (s, 9H); LC-MS (ES.sup.+): m/z 1040.10 [MH.sup.+],
t.sub.R=2.26 min (3.0 minute run).
[0539] Examples 74 and 76 were synthesized according to similar
procedure described for synthesis of Example 66, by using
corresponding starting materials and intermediates. Examples 68-73,
75, 77-79 were synthesized according to similar procedure described
for synthesis of Example 67, by using corresponding starting
materials and intermediates.
TABLE-US-00005 TABLE 5 Exemplary Compounds. Ex # Structure Compound
name and Analytical data 68 ##STR00240## Prepared from ABM-14,
L-20, and ULM-1 (2S,4R)-1-[(2S)-2-[3-(2-{2-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-
yl}phenyl)phenoxy]ethoxy}ethoxy)
propanamido]-3,3-dimethylbutanoyl]-4-
hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.87 (s, 1H), 8.21-8.17 (m, 2H), 8.04 (d, J =
8.0 Hz, 1H), 7.76 (d, J = 8.4 Hz, 2H), 7.63 (d, J = 8.8 Hz, 2H),
7.49-7.41 (m, 6H), 7.07 (d, J = 8.8 Hz, 2H), 4.67 (s, 1H), 4.61-
4.51 (m, 3H), 4.37-4.33 (m, 1H), 4.20-4.18 (m, 2H), 3.92-3.66 (m,
10H), 2.62- 2.45 (m, 5H), 2.26-2.17 (m, 1H), 2.14-2.05 (m, 1H),
1.61 (s, 6H), 1.05 (s, 9H); LC-MS (ES.sup.+): m/z 1054.50
[MH.sup.+], t.sub.R = 2.20 min (3.6 minute run). 69 ##STR00241##
Prepared from ABM-14, L-21, and ULM-1
(2S,4R)-1-[(2S)-2-{5-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-
yl}phenyl)phenoxy]pentanamido}-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.90 (s, 1H), 8.20-8.18
(d, J = 8.4 Hz, 2H), 8.04-8.02 (d, J = 7.6 Hz, 1H), 7.77-7.74 (d, J
= 8.4 Hz, 2H), 7.63-7.61 (d, J = 8.4 Hz, 2H), 7.50-7.48 (m, 2H),
7.50-7.41 (m, 4H), 7.06-7.04 (d, J = 8.8 Hz, 2H), 4.67 (s, 1H),
4.61-4.52 (m, 3H), 4.39-4.35 (m, 1H), 4.08-4.07 (m, 2H), 3.95-3.93
(m, 1H), 3.85-3.81 (m, 1H), 2.48 (s, 3H), 2.41-2.37 (m, 2H),
2.23-2.21 (m, 1H), 2.14-2.10 (m, 1H), 1.86-1.85 (m, 4H), 1.62 (s,
6H), 1.06 (s, 9H); LC-MS (ES.sup.+): m/z 994.40 [MH.sup.+], t.sub.R
= 1.71 min (3.0 minute run). 70 ##STR00242## Prepared from ABM-14,
L-22, and ULM-1 (2S,4R)-1-[(2S)-2-(3-{2-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-
yl{phenyl)phenoxy]ethoxy}propanamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl- 1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.85 (s, 1H), 8.21-8.17 (m, 2H), 8.04 (d, J =
8.0 Hz, 1H), 7.74 (d, J = 8.4 Hz, 2H), 7.61 (d, J = 8.4 Hz, 2H),
7.49-7.39 (m, 6H), 7.08 (d, J = 8.8 Hz, 2H), 4.68 (s, 1H),
4.59-4.51 (m, 3H), 4.37 (s, 1H), 4.23-4.20 (m, 2H), 3.93-3.80 (m,
6H), 2.63-2.45 (m, 2H), 2.45 (s, 3H), 2.23-2.06 (m, 2H), 1.62 (s,
6H), 1.05 (s, 9H); LC-MS (ES.sup.+): m/z 1010.30 [MH.sup.+],
t.sub.R = 1.68 min (3.0 minute run). 71 ##STR00243## Prepared from
ABM-14, L-23, and ULM-1 (2S,4R)-1-[(2S)-2-[2-({5-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-
1-yl}phenyl)phenoxy]pentyl}oxy)acetamido]-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.84 (s, 1 H), 8.19-8.17
(d, J = 8.4 Hz, 2H), 8.04-8.02 (d, J = 8.4 Hz, 1H), 7.73-7.71 (d, J
= 8.4 Hz, 2H), 7.59-7.57 (d, J = 8.4 Hz, 2H), 7.49-7.38 (m, 6H),
7.02-7.00 (d, J = 8.4 Hz, 2H), 4.72 (s, 1H), 4.59-4.46 (m, 3H),
4.37-4.33 (d, J = 10.6 Hz, 1H), 4.08-4.06 (m, 2H), 4.05-4.00 (m,
2H), 3.98-3.83 (m, 2H), 3.64-3.61 (m, 2H), 2.49 (s, 3H), 2.29-2.21
(m, 1H), 2.11-2.01 (m, 1H), 1.90-1.86 (m, 2H), 1.78-1.75 (m, 2H),
1.66-1.62 (m, 2H), 1.61 (s, 6H), 1.06 (s, 9H) LC-MS (ES.sup.+): m/z
1038.38 [MH.sup.+], t.sub.R = 1.68 min (3.0 minute run). 72
##STR00244## Prepared from ABM-14, L-24, and ULM-1
(2S,4R)-1-[(2S)-2-[3-({5-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-
yl}phenyl)phenoxy]pentyl}oxy)propanamido]-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4- methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 8.84 (s, 1 H), 8.19-8.17 (d, J = 8.4 Hz, 2H),
8.04-8.02 (d, J = 8.4 Hz, 1H), 7.73-7.71 (d, J = 8.4 Hz, 2H),
7.59-7.57 (d, J = 8.4 Hz, 2H), 7.49-7.38 (m, 6H), 7.02-7.00 (d, J =
8.4 Hz, 2H), 4.72 (s, 1H), 4.59-4.46 (m, 3H), 4.37-4.33 (d, J =
10.6 Hz, 1H), 4.08-4.06 (m, 2H), 4.05-4.00 (m, 2H), 3.98-3.83 (m,
2H), 3.64-3.61 (m, 2H), 2.49 (s, 3H), 2.29-2.21 (m, 1H), 2.11-2.01
(m, 1H), 1.90-1.86 (m, 2H), 1.78-1.75 (m, 2H), 1.66- 1.62 (m, 2H),
1.61 (s, 6H), 1.06 (s, 9H); LC-MS (ES.sup.+): m/z 1052.39
[MH.sup.+], t.sub.R = 1.81 min (3.0 minute run). 73 ##STR00245##
Prepared from ABM-24, L-29, and ULM-1
(2S,4R)-1-[(2S)-2-[2-(2-{2-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}-2-
fluorophenyl)phenoxy]ethoxy}ethoxy)
acetamido]-3,3-dimethylbutanoyl]-4-
hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)
phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 8.89 (s, 1H), 8.20-8.18 (d, J = 8.4 Hz, 2H),
8.04- 8.02 (d, J = 8.4 Hz, 1H), 7.62-7.59 (m, 1H), 7.59-7.57 (m,
2H), 7.49-7.40 (m, 2H), 7.40-7.30 (m, 2H), 7.30-7.10 (m, 2H), 7.08-
7.06 (d, J = 8.4 Hz, 2H), 4.72 (s, 1H), 4.62- 4.60 (m, 3H),
4.37-4.34 (d, J = 15.2 Hz, 1H), 4.25-4.23 (m, 2H), 4.13-4.09 (m,
2H), 3.97- 3.92 (m, 4H), 3.89-3.79 (m, 4H), 2.46 (s, 3H), 2.24-2.22
(m, 1H), 2.14-2.12 (m, 1H), 1.63 (s, 6H), 1.06 (s, 9H); LC-MS
(ES.sup.+): m/z 1058.35 [MH.sup.+], t.sub.R = 1.47 min (4.6 minute
run). 74 ##STR00246## Prepared from ABM-14, L-25, and ULM-1
5-[4-(4-{3-[4-cyano-3-(trifluoromethyl)
phenyl]-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl}phenyl) phenoxy]pentyl
N-[(2S)-1-[(2S,4R)-4- hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-
yl)phenyl]methyl}carbamoyl)pyrrolidin-1-
yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.87 (s, 1H), 8.18-8.15 (d, J = 10.2 Hz, 2H),
8.02-8.00 (d, J = 8.1 Hz, 1H), 7.75-7.73 (d, J = 8.4 Hz, 2H),
7.63-7.60 (d, J = 8.4 Hz, 2H), 7.47-7.40 (m, 6H), 7.04-7.01 (d, J =
8.7 Hz, 2H), 4.61-4.51 (m, 3H), 4.37-4.32 (m, 2H), 4.16-4.02 (m,
4H), 3.92-3.78 (m, 2H), 2.47 (s, 3H), 2.26-2.11 (m, 1H), 2.10-2.07
(m, 1H), 1.86-1.80 (m, 2H), 1.76-1.64 (m, 2H), 1.60 (m, 8H), 1.03
(s, 9H); LC-MS (ES.sup.+): m/z 1023.82 [MH.sup.+], t.sub.R = 2.36
min (3.6 minute run) 75 ##STR00247## Prepared from ABM-14, L-26,
and ULM-1 (2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-
1-yl}phenyl)phenoxy]butoxy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4- methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 8.83 (s, 1H), 8.19-8.17 (d, J = 8.4 Hz, 2H),
8.04-8.02 (d, J = 9.6 Hz, 1H), 7.75-7.72 (d, J = 8.4 Hz, 2H),
7.60-7.58 (d, J = 8.4 Hz, 2H), 7.59-7.39 (m, 6H), 7.04-7.02 (d, J =
8.8 Hz, 2H), 4.88 (s, 1H), 4.71-4.41 (m, 3H), 4.37-4.32 (d, J =
15.2 Hz, 1H), 4.11-4.09 (m, 2H), 4.08-4.01 (m, 2H), 3.98-3.90 (m,
1H), 3.90-3.83 (m, 1H), 3.69-3.66 (m, 2H), 2.44 (s, 3H), 2.25-2.23
(m, 1H), 2.12-2.10 (m, 1H), 1.98-1.90 (m, 2H), 1.90-1.84 (m, 2H),
1.60 (s, 6H), 1.03 (s, 9H); LC-MS (ES.sup.+): m/z 1024.10
[MH.sup.+], t.sub.R = 2.33 min (4.6 minute run) 76 ##STR00248##
Prepared from ABM-24, L-18, and ULM-1
2-{2-[4-(4-{3-[4-cyano-3-(trifluoromethyl)
phenyl]-5,5-dimethyl-4-oxo-2- sulfanylideneimidazolidin-1-yl}-2-
fluorophenyl)phenoxy]ethoxy}ethyl N-[(2S)-
1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-
1,3-thiazol-5-yl)phenyl]methyl}carbamoyl)
pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2- yl]carbamate .sup.1H
NMR (400 MHz, CD.sub.3OD): .delta. 8.88 (s, 1H), 8.20-8.18 (d, J =
9.6 Hz, 2H), 8.04- 8.02 (d, J = 8.4 Hz, 1H), 7.69-7.63 (m, 1H),
7.58-7.56 (d, J = 8.0 Hz, 2H), 7.48-7.42 (m, 4H), 7.34-7.30 (m,
2H), 7.10-7.08 (d, J = 8.8 Hz, 2H), 4.61-4.57 (m, 3H), 4.53-4.47
(m, 2H), 4.38-4.21 (m, 4H), 3.93-3.90 (m, 3H), 3.84-3.78 (m, 3H),
2.48 (s, 3 H), 2.26-2.17 (m, 1H), 2.11-2.07 (m, 1H), 1.63 (s, 6H),
1.02 (s, 9H); LC-MS (ES.sup.+): m/z 1044.33 [MH.sup.+], t.sub.R =
2.21 min. (3.6 minute run). 77 ##STR00249## Prepared from ABM-14,
L-27, and ULM-1 (2S,4R)-1-[(2S)-2-(2-{3-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-
1-yl}phenyl)phenoxy]propoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4- methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.83 (s, 1H), 8.19-8.16 (d, J = 9.0 Hz, 2H),
8.03-8.01 (d, J = 8.1 Hz, 1H), 7.75-7.72 (d, J = 8.7 Hz, 2H),
7.72-7.69 (d, J = 8.7 Hz, 2H), 7.63-7.36 (m, 6H), 7.08-7.05 (d, J =
8.7 Hz, 2H), 4.72 (s, 1H), 4.62-4.51 (m, 3H), 4.36-4.31 (d, J =
15.3 Hz, 1H), 4.22-4.19 (m, 2H), 4.04-3.98 (m, 2H), 3.91-3.76 (m,
4H), 2.43 (s, 3H), 2.21-2.10 (m, 4H), 1.60 (s, 6H), 1.02 (s, 9H);
Mass (ES.sup.+): m/z 1010.30 [MH.sup.+] 78 ##STR00250## Prepared
from ABM-14, L-28, and ULM-1
(2S,4R)-1-[(2S)-2-(2-{2-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-
1-yl}phenyl)phenoxy]ethoxy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4- methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.79 (s, 1H), 8.71-8.69 (m, 1H), 8.19-8.16 (d,
J = 9.0 Hz, 2H), 8.03-8.01 (d, J = 8.4 Hz, 1H), 7.77-7.75 (d, J =
4.8 Hz, 1H), 7.77-7.75 (d, J = 4.8 Hz, 1H), 7.72-7.64 (m, 4H),
7.55-7.45 (m, 4H), 7.17-7.14 (d, J = 8.7 Hz, 2H), 4.78-4.75 (d, J =
6.6 Hz, 1H), 4.75-4.62 (m, 2H), 4.55-4.52 (m, 1H), 4.28-4.26 (m,
3H), 4.14 (s, 2H), 3.98-3.95 (m, 2H), 3.88-3.84 (m, 2H), 2.38 (s,
3H), 2.29-2.11 (m, 1H), 2.11-2.01 (m, 1H), 1.60 (s, 6H), 1.04 (s,
9H); LC-MS (ES.sup.+): m/z 996.33 [MH.sup.+], t.sub.R = 2.92 min
(5.0 minute run). 79 ##STR00251## Prepared from ABM-24, L-19, and
ULM-3 (2S,4R)-1-[(2S)-2-[2-(2-{2-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-
1-yl}-2-fluorophenyl)phenoxy]ethoxy}ethoxy)
acetamido]-3,3-dimethylbutanoyl]-4-hydroxy-
N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)
phenyl]ethyl]pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 8.76 (s, 1H), 8.08-8.06 (d, J = 9.6 Hz, 2H),
7.91-7.89 (d, J = 7.2 Hz, 1H), 7.56-7.53 (m, 1H), 7.45-7.42 (d, J =
9.2 Hz, 2H), 7.33-7.29 (m, 4H), 7.22- 7.20 (m, 2H), 6.99-6.97 (d, J
= 8.8 Hz, 2H), 4.95-4.93 (m, 1H), 4.60 (s, 1H), 4.50-4.47 (m, 1H),
4.45-4.34 (m, 1H), 4.16-4.14 (m, 2H), 3.98-3.97 (m, 2H), 3.83-3.81
(m, 2H), 3.77-3.74 (m, 1H), 3.67-3.63 (m, 5H), 2.36 (s, 3H),
2.12-2.10 (m, 1H), 1.89-1.85 (m, 1H), 1.51 (s, 6H), 1.37-1.36 (m,
3H), 0.93 (s, 9H); LC-MS (ES.sup.+): m/z 1072.4 [MH.sup.+], t.sub.R
= 1.46 min (4.6 minute run).
Example 80:
(2S,4R)-1-((S)-2-(2-(3-(2-(4-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,-
5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)phenyl)piperidin-1-yl)ethoxy)pr-
opoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-y-
l)benzyl)pyrrolidine-2-carboxamide
##STR00252##
[0540] Step 1: synthesis of
(2S,4R)-1-[(2S)-3,3-dimethyl-2-[2-(3-{2-[(4-methylbenzenesulfonyl)
oxy]ethoxy}propoxy)acetamido]butanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thia-
zol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (BQ)
[0541] To a stirred solution of
2-(3-{2-[(4-methylbenzenesulfonyl)oxy]ethoxy}propoxy)acetic acid
(L-17, 300 mg, 0.90 mmol) in N,N-dimethylformamide (5 mL) was added
EDCI (350 mg, 1.83 mmol), HOBt (240 mg, 1.78 mmol) and DIEA (350
mg, 2.71 mmol) at rt. The resulting solution was stirred at rt for
10 min. Then to the solution was added
(2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1-
,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (ULM-1, 390
mg, 0.91 mmol), and the resulting solution was stirred at rt for 1
h. Water (30 mL) was added and the resulting mixture was extracted
with ethyl acetate (30 mL.times.3). The organic layers were
combined, washed with saturated aqueous solution of sodium chloride
(30 mL), dried over anhydrous sodium sulfate and then concentrated
under reduced pressure to give a crude residue, which was purified
by a flash silica gel chromatography (eluent:
dichloromethane/methanol (v:v=10:1) to give BQ (yield: 64%) as a
yellow solid. LC-MS (ES.sup.+): m/z 745.35 [MH.sup.+], t.sub.R=0.96
min (2.0 minute run).
Step 2: Synthesis of
(2S,4R)-1-[(2S)-2-[2-(3-{2-[4-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5-
,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}phenyl)piperidin-1-yl]e-
thoxy}propoxy)acetamido]-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1-
,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (Example
80)
[0542] To a stirred solution of
4-{4,4-dimethyl-5-oxo-3-[4-(piperidin-4-yl)phenyl]-2-sulfanylideneimidazo-
lidin-1-yl}-2-(trifluoromethyl)benzonitrile (ABM-25, 150 mg, 0.32
mmol),
(2S,4R)-1-[(2S)-3,3-dimethyl-2-[2-(3-{2-[(4-methylbenzenesulfonyl)
oxy]ethoxy}propoxy)acetamido]butanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thia-
zol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (BQ, 236 mg, 0.32
mmol) in N,N-dimethylformamide (5 mL) was added potassium carbonate
(131 mg, 0.95 mmol). The resulting mixture was stirred at
60.degree. C. overnight. The reaction mixture was cooled to rt,
water (20 mL) was added and the resulting mixture was extracted
with ethyl acetate (30 mL.times.3). The organic layers were
combined, washed with saturated aqueous solution of sodium chloride
(20 mL), dried over anhydrous sodium sulfate and then concentrated
under reduced pressure to give a crude residue, which was purified
by Prep-HPLC to give Example 80 (yield: 7%) as a white solid.
.sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.91 (s, 1H), 8.15 (d,
J=4.5 Hz, 2H), 8.02 (d, J=4.5 Hz, 1H), 7.40 (m, 7H), 4.45 (d,
J=12.0 Hz, 1H), 4.45 (m, 4H), 4.02 (d, J=3.9 Hz, 2H), 3.70 (m,
10H), 3.38 (m, 2H), 3.11 (m, 3H), 2.48 (s, 3H), 2.26 (m, 8H), 1.54
(s, 6H), 1.03 (s, 9H); LC-MS (ES.sup.+): m/z 1045.35 [MH.sup.+],
t.sub.R=2.74 min (5.6 minute run).
[0543] Example 81 was synthesized according to similar procedure
described for synthesis of Example 80, by using corresponding
starting materials and intermediates.
[0544] Example 81:
(2S,4R)-1-((S)-2-(2-(4-(2-(4-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,-
5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)phenyl)piperidin-1-yl)ethoxy)bu-
toxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl-
)benzyl)pyrrolidine-2-carboxamide
##STR00253##
[0545] .sup.1H NMR (300 MHz, DMSO): .delta. 8.98 (s, 1H), 8.63-8.61
(m, 1H), 8.40-8.37 (m, 1H), 8.37-8.34 (m, 1H), 8.11-8.01 (m, 1H),
7.44-7.40 (m, 3H), 7.37-7.32 (m, 6H), 4.57-4.54 (d, J=9.6 Hz, 1H),
4.47-4.45 (m, 2H), 4.45-4.44 (m, 2H), 4.39-4.37 (m, 1H), 3.92 (s,
2H), 3.71-3.65 (m, 2H), 3.58-3.47 (m, 5H), 3.45-3.40 (m, 4H),
2.99-2.95 (m, 2H), 2.51 (s, 3H), 2.12-2.02 (m, 3H), 1.93-1.90 (m,
1H), 1.90-1.79 (m, 3H), 1.77-1.71 (m, 5H), 1.67-1.61 (m, 6H), 0.94
(s, 9H); Mass (ES.sup.+): m/z 1059.44 [MH.sup.+].
Example 82:
(2S,4R)--N-(2-(2-(2-(2-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dime-
thyl-4-oxo-2-thioxoimidazolidin-1-yl)phenoxy)ethoxy)ethoxy)ethoxy)-4-(4-me-
thylthiazol-5-yl)benzyl)-4-hydroxy-1-((S)-3-methyl-2-(1-oxoisoindolin-2-yl-
)butanoyl)pyrrolidine-2-carboxamide
##STR00254## ##STR00255##
[0546] Step 1: Synthesis of
4-[3-(4-{2-[2-(2-hydroxyethoxy)ethoxy]ethoxy}phenyl)-4,4-dimethyl-5-oxo-2-
-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
(BR)
[0547] To a stirred solution of
4-[3-(4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-y-
l]-2-(trifluoromethyl)benzonitrile (ABM-3, 405 mg, 1.00 mmol) in
CH.sub.3CN (20 mL) was added potassium carbonate (276 mg, 1.98
mmol) and
2-(2-{2-[(4-methylbenzenesulfonyl)oxy]ethoxy}ethoxy)ethan-1-ol
(L-30, 456 mg, 1.50 mmol) at rt. The resulting mixture was then
heated to 80.degree. C. and stirred at this temperature overnight.
LC-MS indicated formation of the desired product. The reaction
mixture was cooled to rt, concentrated under vacuum to give a crude
residue, which was purified by a flash silica gel chromatography
(eluent: ethyl acetate/petroleum ether (v:v=1:1)) to give BR
(yield: 91%) of as a brown oil.
Step 2: Synthesis of
2-{2-[2-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-su-
lfanylideneimidazolidin-1-yl}phenoxy)ethoxy]ethoxy}ethyl
4-methylbenzene-1-sulfonate (BS)
[0548] To a stirred solution of
4-[3-(4-{2-[2-(2-hydroxyethoxy)ethoxy]ethoxy}phenyl)-4,4-dimethyl-5-oxo-2-
-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
(BR, 490 mg, 0.91 mmol) in dichloromethane (10 mL) was added tosyl
chloride (190 mg, 1.00 mmol), potassium iodide (30.2 mg) and silver
oxide (314 mg) at rt. The resulting mixture was then stirred at
30.degree. C. for 6 h, LC-MS indicated formation of the desired
product. The inorganic salts were removed from the reaction by
filtration, the solution phase was concentrated under vacuum to
give a crude residue, which was purified by a flash silica gel
chromatography (eluent: ethyl acetate/petroleum ether (v:v=1:3)) to
give BS (yield: 60%) of as a light yellow solid.
Step 3: Synthesis of
(2S,4R)-4-(tert-butoxy)-N-{[2-(2-{2-[2-(4-{3-[4-cyano-3-(trifluoromethyl)-
phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}phenoxy)ethoxy-
]ethoxy}ethoxy)-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}-1-[(2S)-3-meth-
yl-2-(1-oxo-2,3-dihydro-1H-isoindol-2-yl)butanoyl]pyrrolidine-2-carboxamid-
e (BT)
[0549] To a stirred solution of
2-{2-[2-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-su-
lfanylideneimidazolidin-1-yl}phenoxy)ethoxy]ethoxy}ethyl
4-methylbenzene-1-sulfonate (BS, 207 mg, 0.30 mmol) and
(2S,4R)-4-(tert-butoxy)-N-{[2-hydroxy-4-(4-methyl-1,3-thiazol-5-yl)phenyl-
]methyl}-1-[(2S)-3-methyl-2-(1-oxo-2,3-dihydro-1H-isoindol-2-yl)butanoyl]p-
yrrolidine-2-carboxamide (ULM-12, 181 mg, 0.30 mmol) in
N,N-dimethylformamide (2 mL) was added potassium carbonate (83 mg,
0.60 mmol) at rt. The resulting mixture was then heated to
80.degree. C. and stirred at the same temperature overnight, and
LC-MS indicated formation of the desired product. The reaction was
then cooled to rt, diluted by water (10 mL) and then extracted with
ethyl acetate (20 mL.times.3). The organic layers were combined,
dried over anhydrous sodium sulfate and concentrated under reduced
pressure to give a crude residue, which was purified by a flash
silica gel chromatography (eluent: ethyl acetate/petroleum ether
(v:v=1:1) to give BT (yield: 54%) as a white solid.
Step 4: Synthesis of
(2S,4R)--N-{[2-(2-{2-[2-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dim-
ethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}phenoxy)ethoxy]ethoxy}ethoxy)-
-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}-4-hydroxy-1-[(2S)-3-methyl-2--
(1-oxo-2,3-dihydro-1H-isoindol-2-yl)butanoyl]pyrrolidine-2-carboxamide
(Example 82)
[0550] To a stirred solution of
(2S,4R)-4-(tert-butoxy)-N-{[2-(2-{2-[2-(4-{3-[4-cyano-3-(trifluoromethyl)-
phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}phenoxy)ethoxy-
]ethoxy}ethoxy)-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}-1-[(2S)-3-meth-
yl-2-(1-oxo-2,3-dihydro-1H-isoindol-2-yl)butanoyl]pyrrolidine-2-carboxamid-
e (BT, 180 mg, 0.16 mmol) in dichloromethane (5 mL) was added
trifluoroacetic acid (0.5 mL) at rt. The resulting solution was
stirred rt for 6 h, LC-MS indicated formation of the desired
product. Saturated aq. solution of sodium bicarbonate was added to
the reaction to neutralize the trifluoroacetic acid. Organic layer
was separated, the aqueous layer was extracted with of
dichloromethane (10 mL.times.2). The organic layers combined, dried
over anhydrous sodium sulfate and concentrated under reduced
pressure to give a crude residue, which was purified by Pre-HPLC to
give Example 82 (yield: 31%) as a white solid. .sup.1H NMR (400
MHz, CD.sub.3OD): .delta. 8.90 (s, 1H), 8.40-8.38 (d, J=8.0 Hz,
2H), 8.29 (s, 1H), 8.09-8.07 (d, J=8.4 Hz, 1H), 7.72-7.70 (d, J=7.6
Hz, 1H), 7.62-7.61 (d, J=4.0 Hz, 2H), 7.50-7.40 (m, 1H), 7.35-7.33
(d, J=7.6 Hz, 1H), 7.27-7.25 (d, J=8.8 Hz, 2H), 7.10-7.06 (m, 3H),
7.05-7.00 (m, 1H), 5.09 (s, 1H), 4.72-4.69 (d, J=10.8 Hz, 1H),
4.61-4.41 (m, 2H), 4.41-4.31 (m, 2H), 4.31-4.21 (m, 2H), 4.21-4.11
(m, 2H), 4.11-4.01 (m, 2H), 3.82-3.71 (m, 5H), 3.69-3.61 (m, 5H),
2.51 (m, 3H), 2.47-2.25 (m, 1H), 2.10-2.00 (m, 1H), 2.00-1.95 (m,
1H), 1.48 (s, 6H), 0.97-0.96 (d, J=6.4 Hz, 3H), 0.74-0.72 (d, J=6.4
Hz, 3H); LC-MS (ES.sup.+): m/z 1068.20 [MH.sup.+], t.sub.R=1.59 min
(3.0 minute run).
[0551] Examples 83-85 were synthesized according to similar
procedure described for synthesis of Example 82, by using
corresponding starting materials and intermediates.
TABLE-US-00006 TABLE 6 Exemplary Compounds. Ex Compound name and #
Structure Analytical data 83 ##STR00256## Prepared from ABM-3,
L-30, and ULM-13 (2S,4R)-N-{[2-(2-{2-[2-(4-{3-[4-
cyano-3-(trifluoromethyl) phenyl]-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl} phenoxy)ethoxy]ethoxy}ethoxy)-
4-(4-methyl-1,3-thiazol-5-yl) phenyl]methyl}-1-[(2S)-2-(6-
fluoro-1-oxo-2,3-dihydro-1H- isoindol-2-yl)-3-methyl-
butanoyl]-4-hydroxy- pyrrolidine-2-carboxamide .sup.1H NMR (400
MHz, CD.sub.3OD): .delta. 8.89 (s, 1H), 8.17-8.15 (d, J = 8.0 Hz,
2H), 8.00-7.98 (d, J = 8.4 Hz, 1H), 7.60-7.56 (m, 1H), 7.49-7.37
(m, 3H), 7.28-7.26 (d, J = 8.8 Hz, 2H), 7.08-7.05 (m, 4H),
4.90-7.83 (m, 1H), 4.59-4.46 (m, 6H), 4.26- 4.25 (m, 2H), 417-4.15
(m, 2H), 3.98-3.86 (m, 6H), 3.79-3.77 (m, 4 H), 2.51 (s, 3H),
2.50-2.49 (m, 1H), 2.25-2.15 (m, 1H), 2.01-2.00 (m, 1H), 1.54 (s, 6
H), 1.07-1.06 (d, J = 6.8 Hz, 3H), 0.85-0.83 (d, J = 6.8 Hz, 3H);
LC-MS (ES.sup.+): m/z 1086.60 [MH.sup.+], t.sub.R = 2.24 min (3.6
minute run). 84 ##STR00257## Prepared from ABM-3, L-30, and ULM-14
(2S,4R)-1-[(2S)-2-(7-cyano-1- oxo-2,3-dihydro-1H-isoindol-2-
yl)-3-methylbutanoyl]-N-{[2-(2- {2-[2-(4-{3-[4-cyano-3-(trifluoro-
methyl)phenyl]-5,5-dimethyl-4- oxo-2-sulfanylideneimidazolidin-
1-yl}phenoxy)ethoxy]ethoxy} ethoxy)-4-(4-methyl-1,3-thiazol-
5-yl)phenyl]methyl}-4-hydroxy- pyrrolidine-2-carboxamide H NMR (400
MHz, CD.sub.3OD): .delta. 8.89 (s, 1H), 8.17 8.15 (d, J = 7.2 Hz,
2H), 8.01-7.98 (d, J = 8.4 Hz, 1H), 7.98-7.76 (m, 3H), 7.44-7.42
(m, 1H), 7.29-7.25 (m, 2H), 7.08-7.04 (m, 4H), 4.87- 7.85 (m, 1H),
4.69-4.41 (m, 6H), 4.25-4.23 (m, 2H), 4.22-4.16 (m, 2H), 4.10-4.00
(m, 1H), 3.94- 3.87 (m, 5H), 3.79-3.77 (m, 4H), 2.51 (s, 3H),
2.50-2.49 (m, 1H), 2.23-2.13 (m, 1H), 2.05-2.00 (m, 1H), 1.54 (s,
6H), 1.10-1.07 (d, J = 6.8 Hz, 3H), 0.88-0.86 (d, J = 6.8 Hz, 3H);
LC-MS (ES.sup.+): m/z 1093.00 [MH.sup.+], t.sub.R = 2.22 min (3.6
minute run). 85 ##STR00258## Prepared from ABM-3, L-31, and ULM-12
(2S,4R)-N-{[2-(2-{[(2R,3R)-3- [2-(4-{3-[4-cyano-3-(trifluoro-
methyl)phenyl]-5,5-dimethyl-4- oxo-2-sulfanylideneimidazolidin-
1-yl}phenoxy)ethoxy]butan-2- yl]oxy}ethoxy)-4-(4-methyl-1,3-
thiazol-5-yl)phenyl]methyl}-4- hydroxy-1-[(2S)-3-methyl-2-(1-
oxo-2,3-dihydro-1H-isoindol- 2-yl)butanoyl]pyrrolidine-2-
carboxamide .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 0.82 (d, J =
6.65 Hz, 3 H), 1.05 (d, J = 6.65 Hz, 3 H), 1.15 (t, J = 5.48 Hz, 6
H), 1.44-1.56 (m, 6 H), 1.98-2.10 (m, 2 H), 2.14-2.24 (m, 1 H),
2.37-2.52 (m, 4 H), 3.52- 3.62 (m, 2 H), 3.89 (td, J = 10.76, 4.70
Hz, 3 H), 3.93-4.01 (m, 3 H), 4.09 (br. s., 2 H), 4.16-4.24 (m, 2
H), 4.44-4.67 (m, 6 H), 4.84 (d, J = 10.96 Hz, 1 H), 6.95- 7.08 (m,
4 H), 7.19-7.30 (m, 2 H), 7.43 (d, J = 7.43 Hz, 1 H), 7.46- 7.51
(m, 1 H), 7.52-7.63 (m, 2 H), 7.78 (d, J = 7.43 Hz, 1 H), 7.97 (d,
J = 7.83 Hz, 1 H), 8.08- 8.17 (m, 2 H), 8.43 (t, J = 5.87 Hz, 1 H),
8.87 (s, 1 H); Mass (ES.sup.+): m/z 1096.37 [MH.sup.+]
Synthesis of Example 86
##STR00259## ##STR00260##
[0552] Step 1: Synthesis of tert-butyl
3-{2-[(5-bromopyridin-2-yl)oxy]ethoxy}propanoate
##STR00261##
[0554] To a stirred solution of 5-bromopyridin-2-ol (3.0 g, 17.24
mmol), tert-butyl 3-(2-hydroxyethoxy)propanoate (3.3 g, 17.19 mmol)
and triphenylphosphine (6.8 g, 25.81 mmol) in tetrahydrofuran
(120.0 mL) was added diethyl diazene-1,2-dicarboxylate (4.49 g,
25.78 mmol) dropwise at 0.degree. C. under an atmosphere of
nitrogen. The resulting solution was stirred overnight at rt. The
reaction mixture was concentrated under reduced pressure to give a
crude residue, which was purified by silica gel flash
chromatography (eluent: ethyl acetate/petroleum ether, v/v=1/3) to
provide the titled product (yield: 50%) as colorless oil.
Step 2: Synthesis of tert-butyl
3-(2-{[5-(4-nitrophenyl)pyridin-2-yl]oxy}ethoxy)propanoate
##STR00262##
[0556] To a stirred mixture of tert-butyl
3-{2-[(5-bromopyridin-2-yl)oxy]ethoxy}propanoate (3.0 g, 8.67 mmol)
and (4-nitrophenyl)boronic acid (1.5 g, 8.87 mmol) in a mixed
solvent of dioxane (90.0 mL) and water (9.0 mL) was added potassium
carbonate (2.4 g, 17.36 mmol) and Pd(PPh.sub.3).sub.4 (450.0 mg,
0.39 mmol) under an atmosphere of nitrogen. The resulting mixture
was stirred for 12 h at 100.degree. C. The bulk of solvent was
removed under reduced pressure, and the resulting aqueous residue
was extracted with ethyl acetate (100 mL.times.2). The organic
layers were combined, washed with brine (70 mL.times.2), dried over
anhydrous sodium sulfate, and concentrated under reduced pressure
to give a crude residue which was purified by silica gel flash
chromatography (eluent: ethyl acetate/petroleum ether, v/v=1/5) to
provide the titled product (yield: 83%) a yellow solid. Mass
(ES.sup.+): m/z 389.00 [MH.sup.+].
Step 3: Synthesis of tert-butyl
3-(2-{[5-(4-aminophenyl)pyridin-2-yl]oxy}ethoxy)propanoate
##STR00263##
[0558] To a stirred solution of tert-butyl
3-(2-{[5-(4-nitrophenyl)pyridin-2-yl]oxy}ethoxy)propanoate (2.8 g,
7.21 mmol) in ethanol (200.0 mL) under an atmosphere of nitrogen
was added palladium on carbon (1.5 g) at rt. The reaction mixture
was then charge with hydrogen gas and stirred at rt for 12 h. The
solids were removed by filtration and the solution phase was
concentrated under reduced pressure to give a crude residue which
was purified by silica gel flash chromatography (eluent: ethyl
acetate/petroleum ether, v/v=1/3) to provide the titled product
(yield: 89%) a yellow oil. LC-MS (ES.sup.+): m/z 358.97
[MH.sup.+].
[0559] Example 86 was synthesized from tert-butyl
3-(2-{[5-(4-aminophenyl)pyridin-2-yl]oxy}ethoxy)propanoate,
according to chemistry highlighted above (steps 4-8), utilizing
similar procedures described for the similar chemistry carried out
for the synthesis of examples 67, 75, 103, by using corresponding
starting materials and intermediates.
[0560] Example 90 was synthesized according to similar procedures
described for the synthesis of examples 86, by using corresponding
starting materials and intermediates.
[0561] Examples 88, 91-92 were synthesized according to similar
procedures described for the synthesis of examples 80, 75, 103, by
using corresponding starting materials and intermediates.
[0562] Examples 87, 89, 93-102, 104-134, 136-142, 146-149 were
synthesized according to similar procedures described for the
synthesis of examples 75, by using corresponding starting materials
and intermediates.
TABLE-US-00007 TABLE 7 Exemplary Compounds. Ex # Structure Compound
name and Analytical data 86 ##STR00264##
(2S,4R)-1-[(2S)-2-[3-(2-{[5-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-
4-oxo-2-sulfanylideneimidazolidin-1-
yl}phenyl)pyridin-2-yl]oxy}ethoxy)
propanamido]-3,3-dimethylbutanoyl]-4-
hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)
phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.80 (s, 1 H), 8.36-8.30 (m, 1 H), 8.17-8.10
(m, 2 H), 7.96- 7.88 (m, 2 H), 7.71-7.65 (m, 2H), 7.46-7.26 (m, 6
H), 6.88-6.80 (m, 1 H), 4.64-4.35 (m, 6 H), 4.30-4.21 (m, 1 H),
3.89-3.65 (m, 8 H), 3.60-3.35 (m, 5 H), 2.23-1.98 (m, 2 H), 1.55
(s, 6 H), 1.02 (s, 9 H); LC-MS (ES.sup.+): m/z 1011.20 [MH.sup.+]
87 ##STR00265## (2S,4R)-1-[(2S)-2-[3-(2-{[6-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}
phenyl)pyridin-3-yl]oxy}ethoxy)
propanamido]-3,3-dimethylbutanoyl]-4-
hydroxy-N-{[4-(4-methyl-1,3-thiazol-
5-yl)phenyl]methyl}pyrrolidine-2- carboxamide .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.80 (s, 1 H), 8.36-8.30 (m, 1 H), 8.17-8.10
(m, 2 H), 8.07-7.92 (m, 3 H), 7.81-7.75 (m, 1 H), 7.46- 7.26 (m, 7
H), 4.61 (s, 1 H), 4.54-4.50 (m, 1 H), 4.49-4.40 (m, 2H), 4.33-4.28
(m, 1 H), 4.26-4.15 (m, 2 H), 3.89-3.65 (m, 6 H), 2.64- 2.40 (m, 2
H), 2.38 (s, 3 H), 2.20-2.10 (m, 1 H), 1.19-1.95 (m, 1 H), 1.55 (s,
6 H), 1.01 (s, 9 H); LC-MS (ES.sup.+): m/z 1011.20 [MH.sup.+] 88
##STR00266## (2S,4R)-1-[(2S)-2-{5-[4-(4-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenyl}phenyl)
piperazin-1-yl]pentanamido}-3,3-dimethyl-
butanoyl]-4-hydroxy-N-{[4-(1,3-oxazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
DMSO): .delta. 8.51-8.58 (m, 1H), 8.42 (s, 1H), 8.20 (d, J = 8.4
Hz, 1H), 8.05 (s, 1H), 7.87 (d, J = 9.3 Hz, 1H), 7.73-7.79 (m, 3H),
7.60-7.65 (m, 5H), 7.38-7.44 (m, 4H), 7.05 (d, J = 9.0 Hz, 2H),
5.13 (m, 1H), 4.58 (d, J = 9.3 Hz, 1H), 4.36-4.45 (m, 3H), 4.23 (m,
1H), 3.68 (m, 2H), 3.31 (s, 2H), 3.21 (m, 4H), 2.53 (s, 2H),
2.27-2.34 (m, 3H), 2.17-2.19 (m, 1H), 2.07 (m, 1H), 1.89 (m, 1H),
1.52 (m, 10H), 0.96 (s, 9H); LC-MS (ES.sup.+): m/z 998.30
[MH.sup.+] 89 ##STR00267##
(2S,4R)-1-[(2S)-2-(2-{4-[(6-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenyl}
pyridin-3-yl)oxy]butoxy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(1,3-
oxazol-5-yl)phenyl]methyl}pyrrolidine-2- carboxamide .sup.1H NMR
(300 MHz, CD.sub.3OD): .delta. 8.38 (s, 1 H), 8.21 (s, 1 H),
8.10-7.95 (m, 3 H), 7.90 (s, 1 H), 7.89-7.80 (m, 1 H), 7.71-7.60
(m, 3 H), 7.55-7.40 (m, 6 H), 4.70 (m, 1 H), 4.63- 4.45 (m, 3 H),
4.40-4.30 (m, 1 H), 4.22-4.13 (m, 2 H), 4.10-3.92 (m, 2 H),
3.90-3.79 (m, 2 H), 3.70-3.60 (m, 2 H), 2.30-2.21 (m, 1 H),
2.14-2.00 (m, 1 H), 2.00-1.90 (m, 2 H), 1.90- 1.80 (m, 2H), 1.58
(s, 6 H), 1.01 (s, 9 H); LC-MS (ES.sup.+): m/z, 961.20 [MH.sup.+]
90 ##STR00268## (2S,4R)-1-[(2S)-2-(2-{4-[(5-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenyl}
pyridin-2-yl)oxy]butoxy}actamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(1,3-
oxazol-5-yl)phenyl]methyl}pyrrolidine-2- carboxamide .sup.1H NMR
(300 MHz, CD.sub.3OD): .delta. 8.42 (s, 1 H), 8.21 (s, 1 H),
8.00-7.95 (m, 2 H), 7.90 (s, 1 H), 7.79-7.71 (m, 2 H), 7.70-7.61
(m, 3 H), 7.55-7.40 (m, 5 H), 6.90 (d, J = 6.6 Hz, 1 H), 4.70 (m, 1
H), 4.63-4.45 (m, 3 H), 4.42-4.30 (m, 3 H), 4.10-3.96 (m, 2 H),
3.90-3.85 (m, 1 H), 3.84-3.76 (m, 1 H), 3.70-3.60 (m, 2 H),
2.30-2.21 (m, 1 H), 2.14-2.00 (m, 1 H), 2.00- 1.90 (m, 2 H),
1.90-1.80 (m, 2H), 1.58 (s, 6 H), 1.01 (s, 9 H); LC-MS (ES.sup.+):
m/z, 961.20 [MH.sup.+] 91 ##STR00269##
(2S,4R)-1-[(2S)-2-{4-[4-(4-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenyl}
phenyl)piperidin-1-yl]butanamide}-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-
(1,3-oxazol-5-yl)phenyl]methyl}pyrrolidine- 2-carboxamide .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.23 (s, 1H), 7.99 (d, J = 8.0
Hz, 1H), 7.91 (s, 1H), 7.80 (d, J = 8.8 Hz, 2H), 7.69-7.63 (m, 5H),
7.49-7.45 (m, 5H), 7.39 (d, J = 8.4 Hz, 2H), 4.67 (s, 1H),
4.60-4.52 (m, 3H), 4.38 (d, J = 15.6 Hz, 1H), 3.95-3.91 (m, 1H),
3.88-3.81 (m, 1H), 3.17-3.15 (m, 2H), 2.66-2.61 (m, 1H), 2.54-2.45
(m, 2H), 2.38-2.31 (m, 2H), 2.29-2.15 (m, 3H), 2.13-2.06 (m, 1H),
1.88- 1.85 (m, 6H), 1.61 (s, 6H), 1.08 (s, 9H); LC- MS (ES.sup.+):
m/z 983.45 [MH.sup.+] 92 ##STR00270##
(2S,4R)-1-[(2S)-2-(2-{2-[4-(4-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenyl}
phenyl)piperidin-1-yl]ethoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-
(1,3-oxazol-5-yl)phenyl]methyl}pyrrolidine- 2-carboxamide .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.19 (s, 1H), 7.99 (d, J = 8.4
Hz, 1H), 7.91 (s, 1H), 7.77-7.73 (m, 2H), 7.69-7.52 (m, 5H),
7.45-7.43 (m, 5H), 7.36 (d, J = 8.4 Hz, 2H), 4.73 (s, 1H),
4.61-4.49 (m, 3H), 4.36-4.32 (m, 1H), 4.13-4.01 (m, 2H), 3.91-3.77
(m, 4H), 3.21-3.12 (m, 2H), 2.78 (t, J = 5.2 Hz, 2H), 2.68-2.61 (m,
1H), 2.37-2.30 (m, 2H), 2.28-2.19 (m, 1H), 2.14-2.05 (m, 1H),
1.92-1.88 (m, 4H), 1.60 (s, 6H), 1.08 (s, 9H); LC-MS (ES.sup.+):
m/z 999.65 [MH.sup.+] 93 ##STR00271##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}
phenyl)phenoxy]butoxy}acetamido)-3-
methylbutanoyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.83 (s, 1 H), 8.67
(t, J = 6.06 Hz, 1 H), 8.18 (d, J = 1.96 Hz, 1 H), 8.15 (d, J =
8.22 Hz, 1 H), 8.00 (dd, J = 8.22, 1.96 Hz, 1 H), 7.69-7.74 (m, 2
H), 7.64 (d, J = 9.00 Hz, 1 H), 7.54- 7.60 (m, 2 H), 7.37-7.46 (m,
6 H), 6.96- 7.02 (m, 2 H), 4.63-4.69 (m, 1H), 4.55-4.61 (m, 1 H),
4.48-4.55 (m, 2 H), 4.34-4.41 (m, 1 H), 4.04-4.10 (m, 2 H),
3.98-4.03 (m, 2 H), 3.83-3.88 (m, 1 H), 3.77-3.82 (m, 1 H), 3.64
(t, J = 6.26 Hz, 2 H), 2.42-2.47 (m, 3 H), 2.25 (dd, J = 13.30,
7.83 Hz, 1 H), 2.14 (dd, J = 13.30, 6.65 Hz, 1 H), 2.07 (ddd, J =
13.30, 9.00, 4.30 Hz, 1H), 1.89-1.97 (m, 2 H), 1.81- 1.89 (m, 2 H),
1.59 (s, 6 H), 1.01 (d, J = 6.65 Hz, 3 H), 0.91 (d, J = 6.26 Hz, 3
H): LC-MS (ES.sup.+): m/z 1010.36 [MH.sup.+] 94 ##STR00272##
(2S,4R)-1-[(2S)-2-{2-[4-(4-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenyl}
phenoxy)butoxy]acetamido}-3,3-dimethyl-
butanoyl]-4-hydroxy-N-{[4-(1,3-oxazol-
5-yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.14 (s, 1 H), 8.00-7.91 (m, 1 H), 7.90-7.80
(m 1 H), 7.71- 7.60 (m, 5 H), 7.59-7.51 (m, 2 H), 7.45-7.30 (m, 5
H), 7.05-6.94 (m, 2 H), 4.67 (s, 1 H), 4.55-4.50 (m, 1 H),
4.49-4.40 (m, 2 H), 4.31- 3.25 (m, 1 H), 4.10-4.00 (m, 2 H),
3.99-3.96 (m, 2 H), 3.90-3.70 (m, 2 H), 3.65-3.55 (m, 2 H),
2.22-2.13 (m, 1 H), 2.14-2.00 (m, 1 H), 2.00-1.72 (m, 4 H), 1.56
(s, 6 H), 1.01 (s, 9 H); LC-MS (ES.sup.+): m/z, 960.3 [MH.sup.+] 95
##STR00273## (2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-
4-oxo-2-sulfanylideneimidazolidin-1-
yl}phenyl)phenoxy]butoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-
[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)
phenyl]ethyl]pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.86 (s, 1H), 8.18-8.15 (d, J = 9.0 Hz, 2H),
8.03-7.99 (m, 1H), 7.76-7.71 (d, J = 14.4 Hz, 2H), 7.64-7.59 (d, J
= 15.3 Hz, 2H), 7.45-7.39 (m, 6H), 7.07-7.04 (d, J = 8.7 Hz, 2H),
5.01-4.99 (m, 1H), 4.70 (s, 1H), 4.61-4.55 (m, 1H), 4.45 (s, 1H),
4.13-4.08 (m, 2H), 4.03-3.96 (m, 2H), 3.84-3.80 (m, 1H), 3.78-3.76
(m, 1H), 3.68- 3.64 (m, 2H), 2.47 (s, 3H), 2.22-2.15 (m, 1H),
1.99-1.85 (m, 5H), 1.60 (s, 6H), 1.51- 1.48 (d, J = 6.9 Hz, 3H),
1.05 (s, 9H); LC-MS (ES.sup.+): m/z 1038.50 [MH.sup.+] 96
##STR00274## (2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-
4-oxo-2-sulfanylideneimidazolidin-1-
yl}phenyl)phenoxy]butoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-
{[4-(1,3-oxazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.23- 8.15 (m, 3H),
8.03-7.99 (d, J = 9.9 Hz, 1H), 7.73-7.65 (m, 4H), 7.60-7.57 (d, J =
8.7 Hz, 2H), 7.46-7.41 (m, 5H), 7.05- 7.00 (d, J = 12.6 Hz, 2H),
4.71 (s, 1H), 4.61-4.50 (m, 3H), 4.36-4.31 (d, J = 15.6 Hz, 1H),
4.10-4.08 (m, 4H), 4.03- 3.82 (m, 2H), 3.68-3.64 (t, J = 7.3 Hz,
2H), 2.22-2.10 (m, 1H), 2.10-2.02 (m, 1H), 1.98-1.85 (m, 4H), 1.60
(s, 6H), 1.05 (s, 9H); LC-MS (ES.sup.+): m/z 994.65 [MH.sup.+] 97
##STR00275## (2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-
4-oxo-2-sulfanylideneimidazolidin-1-
yl}phenyl)phenoxy]butoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-
{[4-(4-methyl-1,3-oxazol-5-yl)phenyl]
methyl}pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz, CD.sub.3OD):
.delta. 8.18-8.15 (d, J = 9.3 Hz, 2H), 8.08 (s, 1H), 8.03-7.99 (d,
J = 9.9 Hz, 1H), 7.73-7.70 (d, J = 8.4 Hz, 2H), 7.61-7.56 (m, 4H),
7.49-7.41 (m, 4H), 7.02-7.00 (d, J = 8.7 Hz, 2H), 4.71 (s, 1H),
4.61-4.52 (m, 3H), 4.37-4.11 (d, J = 15.6 Hz, 2H), 4.11-4.07 (m,
4H), 3.96-3.82 (m, 2H), 3.68-3.64 (t, J = 6.0 Hz, 2H), 2.36 (s,
3H), 2.23-2.14 (m, 1H), 2.14-2.09 (m, 1H), 1.98-1.84 (m, 4H), 1.60
(s, 6H), 1.05 (s, 9H); LC-MS (ES.sup.+): m/z 1008.20 [MH.sup.+] 98
##STR00276## (2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanyleneimidazolidin-1-yl}phenyl)
phenoxy]butoxy}acetamido)-3,3-dimethyl-
butanoyl]-4-hydroxy-N-{[4-(1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.89 (s, 1H), 8.18-8.15 (d, J = 9.0 Hz, 2H),
8.10 (s, 1H), 8.03-7.99 (d, J = 12.0 Hz, 1H), 7.73-7.70 (d, J = 8.4
Hz, 2H), 7.62-7.56 (m, 4H), 7.44-7.41 (m, 4H), 7.05-7.00 (d, J =
14.1 Hz, 2H), 4.71 (s, 1H), 4.61-4.51 (m, 3H), 4.35-4.30 (m, 1H),
4.12-4.08 (m, 2H), 4.08-4.03 (m, 2H), 3.95- 3.82 (m, 2H), 3.68-3.64
(t, J = 6.0 Hz, 2H), 2.22-2.20 (m, 1H), 2.13-2.08 (m, 1H), 1.98-
1.84 (m, 4H), 1.60 (s, 6H), 1.04 (s, 9H); LC-MS (ES.sup.+): m/z
1010.30 [MH.sup.+] 99 ##STR00277##
(2S,4R)-1-[(2S)-2-(2-{4-[3-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-
4-oxo-2-sulfanylideneimidazolidin-1-
yl}phenyl)phenoxy]butoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-
{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]
methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz, CD.sub.3OD):
.delta. 8.82 (s, 1H), 8.20 (d, J = 5.4 Hz, 2H), 8.02 (d, J = 8.0
Hz, 1H), 7.77 (d, J = 5.4 Hz, 2H), 7.52 (m, 4H), 7.44 (m, 3H), 7.24
(d, J = 8.4 Hz, 2H), 6.96 (d, J = 8.4 Hz, 1H), 4.71 (s, 1H), 4.56
(m, 3H), 4.34 (m, 1H), 4.12 (m, 2H), 4.00 (m, 2H), 3.84 (m, 1H),
3.72 (m, 1H), 3.67 (m, 2H), 2.45 (s, 3H), 2.24 (m, 1H), 2.10 (m,
1H), 1.90 (m, 4H), 1.61 (s, 6H), 1.03 (s, 9H); LC-MS (ES.sup.+):
m/z 1024.35 [MH.sup.+] 100 ##STR00278##
(2S,4R)-1-[(2S)-2-{2-[4-(4-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]-3-fluoro-
phenyl}phenoxy)butoxy]acetamido}-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-oxazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, DMSO) .delta. 8.61 (s, 1H), 8.29 (s, 1H),
8.21 (d, J = 8.4 Hz, 1H), 8.08 (s, 1H), 7.78-7.64 (m, 5H), 7.53-
7.42 (m, 6H), 7.04 (m, J = 8.8 Hz, 2H), 5.16 (s, 1H), 4.58 (d, J =
9.6 Hz, 1H), 4.57-4.27 (m, 4H), 4.20 (t, J = 6.8 Hz, 2H), 3.91 (s,
2H), 3.68-3.53 (m, 4H), 2.33 (s, 3H), 2.07 (s, 1H), 1.90-1.72 (m,
5H), 1.60 (s, 3H), 1.48 (s, 3H), 0.95 (s, 9H); LC-MS (ES.sup.+):
m/z 992.30 [MH.sup.+] 101 ##STR00279##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}
phenyl)phenoxy]butoxy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-
[4-(4-methyl-1,3-oxazol-5-l)phenyl]ethyl] pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.19-8.14 (m, 3H),
8.03-8.01 (d, J = 8.4 Hz, 1H), 7.77-7.73 (d, J = 16.0 Hz, 2H),
7.64-7.60 (m, 4H), 7.45-7.42 (m, 4H), 7.07-7.05 (d, J = 8.4 Hz,
2H), 5.01-5.00 (m, 1H), 4.71 (s, 1H), 4.61-4.56 (m, 1H), 4.45 (s,
1H), 4.13-4.10 (m, 2H), 4.07-4.01 (m, 2H), 3.88-3.85 (m, 1H),
3.78-3.75 (m, 1H), 3.69- 3.66 (t, J = 12.0 Hz, 2H), 2.40 (s, 3H),
2.21- 2.19 (m, 1H), 2.00-1.86 (m, 5H), 1.61 (s, 6H), 1.51-1.49 (d,
J = 7.2 Hz, 3H), 1.06 (s, 9H); LC-MS (ES.sup.+): m/z 1022.45
[MH.sup.+] 102 ##STR00280##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(5-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-
4-oxo-2-sulfanylideneimidazolidin-1-yl}
pyridin-2-yl)phenoxy]butoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-
(4-methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.96 (s, 1H), 8.62 (m,
2H), 8.42 (d, J = 8.4 Hz, 1H), 8.33 (s, 1H), 8.12 (m, 4H), 7.89 (m,
1H), 7.44 (m, 5H), 7.07 (d, J = 8.8 Hz, 2H), 5.17 (m, 1H), 4.59 (d,
J = 9.6 Hz, 1H), 4.41-4.48 (m, 1H), 4.38 (m, 2H), 4.29 (m, 1H),
4.07-4.10 (m, 2H), 3.97 (m, 2H), 3.55-3.67 (m, 4H), 2.45 (s, 3H),
2.08 (m, 1H), 1.81-1.91 (m, 3H), 1.72-1.77 (m, 2H), 1.58 (s, 6H),
0.95 (s, 9H); LC-MS (ES.sup.+): m/z 1025.55 [MH.sup.+] 103
##STR00281## (2S,4R)-1-[(2S)-2-[2-(4-{[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}
phenyl)phenyl]amino}butoxy)acetamido]-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-
(4-methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.71 (s, 1H), 8.18-8.15
(d, J = 8.4 Hz, 2H), 8.03-8.00 (d, J = 7.8 Hz, 1H), 7.68-7.66 (d, J
= 8.4 Hz, 2H), 7.47-7.35 (m, 8H), 6.74-6.71 (d, J = 8.7 Hz, 2H),
4.72 (s, 1H), 4.62-4.50 (m, 3H), 4.37-4.32 (d, J = 15.2 Hz, 1H),
4.00- 3.98 (m, 2H), 3.94-3.79 (m, 2H), 3.64-3.61 (m, 2H), 3.21-3.11
(m, 2H), 2.48 (s, 3H), 2.28-2.21 (m, 1H), 2.09-2.05 (m, 1H), 1.93-
1.89 (m, 4H), 1.59 (s, 6H), 1.01 (s, 9H); LC-MS (ES.sup.+): m/z
1023.30 [MH.sup.+]
104 ##STR00282## (2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}
phenyl)phenoxy]butoxy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(1-
methyl-1H-imidazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.18-8.15 (d, J = 9.0
Hz, 2H), 8.02-7.99 (d, J = 10.2 Hz, 1H), 7.73-7.70 (d, J = 8.4 Hz,
2H), 7.59-7.56 (d, J = 8.7 Hz, 2H), 7.50-7.39 (m, 7H), 7.03- 7.00
(d, J = 8.7 Hz, 2H), 6.30 (s, 1H), 4.71 (s, 1H), 4.62-4.50 (m, 3H),
4.39-4.33 (d, J = 15.2 Hz, 1H), 4.11-4.08 (m, 2H), 4.08- 4.00 (m,
2H), 3.87-3.80 (m, 5H), 3.68- 3.64 (t, J = 6.0 Hz, 2H), 2.25-2.15
(m, 1H), 2.10-2.00 (m, 1H), 1.97-1.84 (m, 4H), 1.60 (s, 6H), 1.04
(s, 9H); LC-MS (ES.sup.+): m/z 1007.50 [MH.sup.+] 105 ##STR00283##
(2S,4R)-N-{[4-(4-chloro-1,3-oxazol-5-
yl)phenyl]methyl}-1-[(2S)-2-(2-{4-[4-
(4-{3-[4-cyano-3-(trifluoromethyl) phenyl]-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolin-1-yl}phenyl) phenoxy]butoxy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy- pyrrolidine-2-carboxamide .sup.1H NMR
(400 MHz, CD.sub.3OD): .delta. 8.63- 8.66 (m, 1H), 8.53 (s, 1H),
8.41 (d, J = 8.4 Hz, 1H), 8.32 (s, 1H), 8.12 (d, J = 8.8 Hz, 1H),
7.80 (d, J = 8.0 Hz, 2H), 7.75 (d, J = 8.4 Hz, 2H), 7.67 (d, J =
8.4 Hz, 2H), 7.50 (m, 5H), 7.04 (d, J = 8.8 Hz, 2H), 5.17 (m, 1H),
4.59 (d, J = 8.4 Hz, 1H), 4.48 (m, 2H), 4.39 (m, 1H), 4.32 (m, 1H),
4.08 (m, 2H), 3.97 (m, 2H), 3.55-3.67 (m, 4H), 2.06- 2.08 (m, 1H),
1.81-1.91 (m, 3H), 1.72- 1.77 (m, 2H), 1.55 (s, 6H), 0.95 (s, 9H);
LC-MS (ES.sup.+): m/z 1028.50 [MH.sup.+] 106 ##STR00284##
(2S,4R)-1-[(2S)-2-{2-[4-(4-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]-3-fluoro-
phenyl}phenoxy)butoxy]acetamido}-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(1,3-
oxazol-5-yl)phenyl]methyl}pyrrolidine-2- carboxamide .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.20 (s, 1H), 8.00 (d, J = 8.4 Hz,
1H), 7.90 (s, 1H), 7.70-7.44 (m, 1H), 7.05 (d, J = 8.8 Hz, 2H),
4.72 (s, 1H), 4.61-4.52 (m, 3H), 4.37-4.33 (m, 1H), 4.14-4.02 (m,
4H), 3.98-3.84 (m, 2H), 3.67 (t, J = 6.4 Hz, 2H), 2.24-2.22 (m,
1H), 2.12-2.09 (m, 1H), 1.99-1.86 (m, 4H), 1.66 (s, 3H), 1.54 (s,
3H), 1.06 (s, 9H); LC-MS (ES.sup.+): m/z 978.25 [MH.sup.+] 107
##STR00285## (2S,4R)-1-[(2S)-2-{2-[4-(4-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]-3-fluoro-
phenyl}phenoxy)butoxy]acetamido}-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, DMSO) .delta. 8.96 (s, 1H), 8.61 (m, 1H),
8.20 (d, J = 8.4 Hz, 1H), 8.19 (s, 1H), 7.78-7.64 (m, 5H), 7.70-
7.37 (m, 6H), 7.03 (m, J = 8.8 Hz, 2H), 5.16 (s, 1H), 4.57 (d, J =
9.6 Hz, 1H), 4.57-4.27 (m, 4H), 4.08 (t, J = 6.8 Hz, 2H), 3.96 (s,
2H), 3.66-3.55 (m, 4H), 2.43 (s, 3H), 2.16 (m, 1H), 1.92-1.75 (m,
5H), 1.60 (s, 3H), 1.48 (s, 3H), 0.93 (s, 9H); LC-MS (ES.sup.+):
m/z 1008.50 [MH.sup.+] 108 ##STR00286##
(2S,4R)-1-[(2S)-2-{2-[4-(4-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]-3-fluoro-
phenyl}phenoxy)butoxy]acetamido}-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(1,3-
thiazol-5-yl)phenyl]methyl}pyrrolidine-2- carboxamide .sup.1H NMR
(400 MHz, DMSO) .delta. 9.04 (s, 1H), 8.61-8.56 (m, 1H), 8.27 (s,
1H), 8.21 (d, J = 8.4 Hz, 1H), 8.08 (s, 1H), 7.78-7.36 (m, 11H),
7.06 (d, J = 8.4 Hz, 2H), 5.16 (s, 1H), 4.58-4.56 (m, 1H),
4.47-4.22 (m, 4H), 4.09- 4.06 (m, 2H), 3.96 (s, 2H), 3.66-3.55 (m,
4H), 2.07-2.04 (m, 1H), 1.89-1.72 (m, 5H), 1.60 (s, 3H), 1.48 (s,
3H), 0.95 (s, 9H); LC-MS (ES.sup.+): m/z 994.50 [MH.sup.+] 109
##STR00287## (2S,4R)-1-[(2S)-2-{2-[4-(4-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]-2-fluoro-
phenyl}phenoxy)butoxy]acetamido}-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(1,3-
oxazol-5-yl)phenyl]methyl}pyrrolidine- 2-carboxamide .sup.1H NMR
(300 MHz, CD.sub.3OD): .delta. 8.23 (s, 1H), 8.19-7.99 (d, J = 5.9
Hz, 1H), 7.96 (s, 1H), 7.78-7.61 (m, 4H), 7.58-7.51 (m, 2H),
7.47-7.46 (m, 2H), 7.46-7.41 (m, 3H), 7.31-7.29 (m, 2H), 7.05-7.02
(d, J = 8.7 Hz, 1H), 4.71 (s, 1H), 4.61-4.51 (m, 3H), 4.36-4.31 (d,
J = 15.2 Hz, 1H), 4.13- 4.11 (m, 2H), 4.09-4.01 (m, 2H), 3.96- 3.79
(m, 2H), 3.69-3.65 (t, J = 6.0 Hz, 2H), 2.23-2.20 (m, 1H),
2.13-2.09 (m, 1H), 1.96-1.87 (m, 4H), 1.60 (s, 6H), 1.03 (s, 9H);
LC-MS (ES.sup.+): m/z 978.25 [MH.sup.+] 110 ##STR00288##
(2S,4R)-1-[(2S)-2-{2-[4-(4-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenyl}
phenoxy)butoxy]acetamido}-3,3-dimethyl-
butanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-
oxazol-5-yl)phenyl]methyl}pyrrolidine-2- carboxamide .sup.1H NMR
(300 MHz, CD.sub.3OD): .delta. 8.08 (s, 1H), 7.77-7.72 (m, 3H),
7.69-7.56 (m, 4H), 7.48-7.39 (m, 5H), 7.19-7.17 (d, J = 6.3 Hz,
1H), 7.02-6.99 (d, J = 9.0 Hz, 2H), 4.71 (s, 1H), 4.61-4.52 (m,
3H), 4.36- 4.31 (m, 1H), 4.11-4.08 (m, 2H), 4.03-4.01 (m, 5H),
3.95-3.82 (m, 2H), 3.68-3.64 (m, 2H), 2.36 (s, 3H), 2.22-2.09 (m,
1H), 2.09- 2.01 (m, 1H), 1.95-1.84 (m, 4H), 1.58 (s, 6H), 1.04 (s,
9H); LC-MS (ES.sup.+): m/z 974.30 [MH.sup.+] 111 ##STR00289##
(2S,4R)-1-[(2S)-2-{2-[4-(4-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenyl} phenoxy)butoxy]acetamido}-
3,3-dimethylbutanoyl]-4-hydroxy-N-
{[4-(1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.89 (s, 1H), 8.10 (s,
1H), 7.98-7.95 (d, J = 8.4 Hz, 1H), 7.89-7.88 (d, J = 1.8 Hz, 1H),
7.72-7.56 (m, 7H), 7.44-7.39 (m, 4H), 7.03- 7.00 (d, J = 8.7 Hz,
2H), 4.70 (s, 1H), 4.61- 4.50 (m, 3H), 4.35-4.30 (d, J = 15.2 Hz,
1H), 4.12-4.03 (m, 2H), 4.01-3.95 (m, 2H), 3.86- 3.82 (m, 2H),
3.68-3.64 (m, 2H), 2.22-2.18 (m, 1H), 2.12-2.08 (m, 1H), 1.98-1.85
(m, 4H), 1.58 (s, 6H), 1.04 (s, 9H); LC-MS (ES.sup.+): m/z 976.20
[MH.sup.+] 112 ##STR00290##
(2S,4R)-1-[(2S)-2-{2-[4-(4-{4-[3-(3-chloro-
4-cyanophenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenyl}
phenoxy)butoxy]acetamido}-3,3-dimethyl-
butanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-
thiazol-5-yl)phenyl]methyl}pyrrolidine-2- carboxamide .sup.1H NMR
(300 MHz, CD.sub.3OD): .delta. 8.81 (s, 1H), 7.98-7.95 (d, J = 8.4
Hz, 1H), 7.89-7.88 (d, J = 1.8 Hz, 1H), 7.73-7.64 (m, 3H), 7.58-
7.56 (d, J = 8.7 Hz, 2H), 7.48-7.38 (m, 6H), 7.02-6.99 (d, J = 8.7
Hz, 2H), 4.71 (s, 1H), 4.62-4.51 (m, 3H), 4.36-4.31 (m, 1H), 4.11-
4.07 (m, 2H), 4.02-4.00 (d, J = 5.4 Hz, 2H), 3.87-3.82 (m, 2H),
3.68-3.64 (t, J = 6.0 Hz, 2H), 2.44 (s, 3H), 2.23-2.10 (m, 1H),
2.09- 2.00 (m, 1H), 1.97-1.84 (m, 4H), 1.58 (s, 6H), 1.04 (s, 9H);
LC-MS (ES.sup.+): m/z 990.30 [MH.sup.+] 113 ##STR00291##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}-3-
fluorophenyl)phenoxy]butoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-
(1,3-oxazol-5-yl)phenyl]methyl}pyrrolidine- 2-carboxamide .sup.1H
NMR (300 MHz, DMSO) .delta. 8.62-8.56 (m, 1H), 8.41 (s, 1H), 8.39
(s, 1H), 8.35 (s, 1H), 8.15 (d, J = 8.4 Hz, 1H), 7.76-7.63 (m, 7H),
7.51-7.38 (m, 4H), 7.06 (d, J = 8.7 Hz, 2H), 5.15 (d, J = 3.3 Hz,
1H), 4.58-4.26 (m, 5H), 4.09-4.05 (m, 2H), 3.96 (s, 2H), 3.66-3.56
(m, 4H), 2.12-2.04 (m, 1H), 1.93-1.73 (m, 5H), 1.60 (s, 3H), 1.50
(s, 3H), 0.95 (s, 9H); LC- MS (ES.sup.+): m/z 1012.30 [MH.sup.+]
114 ##STR00292## (2S,4R)-1-[(2S)-2-(2-{3-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}
phenyl)phenoxy]phenoxy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.81 (s, 1 H), 8.14-8.05
(m, 2 H), 8.00-7.95 (m, 1 H), 7.75-7.69 (m, 2 H), 7.65-7.59 (m, 2
H), 7.44- 7.20 (m, 7 H), 7.10-7.00 (m, 2 H), 6.80-6.78 (m, 1 H),
6.75-6.55 (m, 2 H), 4.68 (s, 1 H), 4.60-4.40 (m, 5 H), 4.30-4.20
(m, 1 H), 3.90- 3.65 (m, 2 H), 2.40 (s, 3 H), 2.25-2.21 (m, 1 H),
2.14-2.00 (m, 1 H), 1.55 (s, 6 H), 0.99 (s, 9 H); LC-MS (ES.sup.+):
m/z, 1044.30 [MH.sup.+] 115 ##STR00293##
(2S,4R)-1-[(2S)-2-{2-[4-(4-{4-[3-(4-cyano-
3-methoxyphenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenyl}
phenoxy)butoxy]acetamido}-3,3-dimethyl-
butanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-
oxazol-5-yl)phenyl]methyl}pyrrolidine-2- carboxamide .sup.1H NMR
(300 MHz, CD.sub.3OD): .delta. 8.08 (s, 1H), 7.76-7.69 (m, 3H),
7.60-7.55 (d, J = 15.9 Hz, 4H), 7.48-7.37 (m, 5H), 7.19- 7.16 (d, J
= 9.9 Hz, 1H), 7.02-6.99 (d, J = 8.7 Hz, 2H), 4.71 (s, 1H),
4.61-4.51 (m, 3H), 4.36-4.31 (m, 1H), 4.10-4.00 (m, 7H), 3.98-3.82
(m, 2H), 3.67-3.63 (t, J = 6.0 Hz, 2H), 2.35 (s, 3H), 2.22- 2.12
(m, 1H), 2.12-2.09 (m, 1H), 1.97- 1.84 (m, 4H), 1.58 (s, 6H), 1.04
(s, 9H); LC-MS (ES.sup.+): m/z 971.45 [MH.sup.+] 116 ##STR00294##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-
4-oxo-2-sulfanylideneimidazolidin-1-yl}-3-
fluorophenyl)phenoxy]butoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-
(4-methyl-1,3-oxazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, DMSO) .delta. 8.66-8.61 (m, 1H), 8.42 (d, J =
8.0 Hz, 1H), 8.35 (s, 1H), 8.29 (s, 1H), 8.15 (d, J = 8.4 Hz, 1H),
7.76- 7.64 (m, 4H), 7.53-7.40 (m, 6H), 7.05 (d, J = 8.8 Hz, 2H),
5.16 (s, 1H), 4.58-4.27 (m, 5H), 4.09-4.06 (m, 2H), 3.96 (s, 2H),
3.66-3.55 (m, 4H), 2.33 (s, 3H), 2.07-2.02 (m, 1H), 1.94- 1.73 (m,
5H), 1.61 (s, 3H), 1.50 (s, 3H), 0.95 (s, 9H); LC-MS (ES.sup.+):
m/z 1026.30 [MH.sup.+] 117 ##STR00295##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}-3-
fluorophenyl)phenoxy]butoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-
N-{[4-(1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, DMSO) .delta. 9.04 (s, 1H), 8.60 (s, 1H),
8.42-8.35 (m, 2H), 8.27 (s, 1H), 8.14 (d, J = 8.0 Hz, 2H),
7.75-7.67 (m, 3H), 7.66 (d, J = 8.0 Hz, 1H), 7.59 (m, J = 8.4 Hz,
2H), 7.48 (t, J = 8.4 Hz, 1H), 7.41-7.36 (m, 3H), 7.05 (d, J = 8.8
Hz, 2H), 5.19 (s, 1H), 4.57 (d, J = 9.2 Hz, 1H), 4.58-4.44 (m, 1H),
4.42-4.34 (m, 2H), 4.35-4.33 (m, 1H), 4.08 (s, 2H), 3.96 (s, 2H),
3.66-3.55 (m, 4H), 2.10-2.02 (m, 1H), 1.89-1.72 (m, 5H), 1.61 (s,
3H), 1.50 (s, 3H), 0.95 (s, 9H); LC-MS (ES.sup.+): m/z 1028.30
[MH.sup.+], 118 ##STR00296##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}-3-
fluorophenyl)phenoxy]butoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, DMSO) .delta. 8.96 (s, 1H), 8.61 (s, 1H),
8.42-8.35 (m, 2H), 8.15 (d, J = 1.6 Hz, 2H), 7.76-7.64 (m, 4H),
7.51-7.39 (m, 6H), 7.04 (d, J = 8.8 Hz, 2H), 5.17 (s, 1H), 4.57 (d,
J = 9.6 Hz, 1H), 4.56-4.38 (m, 3H), 4.36-4.27 (m, 1H), 4.08 (s,
2H), 3.96 (s, 2H), 3.66-3.55 (m, 4H), 2.45 (s, 3H), 2.10-2.02 (m,
1H), 1.93-1.84 (m, 1H), 1.84-1.82 (m, 2H), 1.75-1.73 (m, 2H), 1.61
(s, 3H), 1.50 (s, 3H), 0.94 (s, 9H); LC-MS (ES.sup.+): m/z 1042.25
[MH.sup.+] 119 ##STR00297##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{7-[4-cyano-
3-(trifluoromethyl)phenyl]-8-oxo-
6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-
yl}phenyl)phenoxy]butoxy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-oxazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.17-8.15 (d, J = 8.1
Hz, 2H), 8.09 (s, 1H), 8.02-8.00 (d, J = 8.7 Hz, 1H), 7.78-7.75 (d,
J = 8.4 Hz, 2H), 7.62-7.57 (m, 4H), 7.49-7.43 (m, 4H), 7.04-7.01
(d, J = 8.7 Hz, 2H), 4.71 (s, 1H), 4.62-4.53 (m, 3H), 4.37-4.32 (d,
J = 15.3 Hz, 1H), 4.12-4.11 (m, 2H), 4.09-4.01 (m, 2H), 3.96-3.82
(m, 2H), 3.69-3.65 (m, 2H), 2.80- 2.55 (m, 4H), 2.41 (s, 3H),
2.23-2.21 (m, 1H), 2.15-2.10 (m, 2H), 1.98-1.88 (m, 4H), 1.70-1.66
(m, 1H), 1.03 (s, 9H); LC-MS (ES.sup.+): m/z 1020.35 [MH.sup.+] 120
##STR00298## (2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{7-[4-cyano-
3-(trifluoromethyl)phenyl]-8-oxo-
6-sulfanylidene-5,7-diazaspiro[3.4]octan-5-
yl}phenyl)phenoxy]butoxy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-
{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]
methyl}pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz, CD.sub.3OD):
.delta. 8.82 (s, 1H), 8.17-8.15 (d, J = 7.8 Hz, 2H), 8.02-8.00 (d,
J = 8.1 Hz, 1H), 7.78-7.75 (d, J = 8.4 Hz, 2H), 7.61-7.59 (d, J =
8.4 Hz, 2H), 7.48-7.42 (m, 6H), 7.04-7.01 (d, J = 8.7 Hz, 2H), 4.71
(s, 1H), 4.62-4.51 (m, 3H), 4.47-4.32 (d, J = 15.9 Hz, 1H),
4.12-4.10 (m, 2H), 4.08- 4.01 (m, 2H), 3.96-3.82 (m, 2H), 3.69-3.65
(m, 2H), 2.80-2.55 (m, 4H), 2.48 (s, 3H), 2.23-2.21 (m, 1H),
2.14-2.10 (m, 1H), 1.98- 1.89 (m, 4H), 1.70-1.66 (m, 1H), 1.03 (s,
9H); LC-MS (ES.sup.+): m/z 1036.25 [MH.sup.+] 121 ##STR00299##
(2S,4R)-1-[(2S)-2-{2-[4-(4-{4-[3-(3-
chloro-4-cyanophenyl)-5,5-dimethyl-
4-oxo-2-sulfanylideneimidazolidin-1-
yl]phenyl}-3-fluorophenoxy)butoxy]
acetamido}-3,3-dimethylbutanoyl]-4-
hydroxy-N-{[4-(1,3-oxazol-5-yl)phenyl]
methyl}pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz, CD.sub.3OD):
.delta. 8.14 (s, 1 H), 8.00-7.91 (m, 1 H), 7.90-7.80 (m, 1 H),
7.71-7.58 (m, 5 H), 7.50-7.41 (m, 6 H), 6.90- 6.71 (m, 2 H), 4.67
(s, 1 H), 4.58-4.41 (m, 3 H), 4.30-4.22 (m, 1 H), 4.12-4.01 (m, 2
H), 3.99-3.94 (m, 2 H), 3.90-3.70 (m, 2 H), 3.65-3.55 (m, 2 H),
2.22-2.13 (m, 1 H), 2.14-2.00 (m, 1 H), 2.00-1.72 (m, 4 H), 1.56
(s, 6 H), 1.01 (s, 9 H); LC-MS (ES.sup.+): m/z, 978.30 [MH.sup.+]
122 ##STR00300## (2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-
4-oxo-2-sulfanylideneimidazolidin-1-
yl}phenyl)phenoxy]butoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-
{[4-(1H-pyrazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD): 8.25-8.15 (m, 2H), 8.05-8.00 (s,
1 H), 7.78-7.70 (m, 4 H), 7.70-7.58 (m, 3 H), 7.48-7.39 (m, 4 H),
7.08-7.00 (m, 2 H), 6.69-6.60, (s, 1 H), 4.95-4.85 (s, 1 H),
4.65-4.58 (s, 1 H), 4.55- 4.49 (m, 2 H), 4.40-4.30 (s, 1 H),
4.15-4.08 (m, 2 H), 4.05-4.00 (m, 2 H), 3.90-3.85 (s, 1 H),
3.82-3.75 (s, 1 H), 3.70-3.60 (m, 2 H), 2.28-2.20 (s, 1 H),
2.15-2.05 (s, 1 H), 1.98-
1.89 (m, 4 H), 1.63-1.59 (m, 6 H) 1.10-1.00 (m, 9 H); LC-MS
(ES.sup.+): m/z 993.35 [MH.sup.+] 123 ##STR00301##
(2S,4R)-1-[(2S)-2-{2-[4-(4-{4-[3-(3-chloro-
4-cyano-2-fluorophenyl)-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl]
phenyl}phenoxy)butoxy]acetamido}-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(1,3-
oxazol-5-yl)phenyl]methyl}pyrrolidine-2- carboxamide .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.21 (s, 1H), 7.88-7.87 (d, J = 1.6
Hz, 1H), 7.86-7.73 (m, 3H), 7.69-7.67 (d, J = 8.4 Hz, 2H),
7.61-7.59 (d, J = 8.4 Hz, 2H), 7.48-7.43 (m, 5H), 7.05- 7.02 (d, J
= 8.8 Hz, 2H), 4.88 (s, 1H), 4.73- 4.59 (m, 3H), 4.52-4.37 (d, J =
15.2 Hz, 1H), 4.08-4.02 (m, 2H), 3.98-3.82 (m, 2H), 3.89- 3.88 (m,
1H), 3.84-3.83 (m, 1H), 3.69-3.66 (t, J = 6.0 Hz, 2H), 2.23-2.20
(m, 1H), 2.13- 2.04 (m, 1H), 1.97-1.88 (m, 4H), 1.62 (s, 6H), 1.04
(s, 9H); LC-MS (ES.sup.+): m/z 978.26 [MH.sup.+] 124 ##STR00302##
(2S,4R)-1-[(2S)-2-{2-[4-(4-{4-[7-(3-chloro-
4-cyanophenyl)-8-oxo-6-sulfanylidene-5,7-
diazaspiro[3.4]octan-5-yl]phenyl}phenoxy)
butoxy]acetamido}-3,3-dimethylbutanoyl]-
4-hydroxy-N-{[4-(1,3-oxazol-5-yl)phenyl]
methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.18 (s, 1H), 7.99-7.96 (d, J = 8.4 Hz, 1H), 7.89 (s, 1H),
7.79-7.77 (d, J = 8.4 Hz, 2H), 7.67-7.61 (m, 5H), 7.48-7.43 (m,
5H), 7.06-7.04 (d, J = 8.8 Hz, 2H), 4.88 (s, 1H), 4.73-4.59 (m,
3H), 4.52-4.37 (d, J = 15.2 Hz, 1H), 4.14-4.11 (m, 2H), 4.05-4.02
(m, 2H), 3.99-3.83 (m, 2H), 3.70-3.67 (t, J = 6.0 Hz, 2H),
2.66-2.62 (m, 4H), 2.13-2.00 (m, 3H), 1.98-1.88 (m, 4H), 1.80-1.70
(m, 1H), 1.04 (s, 9H); LC-MS (ES.sup.+): m/z 972.25 [MH.sup.+] 125
##STR00303## (2S,4R)-1-[(2S)-2-{2-[4-(4-{4-[3-(4-cyano-
3-methylphenyl)-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenyl}
phenoxy)butoxy]acetamido}-3,3-dimethyl-
butanoyl]-4-hydroxy-N-{[4-(1,3-oxazol-5-
yl)phenyl]methyl}pyrrolidine-2- carboxamide .sup.1H NMR (400 MHz,
DMSO) .delta. 8.60 (t, J = 6.0 Hz, 1H), 8.40 (s, 1H), 7.97 (d, J =
8.0 Hz, 1H), 7.79 (d, J = 8.4 Hz, 2H), 7.67- 7.63 (m, 6H), 7.54 (d,
J = 8.4 Hz, 1H), 7.44-7.39 (m, 5H), 7.05 (d, J = 8.8 Hz, 2H), 5.16
(s, 1H), 4.58-4.56 (m, 1H), 4.47-4.26 (m, 4H), 4.08-4.05 (m, 2H),
3.97 (s, 2H), 3.66-3.57 (m, 4H), 2.56 (s, 3H), 2.06-2.02 (m, 1H),
1.93-1.72 (m, 5H), 1.52 (s, 6H), 0.93 (s, 9H); LC-MS (ES.sup.+):
m/z 940.30 [MH.sup.+] 126 ##STR00304##
(2S,4R)-1-[(2S)-2-{2-[4-(4-{4-[3-(4-
cyano-3-fluorophenyl)-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl]
phenyl}phenoxy)butoxy]acetamido}-
3,3-dimethylbutanoyl]-4-hydroxy-N-
{[4-(1,3-oxazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, DMSO) .delta. 8.60 (t, J = 6.0 Hz, 1H), 8.40
(s, 1H), 8.15 (d, J = 8.0 Hz, 1H), 7.85-7.78 (m, 3H), 7.67- 7.63
(m, 6H), 7.43-7.39 (m, 5H), 7.05 (d, J = 8.8 Hz, 2H), 5.16 (s, 1H),
4.58-4.56 (m, 1H), 4.47-4.26 (m, 4H), 4.08-4.05 (m, 2H), 3.97 (s,
2H), 3.66-3.55 (m, 4H), 2.06- 2.02 (m, 1H), 1.93-1.72 (m, 5H), 1.53
(s, 6H), 0.95 (s, 9H); LC-MS (ES.sup.+): m/z 944.50 [MH.sup.+] 127
##STR00305## (2S,4R)-1-[(2S)-2-(2-{4-[3-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-
4-oxo-2-sulfanylideneimidazolidin-1-
yl}phenyl)phenoxy]phenoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-
(4-methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.81 (s, 1 H), 8.14-8.05
(m, 2 H), 8.00-7.95 (m, 1 H), 7.75-7.69 (m, 2 H), 7.55-7.32 (m, 8
H), 7.20-7.15 (m, 1 H), 7.10-7.00 (m, 4 H), 6.99- 6.85 (m, 1 H),
4.68 (s, 1 H), 4.65-4.60 (m, 2 H), 4.63-4.55 (m, 1 H), 4.50-4.40
(m, 2 H), 4.30-4.20 (m, 1 H), 3.90-3.80 (m, 1H), 3.75- 3.65 (m, 1
H), 2.40 (s, 3 H), 2.25-2.21 (m, 1 H), 2.14-2.00 (m, 1 H), 1.55 (s,
6 H), 0.99 (s, 9 H); LC-MS (ES.sup.+): m/z, 1044.30 [MH.sup.+] 128
##STR00306## (2S,4R)-1-[(2S)-2-[2-(3-{[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-
4-oxo-2-sulfanylideneimidazolidin-1-
yl}phenyl)phenyl]methoxy}propoxy)
acetamido]-3,3-dimethylbutanoyl]-4-
hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2- carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 8.85 (s, 1H), 8.20 (m, 2H), 8.02 (d, J = 8.4
Hz, 1H), 7.80 (d, J = 7.6 Hz, 2H), 7.66 (d, J = 8.0 Hz, 2H), 7.48
(m, 6H), 7.39 (m, 2H), 4.71 (s, 1H), 4.61 (m, 5H), 4.34 (m, 1H),
4.01 (m, 2H), 3.84 (m, 2H), 3.72 (m, 4H), 2.45 (s, 3H), 2.25 (m,
1H), 2.12 (m, 1H), 1.97 (m, 2H), 1.62 (s, 6H), 1.02 (s, 9H); LC-MS
(ES.sup.+): m/z 1024.20 [MH.sup.+] 129 ##STR00307##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-
4-oxo-2-sulfanylideneimidazolidin-1-yl}
phenyl)phenoxy]-3-hydroxybutoxy}
acetamido)-3,3-dimethylbutanoyl]-4-
hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.82 (s, 1H), 8.20 (m, 2H), 8.03 (m, 1H), 7.74
(m, 2H), 7.60 (m, 2H), 7.48 (m, 6H), 7.07 (m, 2H), 4.74 (m, 1H),
4.60-4.53 (m, 3H), 4.37 (m, 1H), 4.21 (m, 1H), 4.08 (m, 4H),
3.92-3.88 (m, 1H), 3.83-3.75 (m, 3H), 2.48 (s, 3H), 2.26 (m, 1H),
2.14 (m, 2H), 1.87 (m, 1H), 1.62 (s, 6H), 1.03 (s, 9H); LC-MS
(ES.sup.+): m/z 1040.25 [MH.sup.+] 130 ##STR00308##
(2S,4R)-1-[(2S)-2-{2-[(2R)-4-[4-(4-{3-[4-
cyano-3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylidene-
imidazolidin-1-yl}phenyl)phenoxy]-2-
hydroxybutoxy]acetamido}-3,3-dimethyl-
butanoyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.84 (s, 1H), 8.18 (d, J
= 8.4 Hz, 2H), 8.04 (d, J = 8.4 Hz, 1H), 7.71 (s, J = 8.4 Hz, 2H),
7.57 (d, J = 8.8 Hz, 2H), 7.44 (m, 6H), 7.02 (d, J = 8.8 Hz, 2H),
4.71 (s, 1H), 4.56 (m, 3H), 4.33 (m, 1H), 4.17 (m, 2H), 4.05 (m,
3H), 3.75 (m, 2H), 3.65 (m, 2H), 2.44 (s, 3H), 2.22 (m, 1H), 2.08
(m, 2H), 1.90 (m, 1H), 1.60 (s, 6H), 1.05 (s, 9H); LC-MS
(ES.sup.+): m/z 1040.20 [MH.sup.+] 131 ##STR00309##
(2S,4R)-1-[(2S)-2-{2-[(2S)-4-[4-(4-{3-[4-
cyano-3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylidene-
imidazolidin-1-yl}phenyl)phenoxy]-2-
hydroxybutoxy]acetamido}-3,3-dimethyl-
butanoyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.84 (s, 1H), 8.18 (d, J
= 8.4 Hz, 2H), 8.04 (d, J = 8.4 Hz, 1H), 7.71 (s, J = 8.4 Hz, 2H),
7.57 (d, J = 8.8 Hz, 2H), 7.44 (m, 6H), 7.02 (d, J = 8.8 Hz, 2H),
4.71 (s, 1H), 4.56 (m, 3H), 4.33 (m, 1H), 4.17 (m, 2H), 4.05 (m,
3H), 3.90 (m, 1H), 3.83 (m, 1H), 3.60 (m, 2H), 2.44 (s, 3H), 2.22
(m, 1H), 2.08 (m, 2H), 1.90 (m, 1H), 1.60 (s, 6H), 1.05 (s, 9H);
LC-MS (ES.sup.+): m/z 1040.20 [MH.sup.+], 132 ##STR00310##
(2S,4R)-1-[(2S)-2-{2-[4-(4-{4-[3-(3-
chloro-4-cyanophenyl)-5,5-dimethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl]
phenyl}phenoxy)butoxy]acetamido}-
3,3-dimethylbutanoyl]-4-hydroxy-N-
[(1S)-1-[4-(1,3-oxazol-5-yl)phenyl] ethyl]pyrrolidine-2-carboxamide
.sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.22 (s, 1H), 7.97-7.95
(d, J = 8.4 Hz, 1H), 7.89-7.88 (d, J = 1.8 Hz, 1H), 7.75-7.58 (m,
7H), 7.47 (s, 1H), 7.43-7.38 (m, 4H), 7.06-7.01 (d, J = 14.1 Hz,
2H), 5.00 (m, 1H), 4.69 (s, 1H), 4.61-4.55 (m, 1H), 4.44 (s, 1H),
4.13-4.09 (t, J = 6.0 Hz, 2H), 4.02-4.00 (d, J = 6.0 Hz, 2H),
3.87-3.76 (m, 2H), 3.68-3.64 (m, 2H), 2.19-2.16 (m, 1H), 2.03-1.84
(m, 5H), 1.58 (s, 6H), 1.49-1.47 (d, J = 6.9 Hz, 3H) 1.04 (s, 9H);
LC-MS (ES.sup.+): m/z 974.20, 976.20 [MH.sup.+] 133 ##STR00311##
(2S,4R)-1-[(2S)-2-{2-[4-(4-{4-[3-(5-
chloro-4-cyano-2-fluorophenyl)-5,5- dimethyl-4-oxo-2-sulfanylidene-
imidazolidin-1-yl]phenyl}phenoxy) butoxy]acetamido}-3,3-dimethyl-
butanoyl]-4-hydroxy-N-{[4-(1,3-
oxazol-5-yl)phenyl]methyl}pyrrolidine- 2-carboxamide .sup.1H NMR
(300 MHz, CD.sub.3OD) .delta. 8.23 (s, 1H), 8.18-7.94 (m, 2H),
7.74-7.65 (m, 6H), 7.50-7.40 (m, 5H), 7.04-7.01 (d, J = 8.7 Hz,
2H), 4.71 (s, 1H), 4.60-4.56 (m, 3H), 4.53-4.34 (d, J = 15.2 Hz,
1H), 4.12-4.08 (m, 2H), 4.08-4.01 (m, 2H), 3.96-3.82 (m, 2H),
3.69-3.65 (m, 2H), 2.23-2.20 (m, 1H), 2.13-2.04 (m, 1H), 1.98-1.85
(m, 4H), 1.59 (s, 6H), 1.05 (s, 9H); LC-MS (ES.sup.+): m/z 978.26
[MH.sup.+] 134 ##STR00312## (2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-
cyano-3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylidene- imidazolidin-1-yl}phenyl)-2-
methylphenoxy]butoxy}acetamido)- 3,3-dimethylbutanoyl]-4-hydroxy-N-
{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]
methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz, DMSO):
.delta. 8.96 (s, 1H), 8.61 (m, 1H), 8.42 (d, J = 7.6 Hz, 1H), 8.33
(s, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.50 (d, J = 8.0 Hz, 2H), 7.43
(d, J = 10.4 Hz, 7H), 7.19 (d, J = 8.0 Hz, 1H), 6.83-6.89 (m, 2H),
5.17 (m, 1H), 4.59 (d, J = 9.6 Hz, 1H), 4.40-4.48 (m, 1H),
4.37-4.38 (m, 2H), 4.25-4.29 (m, 1H), 4.02-4.05 (m, 2H), 3.97 (s,
2H), 3.55-3.69 (m, 4H), 2.45 (s, 3H), 2.25 (s, 3H), 2.05-2.10 (m,
1H), 1.91-1.93 (m, 1H), 1.81-1.84 (m, 2H), 1.72-1.75 (m, 2H), 1.55
(s, 6H), 0.95 (s, 9H); LC-MS (ES.sup.+): m/z 1038.35 [MH.sup.+] 135
##STR00313## (2S,4R)-1-[(2S)-2-[2-(3-{[4-(4-{3-[4-
cyano-3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylidene- imidazolidin-1-yl}phenyl)phenyl]
carbamoyl}propoxy)acetamido]-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-
(4-methyl-1,3-oxazol-5-yl)phenyl] methyl}pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.19- 8.16 (d, J = 12.4
Hz, 2H), 8.13 (s, 1H), 8.04-8.01 (d, J = 10.8 Hz, 1H), 7.78- 7.75
(d, J = 11.2 Hz, 2H), 7.75-7.60 (m, 6H), 7.57-7.44 (m, 4H), 4.87
(s, 1H), 4.73- 4.57 (m, 3H), 4.52-4.37 (d, J = 15.2 Hz, 1H),
4.10-4.05 (m, 2H), 3.96- 3.83 (m, 2H), 3.70-3.66 (m, 2H), 2.59-
2.54 (t, J = 9.6 Hz, 2H), 2.36 (s, 3H), 2.24-2.22 (m, 1H),
2.17-2.04 (m, 3H), 1.05 (s, 6H), 1.03 (s, 9H); LC-MS (ES.sup.+):
m/z 1021.25 [MH.sup.+] 136 ##STR00314##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-
4-oxo-2-sulfanylideneimidazolidin-1-yl}
phenyl)-3-methylphenoxy]butoxy} acetamido)-3,3-dimethylbutanoyl]-4-
hydroxy-N-{[4-(4-methyl-1,3-thiazol-
5-yl)phenyl]methyl}pyrrolidine-2- carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 8.80 (s, 1H), 8.15-8.18 (m, 2H), 7.99-8.02 (m,
1H), 7.72 (d, J = 8.4 Hz, 2H), 7.38-7.47 (m, 8H), 6.98 (d, J = 8.8
Hz, 1H), 4.70 (s, 1H), 4.50-4.60 (m, 3H), 4.31-4.34 (m, 1H),
3.96-4.11 (m, 4H), 3.81-3.87 (m, 2H), 3.65-3.68 (m, 2H), 2.43 (s,
3H), 2.26 (m, 4H), 2.09 (m, 1H), 1.87-1.98 (m, 4H), 1.59 (s, 6H),
1.04 (s, 9H); LC-MS (ES.sup.+): m/z 1038.40 [MH.sup.+] 137
##STR00315## (2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-
4-oxo-2-sulfanylideneimidazolidin-1-yl}-
3-fluorophenyl)phenoxy]butoxy} acetamido)-3,3-dimethylbutanoyl]-4-
hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-
thiazol-5-yl)phenyl]ethyl]pyrrolidine-2- carboxamide .sup.1H NMR
(400 MHz, DMSO) .delta. 8.99 (s, 1H), 8.46-8.40 (m, 2H), 8.36 (s,
1H), 8.15 (d, J = 8.0 Hz, 1H), 7.78-7.67 (m, 4H), 7.45-7.35 (m,
6H), 7.09 (d, J = 8.8 Hz, 2H), 5.15 (s, 1H), 4.93-4.89 (m, 1H),
4.57 (d, J = 9.6 Hz, 1H), 4.46-4.39 (m, 1H), 4.30 (s, 1H),
4.11-4.08 (m, 2H), 3.96 (s, 2H), 3.60-3.56 (m, 4H), 2.46 (s, 3H),
2.07-2.03 (m, 1H), 1.84-1.74 (m, 5H), 1.62 (s, 3H), 1.50 (s, 3H),
1.38 (d, J = 6.8 Hz, 3H), 0.95 (s, 9H); LC-MS (ES.sup.+): m/z
1056.30 [MH.sup.+] 138 ##STR00316##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-
cyano-3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylidene- imidazolidin-1-yl}-3-fluorophenyl)
phenoxy]butoxy}acetamido)-3,3- dimethylbutanoyl]-4-hydroxy-N-[(1S)-
1-[4-(4-methyl-1,3-oxazol-5-yl) phenyl]ethyl]pyrrolidine-2-
carboxamide .sup.1H NMR (400 MHz, DMSO) .delta. 8.46- 8.40 (m, 2H),
8.36 (s, 1H), 8.31 (s, 1H), 8.15 (d, J = 8.4 Hz, 1H), 7.78-7.67 (m,
4H), 7.57-7.48 (m, 3H), 7.40-7.35 (m, 3H), 7.09 (d, J = 8.4 Hz,
2H), 5.15 (s, 1H), 4.93-4.89 (m, 1H), 4.57 (d, J = 9.2 Hz, 1H),
4.46-4.40 (m, 1H), 4.28 (s, 1H), 4.11-4.07 (m, 2H), 3.96 (s, 2H),
3.59- 3.56 (m, 4H), 2.35 (s, 3H), 2.07-2.03 (m, 1H), 1.84-1.73 (m,
5H), 1.62 (s, 3H), 1.51 (s, 3H), 1.39 (d, J = 6.4 Hz, 3H), 0.95 (s,
9H); LC-MS (ES.sup.+): m/z 1040.25 [MH.sup.+] 139 ##STR00317##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-
cyano-3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylidene- imidazolidin-1-yl}phenyl)-2-
methoxyphenoxy]butoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-
{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]
methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz, DMSO)
.delta. 8.96 (s, 1H), 8.61 (s, 1H), 8.41 (d, J = 8.4 Hz, 1H), 8.33
(s, 1H), 8.11 (d, J = 8.0 Hz, 1H), 7.83 (d, J = 8.4 Hz, 2H),
7.45-7.40 (m, 7H), 7.30-7.23 (m, 2H), 7.06 (d, J = 8.4 Hz, 1H),
5.17 (s, 1H), 4.57 (d, J = 9.2 Hz, 1H), 4.46-4.36 (m, 3H), 4.30-
4.28 (m, 1H), 4.06-4.03 (m, 2H), 3.96 (s, 2H), 3.86 (s, 3H),
3.67-3.56 (m, 4H), 2.44 (s, 3H), 2.08 (s, 1H), 1.85-1.75 (m, 5H),
1.55 (s, 6H), 0.95 (s, 9H); LC-MS (ES.sup.+): m/z 1054.25
[MH.sup.+] 140 ##STR00318## (2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-
cyano-3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylidene- imidazolidin-1-yl}phenyl)-3-
methoxyphenoxy]butoxy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-
{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]
methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz, DMSO)
.delta. 8.96 (s, 1H), 8.61 (s, 1H), 8.41 (d, J = 8.4 Hz, 1H), 8.33
(s, 1H), 8.12 (d, J = 1.6 Hz, 1H), 7.64 (d, J = 8.4 Hz, 2H),
7.43-7.37 (m, 7H), 7.28 (d, J = 8.4 Hz, 1H), 6.68- 6.61 (m, 2H),
5.17 (s, 1H), 4.57 (d, J = 9.6 Hz, 1H), 4.46-4.36 (m, 3H), 4.30-
4.28 (m, 1H), 4.06-4.03 (m, 2H), 3.96 (s, 2H), 3.86 (s, 3H),
3.67-3.56 (m, 4H), 2.44 (s, 3H), 2.08 (s, 1H), 1.85-1.75 (m, 5H),
1.56 (s, 6H), 0.95 (s, 9H); LC-MS (ES.sup.+): m/z 1054.25
[MH.sup.+] 141, 142 ##STR00319##
(2S,4R)-1-[(2S)-2-(2-{[(4S)-4-[4-(4-{3-
[4-cyano-3-trifluoromethyl)phenyl]-
5,5-dimethyl-4-oxo-2-sulfanylidene-
imidazolidin-1-yl}phenyl)phenoxy]
pentyl]oxy}acetamido)-3,3-dimethyl-
butanoyl]-4-hydroxy-N-{[4-(4-methyl-
1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
(2S,4R)-1-[(2S)-2-(2-{[(4R)-4-[4-
(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]- 5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1- yl}phenyl)phenoxy]pentyl]oxy}
acetamido)-3,3-dimethylbutanoyl]-4-
hydroxy-N-{[4-(4-methyl-1,3-thiazol-
5-yl)phenyl]methyl}pyrrolidine-2- carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.84 (s, 1H), 8.19-8.17 (d, J = 8.0 Hz, 2H),
8.04-8.02 (d, J = 8.4 Hz, 1H), 7.75-7.73 (d, J = 8.4 Hz, 2H),
7.60-7.58 (d, J = 8.4 Hz, 2H), 7.49-7.41 (m, 6H), 7.03- 7.01 (d, J
= 8.8 Hz, 2H), 4.87 (s, 1H), 4.73-4.58 (m, 4H), 4.50-4.39 (d, J =
15.2 Hz, 1H), 4.02-4.00 (m, 2H), 3.91- 3.88 (m 1H), 3.84-3.83 (m,
1H), 3.64- 3.62 (m, 2H), 2.46 (s, 3H), 2.25-2.23 (m, 1H), 2.13-2.11
(m, 1H), 1.86-1.78 (m, 4H), 1.62 (s, 6H), 1.37-1.34 (m, 3H), 1.12
(s, 9H); LC-MS (ES.sup.+): m/z 1038.15 [MH.sup.+] ##STR00320##
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.84 (s, 1H),
8.19-8.17 (d, J = 8.0 Hz, 2H), 8.04-8.02 (d, J = 8.4 Hz, 1H),
7.75-7.73 (d, J = 8.4 Hz, 2H), 7.60-7.58 (d, J = 8.4 Hz, 2H),
7.49-7.41 (m, 6H), 7.03- 7.01 (d, J = 8.8 Hz, 2H), 4.87 (s, 1H),
4.73-4.58 (m, 4H), 4.50-4.39 (d, J = 15.2 Hz, 1H), 4.02-4.00 (m,
2H), 3.91-3.88 (m, 1H), 3.84-3.83 (m, 1H), 3.64-3.62 (m, 2H), 2.46
(s, 3H), 2.25-2.23 (m, 1H), 2.13-2.11 (m, 1H), 1.86-1.78 (m, 4H),
1.62 (s, 6H), 1.37-1.34 (m, 3H), 1.12 (s, 9H); LC-MS (ES.sup.+):
m/z 1038.15 [MH.sup.+] 143 ##STR00321##
(2S,4R)-1-[(2S)-2-[2-(4-{[4-(4-{3-[4-cyano-
3-(trifluoromethyl)phenyl]-5,5-dimethyl-
4-oxo-2-sulfanylideneimidazolidin-1- yl}phenyl)phenyl]amino}butoxy)
acetamido]-3,3-dimethylbutanoyl]-4-
hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-
oxazol-5-yl)phenyl]ethyl]pyrrolidine-2- carboxamide .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.20- 8.17 (m, 3H), 8.03-8.01 (d, J =
8.1 Hz, 1H), 7.73-7.71 (d, J = 8.4 Hz, 2H), 7.70- 7.67 (d, J = 8.4
Hz, 2H), 7.63-7.61 (d, J = 8.4 Hz, 2H), 7.52-7.40 (m, 4H) 6.78-6.76
(d, J = 8.4 Hz, 2H), 5.02-5.00 (m, 1H), 4.87 (s, 1H), 4.62-4.60 (m,
1H), 4.58-4.56 (m, 1H), 4.07-4.00 (m, 2H), 3.88-3.85 (m, 1H),
3.87-3.77 (m, 1H), 3.65-3.63 (m, 2H), 3.23-3.22 (m, 2H), 2.41 (s,
3H), 2.24-2.22 (m, 1H), 1.97-1.96 (m, 1H), 1.80-1.70 (m, 4H), 1.61
(s, 6H), 1.49-1.48 (d, J = 4.4 Hz, 3H), 1.04 (s, 9H); LC-MS
(ES.sup.+): m/z 1021.25 [MH.sup.+] 144 ##STR00322##
(2S,4R)-1-[(2S)-2-[2-({5-[5-(4-{3-[4-
cyano-3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylidene- imidazolidin-1-yl}phenyl)pyridin-2-
yl]pentyl}oxy)acetamido]-3,3-dimethyl-
butanoyl]-4-hydroxy-N-{[4-(4-methyl-
1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide .sup.1H
NMR (400 MHz, CD.sub.3OD): .delta. 9.01 (s, 1 H), 8.89 (s, 1 H),
8.72-8.70 (m, 1 H), 8.21-8.18 (m, 2 H), 8.04-7.96 (m, 4 H),
7.65-7.47 (m, 2 H), 7.46-7.38 (m, 4 H), 4.73 (s, 1 H), 4.63-4.50
(m, 3 H), 4.41-4.37 (m, 1 H), 4.05-3.99 (m, 2 H), 3.89-3.85 (m, 1
H), 3.85-3.84m (m, 1 H), 3.63-3.60 (m, 2 H), 3.14-3.10 (m, 2 H),
2.45 (s, 3 H), 2.30-2.28 (m, 1 H), 2.15-2.03 (m, 1 H), 1.94-1.93
(m, 2 H), 1.78-1.76 (m, 2 H), 1.63-1.59 (m, 8 H), 1.01 (s, 9 H);
LC-MS (ES.sup.+): m/z 1023.45 [MH.sup.+] 145 ##STR00323##
(2S,4R)-1-[(2S)-2-[2-(4-{[4-(4-{3-[4-
cyano-3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylidene- imidazolidin-1-yl}phenyl)phenyl]
amino}butoxy)acetamido]-3,3- dimethylbutanoyl]-4-hydroxy-N-
[(1S)-1-[4-(4-methyl-1,3-thiazol- 5-yl)phenyl]ethyl]pyrrolidine-2-
carboxamide .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 8.95 (s, 1H),
8.19-8.16 (d, J = 8.7 Hz, 2H), 8.03-8.00 (d, J = 8.1 Hz, 1H),
7.87-7.82 (m, 4H), 7.53-7.37 (m, 8H), 5.01-4.99 (m, 1H), 4.87 (s,
1H), 4.70-4.68 (m, 1H), 4.56-4.54 (m, 1H), 4.08-4.05 (m, 2H),
3.83-3.80 (m, 2H), 3.70-3.59 (m, 2H), 3.52-3.47 (m, 2H), 2.48 (s,
3H), 2.24-2.22 (m, 1H), 1.98-1.89 (m, 5H), 1.61 (s, 6H), 1.61-1.60
(m, 1H), 1.56- 1.54 (m, 2H), 1.03 (s, 9H); LC-MS (ES.sup.+): m/z
1037.10 [MH.sup.+] 146 ##STR00324##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-
cyano-3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylidene- imidazolidin-1-yl}-3-fluorophenyl)
phenoxy]butanamido}acetamido)- 3,3-dimethylbutanoyl]-4-hydroxy-N-
{[4-(4-methyl-1,3-thiazol-5-yl)phneyl]
methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz, CD3OD)
.delta. 8.87 (s, 1H), 8.19 (m, 2H), 8.05 (m, 1H), 7.64 (d, J = 8.8
Hz, 2H), 7.59 (m, 2H), 7.49 (m, 3H), 7.41 (m, 2H), 7.04 (d, J = 8.8
Hz, 2H), 4.88 (s, 1H), 4.66 (m, 3H), 4.38 (m, 1H), 4.11 (m, 2H),
3.92 (m, 3H), 3.80 (m, 1H), 2.54 (m, 2H), 2.47 (s, 3H), 2.23-2.09
(m, 4H), 1.68 (s, 3H), 1.57 (s, 3H), 1.05 (s, 9H); LC-MS
(ES.sup.+): m/z 1055.10 [MH.sup.+] 147, 148 ##STR00325##
(2S,4R)-1-[(2S)-2-(2-{[(2S)-5-[4-(4-{3-
[4-cyano-3-(trifluoromethyl)phenyl]-
5,5-dimethyl-4-oxo-2-sulfanylidene-
imidazolidin-1-yl}phenyl)phenoxy] pentan-2-yl]oxy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-
(4-methyl-1,3-thiazol-5-yl)phenyl] methyl}pyrrolidine-2-carboxamide
(2S,4R)-1-[(2S)-2-(2-{[(2R)-5-[4-
(4-{3-[4-cyano-3-(trifluoromethyl) phenyl]-5,5-dimethyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl} phenyl)phenoxy]pentan-2-yl]oxy}
acetamido)-3,3-dimethylbutanoyl]- 4-hydroxy-4-N-{[4-(4-methyl-
1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide .sup.1H
NMR (400 MHz, CD.sub.3OD): .delta. 8.88 (s, 1H), 8.18-8.15 (m, 2H),
8.02-8.00 (d, J = 8.4 Hz, 1H), 7.72-7.70 (d, J = 8.8 Hz, 2H),
7.58-7.55 (d, J = 8.8 Hz, 2H), 7.47- 7.38 (m, 6H), 7.01-6.99 (d, J
= 4.8 Hz, 2H), 4.86 (s, 1H), 4.58-4.50 (m, 3H), 4.35-4.31 (m, 1H),
4.09-4.05 (m, 3H), 3.86-3.81 (m, 3H), 3.71-3.61 (m, 1H), 2.47 (s,
3H), 2.37-2.23 (m, 1H), 2.11- 2.09 (m, 1H), 2.02-1.87 (m, 2H),
1.84-1.68 (m, 2H), 1.59 (s, 6H), 1.26 (s, 3H), 1.02 (s, 9H); LC-MS
(ES.sup.+): m/z 1038.10 [MH.sup.+] .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 8.88 (s, ##STR00326## 1H), 8.18-8.15 (m, 2H),
8.02-8.00 (d, J = 8.4 Hz, 1H), 7.72-7.70 (d, J = 8.8 Hz, 2H),
7.58-7.55 (d, J = 8.8 Hz, 2H), 7.47-7.38 (m, 6H), 7.01-6.99 (d, J =
4.8 Hz, 2H), 4.87 (s, 1H), 4.70-4.50 (m, 3H), 4.36- 4.32 (m, 1H),
4.09-4.00 (m, 4H), 3.86-3.81 (m, 3H), 2.47 (s, 3H), 2.37-2.33 (m,
1H), 2.11-2.09 ( m, 1H), 2.00-1.85 (m, 2H), 1.84-1.68 (m, 2H), 1.58
(s, 5H), 1.23 (s, 3H), 1.01 (s, 9H); LC-MS (ES.sup.+): m/z 1038.10
[MH.sup.+] 149 ##STR00327## (2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[4-
cyano-3-(trifluoromethyl)phenyl]-5,5-
dimethyl-4-oxo-2-sulfanylidene- imidazolidin-1-yl}phenyl)-3-
fluorophenoxy]butoxy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-
(4-methyl-1,3-thiazol-5-yl)phenyl] methyl}pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD): 8.80 (s, 1H), 8.18-8.12 (m, 2
H), 8.00-7.95 (s, 1 H), 7.65-7.60 (m, 2 H), 7.45-7.35 (m, 7 H),
6.88-6.82 (m, 2 H), 4.65 (s, 1 H), 4.61-4.52 (s, 1 H), 4.50-4.35
(m, 2 H), 4.32-4.22 (s, 1 H), 4.18-4.02 (m, 2 H), 4.00-3.94 (m, 2
H), 3.95-3.75 (m 2 H), 3.74-3.55 (m, 2 H), 2.40 (m, 3 H), 2.28-
2.15 (s, 1 H), 2.14-2.01 (s, 1 H), 2.00- 1.72 (m, 4 H), 1.68-1.48
(m, 6 H), 1.00 (m, 9 H); LC-MS (ES.sup.+): m/z 1042.05
[MH.sup.+]
[0563] Examples 135, 143-145 were synthesized according to similar
procedures described for the synthesis of examples 103, by using
corresponding starting materials and intermediates.
Synthesis of Example 103
##STR00328## ##STR00329##
[0564] Step 1: Synthesis of tert-butyl
N-[4-(4-aminophenyl)phenyl]carbamate
##STR00330##
[0566] To a stirred solution of 4-(4-aminophenyl)aniline (15.0 g,
81.42 mmol) in a mixed solvent of
N,N-dimethylformamide/tetrahydrofuran/water (v/v/v=100/300/50 mL)
was added potassium carbonate (9.5 g, 68.74 mmol) and di-tert-butyl
dicarbonate (13.67 g, 62.63 mmol) at rt. The resulting mixture was
stirred for 5 h at rt. The reaction was then diluted by water (500
mL) and extracted with ethyl acetate (200 mL.times.3). The organic
layers were combined, washed with brine (50 mL.times.2), dried over
anhydrous sodium sulfate, and concentrated under reduced pressure
to give a crude residue which was purified by silica gel flash
chromatography (eluent: ethyl acetate/petroleum ether, v:v=1:2) to
provide the titled product (yield: 97%) as a yellow solid.
Step 2: Synthesis of tert-butyl
N-(4-{4-[(1-cyano-1-methylethyl)amino]phenyl}phenyl)carbamate
##STR00331##
[0568] To a stirred solution of tert-butyl
N-[4-(4-aminophenyl)phenyl]carbamate (7.0 g, 24.62 mmol) in acetone
(100 mL) under an atmosphere of nitrogen was added
trimethylsilanecarbonitrile (4.9 g, 49.49 mmol) drop wise at
0.degree. C., followed by addition of iodine (630.0 mg, 2.48 mmol)
in several batches at 0.degree. C. The resulting mixture was
stirred for 15 h at rt. The reaction was then quenched by the
addition of water (100 mL), and the resulting solution was
extracted with ethyl acetate (100 mL.times.2). The organic layers
were combined, washed with brine (70 mL.times.2), dried over
anhydrous sodium sulfate, and concentrated under reduced pressure
to give a crude residue which was purified by silica gel flash
chromatography (eluent: ethyl acetate/petroleum ether, v:v=1:3) to
provide the titled product (yield: 87%) as a yellow solid. Mass
(ES.sup.+): m/z 352.20 [MH.sup.+].
Step 3: Synthesis of tert-butyl
N-[4-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-4-imino-5,5-dimethyl-2-sul-
fanylideneimidazolidin-1-yl}phenyl)phenyl]carbamate
##STR00332##
[0570] To a stirred solution of tert-butyl
N-(4-{4-[(1-cyano-1-methylethyl)amino]phenyl}phenyl)carbamate (3.1
g, 8.82 mmol) in toluene (40.0 mL) was added
4-dimethylaminopyridine (1.6 g, 13.10 mmol) and
4-isothiocyanato-2-(trifluoromethyl)benzonitrile (2.0 g, 8.76 mmol)
at rt under an atmosphere of nitrogen. The resulting solution was
stirred for 12 h at 100.degree. C. in an oil bath. The reaction
mixture was then concentrated under reduced pressure to give a
crude residue which was purified by silica gel flash chromatography
(eluent: ethyl acetate/petroleum ether, v:v=1:1) to provide the
titled product (yield: 36%) as a yellow solid. Mass (ES.sup.+): m/z
580.30 [MH.sup.+].
Step 4: Synthesis of
4-{3-[4-(4-aminophenyl)phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazol-
idin-1-yl}-2-(trifluoromethyl)benzonitrile
##STR00333##
[0572] To a stirred solution of tert-butyl
N-[4-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-4-imino-5,5-dimethyl-2-sul-
fanylideneimidazolidin-1-yl}phenyl)phenyl]carbamate (2.0 g) in
methanol (20 mL) was added hydrogen chloride (3 N solution in
water, 5 mL) at rt. The resulting solution was stirred for 2 h at
70.degree. C. in an oil bath. The reaction mixture was then
concentrated under reduced pressure to remove the bulk of methanol.
To the resulting aqueous mixture was added sodium bicarbonate (sat.
aqueous solution) to adjust the pH to .about.8, and the resulting
mixture was extracted with ethyl acetate (80 mL.times.3). The
organic layers were combined, washed with brine (30 mL.times.2),
dried over anhydrous sodium sulfate, and concentrated under reduced
pressure to give a crude residue which was purified by silica gel
flash chromatography (eluent: ethyl acetate/petroleum ether,
v:v=1:2) to provide the titled product (yield: 45%) as a yellow
solid. Mass (ES.sup.+): m/z 481.15 [MH.sup.+].
Step 5: Synthesis of tert-butyl
2-(4-{[4-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-s-
ulfanylideneimidazolidin-1-yl}phenyl)phenyl]amino}butoxy)acetate
##STR00334##
[0574] To a stirred solution of
4-{3-[4-(4-aminophenyl)phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazol-
idin-1-yl}-2-(trifluoromethyl)benzonitrile (200.0 mg, 0.42 mmol) in
dichloromethane (10 mL) was added acetic acid (0.01 mL) and
tert-butyl 2-(4-oxobutoxy)acetate (93.0 mg, 0.46 mmol) at rt. The
resulting mixture was stirred for 10 min at rt, then to the mixture
was added sodium triacetoxyborohydride (124.0 mg, 0.59 mmol). The
resulting mixture was stirred overnight at rt. The reaction mixture
was diluted by water (30 mL), extracted with dichloromethane (20
mL.times.3). The organic layers were combined, washed with brine
(20 mL.times.2), dried over anhydrous sodium sulfate, and
concentrated under reduced pressure to give a crude residue which
was purified by silica gel flash chromatography (eluent: ethyl
acetate/petroleum ether, v:v=1:2) to provide the titled product
(yield: 36%). Mass (ES.sup.+): m/z 667.20[MH.sup.+].
Step 6: Synthesis of
2-(4-{[4-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-s-
ulfanylideneimidazolidin-1-yl}phenyl)phenyl]amino}butoxy)acetic
Acid
##STR00335##
[0576] To a stirred solution of tert-butyl
2-(4-{[4-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-s-
ulfanylideneimidazolidin-1-yl}phenyl)phenyl]amino}butoxy)acetate
(100.0 mg, 0.15 mmol) in dichloromethane (10 mL) was added
trifluoroacetic acid (2.0 mL) at rt. The resulting solution was
stirred for 2 h at rt. The reaction mixture was then concentrated
under reduced pressure to give a crude material (yield: 99% based
on crude) which was used for next step reaction without any further
purification. Mass (ES.sup.+): m/z 611.10[MH.sup.+]
Step 7: Synthesis of Example 103
[0577] This compound was synthesized from
2-(4-{[4-(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-s-
ulfanylideneimidazolidin-1-yl}phenyl)phenyl]amino}butoxy)acetic
acid and
(2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1-
,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide
hydrochloride, according to similar procedures in the last step
(amide coupling) described for the synthesis of example 75.
Synthesis of tert-butyl 2-(4-oxobutoxy) acetate
##STR00336##
[0579] To a stirred solution of tert-butyl
2-(4-hydroxybutoxy)acetate (1.0 g, 4.90 mmol) in dichloromethane
(10 mL) was added (1,1,1-triacetoxy)-1,1-dihydro-1,2-benziodoxol-3
(1H)-one (2.7 g, 6.37 mmol) at rt. The resulting mixture was
stirred for 12 h at rt. The reaction mixture was then diluted with
water (20 mL), extracted with ethyl acetate (20 mL.times.3). The
organic layers were combined, washed with brine (20 mL.times.2),
dried over anhydrous sodium sulfate, and concentrated under reduced
pressure to give a crude residue which was purified by silica gel
flash chromatography (eluent: ethyl acetate/petroleum ether,
v/v=1:2) to provide the titled product (yield: 50%) as colorless
oil. .sup.1H NMR (300 MHz, CD.sub.3OD) .delta. 9.68 (s, 1H), 3.95
(s, 2H), 3.48-3.45 (m, 2H), 2.51-2.50 (m, 2H), 1.81-1.63 (m, 2H),
1.42 (s, 9H).
TABLE-US-00008 TABLE 8 Exemplary Compounds. Ex # Structure Compound
name and Analytical data 150 ##STR00337##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{[5-(4-
{[trans-3-(3-chloro-4-cyanophenoxy)-
2,2,4,4-tetramethylcyclobutyl]carbamoyl}
phenoxy)pentyl]oxy}acetamido)butanoyl]-
4-hydroxy-N-{[4-(1,3-thiazol-5-yl)phenyl]
methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz, CDCl.sub.3):
.delta. 0.95 (s, 9H), 1.22 (s, 6H), 1.27 (s, 6H), 1.56-1.58 (m,
2H), 1.68-1.70 (m, 2H), 1.83-1.86 (m, 2H), 2.11-2.12 (m, 1H), 2.54
(br, 1H), 3.52- 3.63 (m, 3H), 3.91-4.16 (m, 7H), 4.28-4.54 (m, 5H),
4.70-4.71 (m, 1H), 6.19 (d, J = 6.8 Hz, 1H), 6.80-6.97 (m, 4H),
7.17 (d, J = 8.4 Hz, 1H), 7.32 (d, J = 6.8 Hz, 2H), 7.48-7.58 (m,
3H), 7.72-7.74 (m, 2H), 8.03-8.10 (m, 2H), 8.78 (br, 1H); LC-MS:
(ES.sup.+): m/z 941.20 [M + H.sup.+] 151 ##STR00338##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{[5-(4-
{[trans-3-(3-chloro-4-cyanophenoxy)-
2,2,4,4-tetramethylcyclobutyl]carbamoyl}
phenoxy)pentyl]oxy}acetamido)butanoyl]-
4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 8.67 (s, 1H), 7.72 (d, J = 9.0 Hz, 2H), 7.57
(d, J = 8.6 Hz, 1H), 7.31-7.38 (m, 4H), 7.20 (d, J = 9.0 Hz, 1H),
6.97 (d, J = 2.3 Hz, 1H), 6.92 (d, J = 8.6 Hz, 1H), 6.81 (dd, J =
2.5, 8.8 Hz, 1H), 6.19 (d, J = 8.2 Hz, 1H), 4.72 (t, J = 7.8 Hz,
1H), 4.47-4.58 (m, 3H), 4.31-4.41 (m, 1H), 3.87-4.18 (m, 7H), 3.73
(s, 1H), 3.58 (br. s., 2H), 3.54 (t, J = 6.5 Hz, 2H), 3.48 (s, 1H),
2.46-2.55 (m, 3H), 2.08-2.17 (m, 1H), 1.80-1.88 (m, 2H), 1.65-1.74
(m, 2H), 1.53-1.61 (m, 2H), 1.46 (s, 1H), 1.26 (br. s., 6H), 1.22
(s, 6H), 0.95 (s, 9H). LC- MS (ES.sup.+): m/z 955.42 [MH.sup.+] 152
##STR00339## (2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{[5-(4-
{[trans-3-(3-chloro-4-cyanophenoxy)-
2,2,4,4-tetramethylcyclobutyl]carbamoyl}
phenoxy)pentyl]oxy}actamido)butanoyl]-
4-hydroxy-N-{[4-(4-methyl-1,3-oxazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.85 (s, 1H), 7.72 (d, J = 8.6 Hz, 2H), 7.57
(d, J = 8.6 Hz, 1H), 7.52 (d, J = 8.2 Hz, 2H), 7.35 (d, J = 8.2 Hz,
3H), 7.20 (d, J = 8.6 Hz, 1H), 6.97 (d, J = 2.7 Hz, 1H), 6.92 (d, J
= 8.6 Hz, 2H), 6.81 (dd, J = 2.3, 8.6 Hz, 1H), 6.20 (d, J = 7.8 Hz,
1H), 4.70 (t, J = 7.8 Hz, 1H), 4.48-4.56 (m, 3H), 4.34 (dd, J =
5.3, 15.1 Hz, 1H), 4.12-4.16 (m, 1H), 4.04-4.09 (m, 2H), 4.01 (t, J
= 6.3 Hz, 2H), 3.85-3.97 (m, 2H), 3.63 (dd, J = 3.3, 11.2 Hz, 1H),
3.53 (t, J = 6.5 Hz, 2H), 2.49 (ddd, J = 4.7, 8.0, 13.1 Hz, 2H),
2.41 (s, 3H), 2.12 (dd, J = 8.2, 13.3 Hz, 1H), 1.80-1.86 (m, 2H),
1.65- 1.72 (m, 2H), 1.53-1.60 (m, 2H), 1.26-1.28 (m, 6H), 1.22 (s,
6H), 0.96 (s, 9H). LC- MS (ES.sup.+): m/z 940.44 [MH.sup.+], 153
##STR00340## (2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{[5-(4-
{[trans-3-(3-chloro-4-cyanophenoxy)-
2,2,4,4-tetramethylcyclobutyl]carbamoyl}
phenoxy)pentyl]oxy}acetamido)butanoyl]-
4-hydroxy-N-{[4-(1,3-oxazol-5-yl)phenyl]
methyl]pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.91 (s, 1H), 7.72 (d, J = 9.0 Hz, 2H), 7.54-7.57 (m, 2H),
7.34 (s, 3H), 7.21 (d, J = 8.6 Hz, 1H) 6.96 (d, J = 2.3 Hs, 1H),
6.92 (d, J = 9.0 Hz, 2H), 6.81 (dd, J = 2.5, 8.8 Hz, 1H), 6.21 (d,
J = 7.8 Hz, 1H), 4.69 (t, J = 8.0 Hz, 1H), 4.48-4.55 (m, 3H), 4.32
(dd, J = 5.3, 15.1 Hz, 1H), 4.15 (d, J = 7.8 Hz, 1H), 3.98-4.08 (m,
4H), 3.84-3.97 (m, 2H), 3.63 (dd, J = 3.5, 11.3 Hz, 1H), 3.53 (t, J
= 6.3 Hz, 2H), 2.40-2.57 (m, 4H), 2.11 (dd, J = 8.0, 13.5 Hz, 1H),
1.79-1.88 (m, 2H), 1.64- 1.73 (m, 2H), 1.51-1.60 (m, 2H), 1.27 (s,
6H), 1.22 (s, 6H), 0.96 (s, 9H). LC-MS (ES.sup.+): m/z 926.42
[MH.sup.+] 154 ##STR00341##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{[5-(4-
{[trans-3-[4-cyano-3-(trifluoro-
methyl)phenoxy]-2,2,4,4-tetramethyl-
phenoxy)pentyl]oxy}acetamido)butanoyl]-4-
hydroxy-N-{[4-(4-methyl-1,3-oxazol-5-yl)
phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.10 (s, 1 H), 7.90-7.83 (m, 1 H), 7.80-7.71
(m, 2 H), 7.60-7.52 (m, 2 H), 7.49-7.541 (m, 2 H), 7.32 (s, 1 H),
7.23-7.19 (m, 1 H), 7.00-6.89 (m, 2 H), 4.67 (s, 1 H), 4.60-4.40
(m, 3 H), 4.35- 4.25 (m, 2 H), 4.15-4.10 (m 1 H), 1.09-3.98 (m, 2
H), 3.97-3.90 (m, 2 H), 3.85- 3.70 (m, 2 H), 3.63-3.49 (m, 2 H),
2.40 (s, 3 H), 2.25-2.10 (m, 1 H), 2.09-2.00 (m, 1 H), 1.89-1.79
(m, 2 H), 1.80-1.45 (m, 4H), 1.33-1.14 (m, 12 H), 1.01 (s, 9 H);
LC-MS (ES.sup.+): m/z, 973.35 [MH.sup.+] 155 ##STR00342##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{[5-(4-
{[trans-3-[4-cyano-3-(trifluoromethyl)phenoxy]-
2,2,4,4-tetramethyl)phenoxy]-2,2,4,4-tetra-
methylcyclobutyl]carbamoyl}phenoxy)pentyl]
oxy}acetamido)butanyl]-4-hydroxy-N-{[4-(4-
methyl-1,3-thiazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (300 MHz, CD.sub.3OD): .delta. 8.84 (s, 1 H), 7.90-7.84
(m, 1 H), 7.80-7.70 (m, 2 H), 7.45-7.32 (m, 4 H), 7.26-7.22 (m, 1
H), 7.28- 7.20 (m, 1 H), 7.00-6.89 (m, 2 H), 4.67 (s, 1 H),
4.60-4.50 (m, 1 H), 4.46-4.40 (m, 1 H), 4.27-4.20 (m, 2 H), 4.13
(s, 1 H), 4.15-4.00 (m 2 H), 3.99-3.93 (m, 2 H), 3.90- 3.80 (m, 2
H), 3.59-3.51 (m, 2 H), 2.40 (s, 3 H), 2.25-2.10 (m, 1 H),
2.11-2.00 (m, 1 H), 1.85-1.75 (m, 2 H), 1.70-1.50 (m, 4 H),
1.33-1.14 (m, 12 H), 1.01 (s, 9 H); LC- MS (ES.sup.+): m/z, 989.30
[MH.sup.+] 156 ##STR00343##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{[5-(4-
{[trans-3-(3-chloro-4-cyanophenoxy)-
2,2,4,4-tetramethylcyclobutyl]carbamoyl}
phenoxy)pentyl]oxy}acetamido)butanoyl]-
4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-
oxazol-5-yl)phenyl]ethyl]pyrrolidine-2- carboxamide .sup.1H NMR
(300 MHz, CD.sub.3OD): .delta. 8.14 (s, 1 H), 7.85-7.80 (m, 2 H),
7.78-7.72 (m, 1 H), 7.65-7.55 (m, 2 H), 7.47-7.40 (m, 2 H), 7.15-
7.10 (m, 1 H), 7.15-6.95 (m, 3 H), 5.03- 4.94 (m, 1 H), 4.67 (s, 1
H), 4.60-4.50 (m, 1 H), 4.46-4.40 (m, 1 H), 4.27-4.25 (m, 1 H),
4.15-4.00 (m, 3 H), 3.99-3.95 (m, 2 H), 3.90-3.80 (m, 1 H),
3.79-3.80 (m, 1 H), 3.63-3.49 (m, 2 H), 2.40 (s, 3 H), 2.25-2.10
(m, 1 H), 2.09-1.80 (m, 3 H), 1.79-1.50 (m, 4 H), 1.48-1.46 (m, 3
H), 1.33-1.14 (m, 12 H), 1.01 (s, 9 H); LC-MS (ES.sup.+): m/z,
953.35 [MH.sup.+] 157 ##STR00344##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{[5-(4-
{[trans-3-(3-chloro-4-cyanophenoxy)-
2,2,4,4-tetramethylcyclobutyl]carbamoyl}
phenoxy)pentyl]oxy}acetamido)butanoyl]-
4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-
thiazol-5-yl)phenyl]ethyl]pyrrolidine-2- carboxamide .sup.1H NMR
(400 MHz, CD.sub.3OD): .delta. 8.90 (s, 1 H), 7.85-7.00 (m, 3 H),
7.50-7.39 (m, 4 H), 7.15-7.10 (s, 1 H), 7.06-6.95 (m, 3 H), 5.05-
4.98 (m, 1 H), 4.70 (s, 1 H), 4.65-4.52 (m, 1 H), 4.48-4.40 (m, 1
H), 4.30 (s, 1 H), 4.15-4.10 (m, 3 H), 4.00 (m, 2 H), 4.02- 3.70
(m, 2 H), 3.70-3.58 (m, 2 H), 2.50 (m, 3 H), 2.45-2.35 (m, 1 H),
2.28-2.15 (m, 1 H), 2.08-1.82 (m, 4 H), 1.80-1.45 (m, 7 H),
1.39-1.20 (m, 12 H), 1.10-1.00 (m, 9H); LC-MS (ES.sup.+): m/z
969.50 [MH.sup.+] 158, 159 ##STR00345##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{[(2R)-6-(4-
{[trans-3-(3-chloro-4-cyanophenoxy)-
2,2,4,4-tetramethylcyclobutyl]carbamoyl}
phenoxy)hexan-2-yl]oxy}acetamido)
butanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-
thiazol-5-yl)phenyl]methyl}pyrrolidine-2- carboxamide
(2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{[(2S)-
6-(4-{[trans-3-(3-chloro-4-cyanophenoxy)-
2,2,4,4-tetramethylcyclobutyl]carbamoyl}
phenoxy)hexan-2-yl]oxy}acetamido)butanoyl]-
4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide ##STR00346## 160, 161
##STR00347## (2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{[(5S)-5-
(4-{[trans-3-(3-chloro-4-cyanophenoxy)-
2,2,4,4-tetramethylcyclobutyl]carbamoyl}
phenoxy)hexyl]oxy}acetamido)butanoyl]-4-
hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)
phenyl]methyl}pyrrolidine-2-carboxamide
(2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{[(5R)-5-
(4-{[trans-3-(3-chloro-4-cyanophenoxy)-
2,2,4,4-tetramethylcyclobutyl]carbamoyl}
phenoxy)hexyl]oxy}acetamido)butanoyl]-4-
hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)
phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.88 (s, 1H), 7.75-7.67 (m, 3 H), 7.44-7.36
(m, 4 H), 7.09 (s, 1 H), 6.96-6.91 (m, 3 H), 4.84 (s, 1 H),
4.66-4.47 (m, 4 H), 4.36-4.31 (m 1 H), 4.26 (s, 1 H), 4.24 (s, 1
H), 4.10 (s, 1 H), 3.93-3.91 (m, 2 H), 3.83-5.78 (m, 2 H),
3.55-3.51 (m, 2 H), 2.43 (s, 3 H), 2.12-2.10 (m, 1 H), 2.09-1.95
(m, 1 H), 1.67-1.62 (m, 6 H), 1.30-1.28 (m, 9 H), 1.18 (s, 6 H),
1.00 (s, 9 H); LC-MS (ES.sup.+): m/z 969.10 [MH.sup.+] .sup.1H NMR
(300 MHz, CD.sub.3OD): .delta. 8.88 (s, 1H), 7.75-7.67 (m, 3 H),
7.44-7.36 (m, 4 H), 7.10 (s, 1 H), 6.96-6.91 (m, 3 H), 4.66 (s, 1
H), 4.58-4.48 (m, 4 H), 4.35-4.03 (m, 1 H), 4.24 (s, 1 H), 4.10 (s,
1 H), 3.92-3.86 (m, 2 H), 3.83-5.55 (m, 2 H), 3.53-3.51 (m, 2 H),
2.43 (s, 3 H), 2.20-2.10 (m, 1 H), 2.09- ##STR00348## 2.01 (m, 1
H), 1.67-1.62 (m, 6 H), 1.30 (s, 9 H), 1.19 (s, 6 H), 1.00 (s, 9
H); LC-MS (ES.sup.+): m/z 969.15 [MH.sup.+]
Synthesis of Example 150
##STR00349##
[0580] Step 1: Synthesis of methyl
4-{[5-({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(1,3-thiazol-5-yl)phenyl]methyl-
}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}methoxy-
)pentyl]oxy}benzoate
##STR00350##
[0582] To a stirred solution of
2-({5-[4-(methoxycarbonyl)phenoxy]pentyl}oxy)acetic acid (200 mg),
(2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(1,3-thiazo-
l-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide hydrogen chloride
salt (149 mg, 0.32 mmol), N-ethyl-N-isopropylpropan-2-amine (185
mg, 1.44 mmol) in anhydrous N,N-dimethylformamide (5 mL) was added
HATU (2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate) (203 mg, 0.54 mmol) at 0.degree. C. The
resulting mixture was allowed to warm up to rt and stirred at rt
for 20 min. TLC and LC-MS showed formation of the desired product.
The mixture was partitioned between ethyl acetate (100 mL) and
water (50 mL). The organic layer was collected, washed with brine
(50 mL), dried over anhydrous sodium sulfate, and concentrated
under reduced pressure to give a crude residue which was purified
by silica gel flash chromatography (eluent 2% methanol in methylene
dichloride) to afford the titled product (yield 25%, 2 steps) as a
white solid. Mass: (ES.sup.+): m/z 695.30 [M+H.sup.+].
Step 2: Synthesis of
4-{[5-({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(1,3-thiazol-5-yl)phenyl]methyl-
}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}methoxy-
)pentyl]oxy}benzoic Acid
##STR00351##
[0584] To a stirred solution of methyl
4-{[5-({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(1,3-thiazol-5-yl)phenyl]methyl-
}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}methoxy-
)pentyl]oxy}benzoate (150 mg, 0.22 mmol) in a mixed solvents of
tetrahydrofuran (4 mL)-water (2 mL)-methanol (1 ml) was added
lithium hydroxide monohydrate (36 mg, 0.86 mmol) at rt. The
resulting mixture was stirred at 35.degree. C. overnight. TLC and
LC-MS showed formation of the desired product. The reaction mixture
was acidified with aqueous HCl (3N) to pH=3-4 and extracted with
methylene dichloride (50 mL.times.2). The organic layers were
combined, washed with brine, dried over Na.sub.2SO.sub.4 and
concentrated to afford the titled product (110 mg, crude) as a
white solid which was used for next step without further
purification. Mass: (ES.sup.+): m/z 681.20 [M+H.sup.+].
Step 3: Synthesis of Example 150
##STR00352##
[0586] To a stirred mixture of
4-{[5-({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(1,3-thiazol-5-yl)phenyl]methyl-
}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}methoxy-
)pentyl]oxy}benzoic acid (110 mg, 0.16 mmol),
2-chloro-4-[trans-3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrile
hydrogen chloride salt (50 mg, 0.16 mmol),
N-ethyl-N-isopropylpropan-2-amine (77 mg, 0.64 mmol) in anhydrous
N,N-dimethylformamide (4 mL) was added HATU
((2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate)) (68 mg, 0.18 mmol) at 0.degree. C. The
resulting mixture was allowed to warm up to rt and stirred at rt
for 20 min. TLC and LC-MS showed formation of the desired product.
The reaction mixture was partitioned between ethyl acetate (100 mL)
and water (40 mL). The organic phase was separated, washed with
brine (50 mL), dried over anhydrous sodium sulfate, and
concentrated under reduced pressure to give a crude residue which
was purified by preparative TLC (eluent: 5% methanol in methylene
dichloride) to afford the titled product (yield 25%, 2 steps) as a
white solid.
Synthesis of 2-({5-[4-(methoxycarbonyl)phenoxy]pentyl}oxy)acetic
Acid
##STR00353##
[0587] Step 1: Synthesis of tert-butyl
2-{[5-(benzyloxy)pentyl]oxy}acetate
##STR00354##
[0589] To a stirred mixture of 5-(benzyloxy)pentan-1-ol (10 g, 51.5
mmol), tert-butyl 2-bromoacetate (40.2 g, 206 mmol) and tetrabutyl
ammonium chloride (14.2 g, 51.5 mmol) in methylene dichloride (60
mL) was added sodium hydroxide (40 ml, 35% in water) at rt, and the
resulting mixture was stirred at rt for 16 h. The reaction mixture
was then partitioned between methylene dichloride (200 mL) and
water (100 mL). The organic layer was collected and washed with
brine (50 mL), dried over anhydrous sodium sulfate, and
concentrated under reduced pressure to give a crude residue which
was purified by silica gel flash chromatography (eluent: 5% ethyl
acetate in hexane) to afford tert-butyl
2-{[5-(benzyloxy)pentyl]oxy}acetate (yield 31.6%) as light yellow
oil. LC-MS: (ES.sup.+): m/z 331.10 [M+Na.sup.+], .sup.1H NMR (400
MHz, CDCl.sub.3): .delta. 1.48 (s, 9H), 1.63-1.67 (m, 6H),
3.46-3.53 (m, 4H), 4.10 (s, 2H), 4.50 (s, 2H), 7.28-7.34 (m,
5H).
Step 2: Synthesis of tert-butyl 2-[(5-hydroxypentyl)oxy]acetate
##STR00355##
[0591] To a stirred solution of tert-butyl
2-{[5-(benzyloxy)pentyl]oxy}acetate (5 g, 16.2 mmol) in ethanol
(100 ml) under a nitrogen atmosphere was added palladium on carbon
(10%, 600 mg) at rt. The resulting mixture was stirred at
50.degree. C. overnight under hydrogen atmosphere (hydrogen
balloon). TLC showed formation of desired product. Palladium on
carbon was removed through filtration and washed with ethyl acetate
(50 mL). The filtrate was concentrated under reduced pressure to
afford tert-butyl 2-[(5-hydroxypentyl)oxy]acetate (2.5 g, crude) as
colorless oil which was used in next step without further
purification.
Step 3: Synthesis of tert-butyl
2-({5-[(4-methylbenzenesulfonyl)oxy]pentyl}oxy)acetate
##STR00356##
[0593] To a stirred solution of tert-butyl
2-[(5-hydroxypentyl)oxy]acetate (2.5 g, crude) and triethylamine
(3.5 g, 34.5 mmol) in anhydrous methylene dichloride (50 mL) was
added a solution of 4-toluenesulfonyl chloride (2.7 g, 13.8 mmol)
in anhydrous methylene dichloride (8 mL) drop wise at 0.degree. C.
The reaction mixture was allowed to warm up to rt and stirred at rt
overnight. TLC showed formation of desired product. The mixture was
quenched with aqueous solution of potassium carbonate (1N, 50 mL)
at rt and extracted with ethyl acetate (50 mL.times.3). The organic
layers were combined, washed with brine (50 mL), dried over
anhydrous sodium sulfate, and concentrated under reduced pressure
to give a crude residue which was purified by silica gel flash
chromatography (eluent: 1% methanol in methylene dichloride) to
afford tert-butyl
2-({5-[(4-methylbenzenesulfonyl)oxy]pentyl}oxy)acetate (yield
35.1%) as colorless oil. Mass: (ES.sup.+): m/z 395.10
[MNa.sup.+].
Step 4: Synthesis of methyl
4-({5-[2-(tert-butoxy)-2-oxoethoxy]pentyl}oxy)benzoate
##STR00357##
[0595] To a stirred mixture of tert-butyl
2-({5-[(4-methylbenzenesulfonyl)oxy]pentyl}oxy)acetate (1.0 g, 2.7
mmol) and potassium carbonate (266 mg, 1.6 mmol) in acetonitrile
(15 mL) was added methyl 4-hydroxybenzoate (500 mg, 3.29 mmol) at
rt. The resulting mixture was refluxed overnight. TLC showed
formation of desired product. The reaction mixture was cooled to
rt, and partitioned between ethyl acetate (150 mL) and water (50
mL). The organic layer was washed with washed with brine (50 mL),
dried over anhydrous sodium sulfate, and concentrated under reduced
pressure to give a crude residue which was purified by silica gel
flash chromatography (eluent 10% ethyl acetate in hexane) to afford
methyl 4-({5-[2-(tert-butoxy)-2-oxoethoxy]pentyl}oxy)benzoate
(yield 33%) as colorless oil. Mass (ES.sup.+): m/z 353.10
[M+Na.sup.+]; .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 1.48 (s,
9H), 1.55-1.61 (m, 2H), 1.68-1.72 (m, 2H), 1.80-1.87 (m, 2H), 3.55
(t, J=6.4 Hz, 2H), 3.88 (s, 3H), 3.96 (s, 2H), 4.02 (t, J=6.4 Hz,
2H), 6.89 (d, J=9.2 Hz, 2H), 7.97 (d, J=9.2 Hz, 2H).
Step 5: Synthesis of
2-({5-[4-(methoxycarbonyl)phenoxy]pentyl}oxy)acetic Acid
##STR00358##
[0597] To a stirred solution of methyl
4-({5-[2-(tert-butoxy)-2-oxoethoxy]pentyl}oxy)benzoate (300 mg,
0.85 mmol) in DCM (4 mL) was added and TFA (2 ml) at rt, the
resulting solution was stirred at room temperature for 1 h. TLC
showed formation of the desired product. The solvent was evaporated
to afford 2-({5-[4-(methoxycarbonyl)phenoxy]pentyl}oxy)acetic acid
(200 mg, crude) as yellow oil which was used in next step without
further purification.
[0598] Examples 151-157 were synthesized according to similar
procedure described for synthesis of example 150, by using
corresponding starting materials and intermediates.
TABLE-US-00009 TABLE 9 Exemplary Compounds. Ex # Structure Compound
name and Analytical data 162 ##STR00359##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-
{2-[4-(4-{[trans-3-(3-chloro-4-cyanophenoxy)- 2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenoxy)
butoxy]ethoxy}acetamido)butanoyl]-4-
hydroxy-N-{[4-(1,3-thiazol-5-yl)phenyl]methyl}
pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz, CDCl.sub.3):
.delta. 0.95 (s, 9H), 1.22 (s, 6H), 1.27 (s, 6H), 1.74-1.80 (m,
4H), 2.09-2.14 (m, 1H), 2.53-2.60 (m, 1H), 3.54-3.69 (m, 8H),
3.99-4.05 (m, 5H), 4.12-4.16 (m, 2H), 4.28-4.33 (m, 1H), 4.46-4.58
(m, 3H), 4.72 (t, J = 8.0 Hz, 1H), 6.20 (d, J = 8.0 Hz, 1H),
6.79-6.97 (m, 4H), 7.26-7.33 (m, 3H), 7.49 (d, J = 8.0 Hz, 2H),
7.57 (d, J = 8.8 Hz, 1H), 7.72 (d, J = 8.4 Hz, 2H), 8.03 (s, 1H),
8.78 (s, 1H). LC- MS: (ESI.sup.+): m/z 971.20 [M + H].sup.+ 163
##STR00360## (2S,4R)-1-[(2S)-3,3-dimethyl-2-{2-[4-(4-
{[trans-3-(3-chloro-4-cyanophenoxy)-
2,2,4,4-tetramethylcyclobutyl]carbamoyl}
phenoxy)butoxy]acetamideo}butanoyl]-4-
hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)
phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.85 (s, 1 H), 7.75-7.81 (m, 2 H), 7.72 (d,
J = 9.00 Hz, 1 H), 7.44-7.50 (m, 2 H), 7.38-7.43 (m, 2 H), 7.13 (d,
J = 2.35 Hz, 1 H), 6.94-7.02 (m, 3 H), 4.70 (s, 1 H), 4.54-4.61 (m,
2 H), 4.48-4.54 (m, 2 H), 4.36 (d, J = 15.65 Hz, 1 H), 4.28 (s, 1
H), 4.14 (s, 1 H), 4.10 (t, J = 6.06 Hz, 2 H), 4.01 (d, J = 7.43
Hz, 2 H), 3.85-3.90 (m, 1 H), 3.77-3.84 (m, 1 H), 3.64 (t, J = 6.26
Hz, 2 H), 2.45 (s, 3 H), 2.24 (dd, J = 13.30, 7.43 Hz, 1 H), 2.09
(ddd, J = 13.21, 9.10, 4.30 Hz, 1 H), 1.89-1.98 (m, 2 H), 1.80-1.88
(m, 2 H), 1.28 (s, 6 H), 1.22 (s, 6 H), 0.99- 1.06 (m, 9 H); LC-MS
(ES.sup.+): m/z 941.41 [MH.sup.+] 164 ##STR00361##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-{2-[4-(4-
{[trans-3-(3-chloro-4-cyanophenoxy)-
2,2,4,4-tetramethylcyclobutyl]carbamoyl}
phenoxy)butoxy]acetamido}butanoyl]-4-
hydroxy-N-{[4-(4-methyl-1,3-oxazol-5-yl)
phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 8.12 (s, 1 H), 7.75-7.81 (m, 2 H), 7.72 (d,
J = 9.00 Hz, 1 H), 7.56-7.64 (m, 2 H), 7.47 (d, J = 8.61 Hz, 2 H),
7.13 (d, J = 2.35 Hz, 1 H), 6.95-7.03 (m, 3 H), 4.70 (s, 1 H),
4.56-4.61 (m, 1 H), 4.55 (s, 1 H), 4.46-4.53 (m, 2 H), 4.35 (d, J =
15.65 Hz, 1 H), 4.28 (s, 1 H), 4.12-4.15 (m, 1 H), 4.06-4.12 (m, 2
H), 3.98-4.03 (m, 2 H), 3.85-3.92 (m, 1 H), 3.78-3.84 (m, 1 H),
3.65 (t, J = 6.06 Hz, 2 H), 2.38 (s, 3 H), 2.19-2.28 (m, 1 H), 2.08
(ddd, J = 13.30, 9.19, 4.50 Hz, 1 H), 1.91-1.98 (m, 2 H), 1.82-1.89
(m, 2 H), 1.28 (s, 6H), 1.22 (s, 6 H), 1.04 (s, 9 H); LC-MS
(ES.sup.+): m/z 925.43 [MH.sup.+] 165 ##STR00362##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-{2- [4-(4-{[trans-3-[4-cyano-3-
(trifluoromethyl)phenoxy]-2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenoxy)
butoxy]acetamido}butanoyl]-4-hydroxy-
N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]
methyl}pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz, CD.sub.3OD):
.delta. 8.88 (s, 1H), 7.75-7.67 (m, 3 H), 7.44-7.36 (m, 4 H), 7.09
(s, 1 H), 6.96-6.91 (m, 3 H), 4.84 (s, 1 H), 4.66-4.47 (m, 4 H),
4.36-4.31 (m, 1 H), 4.26 (s, 1 H), 4.24 (s, 1 H), 4.10 (s, 1 H),
3.93-3.91 (m, 2 H), 3.83-5.78 (m, 2 H), 3.55-3.51 (m, 2 H), 2.43
(s, 3 H), 2.12-2.10 (m, 1 H), 2.09-1.95 (m, 1 H), 1.67-1.62 (m, 6
H), 1.30-1.28 (m, 9 H), 1.18 (s, 6 H), 1.00 (s, 9 H); LC-MS
(ES.sup.+): m/z 969.10 [MH.sup.+] 166 ##STR00363##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-{2-[4- (4-{[trans-3-[4-cyano-3-
(trifluoromethyl)phenoxy]-2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenoxy)
butoxy]acetamido}butanoyl]-4-hydroxy-
N-{[4-(4-methyl-1,3-oxazol-5-yl)phenyl]methyl}
pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz, CD.sub.3OD): 8.09
(s, 1H), 7.89 (d, 1 H), 7.80-7.70 (m, 2 H), 7.69- 7.50 (m, 2 H),
7.49-7.40 (m, 2 H), 7.32 (s, 1 H), 7.28-7.08 (m, 1 H), 7.00-6.82
(m, 2 H), 4.72 (s, 1 H), 4.60-4.40 (m, 3 H), 4.39-4.20 (m, 2 H),
4.19-4.00 (m, 3 H), 3.99- 3.95 (m, 2 H), 3.92-3.70 (m, 2 H),
3.69-3.53 (m, 2 H), 2.40-2.32 (m, 3 H), 2.30-2.18 (m, 1 H),
2.15-2.01 (m, 1 H), 2.00-1.60 (m, 4 H), 1.35-1.28 (m, 6 H),
1.25-1.15 (m, 6 H), 1.03-1.00 (m, 9 H); LC-MS (ES.sup.+): m/z
959.60 [MH.sup.+]. 167 ##STR00364##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-{2-[4-
(4-{[trans-3-(3-chloro-4-cyanophenoxy)-
2,2,4,4-tetramethylcyclobutyl]carbamoyl}
phenoxy)butoxy]acetamido}butanoyl]-4-
hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-
thiazol-5-yl)phenyl]ethyl]pyrrolidine-2- carboxamide .sup.1H NMR
(400 Mhz, CD.sub.3OD): 8.82 (s, 1H), 7.81-7.75 (m, 2 H), 7.74-7.62
(s, 1 H), 7.61-7.53 (m, 2 H), 7.49-7.35 (m, 2 H), 7.19-7.10 (s, 1
H), 7.08-6.80 (m, 3 H), 5.08- 4.91 (m, 1 H), 4.65 (s, 1 H),
4.60-4.59 (m, 1 H), 4.45-4.36 (m, 1 H), 4.22 (s, 1 H), 4.11-4.05
(m, 3 H), 4.01-3.96 (m, 2 H), 3.95-3.70 (m, 2 H), 3.69-3.45 (m, 2
H), 2.40- 2.35 (m, 3 H), 2.21-2.04 (m, 1 H), 2.00-1.70 (m, 4 H),
1.60-1.40 (m, 3 H), 1.21-1.12 (m, 12 H), 1.00-0.95 (m, 9 H); LC-MS
(ES.sup.+): m/z 478.45 [(M/2)H.sup.+] 168 ##STR00365##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-{2-[4-(4-
{[trans-3-(3-chloro-4-cyanophenoxy)-
2,2,4,4-tetramethylcyclobutyl]carbamoyl}
phenoxy)butoxy]acetamido}butanoyl]-4-
hydroxy-N-[(1S)-1-{4-(4-methyl-1,3-
oxazol-5-yl)phenyl]ethyl]pyrrolidine-2- carboxamide .sup.1H NMR
(400 MHz, CD.sub.3O): 8.82 (s, 1H), 7.81-7.75 (m, 2 H), 7.74-7.62
(s, 1 H), 7.61-7.53 (m, 2 H), 7.49-7.35 (m, 2 H), 7.19-7.10 (s, 1
H), 7.08-6.80 (m, 3 H), 5.08- 4.91 (m, 1 H), 4.65 (s, 1 H),
4.60-4.59 (m, 1 H), 4.45-4.36 (m, 1 H), 4.22 (s, 1 H), 4.11-4.05
(m, 3 H), 4.01-3.96 (m, 2 H), 3.95-3.70 (m, 2 H), 3.69-3.45 (m, 2
H), 2.40- 2.35 (m, 3 H), 2.21-2.04 (s, 1 H), 2.00-1.70 (m, 4 H),
1.60-1.40 (m, 3 H), 1.21-1.12 (m, 12 H), 1.00-0.95 (m, 9 H); LC-MS
(ES.sup.+): m/z 478.45 [MH.sup.+] 169 ##STR00366##
(2S,4R)-N-[(4-chlorophenyl)methyl]-1-[(2S)-
3,3-dimethyl-2-{2-[4-(4-{[trans-3-(3-
chloro-4-cyanophenoxy)-2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenoxy)
butoxy]acetamido}butanoyl]-4- hydroxypyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 7.80 (d, J = 8.61 Hz,
2 H), 7.72 (d, J = 9.00 Hz, 1 H), 7.24-7.37 (m, 4 H), 7.13 (d, J =
2.35 Hz, 1 H), 6.94-7.04 (m, 3 H), 4.69 (s, 1 H), 4.54 (dd, J =
8.80, 7.63 Hz, 1 H), 4.43-4.51 (m, 2 H), 4.24-4.32 (m, 2 H), 4.08-
4.16 (m, 3 H), 3.95-4.06 (m, 2 H), 3.84-3.90 (m, 1 H), 3.76-3.83
(m, 1 H), 3.65 (t, J = 6.26 Hz, 2 H), 2.21 (dd, J = 13.11, 7.63 Hz,
1 H), 2.06 (ddd, J = 13.30, 9.19, 4.50 Hz, 1 H), 1.90-1.98 (m, 2
H), 1.80-1.89 (m, 2 H), 1.28 (s, 6 H), 1.22 (s, 6 H), 0.95- 1.15
(m, 9 H); LC-MS (ES+): m/z 878.28 [MH+] 170 ##STR00367##
(2S,4R)-N-[(4-cyanophenyl)methyl]-
1-[(2S)-3,3-dimethyl-2-{2-[4-(4-{[trans-3-(3-
chloro-4-cyanophenoxy)-2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenoxy)
butoxy]acetamido}butanoyl]-4- hydroxypyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 7.80 (d, J = 8.61 Hz,
2 H), 7.72 (d, J = 8.61 Hz, 1 H), 7.64 (d, J = 8.22 Hz, 2 H), 7.54
(d, J = 8.22 Hz, 2 H), 7.13 (d, J = 2.35 Hz, 1 H), 6.94-7.05 (m, 3
H), 4.69 (s, 1 H), 4.49-4.62 (m, 4 H), 4.34 (d, J = 16.04 Hz, 1 H),
4.29 (s, 1 H), 4.08-4.17 (m, 3 H), 3.95-4.06 (m, 2 H), 3.85-3.91
(m, 1 H), 3.80 (dd, J = 11.5, 3.72 Hz, 1 H), 3.65 (t, J = 6.06 Hz,
2 H), 2.23 (dd, J = 13.11, 7.63 Hz, 1 H), 2.06 (ddd, J = 13.11,
9.19, 4.30 Hz, 1 H), 1.90-1.99 (m, 2 H), 1.81-1.90 (m, 2 H), 1.28
(s, 6 H), 1.22 (s, 6 H), 0.92-1.18 (m, 9 H); LC-MS (ES.sup.+): m/z
869.32 [MH.sup.+] 171 ##STR00368##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-{2-[4-(4-
{[trans-3-(3-chloro-4-cyanophenoxy)-
2,2,4,4-tetramethylcyclobutyl]carbamoyl}
phenoxy)butoxy]acetamido}butanoyl]-4-
hydroxy-N-[(1R)-1-[4-(4-methyl-1,3-thiazol-
5-yl)phenyl]ethyl]pyrrolidine-2- carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.85 (s, 1 H), 7.79 (m, 3H), 7.58 (d, J = 8.4
Hz, 2H), 7.42 (d, J = 8.0 Hz, 2H), 7.15 (s, 1 H), 7.01 (m, 3H),
5.00 (m, 1H), 4.69 (m, 2H), 4.53 (s, 1H), 4.30 (s, 1H), 4.16 (s,
1H), 4.13 (m, 2H), 4.01 (s, 2H), 3.91-3.85 (m, 1H), 3.85-3.78 (m,
1H), 3.65 (m, 2H), 2.46 (s, 3H), 2.30-2.19 (m, 1H), 2.18-2.05 (m,
1H), 1.99-1.92 (m, 2H), 1.89-1.82 (m, 2H), 1.53 (m, 3H), 1.30 (s,
6H), 1.24 (s, 6H), 0.92 (s, 9H); Mass (ES.sup.+): m/z 955.45
[MH.sup.+]
Synthesis of Example 163
##STR00369##
[0599] Step 1: synthesis of methyl
4-[4-({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)pheny-
l]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl-
}methoxy)butoxy]benzoate
##STR00370##
[0601] To a stirred solution of
2-{4-[4-(methoxycarbonyl)phenoxy]butoxy}acetic acid (22.0 mg, 77.9
.mu.mol) and
(2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-m-
ethyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide
hydrochloride (36.3 mg, 77.9 .mu.mol) in methylene chloride (2.0
me) was added O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
tetrafluoroborate (25.0 mg, 77.9 .mu.mol) and diisopropylethylamine
(40.5 .mu.L, 233 .mu.mol) at rt. The reaction mixture was stirred
at rt for 30 minutes, LC-MS indicated formation of the desired
product. The reaction mixture was concentrated under reduced
pressure. The crude material was purified by flash silica gel
chromatography on a Teledyne Combiflash ISCO (gradient eluent:
Heptane/Acetone (v:v=100:0 to 0:100)) to give the titled product
(yield: 78%) as a white solid. LC-MS (ES.sup.+): m/z 695.3138
[MH.sup.+].
Step 2: Synthesis of
4-[4-({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)pheny-
l]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl-
}methoxy)butoxy]benzoic Acid
##STR00371##
[0603] To a stirred solution of methyl
4-[4-({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)pheny-
l]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl-
}methoxy)butoxy]benzoate (42.4 mg, 61.0 .mu.mol) in methanol (2.0
mL) was added 1 M NaOH in water (0.5 mL, 12.5 mmol) at rt. The
reaction mixture was stirred at rt for 16 hours. LC-MS indicated
formation of the desired product. The reaction mixture was quenched
with 1.0 M aqueous HCl and then concentrated under reduced pressure
to remove the methanol. The aqueous residue was extracted with
EtOAc (15 mL.times.2). The organic layer was washed with brine (5
mL), dried over Na.sub.2SO.sub.4, filtered and concentrated under
reduced pressure to give the titled product (yield: 82%) as a white
solid. The material was used in next step without any further
purification. Mass (ES.sup.+): m/z 681.2986 [MH.sup.+].
Step 3: Synthesis of Example 163
[0604] To a stirred solution of
2-chloro-4-[trans-3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrile
(13.9 mg, 50.2 .mu.mol) and
4-[4-({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)pheny-
l]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl-
}methoxy)butoxy]benzoic acid (34.2 mg, 50.2 .mu.mol) in methylene
chloride (2.0 mL) was added
O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
tetrafluoroborate (16.1 mg, 50.2 .mu.mol) and diisopropylethylamine
(26.0 .mu.L, 150 .mu.mol) at rt. The reaction mixture was stirred
at rt for 1.5 hours. LC-MS indicated formation of the desired
product. The reaction mixture was quenched with water (5 mL) and
extracted with DCM (15 mL.times.3). The organic layers were
combined, washed with aqueous NaHCO.sub.3 (5 mL), brine (5 mL),
dried over Na.sub.2SO.sub.4, filtered and concentrated under
reduced pressure to give a crude material, which was purified by
flash silica gel chromatography on a Teledyne Combiflash ISCO
(eluent: DCM/MeOH (v:v=90:10)) to give the titled product (yield:
39%) as an off white solid.
Synthesis of 2-{4-[4-(methoxycarbonyl)phenoxy]butoxy}acetic
Acid
##STR00372##
[0605] Step 1: synthesis of tert-butyl
2-{4-[(4-methylbenzenesulfonyl)oxy]butoxy}acetate
##STR00373##
[0607] This material was synthesized from tert-butyl
2-(4-hydroxybutoxy)acetate and 4-toluenesulfonyl chloride according
to similar procedures described above for the synthesis of
tert-butyl
2-({5-[(4-methylbenzenesulfonyl)oxy]pentyl}oxy)acetate.
Step 2: synthesis of methyl
4-{4-[2-(tert-butoxy)-2-oxoethoxy]butoxy}benzoate
[0608] To a stirred mixture of methyl 4-hydroxybenzoate (27.99 mg,
184.0 .mu.mol) and tert-butyl
2-{4-[(4-methylbenzenesulfonyl)oxy]butoxy}acetate in acetonitrile
(2.0 mL) was added potassium carbonate (34.67 mg, 250.9 .mu.mol) at
rt. The reaction mixture was then stirred at 80.degree. C. for 16
hours. LC-MS indicated formation of the desired product. The
reaction mixture was concentrated under reduced pressure to give a
crude residue, which was purified by flash silica gel
chromatography on a Teledyne Combiflash ISCO (gradient eluent:
heptane/acetone (v:v=100:0 to 50:50)) to give the titled product
(yield: 94%) as a clear oil. Mass (ES.sup.+): m/z 361.16
[M+Na].
Step 3: Synthesis of Synthesis of
2-{4-[4-(methoxycarbonyl)phenoxy]butoxy}acetic Acid
[0609] To a stirred solution of methyl
4-{4-[2-(tert-butoxy)-2-oxoethoxy]butoxy}benzoate (53.1 mg, 156
.mu.mol) in dichloromethane (1.0 mL) was added trifluoroacetic acid
(1.0 mL, 12.9 mmol) at rt. The reaction mixture was then stirred at
rt for 30 minutes. LC-MS indicated formation of the desired
product. The reaction mixture was concentrated under reduced
pressure to give the titled product (yield: 99% based on crude
material) as an off white solid. The crude material was then used
in next step without any further purification. Mass (ES.sup.+): m/z
305.10.
[0610] Examples 162, 164-171 were synthesized according to similar
procedure described for synthesis of example 163, by using
corresponding starting materials and intermediates.
TABLE-US-00010 TABLE 10 Exemplary Compounds Ex# Structure Compound
name and Analytical data 172 ##STR00374##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-[2-({5-[(4-
{[trans-3-(3-chloro-4-cyanophenoxy)- 2,2,4,4-tetramethyl-
cyclobutyl]carbamoyl}phenyl)amino]
pentyl}oxy)acetamido]butanoyl]-4-hydroxy-
N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]
methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.68 (s, 1H), 7.63 (d, J = 8.6 Hz, 2H), 7.57 (d, J = 8.6
Hz, 1H), 7.35 (q, J = 8.5 Hz, 4H), 6.97 (d, J = 2.3 Hz, 1H), 6.81
(dd, J = 2.5, 8.8 Hz, 1H), 6.60 (d, J = 9.0 Hz, 2H), 6.07-6.12 (m,
1H), 4.74 (s, 1H), 4.50-4.59 (m, 3H), 4.37 (d, J = 5.1 Hz, 1H),
4.11-4.17 (m, 2H), 3.64 (dd, J = 3.5, 11.3 Hz, 1H), 3.53 (d, J =
7.0 Hz, 2H), 3.19 (t, J = 7.0 Hz, 2H), 2.55-2.61 (m, 1H), 2.52 (s,
3H), 2.10-2.19 (m, 2H), 1.65-1.71 (m, 4H), 1.50-1.53 (m, 2H),
1.24-1.33 (m, 9H), 1.22 (s, 6H), 0.96 (s, 9H), 0.86-0.91 (m, 3H).
LC-MS (ES.sup.+): m/z 955.43 [MH.sup.+] 173 ##STR00375##
(2S,4R)-1-[(2S)-3,3-dimethyl-4-[2-({5-[(4-
{[trans-3-(3-chloro-4-cyanophenoxy)- 2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenyl)
amino]pentyl}oxy)acetamido]butanoyl]-4-
hydroxy-N-{[4-(4-methyl-1,3-oxazol-5-yl)
phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. 7.82 (s, 1H), 7.63 (d, J = 8.6 Hz, 2H), 7.53
(d, J = 8.6 Hz, 2H), 7.35 (s, 2H), 7.18-7.21 (m, 1H), 6.97 (d, J =
2.3 Hz, 1H), 6.81 (dd, J = 2.3, 8.6 Hz, 1H), 6.59 (d, J = 8.6 Hz,
2H), 6.08-6.12 (m, 1H), 4.73 (t, J = 8.0 Hz, 1H), 4.49-4.60 (m,
3H), 4.32-4.39 (m, 1H), 4.11-4.17 (m, 2H), 3.63 (dd, J = 3.5, 11.3
Hz, 1H), 3.49- 3.57 (m, 2H), 3.18 (t, J = 6.8 Hz, 2H), 2.53- 2.61
(m, 1H), 2.42 (s, 3H), 2.08-2.18 (m, 2H), 1.68 (td, J = 7.2, 14.5
Hz, 4H), 1.50-1.53 (m, 2H), 1.26 (d, J = 0.8 Hz, 9H), 1.22 (s, 6H),
0.96 (s, 9H), 0.86-0.91 (m, 3H). LC-MS (ES.sup.+): m/z 939.46
[MH.sup.+] 174 ##STR00376##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-[2-({5-[(4-
{[trans-3-(3-chloro-4-cyanophenoxy)- 2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenyl)
amino]pentyl}oxy)acetamido]butanoyl]-4-
hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-
5-yl)phenyl]ethyl]pyrrolidine-2- carboxamide .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.88 (s, 1 H), 7.80-7.65 (m, 3 H), 7.50-7.33
(m, 4 H), 7.16 (s, 1H), 7.03-6.93 (m, 1 H), 6.54-6.43 (m, 2 H),
5.02-4.95 (m, 1 H), 4.67 (s, 1 H), 4.65-4.50 (m, 1 H), 4.46-4.40
(m, 1 H), 4.29-4.25 (m, 1 H), 4.20-4.15 (m, 1 H), 4.04- 3.90 (m, 2
H), 3.89-3.85 (m, 1 H), 3.80-3.73 (m, 1 H), 3.66-3.52 (m, 2H),
3.20-3.10 (m, 2 H), 2.40 (s, 3 H), 2.25-1.95 (m, 1 H), 2.02-1.90
(m, 1 H), 1.80-1.68 (m, 4 H), 1.65-1.50 (m, 2 H), 1.49-1.43 (m,
2H), 1.30-1.23 (m, 6 H), 1.22-1.15 (m, 6 H), 1.01 (s, 9 H); LC-MS
(ES.sup.+): m/z, 968.40 [MH.sup.+] 175 ##STR00377##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{4-[(4-
{[trans-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenyl)
amino]butoxy}acetamido)butanoyl]- 4-hydroxy-
N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]
methyl}pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz, CD.sub.3OD):
.delta. 8.88 (s, 1 H), 7.750-7.65 (m, 3 H), 7.50-7.33 (m, 4 H),
7.10-7.05 (m, 1H), 6.99-6.90 (m, 1 H), 6.54-6.43 (m, 2 H), 4.67 (s,
1 H), 4.60-4.50 (m, 3 H), 4.48-4.45 (m, 1 H), 4.21 (s, 1 H),
4.13-4.05 (m, 1 H), 3.98-3.90 (m, 2 H), 3.88- 3.70 (m, 2 H),
3.66-3.48 (m, 2 H), 3.20-3.03 (m, 2 H), 2.40 (s, 3 H), 2.25-2.12
(m, 1 H), 2.09-1.99 (m, 1 H), 1.80-1.68 (m, 4 H), 1.30-1.10 (m, 12
H), 1.01 (s, 9 H); LC-MS (ES.sup.+): m/z, 940.15 [MH.sup.+] 176
##STR00378## (2S,4R)-1-[(2S)-2-{2-({5-[(2-fluoro-4-{[trans-
3-(3-chloro-4-cyanophenoxy)-2,2,4,4-
tetramethylcyclobutyl]carbamoyl}
phenyl)-methyl-pentyl}oxy)acetamido]-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4- methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (300 MHz,
CD.sub.3OD): .delta. 8.86 (s, 1 H), 7.80-7.70 (m, 1 H), 7.60-7.55
(m, 1 H), 7.50-7.37 (m, 4H), 7.14 (s, 1 H), 7.00-6.93 (m, 1 H),
6.80-6.65 (m, 1 H), 4.70 (s, 1 H), 4.65-4.50 (m, 3 H), 4.40-4.30
(m, 1 H), 4.29-4.25 (m, 1 H), 4.20-4.15 (m, 1 H), 4.04- 3.90 (m, 2
H), 3.89-3.85 (m, 1 H), 3.80-3.73 (m, 1 H), 3.70-3.65 (m, 1 H),
3.60-3.52 (m, 2H), 3.30-3.15 (m, 2 H), 2.40 (s, 3 H), 2.25-1.95 (m,
1 H), 2.02-1.90 (m, 1 H), 1.80-1.68 (m, 4 H), 1.65-1.50 (m, 2 H),
1.30-1.23 (m, 6 H), 1.22-1.15 (m, 6 H), 1.01 (s, 9 H); LC-MS
(ES.sup.+): m/z, 972.10 [MH.sup.+] 177 ##STR00379##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{4-[(4-
{[trans-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenyl)
amino]butoxy}acetamido)butanoyl]-4-
hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-
5-yl)phenyl]ethyl]pyrrolidine-2- carboxamide .sup.1H NMR (400 MHz,
CD3OD) .delta. 8.86 (s, 1H), 7.72-7.64 (m, 3H), 7.44 (s, 4H), 7.12
(s, 1H), 6.98 (d, J = 2.4 Hz, 1H), 6.64 (d, J = 8.8 Hz, 2H), 5.00
(d, J = 6.8 Hz, 1H), 4.69 (s, 1H), 4.62-4.58 (m, 1H), 4.44 (s, 1H),
4.28 (s, 1H), 4.12 (s, 1H), 4.00-3.93 (m, 2H), 3.87-3.75 (m, 2H),
3.65-3.59 (m, 2H), 3.21 (s, 2H), 2.47 (s, 3H), 2.27-2.15 (m, 1H),
1.95 (m, 1H), 1.76 (s, 4H), 1.58-1.49 (m, 3H), 1.26 (d, J = 9.6 Hz,
12H), 1.02 (s, 9H); Mass (ES.sup.+): m/z 955.20 [MH.sup.+] 178
##STR00380## (2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{4-[(4-
{[trans-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenyl)
amino]butoxy}acetamido)butanoyl]-4-
hydroxy-N-[(1R)-1-[4-(4-methyl-1,3-
thiazol-5-yl)phenyl]ethyl]pyrrolidine-2- carboxamide .sup.1H NMR
(400 MHz, DMSO) .delta. 8.96 (s, 1H), 8.49 (d, J = 7.6 Hz, 1H),
7.90 (d, J = 8.8 Hz, 1H), 7.63 (d, J = 8.4 Hz, 2H), 7.51 (d, J =
8.0 Hz, 2H), 7.42-7.21 (m, 4H), 7.20 (s, 1H), 7.00 (d, J = 8.8 Hz,
1H), 6.55 (d, J = 8.8 Hz, 2H), 6.19 (s, 1H), 5.16 (s, 1H), 4.89 (s,
1H), 4.56-4.47 (m, 2H), 4.36-4.40 (m, 2H), 4.03 (d, J = 9.2 Hz,
1H), 3.94 (s, 2H), 3.67-3.57 (m, 2H), 3.56-3.50 (m, 2H), 3.07 (s,
2H), 2.44 (s, 3H), 2.08-2.01 (m, 1H), 1.98-1.92 (m, 1H), 1.64 (m,
4H), 1.38 (d, J = 6.8 Hz, 3H), 1.20 (s, 6H), 1.11 (s, 6H), 0.91 (s,
9H); Mass (ES.sup.+): m/z 954.15 [MH.sup.+].
Synthesis of Example 172
##STR00381## ##STR00382##
[0611] Step 7: Synthesis of Example 172
[0612] TBTU (21.5 mg, 0.067 mmol) was added to a solution of
4-{[5-({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phen-
yl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoy-
l}methoxy)pentyl]amino}benzoic acid (31 mg, 0.044 mmol),
2-chloro-4-[trans-3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrile
(12.4 mg, 0.044 mmol) in DMF (3.0 mL) and DIPEA (15.4 .mu.L, 0.089
mmol) at rt. The resulting reaction mixture was stirred at rt for 1
hr. LC-MS indicated formation of the desired product. The reaction
mixture was diluted with EtOAc (30 mL), washed with water (15
mL.times.2), brine (15 mL.times.1), filtered through a Biotage
universal phase separator and then concentrated under reduced
pressure to give a crude residue, which was purified by silica gel
chromatography on a Teledyne Combiflash ISCO system eluting with
MeOH/DCM (v/v=0:100 to 10:90) to yield the desired title product
(yield: 41%).
Step 6: Synthesis of
4-{[5-({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phen-
yl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoy-
l}methoxy)pentyl]amino}benzoic Acid
##STR00383##
[0614] Lithium hydroxide (9.0 mg, 0.38 mmol) was added to a
solution of methyl
4-{[5-({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5--
yl)phenyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]c-
arbamoyl}methoxy)pentyl]amino}benzoate (96 mg, 0.14 mmol) in a
mixed solvent of THF/water/methanol (v/v/v=1/1/1, 2.00 mL) at rt.
The resulting mixture was stirred at rt overnight. Aqueous HCl (1
N) was added to the reaction mixture to adjust pH to .about.3. The
resulting mixture was diluted with EtOAc (30 mL), washed with brine
(15 mL.times.2), dried over sodium sulfate, filtered through a
Biotage Universal Phase Separator and then concentrated under
reduced pressure to give a crude product, which was used for next
step without any further purification. LC-MS (ES.sup.+): m/z
694.33[MH.sup.+].
Step 5: Synthesis of methyl
4-{[5-({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phen-
yl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoy-
l}methoxy)pentyl]amino}benzoate
##STR00384##
[0616] TBTU (81.5 mg, 0.25 mmol) was added to a solution of
2-[(5-{[4-(methoxycarbonyl)phenyl]amino}pentyl)oxy]acetic acid
(50.0 mg, 0.17 mmol),
(2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1-
,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (72.8 mg,
0.17 mmol) in DMF (3.0 mL) and DIPEA (59 .mu.L, 0.34 mmol) at rt.
The resulting mixture was stirred at rt for 1 h. The reaction
mixture was diluted with EtOAc (30 mL), washed with water (15
mL.times.2), brine (15 mL.times.1), dried over sodium sulfate,
filtered through a Biotage universal phase separator and then
concentrated under reduced pressure to give a crude residue, which
was purified by silica gel chromatography on a Teledyne Combiflash
ISCO system eluting with MeOH/DCM (v/v=0:100 to 10:90) to yield the
titled product (yield: 51%, 2 steps). LC-MS (ES.sup.+): m/z 708.35
[MH.sup.+].
Step 4: Synthesis of
2-[(5-{[4-(methoxycarbonyl)phenyl]amino}pentyl)oxy]acetic Acid
##STR00385##
[0618] Trifluoroacetic acid (2.63 mL, 34.5 mmol) was added to a
solution of methyl
4-{[5-(2-methoxy-2-oxoethoxy)pentyl]amino}benzoate (270 mg, 0.7682
mmol) in DCM (3.00 ml) at rt. The resulting mixture was stirred at
45.degree. C. for 2 h. The reaction mixture was then concentrated
under reduced pressure to give a crude product, which was used for
next step without any further purification. LC-MS (ES.sup.+): m/z
296.15 [MH.sup.+].
Step 3: Synthesis of methyl
4-({5-[2-(tert-butoxy)-2-oxoethoxy]pentyl}amino)benzoate
##STR00386##
[0620] To a solution of tert-butyl 2-[(5-oxopentyl)oxy]acetate (269
mg, 1.24 mmol) and methyl 4-aminobenzoate (187 mg, 1.24 mmol) in
dichloroethane (5.00 mL) was added acetic acid (199 .mu.L, 2.48
mmol) and sodium triacetoxyborohydride (394 mg, 1.86 mmol) at rt.
The reaction mixture was stirred at rt for 18 h. NaOH (1N solution
in water) was then added to neutralize the acetic acid, the
resulting reaction mixture was extracted with DCM (100 mL.times.3).
The organic layers were combined, dried over anhydrous sodium
sulfate and concentrated under reduced pressure to give a crude
residue, which was purified by silica gel chromatography on a
Teledyne Combiflash ISCO system eluting with MeOH/DCM (v/v=0:100 to
15:85) to yield the desired title product (yield: 62%). LC-MS
(ES.sup.+): m/z 352.21 [MH.sup.+]
Step 2: Synthesis of tert-butyl 2-[(5-oxopentyl)oxy]acetate
##STR00387##
[0622] To a solution of tert-butyl 2-(hex-5-en-1-yloxy)acetate
(300.0 mg, 1.40 mmol) in acetone (15.00 ml) were added potassium
osmate(VI) dihydrate (15.5 mg, 0.042 mmol), follow by NMO (491.9
mg, 4.20 mmol) in water (4.5 ml) at rt. The resulting reaction
mixture was stirred for 18 h at rt. The reaction was monitored by
TLC (EtOAc/Heptane, v/v=25/75). Sodium periodate (898.2 mg, 4.20
mmol) was then added to the reaction mixture, the reaction was
stirred at rt for another 3 h. The reaction mixture was diluted
with water (10 mL) and DCM (100 mL). The organic layer was
separated and the aqueous layer was extracted with DCM (100
mL.times.3). The combined organic layers were washed with brine (10
mL.times.2) and then passed through a Universal Biotage Phase
Separator and concentrated under reduced pressure to give a crude
residue, which was purified by silica gel chromatography on a
Teledyne Combiflash ISCO system eluting with EtOAc/Heptane
(v/v=0:100 to 50:50) to yield the titled product (yield 90%).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.75 (t, J=1.8 Hz, 1H),
3.89-3.93 (m, 2H), 3.51 (t, J=6.1 Hz, 2H), 2.47 (dt, J=1.6, 7.2 Hz,
2H), 1.69-1.78 (m, 2H), 1.64 (d, J=8.2 Hz, 2H), 1.46 (s, 9H).
Step 1: Synthesis of tert-butyl 2-(hex-5-en-1-yloxy)acetate
##STR00388##
[0624] Tetrabutylammonium hydrogen sulfate (677.7 mg, 2.0 mmol) was
added to a mixture of sodium hydroxide (23.9 g, 599 mmol) in water
(20.0 mL) and toluene (20.00 ml) at 20.degree. C. To this mixture
was added hex-5-en-1-ol (2.00 g, 20.0 mmol), the resulting mixture
was stirred at 20.degree. C. for 1 h. The reaction was then cooled
to 5.degree. C. and tert-butyl 2-bromoacetate (20.0 mmol, 3.89 g)
was added slowly while maintaining the internal temperature below
15.degree. C. The reaction mixture was then stirred at rt for
additional 16 h. The mixture was diluted with heptane (30 mL) and
washed with water (20 mL). The organic phase was dried over
anhydrous sodium sulfate, filtered and concentrated under reduced
pressure to give a crude residue, which was purified by silica gel
chromatography on a Teledyne Combiflash ISCO system (gradient
eluent: EtOAc/Heptane, v/v=0/100 to 25/75) to afford the desired
product (33%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 5.75-5.87
(m, 1H), 4.82-5.10 (m, 2H), 3.95 (s, 2H), 3.52 (t, J=6.7 Hz, 2H),
2.08 (d, J=7.0 Hz, 2H), 1.57-1.69 (m, 2H), 1.45-1.53 (m, 11H).
LC-MS (ES.sup.+): m/z 237.14 [MNa.sup.+]
[0625] Examples 173-178 were synthesized according to similar
procedure described for synthesis of example 172, by using
corresponding starting materials and intermediates.
[0626] Alternatively, steps 5-7 of example 174 is synthesized as
following:
Step 7: synthesis of
(2S,4R)-1-((S)-2-(2-((5-((4-((trans-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-t-
etramethylcyclobutyl)carbamoyl)phenyl)amino)pentyl)oxy)acetamido)-3,3-dime-
thylbutanoyl)-4-hydroxy-N--((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)py-
rrolidine-2-carboxamide
##STR00389##
[0628] A solution of
4-((5-(2-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)ph-
enyl)
ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-
-2-oxoethoxy)pentyl) amino)benzoic acid (1.17 g, 1.65 mmol) in
methylene chloride (10 mL) was charged with HATU (688 mg, 1.81
mmol) and diisopropylethylamine (859 .mu.L, 4.94 mmol). The
reaction mixture was allowed to stir at room temperature for 10
minutes, then
4-(trans-3-amino-2,2,4,4-tetramethylcyclobutoxy)-2-chlorobenzonitrile
hydrochloride (545 mg, 1.73 mmol) was added. The reaction mixture
was stirred at room temperature for 30 minutes. The reaction
mixture was diluted with DCM (30 mL), then washed with water (10
mL), brine (10 mL), dried over Na2SO4, filtered and concentrated
under reduced pressure. The crude material was purified by silica
gel chromatography on a Teledyne Combiflash ISCO eluting with
DCM/MeOH (100:0 to 90:10 to yield the desired product as a white
solid (0.86 g, 54%). LC-MS (ES+): m/z 968.42 [MH+].
Step 6: synthesis of
4-((5-(2-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)ph-
enyl)
ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-
-2-oxoethoxy)pentyl) amino)benzoic Acid
##STR00390##
[0630] A solution of methyl
4-((5-(2-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)ph-
enyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)--
2-oxoethoxy)pentyl)amino)benzoate (1.2 g, 1.66 mmol) in methanol (5
mL) was charged with 3 M NaOH (2.0 mL, 50.0 mmol). The reaction
mixture was allowed to stir at room temperature for 72 hours. The
reaction mixture was quenched with 1.0 M HCl and then concentrated
under reduced pressure to remove the methanol. The aqueous was
extracted with EtOAc (25 mL.times.3). The combined organic layers
were washed with brine (15 mL), dried over Na2SO4, filtered and
concentrated under reduced pressure. The crude material was
purified by silica gel chromatography on a Teledyne Combiflash ISCO
eluting with DCM/MeOH (100:0 to 90:10) to yield the desired product
as a white solid (1.17 g, 100%). LC-MS (ES+): m/z 708.32 [MH+].
Step 5: Synthesis of methyl
4-((5-(2-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)ph-
enyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)--
2-oxoethoxy)pentyl)amino)benzoate
##STR00391##
[0632] A solution of
2-((5-((4-(methoxycarbonyl)phenyl)amino)pentyl)oxy)acetic acid
(1.68 g, 5.68 mmol) and
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N--((S)-1-(4-(4-me-
thylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide
hydrochloride (2.73 g, 5.68 mmol) in methylene chloride (15 mL) was
charged with O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
tetrafluoroborate (1.82 g, 5.68 mmol) and diisopropylethylamine
(2.95 mL, 17.0 mmol). The reaction mixture was allowed to stir at
rt for 30 minutes. The reaction mixture was quenched with water (15
mL) and then extracted with DCM (15 mL). The organic layer was
washed with brine (15 mL), dried over Na2SO4, filtered and
concentrated under reduced pressure. The crude material was
purified by silica gel chromatography on a Teledyne Combiflash ISCO
eluting with DCM/MeOH (100:0 to 90:10) to yield the desired product
as a white solid (1.2 g, 29%). LC-MS (ES+): m/z 722.34 [MH+].
TABLE-US-00011 TABLE 11 Exemplary Compounds. Ex# Structure Compound
name and Analytical data 179 ##STR00392##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-{4-[4-(4-{[trans-
3-(3-chloro-4-cyanophenoxy)-2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenyl)phenoxy]
butanamido}butanoyl]-4-hydroxy-N-{[4-
(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine- 2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.87 (s, 1 H),
7.84-7.90 (m, 2 H), 7.73 (d, J = 8.61 Hz, 1 H), 7.66-7.71 (m, 2 H),
7.58-7.63 (m, 2 H), 7.45-7.49 (m, 2 H), 7.38-7.43 (m, 2 H), 7.14
(d, J = 2.35 Hz, 1 H), 7.01-7.06 (m, 2 H), 6.99 (dd, J = 8.80, 2.54
Hz, 1 H), 4.65 (s, 1 H), 4.56-4.60 (m, 1 H), 4.52-4.55 (m, 1 H),
4.51 (br. s., 1 H), 4.35 (d, J = 15.65 Hz, 1 H), 4.31 (s, 1 H),
4.18 (s, 1 H), 4.06 (ddt, J = 9.39, 6.36, 3.28, 3.28 Hz, 2 H), 3.93
(d, J = 10.96 Hz, 1 H), 3.81 (dd, J = 10.96, 3.91 Hz, 1 H),
2.48-2.57 (m, 2 H), 2.42-2.47 (m, 3 H), 2.22 (dd, J = 13.11, 7.63
Hz, 1 H), 2.06-2.15 (m, 3 H), 1.31 (s, 6 H), 1.25 (s, 6 H), 1.04
(s, 9 H); LC-MS (ES.sup.+): m/z 973.41 [MH.sup.+] 180 ##STR00393##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-{4-[4-(4-{[trans-
3-(3-chloro-4-cyanophenoxy)-2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenyl)phenoxy]
butanamido}butanoyl]-4-hydroxy-N-{[4-
(4-methyl-1,3-oxazol-5-yl)phenyl]methyl} pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.14 (s, 1 H), 7.87
(d, J = 8.22 Hz, 2 H), 7.73 (d, J = 8.61 Hz, 1 H), 7.67-7.71 (m, 2
H), 7.57-7.63 (m, 4 H), 7.45-7.51 (m, 2 H), 7.14 (d, J = 2.74 Hz, 1
H), 7.03 (d, J = 9.00 Hz, 2 H), 6.99 (dd, J = 8.80, 2.54 Hz, 1 H),
4.65 (s, 1 H), 4.55-4.59 (m, 1 H), 4.47-4.55 (m, 2 H), 4.34 (d, J =
15.65 Hz, 1 H), 4.31 (s, 1 H), 4.19 (s, 1 H), 4.06 (tt, J = 6.16,
3.23 Hz, 2 H), 3.93 (d, J = 10.96 Hz, 1 H), 3.81 (dd, J = 10.96,
3.91 Hz, 1 H), 2.48-2.55 (m, 2 H), 2.39 (s, 3 H) 2.22 (dd, J =
13.30, 7.43 Hz, 1 H), 2.06-2.14 (m, 3 H), 1.31 (s, 6 H), 1.25 (s, 6
H), 1.04 (s, 9 H); LC-MS (ES.sup.+): m/z 957.44 [MH.sup.+] 181
##STR00394## (2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{2-[4-(4-{[trans-3-
(3-chloro-4-cyanophenoxy)-2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenyl)phenoxy]
ethoxy}acetamido)butanoyl]-4-hydroxy-
N-{[4-(4-methyl-1,3-oxazol-5-yl)phenyl]methyl}
pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
ppm 8.05 (s, 1 H), 7.81-7.87 (m, 2 H), 7.73 (d, J = 9.00 Hz, 1 H),
7.58-7.64 (m, 2 H), 7.51-7.58 (m, 4 H), 7.43-7.51 (m, 2 H),
7.10-7.19 (m, 3 H), 6.99 (dd, J = 9.00, 2.35 Hz, 1 H), 4.76 (s, 1
H), 4.55-4.64 (m, 3 H), 4.51 (d, J = 1.96 Hz, 1 H), 4.31 (t, J =
7.83 Hz, 2 H), 4.25 (q, J = 4.17 Hz, 2 H), 4.19 (s, 1 H), 4.14 (s,
2 H), 3.96 (t, J = 4.30 Hz, 2 H), 3.86-3.91 (m, 1 H), 3.78-3.86 (m,
1 H), 2.26-2.32 (m, 3 H), 2.18-2.26 (m, 1 H), 2.05-2.13 (m, 1 H),
1.31 (s, 6 H), 1.25 (s, 6 H), 0.99-1.11 (m, 9 H); LC-MS (ES.sup.+):
m/z 973.43 [MH.sup.+] 182 ##STR00395##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{2-[4-(4-{[trans-
3-(3-chloro-4-cyanophenoxy)-2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenyl)phenoxy]
ethoxy}acetamido)butanoyl]-4-hydroxy-
N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}
pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
ppm 8.66 (s, 1 H), 7.82 (d, J = 8.22 Hz, 2 H), 7.60 (dd, J = 11.54,
8.41 Hz, 3 H), 7.53 (d, J = 8.61 Hz, 2 H), 7.27-7.41 (m, 6 H), 7.04
(d, J = 8.61 Hz, 2 H), 6.99 (d, J = 2.35 Hz, 1 H), 6.83 (dd, J =
8.80, 2.15 Hz, 1 H), 6.31 (d, J = 8.22 Hz, 1 H), 4.75 (t, J = 7.83
Hz, 1 H), 4.52-4.64 (m, 2 H), 4.50 (d, J = 8.61 Hz, 1H), 4.34 (dd,
J = 14.87, 5.48 Hz, 1 H), 4.17-4.24 (m, 3 H), 4.04-4.17 (m, 4 H),
3.88-3.97 (m, 2 H), 3.63 (dd, J = 11.35, 3.52 Hz, 1 H), 2.61 (ddd,
J = 13.30, 7.83, 4.70 Hz, 1 H), 2.49 (s, 3 H), 2.12 (dd, J = 13.69,
8.22 Hz, 1 H), 1.31 (s, 6 H), 1.26 (s, 6 H), 0.96 (s, 9 H); LC-MS
(ES.sup.+): m/z 989.27 [MH.sup.+]
[0633] Examples 179-181 were synthesized according to similar
procedure described for synthesis of example 182, by using
corresponding starting materials and intermediates.
Synthesis of Example 182
##STR00396## ##STR00397##
[0634] Step 8: Synthesis of Example 182
[0635] To a stirred solution of
4-{4-[2-({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)ph-
enyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbam-
oyl}methoxy)ethoxy]phenyl}benzoic acid (89.0 mg, 122 .mu.mol) in
methylene chloride (2.0 mL) was added HATU (55.5 mg, 146 .mu.mol)
and diisopropylethylamine (63.7 .mu.L, 366 .mu.mol). The reaction
mixture was stirred at rt for 10 minutes. The reaction mixture was
then charged with
2-chloro-4-[trans-3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrile
(34.0 mg, 122 .mu.mol). The reaction was stirred at rt for 30
minutes. The reaction was monitored by LC-MS, which indicated
completion of reaction. The reaction mixture was quenched with
water (5 mL) and then extracted with DCM (25 mL). The organic layer
was washed with brine (5 mL), dried over Na.sub.2SO.sub.4, filtered
and concentrated under reduced pressure to give a crude material,
which was purified by flash silica gel chromatography on a Teledyne
Combiflash ISCO (eluent: DCM/MeOH (v:v=90:10)) to give titled
product (yield: 37%) as a white solid.
Step 7: Synthesis of
4-{4-[2-({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)ph-
enyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbam-
oyl}methoxy)ethoxy]phenyl}benzoic Acid
##STR00398##
[0637] To a stirred solution of ethyl
4-{4-[2-({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)ph-
enyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbam-
oyl}methoxy)ethoxy]phenyl}benzoate (188.4 mg, 248 .mu.mol) in
methanol (2.0 mL) was added 1 M NaOH in water (0.5 mL, 12.5 mmol).
The reaction mixture was stirred at rt for 16 h. The reaction was
monitored by LC-MS, which indicated completion of reaction. The
reaction mixture was quenched with 1.0 M HCl in water and then
concentrated under reduced pressure to remove the methanol. The
aqueous was extracted with EtOAc (25 mL). The organic layer was
washed with brine (5 mL), dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure to give a crude material, which
was purified by flash silica gel chromatography on a Teledyne
Combiflash ISCO (eluent: DCM/MeOH (v:v=90:10)) to give titled
product (yield: 50%) as a white solid. LC-MS (ES.sup.+): m/z 729.18
[MH.sup.+]
Step 6: Synthesis of ethyl
4-{4-[2-({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)ph-
enyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbam-
oyl}methoxy)ethoxy]phenyl}benzoate
##STR00399##
[0639] To a stirred solution of
2-(2-{4-[4-(ethoxycarbonyl)phenyl]phenoxy}ethoxy)acetic acid (100
mg, 290.3 .mu.mol) and
(2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-m-
ethyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide
hydrochloride (135.5 mg, 290.3 .mu.mol) in Dichloromethane (2.0 mL)
was added O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
tetrafluoroborate (93.20 mg, 290.3 .mu.mol) and
diisopropylethylamine (151.6 .mu.L, 870.9 .mu.mol). The reaction
mixture was stirred at rt for 30 minutes. The reaction was
monitored by LC-MS, which indicated completion of reaction. The
reaction mixture was concentrated under reduced pressure to give a
crude material, which was purified by flash silica gel
chromatography on a Teledyne Combiflash ISCO (gradient eluent:
Heptane/Acetone (v:v=100:0 to 0:100)) to give titled product
(yield: 86%) as a white solid. LC-MS (ES.sup.+): m/z 757.3283
[MH.sup.+].
Step 5: Synthesis of
2-(2-{4-[4-(ethoxycarbonyl)phenyl]phenoxy}ethoxy)acetic Acid
##STR00400##
[0641] To a stirred solution of ethyl
4-(4-{2-[2-(tert-butoxy)-2-oxoethoxy]ethoxy}phenyl)benzoate (245
mg, 611 .mu.mol) in methylene chloride (1.0 mL) was added
trifluoroacetic acid (1.0 mL, 12.9 mmol). The reaction mixture was
stirred at rt for 30 minutes. The reaction was monitored by LC-MS,
which indicated completion of reaction. The reaction mixture was
concentrated under reduced pressure to give titled product (yield:
100% based on crude) as an off white solid. The material was used
in next step without any further purification. LC-MS (ES.sup.+):
m/z 345.1330 [MH.sup.+].
Step 4: Synthesis of ethyl
4-(4-{2-[2-(tert-butoxy)-2-oxoethoxy]ethoxy}phenyl)benzoate
##STR00401##
[0643] To a stirred mixture of ethyl
4'-hydroxy-[1,1'-biphenyl]-4-carboxylate (146.6 mg, 605.3 .mu.mol)
and tert-butyl 2-{2-[(4-methylbenzenesulfonyl)oxy]ethoxy}acetate
(200.0 mg, 605.3 .mu.mol) in acetonitrile (2.0 mL) was added
potassium carbonate (125.4 mg, 907.9 .mu.mol) at rt. The reaction
mixture was then stirred at 80.degree. C. for 16 h. The reaction
was monitored by LC-MS, which indicated completion of reaction. The
reaction mixture was concentrated under reduced pressure to give a
crude material, which was purified by flash silica gel
chromatography on a Teledyne Combiflash ISCO (gradient eluent:
Heptane/EtOAc (v:v=100:0 to 50:50)) to give titled product (yield:
99%) as a clear oil. LC-MS (ES.sup.+): m/z 423.18 [MNa.sup.+].
Step 3: synthesis of tert-butyl
2-{2-[(4-methylbenzenesulfonyl)oxy]ethoxy}acetate
##STR00402##
[0645] To a stirred solution of tert-butyl
2-(2-hydroxyethoxy)acetate (1.44 g, 0.19 mmol) in methylene
chloride (10.0 mL) was added 4-methylbenzene-1-sulfonyl chloride
(1.713 g, 0.21 mmol) and triethylamine (1.707 mL, 12.25 mmol) at
rt. The reaction mixture was stirred at rt for 16 h. The reaction
was monitored by LC-MS, which indicated completion of reaction. The
reaction mixture was concentrated under reduced pressure give a
crude material, which was purified by flash silica gel
chromatography on a Teledyne Combiflash ISCO (gradient eluent:
Heptane/Acetone (v:v=100:0 to 0:100)) to give titled product
(yield: 69%) as a clear oil. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 7.77-7.83 (m, 2H), 7.44 (d, J=7.83 Hz, 2H), 4.14-4.19
(m, 2H), 3.93 (s, 2H), 3.68-3.74 (m, 2H), 2.46 (s, 3H), 1.46 (s,
9H); LC-MS (ES.sup.+): m/z 353.1053 [MNa.sup.+], t.sub.R=2.56
min.
Step 2: Synthesis of tert-butyl 2-(2-hydroxyethoxy)acetate
##STR00403##
[0647] To a stirred solution of tert-butyl
2-[2-(benzyloxy)ethoxy]acetate in Ethanol (10.0 mL) was added
palladium on carbon (10% wt.) (1.99 g, 1.87 mmol). The reaction
mixture was evacuated and purged with H.sub.2 gas (3.times.). The
reaction mixture was stirred at rt under an atmosphere of H.sub.2
for 16 h. The reaction was monitored by TLC analysis, which
indicated completion of reaction. The reaction mixture was filtered
through a pad of celite and the filtrate was concentrated under
reduced pressure to give titled product (yield: 87% based on crude)
as a clear oil. The crude material was used in next step reaction
without any further purification.
Step 1: Synthesis of tert-butyl 2-[2-(benzyloxy)ethoxy]acetate
##STR00404##
[0649] To a stirred solution of 2-(benzyloxy)ethanol (5.0 g, 32.8
mmol) and tert-butyl 2-bromoacetate (7.02 g, 36.0 mmol) in
acetonitrile (10.0 mL) was added potassium carbonate (6.78 g, 49.1
mmol) at rt. The reaction mixture then stirred at 80.degree. C. for
16 h. The reaction was monitored by TLC analysis, which indicated
completion of reaction. The reaction mixture was diluted with water
(10.0 mL) and extracted with EtOAc (20.0 mL). The organic layer was
washed with water (5.0 mL), brine (5.0 mL), dried over
Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure
to give titled product (yield: 100% based on crude) as a yellow
oil. This crude material was used in next step reaction without any
further purification.
TABLE-US-00012 TABLE 12 Exemplary Compounds. Ex# Structure Compound
name and Analytical data 183 ##STR00405##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{[4-(4-{[trans-3-(3-chloro-4-cyanopheno-
xy)-2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenoxy)phenyl]methoxy}acetamido)butanoyl-
]-4-hydroxy-N-
{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.83-8.90 (m, 1 H),
7.79-7.86 (m, 2 H), 7.72 (d, J = 8.61 Hz, 1 H), 7.43-7.50 (m, 4 H),
7.37-7.42 (m, 2 H), 7.13 (d, J = 2.35 Hz, 1 H), 7.00-7.09 (m, 4 H),
6.98 (dd, J = 9.00, 2.35 Hz, 1 H), 4.71 (s, 1 H), 4.63 (s, 2 H),
4.55-4.61 (m, 2 H), 4.47-4.54 (m, 2 H), 4.35 (d, J = 15.65 Hz, 1
H), 4.28 (s, 1 H), 4.15 (s, 1 H), 4.00-4.08 (m, 2 H), 3.86-3.92 (m,
1 H), 3.77-3.84 (m, 1 H), 2.44-2.48 (m, 3 H), 2.24 (dd, J = 13.30,
7.43 Hz, 1 H), 2.09 (ddd, J = 13.21, 9.10, 4.30 Hz, 1 H), 1.28 (s,
6 H), 1.22 (s, 6 H), 1.00-1.09 (m, 9 H); LC-MS (ES.sup.+): m/z
975.39 [MH.sup.+] 184 ##STR00406##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{[4-(4-{[(1r,3r)-3-(3-chloro-4-cyanophe-
noxy)-2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenoxy)phenyl]methoxy}acetamido)butanoyl-
]-4-hydroxy-N-
{[4-(4-methyl-1,3-oxazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.10-8.15 (m, 1 H),
7.79-7.85 (m, 2 H), 7.72 (d, J = 9.00 Hz, 1 H), 7.55-7.61 (m, 2 H),
7.44-7.51 (m, 4 H), 7.12 (d, J = 2.35 Hz, 1 H), 7.00-7.09 (m, 4 H),
6.98 (dd, J = 9.00, 2.35 Hz, 1 H), 4.71 (s, 1 H), 4.63 (s, 2 H),
4.55-4.61 (m, 2 H), 4.46-4.54 (m, 2 H), 4.34 (d, J = 15.26 Hz, 1
H), 4.28 (s, 1 H), 4.15 (s, 1 H), 4.07 (s, 1 H), 4.02-4.06 (m, 1
H), 3.85-3.92 (m, 1 H), 3.77-3.84 (m, 1 H), 2.35-2.42 (m, 3 H),
2.23 (dd, J = 13.30, 7.43 Hz, 1 H), 2.04-2.12 (m, 1 H), 1.28 (s, 6
H), 1.22 (s, 6 H), 0.97-1.12 (m, 9 H); LC-MS (ES.sup.+): m/z 959.41
185 ##STR00407##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{2-[4-(4-{[trans-3-(3-chloro-4-cyanophe-
noxy)-2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenoxy)phenoxy]ethoxy}acetamido)butanoyl-
]-4-hydroxy-N-
{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.83 (s, 1 H),
7.74-7.82 (m, 2 H), 7.72 (d, J = 8.61 Hz, 1 H), 7.42-7.49 (m, 2 H),
7.33-7.40 (m, 2 H), 7.12 (d, J = 2.35 Hz, 1 H), 7.06-7.11 (m, 2 H),
6.87-7.01 (m, 5 H), 4.74 (s, 1 H), 4.55-4.61 (m, 2 H), 4.49-4.55
(m, 2 H), 4.32 (d, J = 15.26 Hz, 1 H), 4.28 (s, 1 H), 4.17-4.22 (m,
2 H), 4.14 (s, 1 H), 4.13 (s, 2 H), 3.91-3.96 (m, 2 H), 3.85-3.90
(m, 1 H), 3.79-3.85 (m, 1 H), 2.40-2.49 (m, 3 H), 2.23 (dd, J =
13.30, 7.83 Hz, 1 H), 2.05-2.14 (m, 1 H), 1.28 (d, J = 1.17 Hz, 6
H), 1.22 (s, 6 H), 1.01-1.09 (m, 9 H); LC-MS (ES.sup.+): m/z
1005.40 [MH.sup.+] 186 ##STR00408##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{2-[4-(4-{[trans-3-(3-chloro-4-cyanophe-
noxy)-2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenoxy)phenoxy]ethoxy}acetamido)butanoyl-
]-4-hydroxy-N-
{[4-(4-methyl-1,3-oxazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 8.10 (s, 1 H),
7.74-7.83 (m, 2 H), 7.72 (d, J = 8.61 Hz, 1 H), 7.52-7.59 (m, 2 H),
7.43-7.50 (m, 2 H), 7.07-7.15 (m, 3 H), 6.86-7.02 (m, 5 H), 4.75
(s, 1 H), 4.55-4.61 (m, 2 H), 4.52 (d, J = 8.61 Hz, 2 H), 4.33 (s,
1 H), 4.26-4.31 (m, 1 H), 4.21 (q, J = 3.78 Hz, 2 H), 4.10-4.17 (m,
3 H), 3.94 (dd, J = 4.70, 3.91 Hz, 2 H), 3.85-3.91 (m, 1 H),
3.78-3.85 (m, 1 H), 2.33 (s, 3 H), 2.23 (dd, J = 13.11, 7.63 Hz, 1
H), 2.09 (ddd, J = 13.30, 9.19, 4.50 Hz, 1 H), 1.28 (s, 6 H), 1.22
(s, 6 H), 1.00-1.10 (m, 9 H); LC-MS (ES.sup.+): m/z 989.44
[MH.sup.+] 187 ##STR00409##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{[4-(4-{[trans-3-(3-chloro-4-cyanopheno-
xy)-2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenoxy)phenyl]formamido}acetamido)butano-
yl]-4-hydroxy-
N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide
Mass (ES.sup.+): m/z 988.10 [MH.sup.+]
[0650] Examples 184-187 were synthesized according to similar
procedure described for synthesis of example 183, by using
corresponding starting materials and intermediates.
Synthesis of Example 183
##STR00410##
[0651] Step 7: Synthesis of Example 183
[0652] To a stirred solution of
2-chloro-4-[trans-3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrile
(25.3 mg, 90.9 .mu.mol) and
4-{4-[({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phen-
yl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoy-
l}methoxy)methyl]phenoxy}benzoic acid (65 mg, 90.9 .mu.mol) in
methylene chloride (2.0 mL) was added
O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
tetrafluoroborate (29.1 mg, 90.9 .mu.mol) and diisopropylethylamine
(47.3 .mu.L, 272 .mu.mol) at rt. The reaction mixture was stirred
at rt for 30 minutes. The reaction was monitored by LC-MS, which
indicated completion of reaction. The reaction mixture was diluted
with water (5 mL) and extracted with DCM (25 mL). The organic layer
was separated and washed with brine (5 mL), dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure
to give a crude material, which was purified by flash silica gel
chromatography on a Teledyne Combiflash ISCO (eluent: DCM/MeOH
(v:v=90:10)) to give titled product (yield: 22%) as a white
solid.
Step 6: Synthesis of
4-{4-[({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phen-
yl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoy-
l}methoxy)methyl]phenoxy}benzoic Acid
##STR00411##
[0654] To a stirred solution of methyl
4-{4-[({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phen-
yl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoy-
l}methoxy)methyl]phenoxy}benzoate (68 mg, 93.2 .mu.mol) in methanol
(2.0 mL) was added 1 M NaOH solution in water (0.5 mL, 12.5 mmol)
at rt. The reaction mixture was allowed to stir at rt for 16 hours.
The reaction was monitored by LC-MS, which indicated completion of
reaction. The reaction mixture was quenched with 1.0 M HCl solution
in water (0.5 mL) and then concentrated under reduced pressure to
remove the methanol. The aqueous was extracted with EtOAc (25 mL).
The organic layer was separated, washed with brine (5 mL), dried
over Na.sub.2SO.sub.4, filtered and concentrated under reduced
pressure to give titled product (yield: 98% based on crude) as a
white solid. This material was used in next step reaction without
any further purification. LC-MS (ES.sup.+): m/z
715.28[MH.sup.+].
Step 5: Synthesis of methyl
4-{4-[({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phen-
yl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoy-
l}methoxy)methyl]phenoxy}benzoate
##STR00412##
[0656] To a stirred solution of
2-({4-[4-(methoxycarbonyl)phenoxy]phenyl}methoxy)acetic acid (30.0
mg, 94.8 .mu.mol) and
(2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-m-
ethyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide
hydrochloride (44.2 mg, 94.8 .mu.mol) in methylene chloride (2.0
mL) was added O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
tetrafluoroborate (30.4 mg, 94.8 .mu.mol) and diisopropylethylamine
(49.4 .mu.L, 284 .mu.mol) at rt. The reaction mixture was allowed
to stir at rt for 30 minutes. The reaction was monitored by LC-MS,
which indicated completion of reaction. The reaction mixture was
concentrated under reduced pressure to give a crude material, which
was purified by flash silica gel chromatography on a Teledyne
Combiflash ISCO (gradient eluent: Heptane/Acetone (v:v=100:0 to
0:100)) to give titled product (yield: 99%) as a white solid. LC-MS
(ES.sup.+): m/z 729.30 [MH.sup.+].
Step 4: 2-({4-[4-(methoxycarbonyl)phenoxy]phenyl}methoxy)acetic
Acid
##STR00413##
[0658] A solution of methyl
4-(4-{[2-(tert-butoxy)-2-oxoethoxy]methyl}phenoxy)benzoate (200.0
mg, 537 .mu.mol) in hydrogen chloride solution (4 M in dioxane, 2.0
mL) was stirred at room temperature for 2 h. The reaction was
monitored by LC-MS, which indicated completion of reaction. The
reaction mixture was concentrated under reduced pressure to give
titled product (yield: 95% based on crude) as an off white solid.
This material used in next step reaction without any further
purification. LC-MS (ES.sup.+): m/z 339.0858 [MNa.sup.+].
Step 3: Synthesis of methyl
4-(4-{[2-(tert-butoxy)-2-oxoethoxy]methyl}phenoxy)benzoate
##STR00414##
[0660] To a stirred mixture of sodium hydroxide (1.16 g, 29 mmol)
in water (2.0 mL) and toluene (2.0 mL) at 20.degree. C. was charged
with tetrabutylammonium hydrogen sulfate (32.86 mg, 96.79 .mu.mol),
followed by methyl 4-[4-(hydroxymethyl)phenoxy]benzoate (250.0 mg,
967.9 .mu.mol), the resulting mixture was stirred at 20.degree. C.
for 1 h. The mixture was then cooled to 5.degree. C., tert-butyl
2-bromoacetate (207.5 mg, 1.064 mmol) was added slowly and the
internal temperature was maintained below 15.degree. C. Upon the
completion of this addition, the reaction mixture was allowed to
warm up to rt and stirred for 16 h at rt. The reaction was
monitored by LC-MS, which indicated completion of reaction. The
mixture was diluted with water (5 mL) and extracted with EtOAc (30
mL). The organic layer was separated, dried over anhydrous sodium
sulfate, filtered and concentrated under reduced pressure to a give
a crude material, which was purified by flash silica gel
chromatography on a Teledyne Combiflash ISCO (eluent (gradient):
Heptane/EtOAc (v:v=100:0 to 70:30)) to give titled product (yield:
56%) as a white solid. LC-MS (ES.sup.+): m/z 395.15
[MNa.sup.+].
Step 2: Synthesis of methyl
4-[4-(hydroxymethyl)phenoxy]benzoate
##STR00415##
[0662] To a stirred solution of methyl 4-(4-formylphenoxy)benzoate
(750.0 mg, 2.92 mmol) in methanol (2.0 mL) was added sodium
borohydride (121 mg, 3.21 mmol) at rt. The reaction mixture was
allowed to stir at rt for 30 min. The reaction was monitored by
LC-MS, which indicated completion of reaction. The reaction mixture
was slowly quenched with 1N HCl (solution in water), concentrated
under reduced pressure to remove the bulk of methanol, and then
extracted with DCM (30 mL). The organic layer was separated, washed
with brine (5 mL), dried over Na.sub.2SO.sub.4, filtered and
concentrated under reduced pressure to give a crude material, which
was purified by flash silica gel chromatography on a Teledyne
Combiflash ISCO (eluent (gradient): Heptane/EtOAc (v:v=100:0 to
50:50)) to give titled product (yield: 94%) as a white solid. LC-MS
(ES.sup.+): m/z 259.10 [MH.sup.+].
Step 1: Synthesis of methyl 4-(4-formylphenoxy)benzoate
##STR00416##
[0664] To a stirred mixture of methyl 4-hydroxybenzoate (1.0 g,
6.57 mmol) and potassium carbonate (1.36 g, 9.85 mmol) in
dimethylformamide (2.0 mL) was added 4-fluorobenzaldehyde (815 mg,
6.57 mmol) at rt. The reaction mixture was then stirred at
80.degree. C. for 16 h. The reaction was monitored by LC-MS, which
indicated completion of reaction. The reaction mixture was cooled
to rt, diluted with water (10 mL) and extracted with EtOAc (50
mL.times.2). The organic layer was separated, washed with brine (10
mL.times.2), dried over Na.sub.2SO.sub.4, filtered and concentrated
under reduced pressure to give a crude material, which was purified
by flash silica gel chromatography on a Teledyne Combiflash ISCO
(eluent (gradient): Heptane/EtOAc (v:v=100:0 to 50:50)) to give
titled product (yield: 90%) as a white solid. LC-MS (ES.sup.+): m/z
257.08 [MH.sup.+].
TABLE-US-00013 TABLE 13 Exemplary Compounds. Ex# Structure Compound
name and Analytical data 188 ##STR00417##
(2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{[5-(4-{[trans-
3-(3-chloro-4-cyanophenoxy)-2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenoxy)pentyl]
amino}acetamido)butanoyl]-4-hydroxy-N-{[4-
(4-methyl-1,3-oxazol-5-yl)phenyl]methyl}pyrrolidine- 2-carboxamide
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.68 (s, 1H), 7.63 (d, J
= 8.6 Hz, 2H), 7.57 (d, J = 8.6 Hz, 1H), 7.35 (q, J = 8.5 Hz, 4H),
6.97 (d, J = 2.3 Hz, 1H), 6.81 (dd, J = 2.5, 8.8 H, 1H), 6.60 (d, J
= 9.0 Hz, 2H), 6.07-6.12 (m, 1H), 4.74 (s, 1H), 4.50-4.59 (m, 3H),
4.37 (d, J = 5.1 Hz, 1H), 4.11-4.17 (m, 2H), 3.64 (dd, J = 3.5,
11.3 Hz, 1H), 3.53 (d, J = 7.0 Hz, 2H), 3.19 (t, J = 7.0 Hz, 2H),
2.55-2.61 (m, 1H), 2.52 (s, 3H), 2.10-2.19 (m, 2H), 1.65-1.71 (m,
4H), 1.50-1.53 (m, 2H), 1.24-1.33 (m, 9H), 1.22 (s, 6H), 0.96 (s,
9H), 0.86-0.91 (m, 3H). LC-MS (ES.sup.+): m/z 954.43 [MH.sup.+] 189
##STR00418## (2S,4R)-1-[(2S)-3,3-dimethyl-2-(2-{[5-(4-{[trans-3-
(3-chloro-4-cyanophenoxy)-2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenoxy)pentyl]amino}
acetamido)butanoyl]-4-hydroxy-N-{[4-
(4-methyl-1,3-oxazol-5-yl)phenyl]methyl}pyrrolidine- 2-carboxamide
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.79 (s, 1H), 7.72 (d, J
= 8.6 Hz, 2H), 7.54-7.60 (m, 1H), 7.51 (d, J = 8.2 Hz, 2H), 7.34
(d, J = 8.2 Hz, 2H), 6.96 (d, J = 2.3 Hz, 1H), 6.88 (d, J = 9.0 Hz,
2H), 6.81 (dd, J = 2.3, 9.0 Hz, 1H), 4.53-4.67 (m, 2H), 4.40 (br.
s., 1H), 4.14 (d, J = 8.2 Hz, 1H), 4.05 (s, 1H), 3.92 (br. s., 2H),
3.74 (br. s., 1H), 3.60 (d, J = 8.6 Hz, 1H), 2.39 (s, 3H), 2.23
(br. s., 2H), 1.71 (br. s., 4H), 1.43 (br. s., 2H), 1.27 (s, 12H),
1.22 (s, 6H), 0.99 (br. s., 8H), 0.86-0.93 (m, 6H). LC-MS
(ES.sup.+): m/z 938.45 [MH.sup.+]
[0665] Example 189 was synthesized according to similar procedure
described for synthesis of example 188, by using corresponding
starting materials and intermediates.
Synthesis of Example 188
##STR00419## ##STR00420##
[0666] Step 7: Synthesis of Example 188
[0667] Trifluoroacetic acid (1.12 mL, 14.7 mmol) was added to a
stirred solution of tert-butyl
N-({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-oxazol-5-yl)phenyl]me-
thyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}met-
hyl)-N-[5-(4-{[trans-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclob-
utyl]carbamoyl}phenoxy)pentyl]carbamate (34 mg, 0.0327 mmol) in DCM
(3.00 ml) at rt. The resulting mixture was stirred at 45.degree. C.
for 48 h. The reaction mixture was then concentrated under reduced
pressure to give a crude material, which was purified by flash
silica gel chromatography on a Teledyne Combiflash ISCO system,
eluting with MeOH/DCM (gradient: v:v=0:100 to 10:90) to yield the
desired title product (yield: 62%).
Step 6: Synthesis of tert-butyl
N-({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-methyl-1,3-thiazol-5-yl)phenyl]m-
ethyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl}me-
thyl)-N-[5-(4-{[trans-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclo-
butyl]carbamoyl}phenoxy)pentyl]carbamate
##STR00421##
[0669] TBTU (23.0 mg, 0.072 mmol) was added to a stirred solution
of
4-[(5-{[(tert-butoxy)carbonyl]({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-meth-
yl-1,3-thiazol-5-yl)phenyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl--
1-oxobutan-2-yl]carbamoyl}methyl)amino}pentyl)oxy]benzoic acid (38
mg, 0.04786 mmol) and
2-chloro-4-[trans-3-amino-2,2,4,4-tetramethylcyclobutoxy]benzonitrile
(13.3 mg, 0.04786 mmol) in DMF (3.0 mL) and DIPEA (16.5 .mu.L,
0.095 mmol) at rt. The resulting mixture was stirred at rt for 1 h.
The reaction was then diluted with EtOAc (30 mL), washed with brine
(5 mL.times.2), filtered through a Biotage Universal Phase
Separator and then concentrated under reduced pressure to give a
crude material, which was purified by flash silica gel
chromatography on a Teledyne Combiflash ISCO system, eluting with
MeOH/DCM (gradient: v:v=0:100 to 10:90) to yield the desired title
product (yield: 60%).
Step 5: Synthesis of
4-[(5-{[(tert-butoxy)carbonyl]({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-meth-
yl-1,3-thiazol-5-yl)phenyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl--
1-oxobutan-2-yl]carbamoyl}methyl)amino}pentyl)oxy]benzoic Acid
##STR00422##
[0671] Lithium hydroxide (3.0 mg, 0.128 mmol) was added to a
stirred solution of methyl
4-[(5-{[(tert-butoxy)carbonyl]({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-meth-
yl-1,3-thiazol-5-yl)phenyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl--
1-oxobutan-2-yl]carbamoyl}methyl)amino}pentyl)oxy]benzoate (37 mg,
0.046 mmol) in a mixed solvent of THF/water (v:v=1:1, 2.00 mL) at
rt. The resulting reaction mixture was stirred at rt overnight. To
the reaction mixture was added 1N HCl (aqueous solution) to adjust
pH=.about.3. The resulting mixture was extracted with EtOAc (20
mL.times.2), washed with brine (5 mL.times.2), filtered through a
Biotage Universal Phase Separator and then concentrated under
reduced pressure to give a crude material (yield: 100% based on
crude). This crude product was used for the next step reaction
without any further purification.
Step 4: Synthesis of methyl
4-[(5-{[(tert-butoxy)carbonyl]({[(2S)-1-[(2S,4R)-4-hydroxy-2-({[4-(4-meth-
yl-1,3-thiazol-5-yl)phenyl]methyl}carbamoyl)pyrrolidin-1-yl]-3,3-dimethyl--
1-oxobutan-2-yl]carbamoyl}methyl)amino}pentyl)oxy]benzoate
##STR00423##
[0673] TBTU (36.6 mg, 0.1142 mmol) was added to a stirred solution
of
2-{[(tert-butoxy)carbonyl]({5-[4-(methoxycarbonyl)phenoxy]pentyl})amino}a-
cetic acid (37 mg, 0.076 mmol) and
(2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1-
,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (32.8 mg,
0.076 mmol) in DMF (3.0 mL) and DIPEA (26.4 .mu.L, 0.15 mmol) at
rt. The resulting reaction mixture was stirred at rt for 1 hr. The
reaction was then diluted with EtOAc (30 mL), washed with brine (10
mL), filtered through a Biotage Universal Phase Separator and then
concentrated under reduced pressure to give a crude material, which
was purified by flash silica gel chromatography on a Teledyne
Combiflash ISCO system, eluting with MeOH/DCM (gradient: v/v=0/100
to 10/90) to yield the desired title product (yield: 64%).
Step 3: Synthesis of
2-{[(tert-butoxy)carbonyl]({5-[4-(methoxycarbonyl)phenoxy]pentyl})amino}a-
cetic Acid
##STR00424##
[0675] Palladium on carbon (96.8 mg, 0.91 mmol) was added to a
stirred solution of methyl
4-[(5-{[2-(benzyloxy)-2-oxoethyl][(tert-butoxy)carbonyl]amino}pentyl)oxy]-
benzoate (83.0 mg, 0.171 mmol) in ethanol (20 ml) at rt. The
reaction mixture was degassed and charged with H.sub.(g) and then
stirred at rt for 16 h under a hydrogen atmosphere. Solids were
then removed by filtration and the solvent was concentrated under
reduced pressure to give a crude material (yield: 98% based on
crude). This crude product was used for the next step reaction
without any further purification.
Step 2: Synthesis of methyl
4-[(5-{[2-(benzyloxy)-2-oxoethyl][(tert-butoxy)carbonyl]amino}pentyl)oxy]-
benzoate
##STR00425##
[0677] Di-tert-butyl dicarbonate (47.7 .mu.L, 0.21 mmol) was added
to a stirred solution of methyl
4-[(5-{[2-(benzyloxy)-2-oxoethyl]amino}pentyl)oxy]benzoate (73.0
mg, 0.19 mmol) in THF (5.0 ml) at rt. The reaction mixture was
heated to reflux at 80.degree. C. and stirred at 80.degree. C. for
14 h. The reaction was then cooled to rt, diluted with ethyl
acetate (20 mL), washed with saturated aq. NaHCO.sub.3 (10 mL). The
organic layer was separated and filtered using a Biotage Universal
Phase Separator and then concentrated under reduced pressure to
give a crude material, which was purified by flash silica gel
chromatography on a Teledyne Combiflash ISCO system, eluting with
EtOAc/Heptane (gradient v:v=0:100 to 40:60) to yield the desired
title product (yield: 95%).
Step 1: Synthesis of methyl
4-[(5-{[2-(benzyloxy)-2-oxoethyl]amino}pentyl)oxy]benzoate
##STR00426##
[0679] To a stirred mixture of methyl 4-[(5-oxopentyl)oxy]benzoate
(269 mg, 1.13 mmol) and benzyl 2-aminoacetate hydrochloride (186
mg, 1.13 mmol) in DCE (5.00 mL) was added acetic acid (181 .mu.L,
2.26 mmol) and sodium triacetoxyborohydride (358 mg, 1.69 mmol) at
rt. The reaction mixture was stirred at rt for 18 h. To the
reaction mixture was added 1N NaOH aqueous solution to adjust
pH=.about.10, the resulting mixture was then extracted with DCM (30
mL.times.3). The organic layer was separated, washed with brine (10
mL.times.2), dried over Na.sub.2SO.sub.4, filtered and concentrated
under reduced pressure to give a crude material, which was purified
by flash silica gel chromatography on a Teledyne Combiflash ISCO,
eluting with MeOH/DCM (gradient v:v=0:100 to 15:85) to yield the
titled product (17%).
TABLE-US-00014 TABLE 14 Exemplary Compound. Ex# Structure Compound
name and Analytical data 190 ##STR00427##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[6-cyano-5-(trifluoromethyl)pyridin-3-yl-
]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}phenyl)phenoxy]buto-
xy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(1,3-oxazol-5-yl)phenyl]methyl}pyrr-
olidine-2- carboxamide .sup.1H NMR (300 MHz, CD.sub.3OD): .delta.
9.14 (s, 1 H), 8.65 (d, J = 2.1 Hz, 1 H), 8.21-8.10 (m, 1 H),
7.74-7.50 (m, 6 H), 7.47-7.29 (m, 5 H), 7.10-6.97 (m, 2 H),
4.70-4.22 (m, 5 H), 4.15- 3.96 (m, 4 H), 3.95-3.70 (m, 2 H),
3.70-3.50 (m, 2 H), 2.24-2.00 (m, 2 H), 2.00-1.80 (m, 4 H), 1.57
(s, 6 H), 1.00 (s, 9 H); LC-MS (ES.sup.+): m/z, 995.20 [MH.sup.+]
191 ##STR00428##
(2S,4R)-1-[(2S)-2-{2-[4-(4-{4-[3-(5-chloro-6-cyanopyridin-3-yl)-5,5-dimet-
hyl-4-oxo-2-
sulfanylideneimidazolidin-1-yl]phenyl}phenoxy)butoxy]acetamido}-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(1,3-oxazol-5-yl)phenyl]methyl}pyrrolid-
ine-2- carboxamide Mass (ES.sup.+): m/z 961.20 [MH.sup.+] 192
##STR00429##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[6-cyano-5-(trifluoromethyl)pyridin-3-yl-
]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}phenyl)phenoxy]buto-
xy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-oxazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide Mass (ES.sup.+): m/z
1009.20 [MH.sup.+] 193 ##STR00430##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[6-cyano-5-(trifluoromethyl)pyridin-3-yl-
]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}phenyl)phenoxy]buto-
xy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide Mass (ES.sup.+): m/z
1025.45 [MH.sup.+] 194 ##STR00431##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[6-cyano-5-(trifluoromethyl)pyridin-3-yl-
]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}phenyl)phenoxy]buto-
xy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-
yl)phenyl]ethyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 9.19 (s, 1H), 8.86 (s, 1H), 8.70 (s, 1H), 7.75
(d, J = 8.8 Hz, 2H), 7.62 (d, J = 8.8 Hz, 2H), 7.40 (m, 6H), 7.05
(d, J = 8.8 Hz, 2H), 5.00 (d, J = 7.2 Hz, 1H), 4.56 (s, 1H), 4.64
(m, 1H), 4.44 (m, 1H), 4.10 (m, 2H), 4.06 (m, 2H), 3.86 (m, 1H),
3.76 (m, 1H), 3.66 (m, 2H), 2.47 (s, 3H), 2.22 (m, 1H), 1.92 (m,
5H), 1.62 (s, 6H), 1.49 (d, J = 6.8 Hz, 3H), 1.02 (s, 9H); LC-MS
(ES+): m/z 1039.50 [MH.sup.+] 195 ##STR00432##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[6-cyano-5-(trifluoromethyl)pyridin-3-yl-
]-5,5-
dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}phenyl)phenoxy]buto-
xy}acetamido)-
3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-oxazol-5-
yl)phenyl]ethyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 9.19 (s, 1H), 8.70 (s, 1H), 8.12 (s, 1H),
7.75-7.71 (d, J = 8.4 Hz, 2H), 7.61-7.55 (m, 4H), 7.42-7.38 (m,
4H), 7.05-7.01 (d, (d, J = 8.8 Hz, 2H), 5.00-4.96 (d, J = 7.2 Hz,
1H), 4.56 (s, 1H), 4.64-4.62 (m, 1H), 4.44-4.41 (m, 1H), 4.12- 4.01
(m, 2H), 4.00-3.98 (m, 2H), 3.86-3.81 (m, 1H), 3.74-3.71 (m, 1H),
3.67-3.65 (m, 2H), 2.38 (s, 3H), 2.22-2.18 (m, 1H), 1.98-1.88 (m,
3H), 1.88-1.82 (m ,2H), 1.62 (s, 6H), 1.48-1.46 (d, J = 6.8 Hz,
3H), 1.03 (s, 9H); LC-MS (ES+): m/z 1023.50 [MH.sup.+] 196
##STR00433##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[6-cyano-5-(trifluoromethyl)pyridin-3-yl-
]-5,5- dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-3-
fluorophenyl)phenoxy]butoxy}acetamido)-3,3-dimethylbutanoyl]-4-hydroxy-N--
[(1S)-1-
[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxam-
ide Mass (ES.sup.+): m/z 1057.15 [MH.sup.+] 197 ##STR00434##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{3-[6-cyano-5-(trifluoromethyl)pyridin-3-yl-
]-5,5- dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-3-
fluorophenyl)phenoxy]butoxy}acetamido)-3,3-dimethylbutanoyl]-4-hydroxy-N--
{[4-(4-
methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide
Mass (ES.sup.+): m/z 1043.20 [MH.sup.+] 198 ##STR00435##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl-
]-8-oxo-6-
sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl}phenyl)phenoxy]buto-
xy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-oxazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 9.20 (s, 1H), 8.68 (s, 1H), 8.10 (s, 1H),
7.78-7.75 (d, J = 8.4 Hz, 2H), 7.69-7.60 (m ,4H), 7.48-7.45 (m,
4H), 7.08-7.01 (d, J = 8.8 Hz, 2H), 4.73 (s, 1H), 4.56-4.51 (m,
3H), 4.33-4.30 (m, 1H), 4.17-4.09 (m, 2H), 4.06-4.01 (m, 2H),
3.92-3.85 (m, 2H), 3.83-3.78 (m, 2H), 2.80-2.61 (m, 4H), 2.38 (s,
3H), 2.3-2.02 (m, 3H), 1.99-1.85 (m, 4H), 1.72-1.61 (m, 1H),
1.48-1.39 (m, 2H), 1.05 (s, 9H); LC-MS (ES.sup.+): m/z 1021.40
[MH.sup.+] 199 ##STR00436##
(2S,4R)-1-[(2S)-2-(2-{4-[4-(4-{7-[6-cyano-5-(trifluoromethyl)pyridin-3-yl-
]-8-oxo-6-
sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl}phenyl)phenoxy]buto-
xy}acetamido)-3,3-
dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2-carboxamide .sup.1H NMR (400 MHz,
CD.sub.3OD): .delta. 9.20 (s, 1H), 8.90 (s, 1H), 8.68 (s, 1H), 7.78
(d, J = 8.4 Hz, 2H), 7.61 (d, J = 8.8 Hz, 2H), 7.52-7.41 (m, 6H),
7.04 (d, J = 8.4 Hz, 2H), 4.73 (s, 1H), 4.60-4.51 (m, 3H),
4.37-4.35 (m, 1H), 4.17-4.11 (m, 2H), 4.05-4.01 (m, 2H), 3.90- 3.88
(m, 1H), 3.845-3.78 (m, 1H), 3.68-3.65 (m, 2H), 2.76-2.60 (m, 4H),
2.42 (s, 3H), 2.30-2.05 (m, 3H), 2.01-1.85 (m, 4H), 1.68-1.64 (m,
1H), 1.41-1.29 (m, 3H), 1.05 (s, 9H); LC-MS (ES+): m/z 1037.10
[MH.sup.+]
[0680] Examples 191-199 was synthesized according to similar
procedure described for synthesis of example 190, by using
corresponding starting materials and intermediates.
Synthesis of Example 190
##STR00437##
[0681] Step 1: Synthesis of
5-{3-[4-(4-hydroxyphenyl)phenyl]-5-imino-4,4-dimethyl-2-sulfanylideneimid-
azolidin-1-yl}-3-(trifluoromethyl)pyridine-2-carbonitrile
##STR00438##
[0683] To a stirred solution of
5-isothiocyanato-3-(trifluoromethyl)pyridine-2-carbonitrile (440.0
mg, 1.92 mmol) in N,N-dimethylpyridin-4-amine (322.0 mg, 2.64 mmol)
and toluene (10.0 mL) was added
2-[[4-(4-hydroxyphenyl)phenyl]amino]-2-methylpropanenitrile (400.0
mg, 1.59 mmol) under a nitrogen atmosphere at rt. The resulting
solution was stirred at 100.degree. C. for 12 h. The reaction
mixture was then concentrated under reduced pressure to give a
crude material, which was purified by flash silica gel
chromatography (eluent: ethyl acetate/petroleum ether, v/v=1/1) to
give the titiled product (yield: 17%). Mass (ES.sup.+): m/z
482.20[MH.sup.+].
Step 2: Synthesis of
5-{3-[4-(4-hydroxyphenyl)phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidaz-
olidin-1-yl}-3-(trifluoromethyl)pyridine-2-carbonitrile
##STR00439##
[0685] To a stirred solution of
5-{3-[4-(4-hydroxyphenyl)phenyl]-5-imino-4,4-dimethyl-2-sulfanylideneimid-
azolidin-1-yl}-3-(trifluoromethyl)pyridine-2-carbonitrile (160.0
mg, 0.33 mmol) in methanol (5.0 mL) was added hydrogen chloride
aqueous solution (2N, 2.0 mL) at rt. The resulting solution was
then refluxed for 2 h. The reaction was cooled to rt, concentrated
under reduced pressure to give a crude material, which was purified
by flash silica gel chromatography (eluent: ethyl acetate/petroleum
ether, v/v=1/1) to give the titled product (yield: 69%) as a yellow
solid. LC-MS (ES.sup.+): m/z 481.15[MH.sup.+].
Step 3. Synthesis of tert-butyl
2-{4-[4-(4-{3-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-5,5-dimethyl-4-ox-
o-2-sulfanylideneimidazolidin-1-yl}phenyl)phenoxy]butoxy}acetate
##STR00440##
[0687] To a stirred solution of
5-{3-[4-(4-hydroxyphenyl)phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidaz-
olidin-1-yl}-3-(trifluoromethyl)pyridine-2-carbonitrile (110.0 mg,
0.23 mmol) and tert-butyl
2-{4-[(4-methylbenzenesulfonyl)oxy]butoxy}acetate (163.0 mg, 0.45
mmol) in N,N-dimethylformamide (3.0 mL) was added potassium
carbonate (62.9 mg, 0.46 mmol) at rt. The resulting mixture was
stirred at 60.degree. C. for 3 h. The reaction was then cooled to
rt, diluted with water (10 mL) and extracted with ethyl acetate (30
mL.times.3). The organic layers were combined, dried over anhydrous
sodium sulfate, concentrated under reduced pressure to give a crude
material, which was purified by flash silica gel chromatography
(eluent: ethyl acetate/petroleum ether, v/v=1/1) to give the titled
product (yield: 98%) as a yellow solid.
Step 4. Synthesis of
2-{4-[4-(4-{3-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-5,5-dimethyl-4-ox-
o-2-sulfanylideneimidazolidin-1-yl}phenyl)phenoxy]butoxy}acetic
Acid
##STR00441##
[0689] To a stirred solution of tert-butyl
2-{4-[4-(4-{3-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-5,5-dimethyl-4-ox-
o-2-sulfanylideneimidazolidin-1-yl}phenyl)phenoxy]butoxy}acetate
(150.0 mg, 0.22 mmol) in dichloromethane (2.0 mL) was added
trifluoroacetic acid (2.0 mL) at rt. The resulting solution was
stirred for 2 h at rt. The resulting mixture was concentrated under
reduced pressure to give a crude material, which was used for next
step reaction without any further purifications. Mass (ES.sup.+):
m/z 613.00 [MH.sup.+].
Step 5. Synthesis of Example 190
##STR00442##
[0691] To a stirred solution of
2-{4-[4-(4-{3-[6-cyano-5-(trifluoromethyl)pyridin-3-yl]-5,5-dimethyl-4-ox-
o-2-sulfanylideneimidazolidin-1-yl}phenyl)phenoxy]butoxy}acetic
acid (80.0 mg, 0.13 mmol) and
(2S,4R)-1-[(2S)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(1,3-oxazol-
-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide (53.8 mg, 0.13 mmol)
in N,N-dimethylformamide (2.0 mL) was added
O-(7-azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium
hexafluorophosphate (51.0 mg, 0.13 mmol) and
N-ethyl-N-isopropylpropan-2-amine (43.0 mg, 0.33 mmol) at rt. The
resulting solution was stirred for 2 h at rt. LC-MS indicated
formation of the desired product. The reaction mixture was diluted
with water (10 mL) and extracted with ethyl acetate (50
mL.times.3). The organic layers were combined, washed with brine
(10 mL), dried over anhydrous sodium sulfate and concentrated under
reduced pressure to give a crude material, which was purified by a
silica gel flash chromatography (eluent: ethyl acetate/petroleum
ether, v/v=1/1) to give the titled product as a white solid (yield:
45%).
TABLE-US-00015 TABLE 15 Exemplary Compounds. Ex# Structure Compound
name and Analytical data 200 ##STR00443##
(2S,4R)-1-[(2S)-2-(2-{[6-({4-[3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-o-
xo-1-
sulfanylideneimidazolidin-1-yl]phenoxy}methyl)spiro[3.3]heptan-2-
yl]methoxy}acetamido)-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(1,3-oxazol-5-
- yl)phenyl]methyl}pyrrolidine-2-carboxamide Mass (ES.sup.+): m/z
950.50 [MH.sup.+] 201 ##STR00444##
(2S,4R)-1-[(2S)-2-[2-({6-[(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-d-
imethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}phenoxy)methyl]spiro[3.3]h-
eptan-2-
yl}methoxy)acetamido]-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-me-
thyl-1,3- thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.86 (s, 1H), 8.16 (d, J
= 8 Hz, 2H), 8.01 (d, J = 8.4 Hz, 1H), 7.51-7.42 (m, 4H), 7.27 (d,
J = 8.8 Hz, 2H), 7.07-7.00 (m, 2H), 4.71 (s, 1H), 4.63-4.53 (m,
3H), 4.38-4.33 (m, 1H), 4.04-3.95 (m, 2H), 3.93-3.85 (m, 3H),
3.84-3.80 (m, 1H), 3.53 (s, 2H), 2.63-2.59 (m, 1H), 2.57-2.49 (m,
4H), 2.29-2.19 (m, 3H), 2.18- 2.06 (m, 3H), 2.01-1.87 (m, 4H), 1.55
(s, 6H), 1.05 (s, 9H); LC-MS (ES.sup.+): m/z 1014.20 [MH.sup.+] 202
##STR00445##
(2S,4R)-1-[(1S)-2-[2-({6-[(4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-d-
imethyl-4-
oxo-2-sulfanylideneimidazolidin-1-yl}phenoxy)methyl]spiro[3.3]h-
eptan-2-
yl}methoxy)acetamido]-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[-
4-(4-methyl-1,3-
thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide .sup.1H NMR
(400 MHz, DMSO) .delta. 8.99 (s, 1H), 8.45 (d, J = 7.6 Hz, 1H),
8.39 (d, J = 8.0 Hz, 1H), 8.29 (s, 1H), 8.08 (d, J = 9.6 Hz, 1H),
7.44 (d, J = 8.4 Hz, 2H), 7.38-7.25 (m, 5H), 7.07 (d, J = 8.8 Hz,
2H), 5.17 (s, 1H), 4.91 (s, 1H), 4.54 (d, J = 9.6 Hz, 1H), 4.45-
4.38 (m, 1H), 4.29 (s, 1H), 3.96-3.94 (m, 2H), 3.93-3.90 (m, 2H),
3.60-3.57 (m, 2H), 3.43 (s, 2H), 2.59-2.41 (m, 5H), 2.23-2.04 (m,
5H), 1.93-1.77 (m, 5H), 1.49 (s, 6H), 1.37 (d, J = 7.2 Hz, 3H),
0.95 (s, 9H); LC-MS (ES.sup.+): m/z 1028.20 [MH.sup.+] 203
##STR00446##
(2S,4R)-1-[(2S)-2-[2-({6-[(4-{7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-
-6-
sulfanylidene-5,7-diazaspiro[3.4]octan-5-yl}phenoxy)methyl]spiro[3.3]h-
eptan-2-
yl}methoxy)acetamido]-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-me-
thyl-1,3- thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide Mass
(ES.sup.+): m/z 1026.25 [MH.sup.+]
[0692] Example 201 was synthesized according chemistry shown below,
utilizing similar procedures used for the synthesis of example
75.
##STR00447##
[0693] Examples 200, 202-203 was synthesized according to similar
procedure described for synthesis of example 201, by using
corresponding starting materials and intermediates.
TABLE-US-00016 TABLE 16 Exemplary Compounds. Ex# Structure Compound
name and Analytical data 204 ##STR00448##
(2S,4R)-1-[(2S)-2-[2-(2-{[4-(4-{[3-
(3-chloro-4-cyanophenoxy)-2,2,4,4-
tetramethylcyclobutyl]carbamoyl}phenyl)
phenyl]amino}ethoxy)acetamido]-
3,3-dimethylbutanoyl]-4-hydroxy-N-{[4- (4-methyl-1,3-thiazol-5-
yl)phenyl]methyl}pyrrolidine-2- carboxamide Mass (ES.sup.+): m/z
988.20 [MH.sup.+]
TABLE-US-00017 TABLE 17 Additional Exemplary Compounds. Structure
205 ##STR00449## 206 ##STR00450## 207 ##STR00451## 208 ##STR00452##
209 ##STR00453## 210 ##STR00454## 211 ##STR00455## 212 ##STR00456##
213 ##STR00457## 214 ##STR00458## 215 ##STR00459## 216 ##STR00460##
217 ##STR00461## 218 ##STR00462## 219 ##STR00463## 220 ##STR00464##
221 ##STR00465## 222 ##STR00466## 223 ##STR00467## 224 ##STR00468##
225 ##STR00469## 226 ##STR00470## 227 ##STR00471## 228 ##STR00472##
229 ##STR00473## 230 ##STR00474## 231 ##STR00475## 232 ##STR00476##
233 ##STR00477## 234 ##STR00478## 235 ##STR00479## 236 ##STR00480##
237 ##STR00481## 238 ##STR00482## 239 ##STR00483## 240 ##STR00484##
241 ##STR00485## 242 ##STR00486## 243 ##STR00487## 244 ##STR00488##
245 ##STR00489## 246 ##STR00490## 247 ##STR00491## 248 ##STR00492##
249 ##STR00493## 250 ##STR00494## 251 ##STR00495## 252 ##STR00496##
253 ##STR00497## 254 ##STR00498## 255 ##STR00499## 256 ##STR00500##
257 ##STR00501## 258 ##STR00502## 259 ##STR00503## 260 ##STR00504##
261 ##STR00505## 262 ##STR00506## 263 ##STR00507## 264 ##STR00508##
265 ##STR00509## 266 ##STR00510## 267 ##STR00511## 268 ##STR00512##
269 ##STR00513## 270 ##STR00514## 271 ##STR00515## 272 ##STR00516##
273 ##STR00517## 274 ##STR00518## 275 ##STR00519## 276 ##STR00520##
277 ##STR00521## 278 ##STR00522## 279 ##STR00523## 280 ##STR00524##
281 ##STR00525## 282 ##STR00526## 283 ##STR00527## 284 ##STR00528##
285 ##STR00529## 286 ##STR00530## 287 ##STR00531## 288 ##STR00532##
289 ##STR00533## 290 ##STR00534## 291 ##STR00535## 292 ##STR00536##
293 ##STR00537## 294 ##STR00538## 295 ##STR00539## 296 ##STR00540##
297 ##STR00541## 298 ##STR00542## 299 ##STR00543## 300 ##STR00544##
301 ##STR00545## 302 ##STR00546## 303 ##STR00547## 304 ##STR00548##
305 ##STR00549## 306 ##STR00550## 307 ##STR00551## 308 ##STR00552##
309 ##STR00553## 310 ##STR00554## 311 ##STR00555## 312 ##STR00556##
313 ##STR00557## 314 ##STR00558## 315 ##STR00559## 316 ##STR00560##
317 ##STR00561## 318 ##STR00562## 319 ##STR00563## 320 ##STR00564##
321 ##STR00565## 322 ##STR00566## 323 ##STR00567## 324 ##STR00568##
325 ##STR00569## 326 ##STR00570##
327 ##STR00571## 328 ##STR00572## 329 ##STR00573## 330 ##STR00574##
331 ##STR00575## 332 ##STR00576## 333 ##STR00577## 334 ##STR00578##
335 ##STR00579## 336 ##STR00580## 337 ##STR00581## 338 ##STR00582##
339 ##STR00583## 340 ##STR00584## 341 ##STR00585## 342 ##STR00586##
343 ##STR00587## 344 ##STR00588## 345 ##STR00589## 346 ##STR00590##
347 ##STR00591## 348 ##STR00592## 349 ##STR00593## 350 ##STR00594##
351 ##STR00595## 352 ##STR00596## 353 ##STR00597## 354 ##STR00598##
355 ##STR00599## 356 ##STR00600## 357 ##STR00601## 358 ##STR00602##
359 ##STR00603## 360 ##STR00604## 361 ##STR00605## 362 ##STR00606##
363 ##STR00607## 364 ##STR00608## 365 ##STR00609## 366 ##STR00610##
367 ##STR00611## 368 ##STR00612## 369 ##STR00613## 370 ##STR00614##
371 ##STR00615## 372 ##STR00616## 373 ##STR00617## 374 ##STR00618##
375 ##STR00619## 376 ##STR00620## 377 ##STR00621## 378 ##STR00622##
379 ##STR00623## 380 ##STR00624## 381 ##STR00625## 382 ##STR00626##
383 ##STR00627## 384 ##STR00628## 385 ##STR00629## 386 ##STR00630##
387 ##STR00631## 388 ##STR00632## 389 ##STR00633## 390 ##STR00634##
391 ##STR00635## 392 ##STR00636## 393 ##STR00637## 394 ##STR00638##
395 ##STR00639## 396 ##STR00640## 397 ##STR00641## 398 ##STR00642##
399 ##STR00643## 400 ##STR00644## 401 ##STR00645## 402 ##STR00646##
403 ##STR00647## 404 ##STR00648## 405 ##STR00649## 406 ##STR00650##
407 ##STR00651## 408 ##STR00652## 409 ##STR00653## 410 ##STR00654##
411 ##STR00655## 412 ##STR00656## 413 ##STR00657## 414 ##STR00658##
415 ##STR00659## 416 ##STR00660## 417 ##STR00661## 418 ##STR00662##
419 ##STR00663## 420 ##STR00664## 421 ##STR00665## 422 ##STR00666##
423 ##STR00667## 424 ##STR00668## 425 ##STR00669## 426 ##STR00670##
427 ##STR00671## 428 ##STR00672## 429 ##STR00673## 430 ##STR00674##
431 ##STR00675## 432 ##STR00676## 433 ##STR00677## 434 ##STR00678##
435 ##STR00679## 436 ##STR00680## 437 ##STR00681## 438 ##STR00682##
439 ##STR00683## 440 ##STR00684## 441 ##STR00685## 442 ##STR00686##
443 ##STR00687## 444 ##STR00688## 445 ##STR00689## 446 ##STR00690##
447 ##STR00691## 448 ##STR00692## 449 ##STR00693## 450 ##STR00694##
451 ##STR00695##
452 ##STR00696## 453 ##STR00697## 454 ##STR00698## 455 ##STR00699##
456 ##STR00700## 457 ##STR00701## 458 ##STR00702## 459 ##STR00703##
460 ##STR00704## 461 ##STR00705## 462 ##STR00706## 463 ##STR00707##
464 ##STR00708## 465 ##STR00709## 466 ##STR00710## 467 ##STR00711##
468 ##STR00712## 469 ##STR00713## 470 ##STR00714## 471 ##STR00715##
472 ##STR00716## 473 ##STR00717## 474 ##STR00718## 475 ##STR00719##
476 ##STR00720## 477 ##STR00721## 478 ##STR00722## 479 ##STR00723##
480 ##STR00724## 481 ##STR00725## 482 ##STR00726## 483 ##STR00727##
484 ##STR00728## 485 ##STR00729## 486 ##STR00730## 487 ##STR00731##
488 ##STR00732## 489 ##STR00733## 490 ##STR00734## 491 ##STR00735##
492 ##STR00736## 493 ##STR00737## 494 ##STR00738## 495 ##STR00739##
496 ##STR00740## 497 ##STR00741## 498 ##STR00742## 499 ##STR00743##
500 ##STR00744## 501 ##STR00745## 502 ##STR00746## 503 ##STR00747##
504 ##STR00748## 505 ##STR00749## 506 ##STR00750## 507 ##STR00751##
508 ##STR00752## 509 ##STR00753## 510 ##STR00754## 511 ##STR00755##
512 ##STR00756## 513 ##STR00757## 514 ##STR00758## 515 ##STR00759##
516 ##STR00760## 517 ##STR00761## 518 ##STR00762## 519 ##STR00763##
520 ##STR00764## 521 ##STR00765## 522 ##STR00766## 523 ##STR00767##
524 ##STR00768## 525 ##STR00769## 526 ##STR00770## 527 ##STR00771##
528 ##STR00772## 529 ##STR00773## 530 ##STR00774## 531 ##STR00775##
532 ##STR00776## 533 ##STR00777## 534 ##STR00778## 535 ##STR00779##
536 ##STR00780## 537 ##STR00781## 538 ##STR00782## 539 ##STR00783##
540 ##STR00784## 541 ##STR00785## 542 ##STR00786## 543 ##STR00787##
544 ##STR00788## 545 ##STR00789## 546 ##STR00790## 547 ##STR00791##
548 ##STR00792## 549 ##STR00793## 550 ##STR00794## 551 ##STR00795##
552 ##STR00796## 553 ##STR00797## 554 ##STR00798## 555 ##STR00799##
556 ##STR00800## 557 ##STR00801## 558 ##STR00802## 559 ##STR00803##
560 ##STR00804## 561 ##STR00805## 562 ##STR00806## 563 ##STR00807##
564 ##STR00808## 565 ##STR00809## 566 ##STR00810## 567 ##STR00811##
568 ##STR00812## 569 ##STR00813## 570 ##STR00814## 571 ##STR00815##
572 ##STR00816## 573 ##STR00817## 574 ##STR00818## 575 ##STR00819##
576 ##STR00820## 577 ##STR00821##
578 ##STR00822## 579 ##STR00823## 580 ##STR00824## 581 ##STR00825##
582 ##STR00826## 583 ##STR00827## 584 ##STR00828## 585 ##STR00829##
586 ##STR00830## 587 ##STR00831## 588 ##STR00832## 589 ##STR00833##
590 ##STR00834## 591 ##STR00835## 592 ##STR00836## 593 ##STR00837##
Measured Mass Ion Data MH.sup.+ 1 MH.sup.+ 2 205 1082.37 206
1024.33 207 1152.45 208 1096.41 209 964.33 210 1112.38 211 1156.41
212 1140.44 213 1200.44 214 1170.42 215 1184.44 216 1110.43 217
1124.44 218 1198.46 219 1256.50 220 1284.53 221 1096.39 222 1138.46
223 1152.47 224 1180.50 225 1050.40 226 1090.47 227 1076.46 228
1020.40 229 1068.36 230 1008.36 231 959.36 232 1003.38 233 934.32
234 1108.44 235 1052.37 236 920.29 237 904.30 238 992.35 239
1008.34 240 1022.36 241 1038.33 242 1020.38 243 978.35 244 948.34
245 1037.37 246 1004.40 247 1006.38 248 1022.35 249 1040.40 250
1052.35 251 1006.35 252 1036.36 253 1022.36 254 994.31 255 1034.40
256 1008.32 257 1010.34 258 1024.35 259 1052.38 260 1024.34 261
980.28 262 1036.37 263 1054.35 264 1026.32 265 266 1008.33 267
1022.35 268 1006.37 269 1036.36 270 1050.38 271 952.27 272 966.29
273 1050.36 274 1040.34 275 996.31 276 1010.33 277 996.32 278
1010.33 279 1066.36 280 980.30 281 994.32 282 1048.30 283 1026.32
284 1072.34 285 1086.36 286 1058.33 287 1077.41 288 1054.37 289
1063.41 290 1045.38 291 1093.38 292 1024.44 293 1059.48 294 1073.49
295 1020.46 296 1054.46 297 1122.49 298 1054.46 299 1022.41 300
1006.44 301 1020.45 302 1024.42 303 1010.41 304 1108.44 305 1032.46
306 1010.41 307 1006.44 308 1020.47 309 1015.49 310 1062.51 311
1031.48 312 1006.45 313 1031.48 314 974.40 315 1006.46 316 1005.48
317 1019.50 318 1031.40 319 988.32 320 1020.38 321 1006.37 322
1019.40 323 992.34 324 1017.39 325 1017.40 326 1018.20 327 1032.55
328 1047.34 329 1002.10 330 331.05 331 1089.39 332 1167.43 333
1005.40 334 1004.40 335 942.40 336 960.50 337 942.40 338 957.40 339
959.20 340 1023.40 341 978.55 342 934.30 343 920.30 344 956.30 345
956.35 346 347 945.40 348 961.35 349 972.40 350 976.35 351 -- 352
993.25 353 978.35 354 960.35 355 990.45 356 990.45 357 1020.40 358
994.10 359 950.20 360 978.20 361 992.20 362 977.25 363 994.40 364
988.40 365 1021.20 366 964.20 367 994.40 368 978.30 369 960.30 370
994.40 371 983.30 372 983.50 373 1034.40 374 1026.35 375 1059.36
376 975.30 377 989.30 378 1032.34 379 1025.37 380 975.30 381
1026.16 382 1026.16 383 1025.30 384 1041.30 385 991.26 993.26 386
1011.30 387 927.37 929.37 388 951.23 953.23 389 1055.10 390 1022.25
391 1024.15 392 941.39 943.39 393 954.31 956.31 394 988.37 990.37
395 1045.35 396 1012.15 397 1012.15 398 968.32 970.32 399 1026.15
400 1042.20 401 1040.35 402 1021.20 403 1040.15 404 980.52 982.52
405 989.40 991.40 406 989.40 991.40 407 920.58 922.58 408 1040.10
409 954.38 956.38 410 966.37 968.41 411 938.44 940.44 412 966.42
968.42 413 1006.30 414 1083.34 415 954.40 956.40 416 941.38 943.38
417 1003.39 1005.39 418 1045.38
419 1045.38 420 1050.39 421 1081.38 422 1042.39 1044.39 423 1013.42
424 1064.36 425 986.46 988.46 426 1064.37 427 1030.38 428 1030.38
429 1067.38 430 1066.38 431 1016.37 432 1004.38 1006.38 433 1074.45
1076.45 434 1029.39 435 1029.39 436 975.40 977.40 437 975.40 977.40
438 995.46 997.46 439 1036.40 440 1030.38 441 1004.30 1006.40 442
981.40 983.40 443 1007.42 444 985.43 987.43 445 1003.42 1005.43 446
990.41 992.41 447 980.45 982.45 448 1003.30 1005.40 449 986.40
988.40 450 1003.40 1005.40 451 967.43 452 1017.45 453 1021.39 454
968.45 970.45 455 968.45 970.45 456 994.55 996.45 457 968.35 970.35
458 968.35 970.35 459 968.35 970.35 460 1096.43 1098.43 461 1065.38
1067.38 462 1166.46 1168.46 463 1067.40 1069.40 464 1003.50 465
1038.50 1040.50 466 1038.55 1040.55 467 1025.36 1027.36 468 1038.37
1040.37 469 1010.34 1012.35 470 1012.35 1014.35 471 1012.35 1014.36
472 1037.25 1039.24 473 982.35 984.35 474 984.33 986.33 475 984.33
986.33 476 1003.26 1005.26 477 927.30 478 995.30 997.30 479 952.30
480 881.34 883.34 481 989.28 991.28 482 969.33 971.33 483 1002.33
1004.33 484 988.31 990.31 485 968.83 970.83 486 969.33 971.33 487
940.30 488 926.29 928.29 489 912.23 914.23 490 898.26 900.26 491
1003.60 492 882.26 884.26 493 1139.41 1141.41 494 1040.35 1042.35
495 986.32 988.32 496 912.28 914.28 497 1003.45 498 897.27 899.27
499 938.27 940.37 500 916.31 918.31 501 916.31 918.31 502 984.30
986.30 503 955.32 957.32 504 942.33 944.33 505 926.37 927.36 506
926.37 927.40 507 782.30 784.30 508 998.36 1000.36 509 769.27
771.27 510 912.35 914.35 511 914.36 916.36 512 901.33 903.33 513
1025.29 1027.29 514 998.34 1000.34 515 998.34 1000.34 516 955.33
957.33 517 939.45 941.45 518 926.43 928.43 519 783.30 785.30 520
868.34 870.34 521 965.34 967.34 522 887.37 889.37 523 883.35 885.35
524 916.34 918.34 525 980.37 982.37 526 925.43 927.43 527 925.44
927.43 528 925.43 927.43 529 951.44 953.44 530 925.44 927.43 531
936.44 938.44 532 936.44 938.44 533 936.44 938.44 534 936.44 938.44
535 936.44 938.44 536 935.45 937.45 537 940.35 942.35 538 955.41
957.41 539 883.41 885.41 540 917.39 919.39 541 896.43 898.43 542
882.41 884.41 543 1025.38 1027.38 544 981.43 983.43 545 1110.30 546
1055.30 547 868.40 870.40 548 883.40 885.40 549 931.86 933.86 550
917.38 919.38 551 883.41 885.41 552 891.38 893.38 553 989.40 991.40
554 1024.15 555 980.43 982.43 556 982.45 984.45 557 883.39 885.39
558 888.38 890.38 559 1070.15 560 968.41 970.41 561 955.40 957.40
562 968.41 970.41 563 973.36 975.36 564 953.37 955.37 565 1036.20
566 1056.15 567 1056.15 568 910.40 912.40 569 926.39 928.39 570
942.36 944.36 571 953.33 572 892.35 894.35 573 926.34 928.34 574
1070.15 575 1054.00 576 1054.20 577 973.63 975.36 578 579 580 581
582 583 584 585 586 587 588 589 590 591 592 593
[0694] In certain embodiments, the description provides a compound
having a structure selected from the group consisting of Examples
1-593 (see Tables 2-17), a salt, a polymorph, and prodrug thereof.
In certain additional embodiments, the description provides a
composition comprising at least one of the compounds of Examples
1-593, including a salt, polymorph, and prodrug thereof. In still
additional embodiments, the description provides a therapeutic
composition comprising at least one of the compounds of Examples
1-593, including a salt, a polymorph, and a prodrug thereof, and a
pharmaceutically acceptable carrier.
Examples--In Vitro and In Vivo Assays
[0695] The experimental results presented below are made with
reference to the Tables and FIGS. 1-7.
[0696] 1. Androgen Receptor ELISA Assay.
[0697] Compounds have been evaluated in this assay in LNCaP and/or
VCaP cells utilizing similar protocols. The protocols used with
VCaP cells are described below. The androgen receptor ELISA assay
was performed using PathScan AR ELISA (Cell Signaling
Catalog#12850) according to the following assay steps:
[0698] VCaP cells are seeded at 30,000 cells/well at a volume of
200 .mu.L/well in VCaP assay medium [Phenol red free RPMI (Gibco
Cat#11835-030); 5% Charcoal Stripped (Dextran treated) FBS (Omega
Scientific, Cat#FB-04); Pen/Strep Life Technologies (Gibco Cat#:
10378-016); 0.1 nM R1881 (Sigma, Cat# R0908) is added upon the
start of the assay, not during initial plating of the cells) in
Corning 3904 plates. The cells are grown for a minimum of 3
days.
[0699] First, cells are dosed with compounds diluted in 0.1%
DMSO--use a polypropylene plate according to the following
protocol: (1)(i) make 1000.times. stock plate in DMSO; (ii) 20 mM
stock diluted 1/6.7 with DMSO (5 .mu.L+28.3 .mu.L DMSO)=3 mM into
row H; (iii) perform serial dilutions in/2 log doses (10 .mu.L of
PROTAC+20 .mu.L DMSO) from row H towards row B. Reserve row A for
DMSO; (iv) 7 doses total (final concentration in this 1000.times.
plate will be 3 mM, 1 mM, 333 .mu.M, 111 .mu.M, etc). (2)(i) Make
10.times. stock plate in media; (ii) transfer 2.5 .mu.L of the
1000.times. stock to a new 10.times. stock plate (use 12 channel
pipet, start at A (DMSO control) work thru H. When 247.5 .mu.L of
media is added to this plate, it will serve as a 10.times. stock;
(iii) make media+1 nM R1881 for making 10.times. stock plate; (iv)
add 247.5 .mu.L of media with 1 nM R1881 to each well of the
10.times. stock plate, mix.
[0700] Then 22 .mu.L of 10.times. stock is added to cells and
incubated for 24 h. 1.times. Cell Signaling Cell lysis buffer is
made (Catalogue #9803; comes with the kit)--prepare for 50
.mu.L/well. Keep on ice. Media is aspirated, and 50 .mu.L 1.times.
cell lysis buffer/well is added. The cells are placed on ice for 10
minutes. The solution is mixed and transferred to PCR plate, and
centrifuged at 4 C for 10 minutes at 4000 rpm.
[0701] 5 .mu.L is transferred to fresh plate (use immediately or
freeze -80 C); 115 .mu.L ELISA Dilutant is added (0.15 ug/ml--0.075
ug/ml; comes with the PathScan ELISA).
[0702] Add 100 .mu.L/well AR Elisa; cover and shake, 37 C for 2
hrs; dump, tap, wash 4.times.200 .mu.L ELISA wash buffer; add 100
.mu.L/well mouse AR detection Ab; cover and shake, 37 C for 1 hr;
dump, tap, wash 4.times.200 .mu.L ELISA wash buffer; add 100
.mu.L/well anti-mouse--HRP conjugated Ab (comes with the kit);
cover and shake, 37 C for 30 min; allow TMB reagent to come to RT;
dump, tap, wash 4.times.200 .mu.L Elisa wash buffer; tap; add 100
.mu.L TMB, shake 5 min--while watching color. Add the stop reagent
when light blue color develops. Add 100 .mu.L Stop solution; shake
and read at 450 nM.
[0703] Progression of prostate cancer in patients treated with
anti-androgen therapy usually involves one of several mechanisms of
enhanced Androgen Receptor (AR) signaling, including increased
intratumoral androgen synthesis, increased AR expression and AR
mutations. PROTACs (PROteolysis TArgeting Chimera), which uses
bi-functional molecules that simultaneously bind a target of choice
and an E3 ligase, cause ubiquitination via induced proximity and
degradation of the targeted, pathological protein. As opposed to
traditional target inhibition, which is a competitive process,
degradation is a progressive process. As such, it is less
susceptible to increases in endogenous ligand, target expression,
or mutations in the target. Thus this technology seems ideal for
addressing the mechanisms of AR resistance in patients with
prostate cancer.
[0704] AR PROTACs degrade AR in LNCaP and VCaP cells, with nM to pM
potency, and had a >85% reduction in AR concentration
(D.sub.max). Degradation was rapid, with 50% of AR lost within 15
minutes and maximal degradation observed by 4 hours. The duration
of AR knockdown was long-lasting, with no recovery of AR observed
over several days. The degradation process in cells was specific,
as PROTACs with an inactive epimer for E3 ligase binding did not
degrade AR. AR PROTACs induced rapid apoptosis and cell death in
VCaP cells. In LNCap and VCaP cell systems, AR PROTACs were
anti-proliferative under conditions in which enzalutamide was
inactive, such as increasing concentrations of the AR agonist R1881
and cells containing the AR.sup.F876L mutation. AR PROTACs
typically had t.sub.1/2 values of several hours and bioavailability
of >50% after ip or sc injection. In mice, AR PROTACs have shown
in vivo activity, including involution of seminal vesicles,
reduction of AR protein levels in the prostate, and regression of
VCaP tumors.
[0705] The following assay results were generated using the
androgen receptor ELISA Assay described above, where compound
potencies were characterized in highest percentage of Androgen
Receptor degradation (D.sub.max) observed and compound
concentration that caused 50% Androgen Receptor degradation
(DC.sub.50).
TABLE-US-00018 TABLE 18 Androgen Receptor degradation (D.sub.max)
observed and compound concentration that caused 50% Androgen
Receptor degradation (DC.sub.50). LNCaP LNCaP VCaP VCaP Dmax
DC.sub.50 Dmax DC.sub.50 Ex # (%) (.mu.M) (%) (.mu.M) 1 ++++ A 2
++++ A 3 ++++ A 4 ++++ A 5 ++++ B 6 ++++ A 7 +++ A 8 ++++ A 9 ++++
A 10 ++++ A 11 ++++ A 12 ++++ B 13 ++ 14 C 15 ++ 16 +++ A ++ 17 ++
18 +++ B 19 +++ A 20 ++++ B 21 ++ 22 +++ A 23 ++++ B 24 ++++ A 25
++++ A 26 +++ A 27 ++++ A 28 ++++ A 29 +++ B 30 ++++ A 31 ++++ A 32
++++ A 33 +++ A 34 +++ A 35 +++ A 36 ++ B 37 ++++ A 38 +++ A 39 ++
A 40 +++ A 41 ++++ A 42 +++ A 43 +++ A 44 ++++ A 45 ++++ A 46 ++++
A 47 +++ A 48 ++++ A 49 +++ A 50 ++++ A 51 ++ A 52 ++++ A 53 ++++ A
54 ++++ A 55 ++ 56 ++ 57 58 59 60 +++ B 61 +++ B 62 +++ C 63 ++++ B
64 +++ B 65 +++ B 66 +++ B 67 72.1 A 68 ++ B 69 ++++ B 70 ++++ A 71
++++ A 72 ++++ B 73 ++++ A 74 ++++ A 75 ++++ A 76 +++ A 77 ++++ A
78 ++++ A 79 ++++ A 80 +++ C 81 +++ C 82 +++ B 83 +++ B 84 +++ B 85
+++ C VCaP VCaP Dmax DC.sub.50 Ex # (%) (.mu.M) 86 ++ 87 ++ 88 89
++++ A 93 94 ++++ A 95 ++++ A 96 +++ A 99 +++ A 100 ++++ A 101 ++++
A 102 ++++ A 103 ++++ A 104 ++++ A 105 +++ B 106 ++++ A 107 ++++ A
108 ++++ A 109 ++++ A 110 ++++ A 111 ++++ A 112 ++++ B 114 +++ A
115 ++++ A 116 ++++ A 117 ++++ A 118 ++++ A 119 +++ A 120 ++++ A
121 ++++ A 122 ++++ A 123 ++++ A 124 +++ A 125 ++++ A 126 +++ A 127
++++ A 128 +++ A 129 +++ A 130 +++ A 131 +++ A 132 ++++ A 133 + 134
++++ A 135 +++ A 136 ++++ A 137 ++++ A 138 ++++ A 139 ++++ A 140
++++ A 141 ++++ A 142 ++++ A 145 ++++ A 147 ++++ A 148 ++++ A 150
++++ A 151 ++++ A 152 ++++ A 153 ++++ A 154 ++++ A 155 ++++ A 156
++++ A 157 ++++ A 158 ++++ A 159 ++++ A 162 ++++ A 163 ++++ A 164
++++ A 165 ++++ A 166 +++ A 172 ++++ A 173 ++++ A 174 +++ A 175 +++
A 180 ++++ A 181 ++++ A 182 ++++ A 183 ++++ A 184 ++++ A 185 ++++ A
186 ++++ A 188 ++++ A 189 +++ A 418 +++ C 419 ++ C 420 ++++ A 421
++++ A 422 ++++ A 423 + C 424 + C 425 ++++ A 426 + C 427 + C 428 +
C 429 ++ C 430 + C 431 + C 432 + C 433 +++ A 434 + C 435 + C 436
+++ 437 + C 438 ++++ A 439 440 441 442 ++++ A 443 444 ++++ A 445
++++ A 446 ++ C 447 ++++ A 448 ++++ A 449 ++++ A 450 ++++ A 451 + C
452 + C 453 + C 454 ++++ A 455 ++ C 456 +++ C 457 ++++ A 458 + C
459 + C 460 ++ C 461 462 ++++ A 463 464 465 ++++ C 466 ++++ A 467
++++ B 468 469 ++++ A 470 ++++ A 471 ++++ A 472 ++ C 473 ++++ A 474
++ A 475 ++ B 476 ++++ A 477 ++++ A 478 + C 479 ++ C 480 ++ C 481
++ C 482 + C 483 ++++ A 484 ++++ A
485 +++ A 486 487 488 489 490 491 492 493 494 495 496 ++++ A 497
+++ A 498 +++ A 499 ++++ A 500 ++ C 501 ++ C 502 +++ A 503 ++ B 504
++++ A 505 +++ A 506 ++ C 507 +++ A 508 ++ C 509 ++++ A 510 ++ C
511 +++ A 512 +++ A 513 +++ B 514 ++++ A 515 ++ C 516 ++++ A 517
+++ A 518 ++++ A 519 + C 520 ++ C 521 ++ C 522 +++ A 523 +++ A 524
+++ A 525 +++ A 526 ++++ A 527 +++ A 528 ++ C 529 +++ A 530 + C 531
++++ A 532 ++ C 533 +++ A 534 ++ C 535 +++ A 536 ++ C 537 ++ C 538
++ C 539 +++ A 540 ++ C 541 ++++ A 542 ++++ A 543 ++++ A 544 ++++ A
545 ++++ A 546 +++ A 547 + C 548 +++ A 549 ++++ A 550 ++++ A 551
++++ A 552 +++ A 553 +++ A 554 ++++ A 555 +++ A 556 ++++ A 557 ++++
A 558 559 560 ++++ A 561 562 563 564 +++ A 565 ++++ A 566 ++++ A
567 +++ A 568 ++++ A 569 ++++ A 570 ++++ A 571 ++++ A 572 ++++ A
573 ++++ A 574 ++++ A 575 ++++ A 576 ++++ A 577 ++++ A 578 ++++ A
D.sub.max: + (D.sub.max .ltoreq. 25%); ++ (26% .ltoreq. D.sub.max
.ltoreq. 50%); +++ (51% .ltoreq. D.sub.max .ltoreq. 70%); ++++ (71%
.ltoreq. D.sub.max ); DC.sub.50: A (D.sub.max .ltoreq. 50 nM); B
(51 nM .ltoreq. DC.sub.50 .ltoreq. 500 nM); C (501 nM .ltoreq.
DC.sub.50).
[0706] 2. VCaP Cell Proliferation Assay.
[0707] VCaP cells are plated 7,500/well 200 .mu.L/well in VCaP
assay medium [Phenol red free RPMI (Gibco Cat#11835-030); 5%
Charcoal Stripped (Dextran treated) FBS (Omega Scientific,
Cat#FB-04); Pen/Strep Life Technologies (Gibco Cat#: 10378-016);
0.1 nM R1881 (Sigma, Cat#R0908) is added upon the start of the
assay, not during initial plating of the cells).
[0708] The assay was performed as follows: the cells are grown for
a minimum of 3 days to deplete androgens; dosing of PROTACs and
R1881 is performed as for AR ELISA; the baseline reading of Cell
Titer Glo can be performed on day of dosing.
[0709] VCaP cells with 0.1 nM R1881 will double once in 4 days.
Gently draw off 110 .mu.L of media so as not to disturb the
adherent cells; add 110 .mu.L of CTG; incubate with slow shaking
for 20 minutes; and read luminescence on a plate reader.
[0710] VCaP Anti-Proliferation Data:
[0711] GI.sub.50 definition: A (GI.sub.50.ltoreq.50 nM); B (51
nM.ltoreq.GI.sub.50.ltoreq.250 nM); C (251 nM.ltoreq.GI.sub.50)
TABLE-US-00019 TABLE 19 Inhibition of VCaP Proliferation. Ex #
GI.sub.50 75 B 131 B 134 B 150 A 156 A 157 A 163 A 169 B 170 A 172
A 174 A 182 A 183 A 194 B 195 B 197 B 201 B 202 B 204 A Mass Data
Observed Observed Mass 1: Mass 2: Ex # MH+ MH+ GI.sub.50 ABM-26
279.11 281.11 B ABM-27 279.30 281.30 C ABM-28 400.14 402.14 ABM-29
379.17 381.16 B ABM-30 398.13 400.12 A ABM-31 400.14 402.14 B
ABM-32 400.14 402.14 ABM-33 413.20 415.20 B ABM-34 417.16 419.16 C
ABM-35 399.15 401.15 ABM-36 484.16 486.16 A ABM-37 598.29 600.29
A
[0712] These results support that both the difunctional compounds
(ABM-L-ULM) and androgen receptor binding moieties (ABM-e) inhibit
VCaP Proliferation.
[0713] 3. Apoptosis in VCaP Cells.
[0714] FIG. 2 illustrates that compounds as described herein induce
apoptosis in VCaP cells. VCaP cells were cultured in Charcoal
Stripped Serum containing media supplemented with 0.1 nM R1881 for
48 hrs. The degree of apoptosis was ascertained with CaspaseGlo
assay (Promega). These results demonstrated that PROTACs are much
more potent in inducing apoptosis than an AR antagonist
enzalutamide. Further, the degree of AR degradation correlates with
their ability to induce apoptosis in VCaP cells.
[0715] 4. Anti-Proliferation in LNCaP F876L.
[0716] FIG. 3 demonstrates the anti-proliferation in LNCaP F876L
cells observed with treatment with a compounds as described herein.
LNCaP cells transduced with AR F876L construct were cultured in
Charcoal Stripped Serum containing media. Indicated doses of
enzalutamide or Example 1 were added for 7 days. CellTiterGlo
reagent (Promega) was employed to assess proliferation. As shown,
LNCaP cells expressing F876L construct proliferate in response to
increasing doses of enzalutamide, whereas Example 1 did not exhibit
agonist activity. These results demonstrated that AR PROTACs do not
possess agonist activity.
[0717] 5. PSA Suppression in LNCaP F876L
[0718] Compounds as described herein also suppress PSA in LNCaP
F876L cells (See FIG. 4). LNCaP cells transduced with AR F876L
construct were cultured in Charcoal Stripped Serum containing media
supplemented with 0.1 nM R1881 for 7 days. Secreted PSA in the
media was detected by PSA ELISA (Sigma). These results demonstrated
that AR PROTAC is able to suppress the transcriptional activity of
AR in F876L containing cells.
[0719] 6. Prostate Involution in C57B6 Mouse Model.
[0720] FIG. 5 demonstrates that compounds as described herein
induce prostate involution in C57B6 mouse model. 12-week old male
C57BL/6 mice were treated with AR PROTAC Example 163 and its
inactive epimer analog Compound A which is unable to bind to VHL E3
ligase. Enzalutamide (PO, QD, 30 mpk), Example 163 (IP, QD, 1 and 3
mpk) and Compound A (IP, QD, 1 and 3 mpk) were administered for 10
days, upon which the prostates were isolated and weighed. PROTAC
Example 163 demonstrated a significant reduction in prostate
weights, whereas Compound A showed no significant activity. These
results demonstrated that the ability of PROTAC Example 163 to
degrade AR leads to significant prostate involution in mice at very
low doses.
[0721] 7. Tumor Growth Inhibition in VCaP Xenograft Model.
[0722] FIG. 6 illustrates tumor growth inhibition in a VCaP
xenograft model, which was achieved with compounds as described
herein. VCaP cells were implanted into CB 17 scid mice
subcutaneously. Once the tumors were palpable, the mice were
castrated, leading to temporary tumor stasis. Upon regrowth of
tumors, the mice were dosed with enzalutamide (PO, QD, 30 mpk) or
AR PROTAC Example 163 (IP, QD, at 30, 10 and 3 mpk) as indicated.
Tumor growth inhibition was observed in all treatment arms.
[0723] 8. AR Degradation of PROTAC is E3 Ligase Dependent.
[0724] FIG. 7A and FIG. 7B demonstrates that AR degradation
achieved with compounds as described herein is E3 ligase dependent.
For example, in FIG. 7A, AR PROTAC Example 1 was added to LNCaP
cells at indicated concentrations for 24 hours in the presence or
absence of 10 uM VHL E3 ligase ligand compound B. The presence of
compound B competes with AR PROTAC Example 1 in VHL E3 ligase
binding and greatly diminishes the AR degradation activity of AR
PROTAC Example 1. In FIG. 7B, LNCaP cells were treated with AR
PROTAC Example 1 and its inactive epimer analog compound C which is
unable to bind to VHL E3 ligase. While AR PROTAC Example 1 led to
significant degradation of AR, compound C did not. These results
demonstrated that AR PROTAC activity in AR degradation is VHL E3
ligase dependent."
[0725] 9. PROTAC Prodrug Oral Pharmacokinetics and PROTAC
Subcutaneous Pharmacokinetics.
[0726] Representative Pharmacokinetic Procedure
[0727] Male CD-1 mice (6-8 weeks old, weighing 20-30 g, 3 per
study) with free access to food and water were administered with
the test article at 10 mg/kg either by oral gavage or sub-cutaneous
injection in the formulation specified in tables 20 and 21, at 10
mL/kg.
[0728] Approximately 0.04 mL blood samples were collected from the
dorsal metatarsal vein serially at 0.25, 0.5, 1, 2, 4, 8 and 24 h
timepoints; heparin was used as the anticoagulant. The samples were
centrifuged at 4000 g for 5 min at 4.degree. C. then stored at
-75.degree. C. prior to analysis.
[0729] The plasma samples were analysed via an LC/MS/MS method
quantitating for unchanged, administered test article, and/or a
derivative species as appropriate. WinNonlin (Phoenix.TM.) was used
for the pharmacokinetic calculations and modeling, to generate
parameters such as C.sub.max and AUC.
TABLE-US-00020 TABLE 20 Examples of PROTAC prodrug pharmacokinetics
(ESP-4: 5% EtOH, 5% solutol HS15 in PBS; ESD-4 5% EtOH, 15% solutol
in D5W). Plasma Exposure Prodrug Derivative C.sub.max AUC C.sub.max
AUC Ex # Dose/Route Vehicle (ng/mL) (ng h/mL) (ng/mL) (ng h/mL) 464
10 mpk PO ESP-4 48 118 157 571 463 10 mpk PO ESP-4 12 49 15 42 462
10 mpk PO ESP-4 0 0 178 1479 461 10 mpk PO ESP-4 0 0 524 2412 468
10 mpk PO ESP-4 0 0 209 616 470 10 mpk PO ESP-4 346 469 565 1600
469 10 mpk PO ESD-4 181 353 528 4279
TABLE-US-00021 TABLE 21 Examples of PROTAC Subcutaneous
pharmacokinetics (ELP-1: 5% EtOH, 20% labrasol in PBS; ESD-2: 5%
EtOH, 20% solutol in D5W). CD-1 Mouse Plasma Exposure following a
10 mg/kg SC dose C.sub.max AUC.sub.0-24 Vehicle Ex # (ug/mL) (ng
h/niL) ESD-1 1 1.15 15600 ELP-1 80 0.18 2530 ESD-1 150 2.75 40200
ELP-1 182 1.53 29162 ESD-1 174 1.9 35065
[0730] In summary, PROTACs designed to degrade AR are potent (low
nM to pM), specific, rapid (within 2-4 hrs); long-lasting (days);
active in vitro and in vivo, and have cellular efficacy superior to
enzalutamide. AR PROTACs have efficacy in cell systems and work in
vivo (AR degradation in prostate; prostate involution in prostate
and seminal vesicle; tumor xenograft models). Thus, targeted
degradation of AR may provide a novel mechanism for providing
efficacious therapy for patients with prostate cancer for whom
current therapies have failed.
* * * * *